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Abstract 
 
Introduction: Vitamin D is a micronutrient that possesses immunomodulatory actions.  Higher 
vitamin D status has been associated with decreased incidence of acute respiratory infections (ARI) 
in a number of observational studies.  However, mechanistic in vitro work investigating effects of 
vitamin D on the immune response to ARIs is lacking, especially for rhinovirus, which is the most 
common respiratory pathogen.  Results of clinical trials of vitamin D supplementation in the 
prevention of ARIs have also been conflicting, in that some demonstrate a protective effect of this 
intervention against ARI, while others do not.    
 
Methods:  An immunological assay of ex vivo stimulation with TLR ligands and pathogens in blood 
samples from participants with asthma, COPD or neither condition in three randomised controlled 
trials of vitamin D supplementation for the prevention of ARI and exacerbations was developed.  This 
assay was used in conjunction with cellular profiling of clinical trial blood and sputum samples, and a 
rhinovirus-infected human alveolar cell line (A549 cells) to determine the effects of vitamin D in the 
protection against acute respiratory infections. 
 
Results: The main finding of cell culture experiments was that A549 cells pre-treated with 
physiological concentrations of 25-hydroxyvitamin D (25[OH]D, the major circulating vitamin D 
metabolite) had increased resistance to rhinovirus infection, which was associated with attenuation 
of rhinovirus-induced intercellular adhesion molecule-1 (ICAM-1) and platelet-activating factor 
receptor (PafR) expression.  Immunological analysis of clinical trial samples did not demonstrate any 
consistent effect of bolus-dose vitamin D supplementation on circulating or pathogen-stimulated 
inflammatory profiles, or on inflammatory indices in induced sputum.   
 
Conclusions:  Co-incubation with 25(OH)D was associated with transient protection against 
rhinovirus infection in a respiratory epithelial cell line in vitro, but these findings did not translate to 
any changes in cellular profile or inflammatory mediator release in clinical trials samples following in 
vivo vitamin D supplementation.  
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1. Introduction 
 
In this chapter the burden of acute respiratory tract infections and the immune response to them is 
outlined, with specific focus on 3 vulnerable populations – asthmatics, COPD patients and the 
elderly.  Vitamin D supplementation may alleviate some of the burden caused by acute diseases of 
the respiratory tract, and an overview of the literature pertaining to this is described here.  
 
 
1.1 Respiratory tract infections 
 
Acute respiratory tract infections are a leading cause of morbidity and mortality worldwide, and as 
such are a major global health problem.  As well as causing significant morbidity and mortality, they 
are also responsible for a huge economic burden, precipitating considerable absence from work and 
school, and large numbers of visits to clinicians, with a quarter of the population visiting a GP every 
year for respiratory tract infections in England and Wales in 2000 [1].  Approximately 4.25 million 
deaths worldwide every year can be attributed to acute respiratory tract infections [2], with an 
associated disease burden of an estimated 94 million DALYs (disability adjusted life years) [3] making 
them the third leading cause of death worldwide, and the leading killer in developing countries [4].  
Acute respiratory tract infections cause 18% of all deaths in children under five years of age 
worldwide [5], with respiratory syncytial virus (RSV) strongly associated with severe infections 
requiring hospitalization, and resulting in between 66,000 and 199,000 deaths annually [6, 7].  
Furthermore, when also including non-classic acute respiratory infections such as the childhood 
diseases measles and pertussis, and chronic respiratory diseases such as asthma, COPD and 
tuberculosis, the number of deaths caused by diseases of the respiratory system is increased by a 
further 6 million every year [3]. Therefore, the respiratory tract is very important as a site of 
infection and disease, thus making an understanding of respiratory physiology and the immune 
response to respiratory pathogens vital in the development of preventative and therapeutic 
strategies, and to reduce the huge burden resulting from respiratory disease.  
 
The pathogens most commonly associated with acute respiratory tract infections are the viruses 
influenza A and B, rhinoviruses, parainfluenza, RSV, adenoviruses and coronaviruses, and the 
bacteria Streptococcus pneumonia, Haemophilus influenzae, Mycoplasma pneumoniae, Moraxella 
catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa and Legionella spp. [8-11].  Fungal 
species such as Histoplasma capsultum can also cause respiratory tract infections, although these 
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are more common in immunocompromised individuals [12].  Two general categories of acute 
respiratory tract infection exist, with upper respiratory tract infections affecting the airways from 
the nose to the larynx, and including diseases such as the common cold and pharyngitis, and also the 
middle ear infection otitis media.  Lower respiratory tract infections affect the airways downstream 
from the larynx into the bronchi and bronchioles of the lungs, and include diseases such as 
pneumonia and bronchitis.  While lower respiratory tract infections are more severe and result in a 
higher proportion of mortalities, mostly due to pneumonia, upper respiratory tract infections are 
more common and represent a greater economic burden.  The common cold, for example, is the 
most prevalent infectious disease in humans, resulting in an estimated 189 million school days and 
196 million work days lost in the USA each year, and costing the country $40 billion annually [13].  
However, there is also significant overlap between the two categories of acute respiratory tract 
infections, with many pathogens able to infect both the upper and lower respiratory tract, resulting 
in this distinction often being too generalised.  For example, S.pneumoniae colonises the 
nasopharynx causing infection whilst also enabling its spread into lower parts of the respiratory tract 
[14], avian influenza A has been demonstrated to infect both the upper and lower respiratory tract 
[15], and rhinovirus has been shown to be able to replicate and cause bronchiolitis and pneumonia 
in the lower respiratory tract, as well as the common cold in the upper respiratory tract [16, 17].   
 
 
1.2 Immune response to viral respiratory infection 
 
When a virus is inhaled, it first binds to non-specific receptors (usually glycolipids or glycoproteins 
such as intercellular adhesion molecule [ICAM]-1) on the respiratory epithelium.  Membrane fusion 
or endocytosis follows, thus internalizing the virus and enabling subsequent replication, 
transcription and translation of new viruses which can then be released to infect new cells.  
However, once a cell has been infected, pathogen associated molecular patterns (PAMPs) on the 
virus can be recognised by various intracellular innate pathogen recognition receptors (PRRs) such as 
the toll-like receptors (TLRs), retinoic-acid-inducible gene-I (RIG-I)-like receptors (RLRs) and 
nucleotide binding-oligomerisation domain (NOD)-like receptors (NLRs).   Pulmonary epithelial cells 
have been shown to express all of the known human TLRs and RLRs which detect viruses, and ligands 
for these PRRs activate epithelial cells in order to initiate a rapid immune response against viral 
invasion [18].  In addition to direct infection of epithelial cells, intraepithelial dendritic cells (DCs) and 
those residing just below the respiratory epithelium continually sample particles in the airway lumen 
and can internalize them by phagocytosis and macropinocytosis [19].  This pathogen exposure then 
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results in activation of various PRRs, with conventional myeloid DCs (mDCs) expressing all known 
TLRs (except TLR9), as well as NLRs and RLRs, and TLRs 7 and 9 highly expressed in plasmacytoid DCs 
(pDCs) [19-22].  Similarly, tissue resident macrophages are also able to internalise pathogens and 
initiate an immune response following PRR ligation [23].  
 
The intracellular TLRs 3, 7, 8 and 9 are mainly located on the endoplasmic reticulum (ER) membrane 
before UNC93B1-dependent (an ER multi-transmembrane-domain-containing protein) trafficking to 
the endolysosome following viral infection [24, 25].  These nucleic acid-sensing TLRs recognise 
single-stranded RNA (TLR 7/8) or unmethylated CpG double-stranded DNA motifs (TLR 9) of the viral 
genome, or the intermediary double-stranded RNA (TLR 3) produced during viral replication [26-29]. 
TLR3 has been demonstrated to be the most effective activator of the airway epithelial immune 
response [18, 30], although it has also been associated with viral pathogenesis with its stimulation 
resulting in detrimental over-activation of the pro-inflammatory response [31].  TLR4, while usually 
extracellular and implicated in the binding of bacterial lipopolysaccharide (LPS), has been 
demonstrated to traffic to the endolysosome and potentially play a role in viral recognition, as the 
fusion protein of RSV is a ligand for it [29, 32, 33].  However, a direct interaction between RSV 
particles and TLR4 has not been shown, and evidence pertaining to the ability of RSV to elicit a TLR4-
dependent immune response is contradictory [34]. Additionally, TLR2 receptor complexes, which are 
also typically extracellular and associated with bacterial PAMP recognition, have been demonstrated 
to localise to endosomes and induce type I interferon (IFN) responses [35], with the TLR2/6 complex 
recognising RSV and activating a subsequent immune response [36].  Viruses which avoid 
recognition by TLRs, for example by entering epithelial cells by direct membrane fusion rather than 
via endosomes, can be recognised by RLRs which are present throughout the cytosol.  RIG-I is 
activated by short dsRNA (up to 1kb), with the presence of a 5′-triphosphate end greatly enhancing 
the induction of type I IFNs, and it is important in the immune response to many RNA viruses [24, 37, 
38].  The related RNA helicase melanoma differentiation-associated gene 5 (MDA5) on the other 
hand interacts with polyinosinic polycytidylic acid (polyI:C) and long dsRNA (more than 2kb), and is 
crucial in the recognition of picornaviruses [24, 39, 40].  Additionally, the cytosolic NLR NOD2, whilst 
normally associated with the recognition of bacterial muramyl dipeptide, has also been 
demonstrated to be involved in the recognition of the ssRNA genome of RSV [41].   Despite 
differences in viral genomes, replication strategies, and the types of PRRs activated, common 
signalling pathways are utilized.  Thus recognition of viral pathogens elicit conserved outcomes, with 
the interferon regulatory factor (IRF)-mediated production of type I IFNs a central feature, along 
with nuclear factor kappa B (NF-κB)- and mitogen-activated protein kinase (MAPK)- mediated 
regulation of various inflammatory cytokines [29, 42] (Figure 1.1). 
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Figure 1.1: Pathogen recognition receptor signalling following viral infection.  Ligand-induced dimerisation 
occurs following PAMP recognition by endosomal TLRs, with TLR7/8 forming a heterodimer, and the rest 
forming homodimers.  This engages the Toll-IL-1 receptor (TIR) domains present in each TLR to initiate adaptor 
molecule recruitment and signal transduction.  MYD88-dependent signalling results in the formation of an 
IRAK/TRAF6 complex, with TRAF6 subsequently becoming ubiquitinated and activating a complex of TAK1 and 
TAB2/3.  This complex phosphorylates NEMO to activate the IKK complex, which results in the phosphorylation 
and degradation of IκBα, leaving NF-κB free to translocate into the nucleus where it drives the transcription of 
pro-inflammatory cytokine genes.  Simultaneously, TAK1 activates MAPK cascades, resulting in the activation 
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of AP-1 and CREB which drive further transcription of pro-inflammatory cytokines.  TRIF-dependent signalling 
following endosomal TLR3 ligation can also activate NF-κB, AP-1 and CREB via recruitment of TRAF6 and RIP1.  
Alternatively, TRAF3 is recruited, which requires NAP1 and SINTBAD to activate TBK1/IKKε.  This results in the 
phosphorylation of IRF3 which translocates into the nucleus to induce expression of type I IFNs.  TLR7/8 and 
TLR9 initiated recruitment of the TRAF/IRAK/IKKα complex can also phosphorylate IRF7.  IRF7 thus translocates 
into the nucleus and causes the transcription of type I IFN genes.  Upon dsRNA recognition, RIG-I and MDA5 
interact with IPS-1 localized on the mitochondrial membrane through homophilic interactions between their 
CARD domains.  This allows IPS-1 to interact with TRADD and form a complex with FADD and caspase 8/10 to 
activate NF-κB.  Additionally, TRADD can interact with TRAF3 to activate TBK1/IKKε, resulting in the 
phosphorylation and translocation of IRF3 to induce production of type I IFNs.  Similarly, upon recognition of 
ssRNA by NOD2, CARD domains interact with IPS-1 localized on the mitochondrial membrane, thus facilitating 
interaction with TRAF3 to activate TBK1/IKKε and result in transcription of type I IFN genes.  The type I IFNs 
produced bind to their receptor, thus activating the associated TYK2 and JAK1 molecules and resulting in 
phosphorylation of STAT1 and STAT2.  The STAT1/STAT2/IRF9 complex (ISGF3: IFN-stimulated gene factor 3) 
translocates to the nucleus and binds to IFN-stimulated response elements (ISREs) in the DNA to initiate gene 
transcription.  STAT1 homodimers translocate and bind to GAS (IFNγ activated site) elements in the promoter 
region of ISGs, initiating transcription of these genes. 
 
Abbreviations used: AP-1: activator protein 1; CARD: caspase recruitment domain; CpG: cytosine phosphate guanine; CREB: cyclic 
adenosine monophosphate (cAMP)  responsive element-binding protein; ds: double-stranded; FADD: FAS associated death domain; GAS: 
IFN-γ activated site; IFN: interferon; IFNAR1: IFN alpha receptor 1; IκBα: nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor alpha; IKK: inhibitor of NF-κB kinase; IPS-1: IFN-β promoter stimulator 1; IRAK: interleukin-1-receptor-associated kinase 1; IRF: 
interferon regulatory factor; ISG: interferon stimulated gene; ISGF3: interferon-stimulated gene factor 3; ISRE: interferon stimulated 
response element; JAK: janus kinase; JNK: c-jun N-terminal kinase; LRR: leucine rich repeat; MAPK: mitogen activated kinase-like protein; 
MDA5: melanoma differentiation-associated protein kinase; MYD88: myeloid differentiation primary response 88; NAP: NF-κB activating 
kinase (NAK)-associated protein; NEMO: NF-κB essential modulator; NF-κB: nuclear factor kappa B; NOD: nucleotide-binding 
oligomerisation domain; PAMP: pathogen-associated molecular pattern; PRR: pattern recognition receptor; RIG-1: retinoic acid-inducible 
gene-1; RIP1: receptor interacting protein; SINTBAD: similar to NAP-1 TBK adaptor; ss: single-stranded; STAT: signal transducer and 
activator of transcription; TAB: TGF-β activated kinase; TAK: TGF-β activated kinase; TANK: TRAF family member associated NF-κB 
activator; TBK: TANK-binding kinase; TIR: Toll/IL-1 receptor; TLR: Toll-like receptor; TRADD: TNF receptor associated death domain; TRAF: 
TNF receptor associated factor; TRIF: TIR-containing adaptor inducing IFN-β; TYK: tyrosine kinase.  Circled P’s represent phosphorylation.      
           
 
 
 
Upon PAMP-PRR interaction and the activation of signalling transduction pathways, the type I IFNs 
(IFN-α and IFN-β) are some of the earliest cytokines to be produced.  Their transcription and 
subsequent binding to the IFN receptor induces expression of a variety of interferon-stimulated 
genes (ISGs), with their products altering antiviral and immunomodulatory actions to limit and clear 
infection [42].  Features of the induced anti-viral state include resistance to viral replication in all 
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cells, induction of apoptotic cell death in infected cells, increased major histocompatibility complex 
(MHC) class I expression to enhance antigen presentation, activation of dendritic cells (DCs) and 
macrophages, and stimulation of natural killer (NK) cells to enhance their cytolytic activity [43].  The 
inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-12 are also produced at an early stage of the innate 
immune response.  These cytokines promote leukocyte extravasation by increasing endothelial 
expression of adhesion molecules such as ICAM-1 and VCAM-1, increase vascular permeability, 
induce synthesis of acute phase proteins, and contribute to recruitment and activation of cells of the 
adaptive immune response.  Additionally, IL-1β and TNF-α amplify the inflammatory response by 
triggering further NF-κB and MAPK activation [44].  PRR signalling also results in chemokine 
production, with IL-8, CXCL9 / 10 and IL-15 recruiting neutrophils and NK cells respectively [45, 46]. 
While neutrophils are the most rapidly recruited cells to the site of infection during the innate 
immune response and have a well established role in bacterial infections, their function in antiviral 
immunity is less clear and is likely to be minimal, with inhibition of neutrophil recruitment to the 
lung demonstrated to have no effect on the course of influenza infection [47].  
 
PRR signalling also facilitates the maturation and trafficking of dendritic cells, with the release of the 
chemokines CCL2 and CCL20, and increased expression of CCR7 [48, 49].  Thus, around 72 hours 
after infection, DCs with antigen-MHC complexes migrate through the afferent lymph vessels to 
secondary lymph nodes where they form interactions with naive CD4+ and CD8+ T lymphocytes.  
These T-lymphocytes are activated, proliferate, differentiate into effector T-cells and migrate via 
efferent lymph vessels into the circulation.  Multiple chemokines, such as CCL3, CXCL9 and CXCL10, 
are expressed in the respiratory epithelium and result in changes in integrin affinity, allowing 
effector T-cells to bind to the endothelium and migrate into the infected tissue [29, 50-53].  For 
efficient and effective viral clearance Th1 effector T-cells are required, which produce IL-2, TNF-α 
and IFN-γ to activate NK cells and induce generation of cytolytic molecules.  CD8+ effector T-cells and 
NK cells can then induce apoptosis of infected cells via the release of cytolytic granules or by direct 
interaction between surface Fas receptor and Fas ligand (FasL) [29].  B-cells have also been 
demonstrated to play an important role in the immune response to highly pathogenic viral 
infections.  Contact between CD4+ T-cells and naive B-cells in secondary lymphoid tissues results in 
their proliferation and antibody class-switching, with neutralizing virus-specific antibodies crucial for 
optimal viral clearance [29, 54, 55].  Combined, these effector mechanisms of the adaptive immune 
response rapidly clear the viral infection.   
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1.3 Immune response to bacterial respiratory infection 
 
Similarly to viruses, when bacterial respiratory pathogens are inhaled they are recognised by PRRs 
on the respiratory epithelial surface.  TLR2, which forms heterodimers with TLR1 and TLR 6 and 
requires the cofactor CD14, is a key receptor in recognising PAMPs from both S.pneumoniae and 
H.influenzae, two major respiratory bacterial pathogens.  As well as its extracellular location, TLR2 
receptor complexes are also found in endosomes [35, 56], whereby they induce type I IFN 
production, allowing recognition and immune response to viruses.  This internalisation may also be 
important in the innate immune response to bacteria, with the endosomal complex of TLR2/6 and 
CD14 involved in the recognition and subsequent immune response to lipoteichoic acid (LTA) and 
Listeria monocytogenes infection [57, 58], although other studies have demonstrated that bacterial 
ligands are unable to stimulate type I IFN production [59].  Similarly, TLR4 is found both on the 
plasma membrane and in endosomes, eliciting different signal transduction pathways in each 
location [60].  The LPS found in the outer membrane of Gram-negative bacteria such as H.influenzae 
is the major ligand of TLR4, requiring association with the recognition protein MD2 and the cofactor 
CD14 for ligation and subsequent signalling, with CD14 also involved in the internalisation of the 
TLR4 receptor complex [61].  The LPS-induced trafficking of TLR4 to endosomes may be an important 
factor in limiting the immune response to LPS and thus avoiding septic shock [62], and also in 
modulating the immune response by reducing NF-κB- and MAPK-induced chemokine production, 
neutrophil infiltration and tissue damage [63].  Additionally, TLR9 and TLR3, which are traditionally 
thought of as PRRs for viruses, may have a role in the innate immune response to bacteria, with the 
unmethylated CpG DNA (DNA containing motifs of cytosine followed by guanine) of S.pneumoniae 
demonstrated to be a ligand for TLR9 [64], and TLR3 demonstrated to be located on the surface of 
epithelial cells, away from its normal niche of endosomes, from where it has been shown to be able 
to recognise H.influenzae [65].  Cytosolic NLRs may also play a role in respiratory microbial 
recognition, either by direct sensing of intracellular bacterial PAMPs, or by PAMPs that are 
transported into the cytoplasm by type III or IV secretion systems [66].  NOD2 is primarily expressed 
in antigen-presenting cells (APCs) and recognises muramyl dipeptide (MDP), the largest component 
of the peptidoglycan (PGN) bacterial cell wall, while NOD1 is ubiquitously expressed and recognises 
γ-D-glutamyl-mesodiaminopimelic acid (iE-DAP), another substructure of peptidoglycan [66, 67].  
NOD-mediated NF-κB activation has been shown to be essential in the protection against 
S.pneumoniae [68], and the respiratory bacteria P.aeruginosa, S.aureus and M.tuberculosis have also 
all been demonstrated to be detected by NOD 1 or NOD2 [69-72].   
 
21 
 
As with viral infection, PRR ligation by bacterial PAMPs initiates signal transduction pathways, 
resulting in the activation of downstream transcription factors (Figure 1.2).  The inflammatory 
cytokines produced following MAPK and NF-κB activation are central in the innate immune response 
to respiratory bacteria.  While typically associated with their crucial role in the immune response to 
viruses, as previously described, type I IFNs can also be produced in response to bacterial infection, 
with actions such as IFN-β-mediated macrophage production of cytokines and nitrogen radicals 
demonstrated to be important in host resistance to various bacterial species [73, 74].   
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Figure 1.2: Pathogen recognition receptor signalling following bacterial infection.  Ligand-induced dimerisation 
occurs following PAMP recognition by TLRs, with the TLR4/MD2 complex forming a homodimer, and TLR 2 
forming heterodimers with either TLR1 or TLR6.  This engages the Toll-IL-1 receptor (TIR) domains present in 
each TLR to initiate adaptor molecule recruitment and signal transduction.  MYD88-dependent signalling 
results in the formation of an IRAK/TRAF6 complex, with TRAF6 subsequently becoming ubiquitinated and 
activating a complex of TAK1 and TAB2/3.  This complex phosphorylates NEMO to activate the IKK complex, 
which results in the phosphorylation and degradation of IκBα, leaving NF-κB free to translocate into the nucleus 
where it drives the transcription of pro-inflammatory cytokine genes.  Simultaneously, TAK1 activates MAPK 
cascades, resulting in the activation of AP-1 and CREB which drive further transcription of pro-inflammatory 
cytokines.  TLR ligation can also induce translocation of TLR4 homodimers and TLR2 heterodimers to the 
endosome.  TLR4 TRIF-dependent signalling can activate NF-κB, AP-1 and CREB via recruitment of TRAF6 and 
RIP1.  Alternatively, TRAF3 is recruited, which requires NAP1 and SINTBAD to activate TBK1/IKKε.  This results in 
the phosphorylation of IRF3 which translocates into the nucleus to induce expression of type I IFNs.  Endosomal 
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TLR2/6 and TLR2/1 signalling have been demonstrated to facilitate phosphorylation of IRF7 and IRF3 and 
subsequent transcription of type I IFN genes, but the intermediary signalling components are currently 
unknown. Upon recognition of bacterial PAMPS, the CARD domains of NOD2 and NOD1 interact with RICK, 
which in turn is able to activate MAPK signalling, activate NF-κB via the TAK1 TAB2/3 complex, and recruit 
TRAF3 to activate TBK1/IKKε and induce transcription of type I IFN genes.    
 
Abbreviations used: AP-1: activator protein 1; CARD: caspase recruitment domain; CREB: cyclic adenosine monophosphate (cAMP)  
responsive element-binding protein; iE-DAP: γ-D-glutamyl-mesodiaminopimelic acid; IFN: interferon;  IκBα: nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor alpha; IKK: inhibitor of NF-κB kinase; IRAK: interleukin-1-receptor-associated kinase 1; IRF: 
interferon regulatory factor; ISG: interferon stimulated gene; ISRE: interferon stimulated response element; JNK: c-jun N-terminal kinase; 
LPS: lipopolysaccharide; LRR: leucine rich repeat; MAPK: mitogen activated kinase-like protein; MD2: myeloid differentiation protein-2; 
MDP: muramyl dipeptide; MYD88: myeloid differentiation primary response 88; NAP: NF-κB activating kinase (NAK)-associated protein; 
NEMO: NF-κB essential modulator; NF-κB: nuclear factor kappa B; NOD: nucleotide-binding oligomerisation domain; PAMP: pathogen-
associated molecular pattern; PRR: pattern recognition receptor; RICK: receptor-interacting CARD-containing serine/threonine kinase (also 
known as RIP2 or CARDIAK); RIP1: receptor interacting protein; SINTBAD: similar to NAP-1 TBK adaptor; TAB: TGF-β activated kinase; TAK: 
TGF-β activated kinase; TANK: TRAF family member associated NF-κB activator; TBK: TANK-binding kinase; TIR: Toll/IL-1 receptor; TIRAP: 
TIR domain containing adaptor protein; TLR: Toll-like receptor; TRAF: TNF receptor associated factor; TRAM: TRIF-related adaptor 
molecule; TRIF: TIR-containing adaptor inducing IFN-β.  Circled P’s represent phosphorylation.      
 
 
 
 
 
Many of the key processes in the immune response against bacteria are the same as with viruses: 
after PRR ligation and signal transduction, pro-inflammatory cytokines are released, chemokines 
attract immune cells to the site of infection, vascular permeability is increased and sentinel 
macrophages and DCs are activated.  However, there are some key differences in the course of the 
immune response to the two classes of respiratory pathogens.   
 
Bacteria may remain extracellular, and can thus be targeted by antibodies, complement proteins and 
phagocytosis.  Neutrophils and macrophages are vital in the innate response to microbes, as both 
can phagocytose and degrade pathogens.  In addition to this, neutrophils can release cytokines such 
as IL-18 to activate NK cells, and can form neutrophil extracellular traps (NETs) to bind and destroy 
bacteria [75, 76].  Macrophages can produce antimicrobial peptides (AMPs) such as LL-37, and TNF-α 
which is very important in orchestrating the immune response to microbes, as it stimulates acute-
phase protein (APP) synthesis by the liver, as well as enhancing leukocyte migration from the blood, 
activating endothelial cells to trigger blood clotting and containment of infection, stimulating DC 
maturation, and stimulating IL-1 and IL-6 production [77].   
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The acute phase response is the process by which the concentration of plasma proteins increases 
during the inflammatory state.  Notably, lactoferrin sequesters iron to deplete this essential nutrient 
for bacterial utilisation, and also has bactericidal activities on direct contact with microbes [78].  
Other APPs include C-reactive protein and mannose-binding lectin, which can bind to the bacterial 
surface and then associate with the protein C1q, thus initiating the complement cascade.  
Complement can also be activated directly via the pathogen surface, but all pathways ultimately 
result in release of inflammatory mediators, opsonisation of pathogens, and formation of a 
membrane-attack complex which disrupts the lipid bilayer of the bacteria and results in its eventual 
destruction [79].   
 
Similarly to complement proteins, antibodies can opsonise pathogens and facilitate phagocytosis.  
They are produced by activated plasma cells, which are the effector B-cells produced after 
interaction with T-cells, or sometimes after direct binding to certain bacterial surface molecules.  
Antibodies also initiate antibody-dependent cell-mediated cytotoxicity (ADCC), whereby CD16 on NK 
cells recognises the Fc portion of antibodies bound to the bacterial surface and kills the target cell.        
 
S.pneumoniae, H.influenzae and M.catarrhalis are classically thought of as extracellular pathogens, 
but have all been shown to be able to invade cells and survive intracellularly to cause infection [80-
83].  As such, the cytotoxic response of T lymphocytes and NK cells is relevant in bacteria, as well as 
viruses. 
 
 
1.4 Bacterial colonisation of the respiratory tract 
 
Both colonization and infection first require adherence to the epithelial surface of the respiratory 
tract.  S.pneumoniae has a polysaccharide capsule, reducing entrapment by mucus and inhibiting 
opsonophagocytosis, thus enabling access to the epithelium.  The capsule, while effectively 
preventing an immune response being mounted against the pathogen, also inhibits adherence, as 
the adhesins are hidden on the cell wall.  Thus, phase variation occurs between the opaque and 
transparent (thinner capsule) forms of the bacteria and once the cell wall is exposed, adherence can 
occur.  Many host receptors and bacterial components have been implicated in this, and it has been 
suggested that the initial contact occurs via non-specific physicochemical interactions and 
pneumococcal surface adhesion A (PsaA) binding to N-acetyl-glycosamine on resting epithelial cells.  
In non-encapsulated bacteria, such as nontypeable H.influenzae, adherence is achieved via various 
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adhesins, such as those associated with fimbriae.  Due to the lack of a protective capsule, innate 
clearance must be avoided, and this is achieved by mechanisms such as secreting IgA proteases and 
phase variation, which allows selection of the most suitable derivative for the immediate 
environment [84].    This initial colonization is asymptomatic, and is usually cleared by the immune 
system, however, the epithelium can be altered by the local generation of inflammatory factors to 
have different types and numbers of receptors on their surface.  Via the binding of bacterial cell-
surface proteins such as phosphorylcholine (ChoP) to the platelet-activating-factor receptor (Pafr), 
internalisation can occur, resulting in invasive infection [85, 86].  Other epithelial receptors 
implicated in respiratory bacterial adhesion include polymeric immunoglobulin receptor (pIgR), 
ICAM-1 and carcinoembryonic adhesion molecule 1 (CEACAM1) [87-89]. 
 
The upper respiratory tract is a dynamic environment, with constant turnover and acquisition of new 
strains of bacteria.  While some are pathogenic and invade the epithelium to cause disease, some 
bacteria remain on the surface of the epithelium resulting in long-term asymptomatic colonization.  
As such, the upper respiratory tract acts as a reservoir for a diverse range of commensals and 
potentially pathogenic bacteria (termed pathobionts), including S.pneumoniae, H.influenzae and 
M.catarrhalis, resulting in a complex microbial community [90].  The microbiome can offer 
protection to the host from invading pathogens by colonization resistance, whereby competition for 
sites of attachment and nutrients limits infection.  It has also been implicated in controlling 
maturation and regulation of the immune system, by promoting immune homeostasis, aiding the 
development of secondary lymphoid tissues, contributing to IgA and antimicrobial peptide 
production, and mediating correct inflammasome activation  [91, 92].   However, when the balance 
of the microbiome is disrupted it can contribute to acquisition and increased carriage of pathogenic 
bacteria and viral co-infections, resulting in overgrowth and invasion of bacterial pathogens and the 
driving of inflammation and disease [90].      
 
Microbial secretion systems enable a dynamic exchange of molecules, thus facilitating host-bacterial 
interactions, whether beneficial or harmful.  In the gut for example, the bacterial type VI secretion 
system (T6SS) of the pathobiont Helicobacter hepaticus has been demonstrated to limit colonization 
and inflammation by shaping an immunologically tolerant environment.  Therefore, a non-
pathogenic state is actively maintained, promoting a long-term balanced symbiotic relationship 
between microbe and host.  However, disturbances in interactions such as these can promote 
inflammation, with dysbiosis associated with inflammatory disorders such as inflammatory bowel 
disease (IBD) [93].  The exact mechanisms by which these disturbances occur and homeostasis is 
disrupted are unclear, although it has been demonstrated that antibiotic use can disrupt the gut 
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microbiota and result in inflammasome activation by resident pathobionts, thus leading to 
inflammatory disease [94].  While the majority of research into the microbiota has been carried out 
in the gut, similar relationships are likely to exist in the respiratory tract with related mechanisms 
driving dysbiosis and pathobiont-related disease.  Additionally, the gut microbiota has been 
implicated in diseases at distant sites, with a role emerging in atopic diseases such as eczema, 
allergic rhinoconjunctivitis and asthma due to its effects on perinatal programming [95, 96], 
suggesting that the gut microbiome could directly influence diseases of the respiratory tract.  
 
Viruses are also commonly found in the upper respiratory tract of asymptomatic individuals, adding 
to the reservoir of commensals and pathobionts present there [97].  Collectively, this niche of 
potential viral and bacterial pathogens has been implicated in host-to-host transmission, thus 
demonstrating the importance of asymptomatic carriage [98].  While the mechanisms underlying 
how and why asymptomatic pathobiont colonization can result in infectious disease are unclear, the 
microbiome is likely to be an important component in respiratory diseases. 
 
 
1.5 Dual viral and bacterial infections of the respiratory tract 
 
Viral infections are commonly seen to predispose patients to an increased incidence and severity of 
secondary bacterial infections.  The catastrophic influenza A pandemic of 1918 was the origin of the 
theory of viral-bacterial synergism, with many of the 40-50 million deaths attributable to bacterial 
pneumonia [99].  Influenza A, RSV, rhinovirus, parainfluenza, coronavirus and adenovirus infections 
have all been shown to predispose to bacterial infections, with S.pneumoniae, H.influenzae and 
S.aureus being increased most often [88, 100-103].  Additionally, mouse models have suggested that 
this viral predisposition to bacterial infection not only occurs during simultaneous infection, but can 
also take place a week after initial infection, and even after full recovery of viral infection [90, 104, 
105].  The synergism between virus and bacteria also varies in a species- and cell type- dependent 
manner, with influenza A and S.pneumoniae being the most commonly associated pathogens with 
dual infections [106].   
 
S.pneumoniae is commonly involved in causing invasive diseases such as pneumonia, meningitis and 
sepsis, and is part of the commensal flora of the upper respiratory tract, creating a carrier state of 
asymptomatic colonization.  The mechanisms by which asymptomatic colonization of the respiratory 
tract can lead to invasive and often life-threatening disease are largely unknown, but the potential 
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role of viruses has been investigated extensively.  It has been postulated that viral infections can 
facilitate bacterial infection by up-regulating expression of epithelial receptors, impairing mucociliary 
function, altering host immune responses, damaging the epithelial layer and by facilitating direct 
binding to viral glycoproteins [88, 89, 106].  Additionally, influenza virus has been demonstrated to 
impair the ability to tolerate tissue damage, with co-infected lungs presenting with a greater degree 
of airway epithelial necrosis, resulting in increased mortality [107].  IL-10 has also been implicated in 
precipitation of dual infections, with primary influenza infection associated with elevated levels of IL-
10 in the lungs and reduced neutrophil function, resulting in greater susceptibility to secondary 
S.pneumoniae infection, enhanced bacterial outgrowth and increased lethality [105].  Finally, it has 
been demonstrated in COPD patients that rhinovirus infection results in an outgrowth of 
H.influenzae from the existing microbiota, thus precipitating secondary bacterial infections [108].  It 
is likely that a combination of all of these factors contributes to the synergism experienced between 
virus and bacteria, but most focus has been directed towards the increased expression of the 
epithelial receptors required for bacterial adhesion and colonization. 
 
PafR has been shown to be a receptor for S.pneumoniae and H.influenzae, the two most common 
bacterial respiratory pathogens, and its expression has been shown to be increased by RSV, RV-14, 
influenza and coronavirus infections [88, 101, 102].  One possible mechanism by which viral infection 
increases the expression of PAF-r is via the transcription factor NF-κB which is activated in epithelial 
cells after viral recognition [102, 109].  The expression of the bacterial receptors pIgR, CEACAM1 and 
ICAM-1 have also been shown to be increased by NF-κB activation [87, 110, 111], suggesting that 
this may be a common mechanism for all virus-induced up-regulation of bacterial adhesion.  
 
While viral-bacterial co-infections are the most commonly implicated in increased morbidity and 
mortality, dual bacterial infections can also occur.  Co-colonization can be promoted, with, for 
example, M.catarrhalis releasing membrane blebs containing ubiquitous surface proteins which can 
deactivate complement factor C3 and thus protect H.influenzae from complement-mediated killing 
[90, 112].  Additionally, bacterial infections have been shown to increase susceptibility to viral 
infections, with H.influenzae stimulating ICAM-1 expression to provide a receptor for rhinovirus 
[113], a disturbed balance in the microbiota creating opportunity for viral infection, and the viral 
utilization of the microbial environment to escape immune clearance [114].  Therefore, respiratory 
viruses and microbiota may influence each other to affect the pathogenicity and development of 
infection, as has already been demonstrated in the gut [90, 115].   
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Finally, dual viral infections have also been implicated in increased disease severity and higher rates 
of hospitalization and mortality, with rhinovirus, influenza viruses, RSV and adenoviruses the most 
common pathogens [116-118].  However, this is still under debate, with many studies showing no 
effect [119, 120], or even a protective effect of dual viral infections [121].     
 
Therefore, dual infections may result in more severe disease and thus a greater rate of 
hospitalization and mortality.  As such, the mechanisms by which viral and bacterial species 
predispose to infection by other pathogens may be an important determinant in the frequency and 
severity of respiratory disease. 
 
 
1.6 Determinants of vulnerability to respiratory tract infections 
 
While acute respiratory tract infections are a burden in terms of morbidity and economics in 
otherwise healthy immunocompetent individuals, hospitalization and mortality rates are relatively 
low [122-125].  However, certain populations are more vulnerable to contracting acute respiratory 
tract infections and more prone to the associated complications, resulting in higher mortality rates.  
For example, HIV-positive children have been shown to have a higher disease burden and mortality 
rate associated with lower respiratory tract infections [126, 127], rhinovirus infections have been 
associated with considerable morbidity and mortality in myelosuppressed adult cancer patients 
[128], crisis-affected populations have been demonstrated to have high excess mortality due to 
acute respiratory infections [129], and high levels of air pollution and urban particulate matter have 
been linked with respiratory tract infection-associated mortality, showing enhanced pneumococcal 
adhesion to human epithelial cells [130, 131].  Additionally, vaccine and antibiotic use can disrupt 
the microbiome and alter susceptibility to infection.  For example, the widespread use of 
pneumococcal conjugate vaccines has been demonstrated to increase incidence of M.catarrhalis and 
H.influenzae infections [132-134], and antibiotics decrease microbial diversity, which is associated 
with Pseudomonas aeruginosa colonization in cystic fibrosis patients, and an attenuated immune 
response to influenza virus in mouse models [92, 135, 136].  Thus there are many examples of such 
vulnerable populations, but this study will just be focussing on people with asthma or COPD, and 
older adults living in sheltered accommodation. 
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1.6.1 Asthma and COPD 
 
Asthma is defined as a chronic respiratory condition caused by inflamed and hypersensitive bronchi 
which become easily irritated, causing periodic bronchoconstriction [137, 138].  Chronic obstructive 
pulmonary disease is the term now used to encompass emphysema and chronic bronchitis, and is 
defined as chronic airway obstruction due to chronic inflammation caused by airway and 
parenchymal damage, usually as a result of cigarette smoking [139].  While asthma is a disease 
typically consisting of reversible airway obstruction, involving eosinophil and Th2 cell infiltration into 
the airway submucosa, in COPD airway obstruction is classically irreversible, with higher numbers of 
neutrophils in the airway lumen and increased numbers of macrophages and CD8+ T-cells in the 
airway wall [140].  Both diseases have characteristic mucus hypersecretion, and airway obstruction, 
remodelling and hyperresponsiveness, but the clinical course is also intermittently punctuated by 
episodes of acute worsening of symptoms known as exacerbations.  As well as dyspnea, cough, 
wheezing and chest tightness, exacerbations in COPD are also accompanied by increased sputum 
volume and purulence and general fatigue, and such events alter the progression of the disease by 
accelerating the decline in lung function [141].  In 2004 it was estimated that 7% of the UK 
population suffered from asthma, with the disease causing 3 deaths every day and costing the UK 
over £2.3 billion every year [142].  Worldwide, asthma is thought to affect 300 million individuals 
[143].  COPD is also a major public health problem, and is the fourth most common cause of death 
worldwide.  It was estimated to affect 5% of the UK population in 2000, costing the NHS £800 million 
every year [144].  Thus both diseases are a major burden in terms of morbidity, mortality and 
economics, with exacerbations being the major cause of hospitalisations and deaths. 
 
 
1.6.2 Asthma and COPD exacerbations 
 
Exacerbations in asthma and COPD can be caused by pollutants, with exacerbations in asthmatics 
additionally able to be caused by allergens and cold air, but most are precipitated by respiratory 
viruses [145].  While bacterial infections are also found in a significant number of COPD 
exacerbations, with lower airway colonization correlated to disease and exacerbation severity, they 
are also common in stable COPD, suggesting they are not the only causative trigger for 
exacerbations, and frequently there is found to be co-infection with respiratory viruses [146].  
However, the acquisition of new strains to the dynamic niche of colonized bacteria in the respiratory 
tract has been demonstrated to result in exacerbations [147].  The most prevalent exacerbation-
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precipitating pathogens are rhinoviruses, but RSV, influenza, coronaviruses, H. influenzae and 
S.pneumoniae are also commonly implicated [148, 149].   
 
The respiratory viruses implicated in exacerbations have a range of complexities.  Group V contains 
negative-sense, single-stranded RNA viruses, and includes the families Paramyxoviridae and 
Orthomyxoviridae.  The Paramyxoviridae family can be split into 2 sub-families: paramyxovirinae, 
containing parainfluenza viruses, and pneumovirinae, containing metapneumovirus and RSV.  These 
viruses all have a genome of 15 – 19 kilobases, and are enveloped.  Similarly, the Orthomyxoviridae 
family, containing Influenzaviruses A, B and C, is made up of viruses with a genome of 13kb which 
are enveloped.  Group IV, on the other hand, contains positive-sense, single-stranded RNA viruses, 
and includes the families Coronaviridae and Picornaviridae.  The coronavirinae subfamily of the 
Coronaviridae family contains 3 types of coronavirus, as well as the SARS (severe acute respiratory 
syndrome) coronavirus, all of which are enveloped and have a very large 30kb genome.  In 
comparison, the enterovirus genus in the Picornaviridae family, contains all three rhinovirus species, 
which are very small (7.5kb), non-enveloped viruses [150].  The differences between these 
respiratory viral species can potentially affect the immune response generated against them and the 
severity of symptoms caused in infected people, with, for example, non-enveloped viruses hardier 
and able to survive for longer periods of time, smaller viruses associated with more frequent 
outbreaks of disease, and larger viruses associated with a higher fatality rate [151, 152].       
 
Additionally, within the genus enterovirus there are a number of rhinovirus species.  More than 100 
rhinovirus serotypes have been discovered, which are divided into major and minor groups based on 
their receptor usage, and into A and B groups based on antiviral sensitivity and nucleotide sequence 
[153].  Additionally, there are a further 50 – 60 more recently discovered species that have been 
defined as group C rhinoviruses, based on sequence data alone [153, 154].  These newly discovered 
group C rhinoviruses (HRV-C) have been demonstrated to account for the majority of asthma attacks 
in children presenting to hospital, causing more severe symptoms than other rhinovirus groups or 
other respiratory viruses [155, 156].  Group C rhinoviruses have also been associated with atopy, 
with hospital admission due to HRV-C infection increased in atopic subjects, but this interaction not 
observed for other rhinovirus species [157].  Therefore, group C rhinoviruses are likely to be a very 
important cause of asthma and COPD exacerbations, as well as having implications in atopic 
diseases, which includes certain phenotypes of asthma.      
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However, in spite of the burden they cause for people with asthma and COPD, the mechanisms 
behind virus-induced exacerbations are incompletely understood, and are likely different for the 
diverse range of pathogens which can cause them.   
 
 
1.6.2.1 Exacerbation susceptibility 
 
It is unclear whether sufferers of asthma and COPD are more susceptible to viral infections, and also 
why such individuals react differently to these pathogens compared to healthy people.  In asthma 
there is no evidence for an increased risk of contracting a respiratory viral infection, but once 
infected it is more likely to reach the lower respiratory tract, resulting in more severe and longer-
lasting symptoms [158].  In COPD exacerbation frequency increases with increased severity of the 
disease [159, 160], while it has also been suggested that a subgroup of patients may have a distinct 
phenotype of exacerbation susceptibility, independent of GOLD stage, suggesting an underlying 
intrinsic susceptibility to exacerbation-causing triggers such as viral infection [160].  E1A protein 
from latent adenovirus infection, which is common in COPD, has been shown to increase ICAM-1 
expression [161, 162], the main receptor for rhinoviruses, thus suggesting that COPD sufferers may 
be more susceptible to viral infection.  Also, airway epithelial cells cultured from COPD patients have 
been demonstrated to have defective anti-viral responses, with disproportionate cytokine 
production, a compromised epithelial barrier, impaired mucociliary clearance, and high viral load 
[163].  In addition to this, COPD patients commonly have bacterial colonisation of their lower 
airways, partly due to the effects of cigarette smoking on epithelial cilia and mucus production, and 
together these factors may further increase ICAM-1 expression and alter the immune response to 
any viruses that may enter the airways [113, 164, 165].  Finally, it has been suggested that the 
respiratory microbiome of people with asthma and COPD may differ from healthy people, with a 
reduction in Bacteroidetes, and specifically Prevotella spp. which have been shown to directly inhibit 
the growth of other bacteria, and an increase in Proteobacteria, especially Haemophilus spp. [143].  
Whether this difference is a consequence of having a chronic respiratory disease such as asthma or 
COPD, or the result of previous antibiotic usage, remains to be shown.  Additionally, this altered 
respiratory microbiome could play a role in the susceptibility to infection or be a causative 
mechanism for asthma or COPD, but this is also yet to be determined.   
 
Therefore it seems that COPD patients may be more susceptible to contracting respiratory viral 
infections, while asthmatics may just experience more severe symptoms. 
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1.6.2.2 Mechanisms of asthma exacerbations 
 
Respiratory viral infections clearly affect asthmatic and COPD sufferers differently to healthy people, 
with a disrupted immune response resulting in more severe disease and longer-lasting symptoms.  
However, the underlying pathology of the two diseases differs markedly, so mechanisms of virus-
induced exacerbations are likely to be different in each disease.   
 
In studies comparing rhinovirus infections in healthy subjects to those with asthma, there have been 
conflicting results regarding the levels of cytokines and chemokines such as CXCL8, IL-1β, IL-6 and IL-
11, in the airways, with some studies showing an increase and some showing no difference [166-
168].  CXCL8 (also known as IL-8) is a chemotactic factor for neutrophils, and these cells have been 
shown to contribute to the increased inflammatory state during asthma exacerbations.  Neutrophils 
release elastase which can damage host tissue, thus increasing airway sensitivity, and proteases 
which induce mucus production, contributing to airway obstruction [169].  IL-11 may also be 
important in virus-induced asthma exacerbations, as it has been shown to be correlated with a 
detectable wheeze in children, and it may directly increase airway responsiveness [170].  Viral 
infections also trigger increased recruitment of eosinophils in both healthy and asthmatic people, 
but in asthmatics this eosinophilia persists for over six weeks after infection [171] which can 
contribute to airway hyper-responsiveness (AHR). 
 
It has also been shown that the innate immune response is deficient in asthmatic people.  IFN-β is 
vital in limiting viral replication and inducing rapid apoptosis of infected cells, but mRNA and protein 
levels of this cytokine induced after viral infection are reduced in asthmatic bronchial epithelial cell 
cultures.  As a result of this, cytotoxic cell death is increased, causing the release of intact viral 
particles and inflammatory mediators, thus further increasing inflammation [172].  This epithelial 
necrosis can also result in exposure of sensory nerve fibres which can be stimulated by the increased 
numbers of irritants and particles able to cross the damaged epithelial barrier, thus increasing AHR 
and altering parasympathetic bronchoconstriction and the production of mediators of 
bronchodilation [170].  In addition to innate effects, the typically Th2 adaptive immune response in 
asthma patients may increase ICAM-1 levels [173], thus enhancing viral entry, and inhibiting the Th1 
response required for viral clearance.  Th2 cytokines have also been shown to further inhibit 
epithelial repair which is characteristic of asthmatics and correlated with AHR [174].  Due to this Th2 
environment, asthmatic subjects produce significantly lower levels of the pro-inflammatory Th1 
cytokines required for viral clearance than healthy subjects, and administering IFN-γ has been shown 
to fail in over-riding these Th2 effects on the airways [170].   
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1.6.2.3 Mechanisms of COPD exacerbations 
 
Fewer studies have been carried out comparing virus-induced infections in COPD patients versus 
healthy controls to characterise the immune response in exacerbations.  COPD is associated with 
mucosal neutrophil infiltration in the lungs and airways, with BAL and sputum samples containing 
increased levels of pro-inflammatory cytokines such as TNF-α and IL-6.  The extent of the 
neutrophilic inflammation and the levels of cytokines present are increased with disease severity, 
relating to a reduced FEV1, and are also amplified during respiratory infection [175].  Exacerbations 
have been suggested to be correlated with NF-κB activation and various cytokines and chemokines 
(TNF-α, CXCL8, epithelial-derived neutrophils attractant (ENA)-78 and CCL5), so these may be central 
components in the augmented inflammatory response experienced.  There are conflicting results 
surrounding which cells contribute to the increased inflammation of COPD exacerbations, with 
neutrophils, lymphocytes and eosinophils implicated.  These cells may release elastase and reactive 
oxygen species, thus causing tissue damage and also stimulating increased mucus production [149]. 
 
 
1.6.3 Existing treatments and prevention of asthma and COPD exacerbations 
 
Treatment for asthma and COPD currently relies on inhaled bronchodilators and corticosteroids, but 
there is no definitive cure for either disease and such therapies are of limited effectiveness in severe 
cases [176].  Additionally, while exacerbation rates can be reduced by them, they are not completely 
prevented [177, 178]. This potentially relates to the observation that corticosteroids are ineffective 
at reducing neutrophilic inflammation, with asthma exacerbations commonly associated with 
neutrophilia rather than the eosinophilic inflammation of stable patients, and likewise COPD 
exacerbations associated with increased neutrophil inflammation [175, 179-181].  In addition to this, 
many people are insensitive to corticosteroids, there is a large amount of non-compliance, 
tachyphylaxis can cause complications, and adverse effects can include oral candidiasis and 
glaucoma [182].   
 
Treatment for the respiratory pathogens commonly associated with asthma and COPD exacerbations 
is also limited.  Vaccines against the common exacerbation-precipitating pathogens are only 
available and routinely administered in the UK against seasonal influenza, S.pneumoniae and 
H.influenzae Type B [183], but not against nontypeable H.influenzae which is more commonly 
implicated in adult respiratory tract infections [184].  The availability of effective antiviral drugs is 
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also limited, with no clinical treatments for rhinoviruses, the main cause of exacerbations, although 
the drug Pleconaril (Schering-Plough) which inhibits viral capsid uncoating to prevent attachment to 
host receptors such as ICAM-1 [185] is currently in its late clinical trials stage [186].  Treatment of 
bacterial infections is better established, but concerns are emerging about clinical efficacy being 
increasingly limited by antimicrobial resistance to antibiotics [187].  In addition to this, antimicrobial 
agents are frequently prescribed for viral infections, and this inappropriate and widespread use has 
contributed to concerns about emerging antimicrobial resistance among bacteria commonly 
involved in respiratory tract infections [185].  As such, new treatments and therapies are much 
needed in the fight against these two diseases, especially in the prevention of exacerbations. 
 
 
1.6.4 Respiratory tract infections in older adults 
 
Elderly adults (typically defined as those older than 65 years of age) are more susceptible to acute 
respiratory tract infections, with prolonged recovery times, increased health-care use, frequent 
complications and increased mortality [188].  The elderly population is also increasing, representing 
the fastest growing population group in the western world, with 9.4 million people in the UK in 2001, 
and 10.4 million in 2011 [189], thus further adding to this burden. 
 
Various respiratory diseases have been shown to be more prevalent in the elderly.  Community-
acquired pneumonia is the leading infectious driver of morbidity and mortality in the elderly, with 
this age-group accounting for 81% of all cases [190].  A study in the USA showed that the mortality 
rate associated with community-acquired pneumonia doubles as age increases from 65, to 69, to 
>90 years old, with an average length of stay in hospital of 7.6 days, and the overall annual hospital 
costs associated with community-acquired pneumonia in the elderly reaching $4.4 billion [191].  
S.pneumoniae is the most common cause, followed by H.influenzae and S.aureus, and infections 
with these bacteria have been shown to occur more frequently in the elderly compared to younger 
age groups [192].   Influenza also impacts the elderly more than other age groups, with increased 
rates of hospitalization and an estimated 85% of influenza-related deaths occurring in this age-group 
in the USA [193].  Collectively in the USA 59,000 deaths are attributed to pneumonia and influenza in 
the elderly every year [194].  While traditionally thought of as a pathogen only affecting young 
children, RSV is also now considered an important cause of disease in the elderly, with a diminished 
Th1 cytokine response to RSV infection seen in this age group, and progression to pneumonia in 2-
7% of infected individuals [195, 196].   
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While the increased rate of hospitalization and fatalities amongst the elderly in the winter months 
associated with influenza is well established, it is emerging that viruses associated with typically mild 
upper respiratory tract infections such as rhinoviruses and coronaviruses may also be associated 
with severe respiratory illnesses in this population [10, 197].  Rhinovirus accounts for 25-50% of 
respiratory illnesses in the elderly, with documented outbreaks resulting in significant morbidity and 
mortality [198, 199]. 
 
Finally, elderly adults living in sheltered accommodation, nursing homes, or residential care homes, 
as well as the staff working in such facilities, are at increased risk of contracting acute respiratory 
tract infections due to the confined space they inhabit.  Outbreaks of such infections can occur year-
round, with studies reporting rates of 0.42 – 1.2 infections per 1000-resident days, and influenza has 
been implicated as the most commonly reported cause of such outbreaks [200-202].  Additionally, 
the management of infectious diseases is often limited in such facilities, with chronic co-morbidities 
potentially obscuring signs of infection, impaired cognition and hearing impeding expression of 
symptoms, and atypical presentation of diseases such as confusion and afebrile infection in elderly 
people [203].    
 
 
1.6.5 Susceptibility to acute respiratory infection in the elderly 
 
Collectively termed immunosenescence, numerous changes in immune response and immune 
regulation have been shown to change with advanced age and may cause this increased 
susceptibility to respiratory tract infections [204].  Neutrophils are more prone to apoptosis, with a 
decreased ability to produce reactive oxygen species and kill phagocytosed organisms [205-207], 
dendritic cells have a decreased ability to present antigens [208], macrophages are less able to 
produce superoxide anion to kill intracellular bacteria [209], NK cells are less capable of cytolytic 
activity [210], T-cells decrease in number with memory T-cell responses waning and a decline in Fas-
mediated T-cell apoptosis [211, 212], there is a shift from Th1 to Th2 cytokine production [213], B-
cell production decreases [214], and antibodies have a lower affinity and avidity for antigens [215].  
Functional changes to the respiratory system also occur in elderly people.  There is a decrease in 
elastic recoil [216, 217], lung compliance increases due to the loss of structural extracellular matrix 
proteins such as elastin and collagen [204], and there is a decline in mucociliary clearance associated 
with microtubular abnormalities [218].   
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In addition to immunosenescence and functional respiratory changes, there is also thought to be 
age-associated inflammation in the lungs of the elderly.  This low-grade chronic inflammatory state 
is due to a combination of underlying medical conditions, cell damage, dysregulation of cellular 
processes and exposure to infectious agents.  It has been demonstrated to cause augmented NF-κB 
levels and also increased expression of PafR and pIgR, thus potentially increasing bacterial adhesion 
in the airways [87].  Dendritic cells from older adults have also been shown to display an enhanced 
level of activation, with spontaneous secretion of pro-inflammatory cytokines such as IL-6 and TNF-
α, and altered cross-talk with epithelial cells [219].  Additionally, as with asthma and COPD patients, 
the elderly appear to have an altered microbiome, which could affect their susceptibility to infection.  
While the respiratory tract has not yet specifically been studied, work emerging from the gut has 
shown that the elderly have a decreased Firmicutes/Bacteroidetes ratio, a reduction in the numbers 
and diversity of protective commensals such as Bifidobacteria, and an increase in colonization of the 
pathobiont Escherichia coli when compared to younger adults [220, 221]. 
 
Underlying factors relating to age and co-morbidities may also play a role in the susceptibility to 
infection in elderly people.  Xerostomia (impaired salivation), a side-effect of many medications, and 
dysphagia (difficulty swallowing) are common in the elderly and can contribute to impaired 
clearance of organisms, thus enabling oropharyngeal colonization which is a risk factor for 
developing pneumonia [204, 222].  Silent aspiration, whereby gastric contents and food enter the 
bronchial tree, is also common in the elderly, and has been associated with chronic bronchiolar 
inflammation and reduced bactericidal activity due to exposure of respiratory epithelial cells to an 
acidic pH [223, 224].  Malnutrition may also be important, with a low body mass index linked to a 
decreased ability to resist infection, hypoalbuminemia shown to be a risk factor for pneumonia, and 
depressed leptin levels associated with impaired bacterial clearance [204, 225-227].         
 
Therefore, a combination of these factors is likely to be what makes the elderly more susceptible to 
respiratory infections, and makes such infections more severe.  However, there is a large amount of 
variability between individuals, and people age at different rates in terms of their fitness, frailty and 
functional impairment [228], with even centenarians having been shown to mount a robust immune 
response to a variety of stimuli [229]. 
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1.6.6 Existing treatments and prevention of respiratory infections in the elderly 
 
As with asthma and COPD exacerbations, treatment of respiratory tract infections in the elderly 
usually consists of symptom-relieving therapies and the use of antibiotics, with which there are 
concerns about emerging resistance.  Annual influenza vaccines and the pneumococcal 
polysaccharide capsule vaccine are also provided to people aged over 65, and while vaccine 
responses tend to be attenuated in the elderly due to waning immune responses, both vaccines 
have been demonstrated to be safe and effective in this age group [204, 230-233].  However, neither 
vaccine protects against all strains of pathogen, vaccine-induced antibodies have been 
demonstrated to wane over time, thus questioning how long these vaccinations offer protection for, 
and the use of the pneumococcal polysaccharide capsule vaccine has also been questioned [204, 
231, 234, 235].   
 
Therefore, an agent that would help in preventing respiratory tract infections in vulnerable 
populations such as the elderly and people with chronic respiratory conditions would be hugely 
beneficial, potentially reducing hospitalizations, morbidity and mortality. 
 
 
1.7 Vitamin D 
 
Vitamin D has long been known to have effects on calcium homeostasis, with the discovery in the 
early 20th Century that rickets (a disease of vitamin D deficiency) could be cured or prevented with 
cod liver oil, exposure to sunlight and food irradiation [236, 237].  Since then much research has 
been focussed on vitamin D, resulting in its reclassification as a steroid, and the discovery of its 
mode of action via metabolism of the active form 1α,25(OH)2D3 (calcitriol) and subsequent binding 
to vitamin D receptors (VDRs).  Vitamin D (cholecalciferol) is acquired from dietary sources, primarily 
oily fish, or from UV-mediated synthesis in the skin, before it is metabolised in the liver to form 
25(OH)D3.  This 25(OH)D3 is the circulating form of vitamin D, with a half-life estimated to range from 
2 weeks to 2 months [238-240], and its serum concentration is used to define vitamin D status.  
Further hydroxylation results in the synthesis of 1α,25(OH)2D3 and ligation of nuclear VDRs, allowing 
subsequent binding to vitamin D responsive elements in promoter regions of specific genes, 
resulting in the repression or induction of gene transcription [241] (Figure 1.3).  The location of the 
VDR was initially thought to be only in the nucleus, but in the 1980s 1α,25(OH)2D3-mediated non-
genomic rapid responses were discovered.  These responses are too fast to be explained by the 
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ligation of nuclear VDRs and subsequent gene transcription, and thus led to the detection of VDRs 
associated with the plasma membrane or its caveolae components [242-244].  Therefore, while the 
VDR is defined as a member of the nuclear receptor superfamily, which, once ligated and 
heterodimerised with RXR, can penetrate the deep groove of DNA and recognise VDREs to alter gene 
transcription of numerous target genes, it also has a number of non-DNA mediated effects.  Ligation 
of these membrane VDRs results in the activation of second messenger systems such as 
phospholipase C, protein kinase C and phosphatidylinositol-3’-kinase (PI3K), thus initiating various 
intracellular effects such as the opening of voltage-gated calcium channels and Ras/MAPK signal 
transduction [244, 245].  A number of non-genomic mechanisms of the VDR have been described 
[246], such as stimulation of tyrosine phosphorylation cascades in muscle cells resulting in the 
formation of complexes between Src and the VDR which can impact contractility and myogenesis 
[247], inhibition of TGF-β-SMAD signal transduction via direct interaction between the 1,25(OH)2D-
ligated VDR and SMAD3 to suppress renal fibrosis [248], and augmentation of glucose-induced 
insulin release from pancreatic beta-cells via non-genomic effects of the VDR on signal transduction 
[249]. 
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(Adapted from Slatopolsky et al.[250], and Parton and Simons [251]) 
Figure 1.3: Metabolism of 1α,25(OH)2D3.  Vitamin D3 is either obtained from dietary sources or UV synthesis, 
before two hydroxylations occur to produce the active metabolite 1α,25(OH)2D3.  TLR ligation can also increase 
levels of CYP27B1, resulting in enhanced 1α-hydroxylation of 25(OH)D3. The 1α,25(OH)2D3 then binds to nuclear 
or membrane vitamin D receptors (VDRs).  Nuclear VDR ligation results in heterodimerization with retinoid X 
receptor (RXR) and binding to vitamin D responsive elements (VDRE) in promoter regions of responsive genes.  
Components of the RNA polymerase II complex are then recruited for induction of gene transcription, or 
transcription is repressed.  Membrane caveolae-associated VDR ligation results in the activation of second 
messenger systems, with one effect being the initiation of Ras/MAPK signal transduction.  Nuclear MAPK 
modulates gene expression and engages in cross-talk with the VDR-RXR-VDRE complex.   
 
Abbreviations used: 1,25(OH)2D: 1,25-dihydroxyvitamin D; 25(OH)D: hydroxyvitamin D; 7-DHC: 7-dehydrocholesterol; CYP: cytochrome 
p450; MAPK: mitogen-activated protein kinase; mitogen-activated protein kinase kinase; Raf: mitogen-activated protein kinase kinase 
kinase; Ras: mitogen-activated protein kinase kinase kinase kinase; RXR: retinoid X receptor; RNA Pol II: RNA polymerase II complex; VRD: 
vitamin D receptor; VDRE: vitamin D responsive element.  
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The detection of VDR abundance throughout the immune system [252], the observation that VDR 
expression is regulated by immune signalling [253, 254], and the detection of CYP27B1 expression by 
immune cells [254-256] has since directed vitamin D research into the area of immunology.  As such, 
multiple observational studies and randomised control trials have looked into the effects of vitamin 
D in various diseases, with associations of low serum 25(OH)D3 levels seen with autoimmune 
diseases [257], cancer [258], cardiovascular disease [259] and respiratory infections [260], and in 
vitro experiments have tried to determine these effects at a cellular level.  However, results have 
been inconsistent and the hypothesised beneficial effects of vitamin D supplementation in these 
important diseases are currently unclear, with a need for further randomised controlled trials [261]. 
 
 
1.8 Association between vitamin D status and asthma and COPD 
 
Many studies have investigated whether there is a causal relationship between vitamin D deficiency 
and asthma, with the two conditions having similar risk factors (such as African American ethnicity, 
inner-city residence and obesity), and both seeing an increase in prevalence in recent decades [262].  
Additionally, it has been observed that 60 – 70% of severe COPD patients have vitamin D deficiency 
[263], but it is unclear whether this deficiency contributes to COPD pathogenesis, or is just a 
consequence of having COPD.  However, these potential relationships and the use of vitamin D in 
primary prevention are outside the scope of this study, with our focus being on those who already 
have established asthma or COPD, and how vitamin D may improve the course of these diseases by 
restoring function and reducing disease-related complications. 
 
Respiratory tract infections have been shown to be the major precipitants of acute exacerbations in 
asthma and COPD, and it has been suggested that vitamin D may play a positive role in managing 
both the stable disease state and the response to exacerbations, as will be discussed later. 
 
 
1.9 Vitamin D status in older adults 
 
Vitamin D deficiency is common in the elderly in the UK, and is even greater in those living in 
institutions, affecting 30% of men and 33% of women in one study [264].  Randomised controlled 
trials have demonstrated that supplementation with vitamin D is able to prevent falls and fractures 
in this population [265, 266], and as such, the Department of Health advises people aged 65 and 
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over and not exposed to much sunlight to take a daily supplement of 10 micrograms vitamin D [267].  
This prevalence of hypovitaminosis D in elderly populations can likely be attributed to limited solar 
exposure due to altered lifestyle factors such as outdoor activity and clothing, and also a more 
limited variation in diet with a lower vitamin D content [268].  Additionally, dermal production of 
vitamin D following exposure to UVB light decreases with age due to atrophic changes in the skin 
reducing the amount of 7-dehydrocholesterol and the capacity to produce pre-vitamin D3 [269, 270].   
 
 
1.10 Relationship between vitamin D status and acute respiratory tract 
infections 
 
1.10.1 Observational studies 
 
A number of observational studies have demonstrated an inverse association between low vitamin D 
status and increased risk of acute respiratory tract infections [271].  Cross-sectional studies have 
shown a 7% lower risk of acute respiratory infection with every 10nmol/l increase in 25(OH)D 
concentration [272], and an inverse association between serum 25(OH)D concentration and self-
reported recent URTI symptoms, which was seen to be more significant in people with asthma or 
COPD [260].  Furthermore, in hospitalized wheezing children a low serum 25(OH)D concentration 
has been associated with increased risk of infection by RSV, rhinovirus, or by multiple viral causes 
[273].  
 
Case-control studies have demonstrated lower serum 25(OH)D concentrations in people hospitalized 
with LRTIs compared to healthy controls [274-276], with a lower concentration also associated with 
an increased risk of admission to intensive care units [277].  Children with rickets, a disease of 
profound vitamin D deficiency, were also found to be more susceptible to pneumonia [278], and 
have an increased risk of LRTI and a prolonged hospital stay compared to healthy children [279].  
Finally, children hospitalized with either acute bronchiolitis or pneumonia were found to have a 
lower mean vitamin D intake than healthy controls, with an intake of less than 80 international 
units/kg/day increasing the risk of ALRI four-fold [280].  
 
Numerous cohort studies have investigated the relationship between vitamin D status and 
susceptibility to acute respiratory infection, with low serum 25(OH)D concentration associated with 
more days of absence from military duty due to respiratory infection [281], and increased risk of 
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viral ARTI in healthy adults with a longer duration of illness [282].  Serum 1,25(OH)2D concentration 
has also been demonstrated to be inversely associated with risk of febrile respiratory illness in 
institutionalized elderly adults [283], and administration of either calcitriol (1,25(OH)2D) or 
alfacalcidol (1α(OH)D, a precursor of calcitriol) in haemodialysis patients has been associated with a 
preventative effect on the incidence of ARTIs [284].  Finally, cord-blood levels of 25(OH)D at birth 
have been shown to be inversely associated with risk of respiratory infections, and specifically RSV 
bronchiolitis, in early childhood [285-287], and low maternal serum 25(OH)D concentrations have 
been associated with increased risk of LRTI, pneumonia and bronchiolitis in their offspring [288, 
289].     
 
Observational studies have also demonstrated an association between low vitamin D status and lung 
function and measures of asthma and COPD morbidity. In asthmatic children low serum 25(OH)D 
concentration resulted in increased odds of one or more severe asthma exacerbations [290], and 
concentrations of ≤30ng/ml were associated with higher odds of any hospitalization or emergency 
department visit [291].  Cross-sectional data demonstrated with each 10nmol/l increase in 25(OH)D 
concentration, an 8ml increase in FEV1 and a 13ml increase in FVC (forced vital capacity) [272], and 
in another study mean differences of 106ml and 142ml for FEV1 and FVC respectively when 
comparing the highest and lowest quintiles of serum 25(OH)D concentration [292].  Low serum 
25(OH)D concentration was also shown to be associated with impaired lung function, increased 
airway hyperresponsiveness and reduced glucocorticoid response in adult asthma [293], and 
increased corticosteroid use and worsening airflow limitation in childhood asthma [294], with 
reduced odds of hospitalization and anti-inflammatory medication use with every log10 unit increase 
in serum 25(OH)D concentration [295]. 
 
However, while the majority of observational studies have indicated an association between low 
vitamin D status and increased risk of respiratory tract infections, some studies have not shown this 
relationship.  In one case-control study there was no difference in serum 25(OH)D concentration in 
children hospitalized with LRTI compared to healthy controls [296], and in three cohort studies no 
association was demonstrated between serum 25(OH)D concentration and self-reported cases of ARI 
in healthy adults [297], or risk of exacerbation or rhinovirus infection in COPD patients [298, 299].  
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1.10.2 Intervention studies 
 
While the previously described studies indicate an association between low vitamin D status and risk 
of acute respiratory tract infections, inference cannot be made until robust intervention studies 
have been carried out.  A number of randomised clinical trials have investigated whether vitamin D 
supplementation can prevent the incidence of acute respiratory tract infections, with conflicting 
results.  
     
In a study of healthy post-menopausal African-American women who were given 800 international 
units of vitamin D3 per day for 2 years, followed by 2000 IU/day for 1 year, while there was no effect 
on the primary outcome of bone density loss, women in the intervention arm were reported to have 
had less self-reported URTI symptoms during the course of the study [300, 301].  Various trials using 
a range of dosing regimens have also demonstrated a reduction in the intervention arm in the 
number of days absent from military duty due to respiratory tract infections in healthy adults 
(intervention of 400 IU/day for 6 months) [302], incidence of seasonal influenza A infection in 
schoolchildren (1200 IU/day for 4 months) [303], risk of repeat episodes of pneumonia in young 
children diagnosed with non-severe or severe pneumonia (single bolus dose of 100,000 IU) [304], 
and the rate of parent-reported ARI in schoolchildren with vitamin D deficiency (300 IU/day for 7 
weeks) [305].  In children with asthma, vitamin D supplementation reduced the number of asthma 
attacks in children given 1200 IU/day for 4 months [303], prevented exacerbations triggered by ARI 
in children given 500 IU/day + the steroid budesonide for 6 months (compared to those given 
placebo + budesonide) [306], and reduced the number of exacerbations, the requirement of steroids 
and the number of emergency visits, while improving peak expiratory flow rate in children given 
60,000 IU/month for 6 months [307].  Similarly in COPD, an intervention of a monthly bolus dose of 
100,000 IU for one year was shown to cause a reduction in exacerbation rate in people with severe 
25(OH)D3 deficiency at baseline (defined as <10 ng/mL) [308]. 
 
However, not all studies have been able to demonstrate a beneficial effect of vitamin D 
supplementation in preventing acute respiratory tract infections.  While giving elderly patients with 
a recent acute hip fracture high dose vitamin D3 (2000 IU/day versus 800 IU/day) for 1 year 
decreased the rate of hospital readmission due to infection at any site by 90%, there was no 
significant difference between readmission rates specifically due to respiratory tract infections [309].  
Similarly, supplementation of 2000 IU/day for 3 months had no effect on self-reported URTI 
incidence, URTI duration or URTI severity [310], children given 1400 IU/week or a quarterly bolus 
dose of 100,000 IU had no difference in pneumonia incidence [311, 312], and supplementation in 
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adults (1111 – 6800 IU/day or bolus dose of 100,000 – 200,000 IU/month) had no effect on incidence 
of influenza-like illness, or incidence or duration of URTIs [313, 314].  Finally, a recent study in 408 
asthmatic adults with a serum 25(OH)D level of less than 30ng/ml who received a one-off 100,000 IU 
dose followed by 4000 IU/day for 28 weeks demonstrated no change in time to first exacerbation, 
exacerbation rate, lung function, airway hyperreactivity, asthma quality of life or asthma control 
compared to participants on the placebo arm [315].   
 
The differences observed may be due to the various strengths and limitations of each trial [271].  For 
example, looking at ARI incidence as a secondary outcome or in post hoc analysis may result in 
inadequate identification of ARIs, with one study stating a surprisingly low rate of URTIs for a trial of 
that duration [301].  Additionally, specific pathogens were not characterised in the majority of the 
trials, thus not enabling any pathogen-specific effects of vitamin D supplementation to be 
determined.  The baseline vitamin D status of trial participants may also be important, but was not 
measured in all studies, with, for example, important sub-group effects observed in the profoundly 
deficient [308].  The type of dosing regimen used may also be an important determinant, with some 
inadequate to produce a prolonged rise in serum 25(OH)D concentration [311], and others not 
allowing sufficient duration of administration and follow-up to allow prolonged repletion [310].  
Additionally, bolus dosing resulting in a rapid increase followed by a slow decline in 25(OH)D levels 
may have a deleterious effect [316], with concentrations greater than 56ng/ml associated with 
impaired immunity to infection [317], and a chronic exposure to falling 25(OH)D concentration 
associated with an imbalance in the enzymes involved in 1,25(OH)2D extra-renal synthesis and 
catabolism, thus reducing the concentration of this active metabolite at sites of disease [318].        
 
Finally, none of the studies described here performed any genetic analysis of the participants, with 
an individual’s genotype associated with the effectiveness of supplementation, as described below.   
 
 
1.11 Genetic associations between vitamin D and respiratory infections 
 
The association between vitamin D and respiratory tract infections is further supported by genetic 
studies which implicate various polymorphisms in the vitamin D pathway in disease susceptibility.  
Since the actions exerted by 1,25(OH)2D can be explained by its ligation of the VDR, and the 
subsequent activation and binding of the VDR to vitamin D responsive elements, polymorphisms in 
the VDR gene can result in differing effects of vitamin D.  The gene encoding the VDR is located on 
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chromosome 12, spanning approximately 75 kilobases of genomic DNA, with polymorphisms named 
after the restriction endonucleases used for genotyping [319].  Multiple polymorphisms have been 
identified, and are distributed throughout the promoter region exons, coding exons, introns and the 
3’UTR.  The FokI single nucleotide polymorphism (rs2228570) is present in the translation start site, 
and is the only VDR SNP which results in a VDR protein with a different structure [320, 321].  It has 
been associated with risk of RSV bronchiolitis, with homozygosity for the minor f allele resulting in a 
70% higher risk of disease [322-324].  Additionally, in children hospitalised with acute lower 
respiratory tract infections, the ff VDR genotype was seen to be more prominent, further suggesting 
an association between the FokI VDR polymorphism and risk of acute respiratory tract infection 
[325].  Further characterisation of the M1 VDR genotype encoded by the f allele has demonstrated 
functional consequences for the immune response, with stronger inhibition of NFκB regulated 
transcription, and decreased expression of vitamin D stimulated genes due to less efficient 
interaction with transcription factor IIB (TFIIB) when compared to the major F allele M4 VDR [321, 
326].  While vitamin D is normally seen to inhibit the phosphorylation and activation of STAT1 in 
RSV-infected cells [327], this regulation is impaired in cells expressing the M1 VDR variant, resulting 
in diminished control of downstream gene expression.  Since bronchiolitic pathology results from an 
exaggerated immune response, with airways congested with mucus, infiltrated immune cells and 
shed epithelial cells, it is possible that this elevated STAT1 activation could contribute to exacerbated 
RSV disease in ff VDR homozygotes.  As a result, vitamin D supplementation may not be beneficial 
for people with this VDR genotype due to the inability of 1,25(OH)2D to inhibit STAT1 
phosphorylation and dampen immunopathology [328].   
 
Another VDR SNP is TaqI (rs731236), a synonymous codon in the VDR exon, which does not result in 
an altered amino acid sequence.  While not an effect on an acute respiratory infection, the TaqI VDR 
polymorphism has also been demonstrated to modify the effect of vitamin D supplementation on 
time to sputum culture conversion in people with pulmonary tuberculosis, with participants with the 
tt genotype having an enhanced response, thus suggesting an effect on antimicrobial immunity.  A 
response to vitamin D supplementation was not observed in the whole study population, 
demonstrating the potential importance of VDR genotype characterisation when assessing the 
immunomodulatory actions of vitamin D [329].  In vitro, carriage of the t allele has also been 
associated with increased 1,25(OH)2D-induced phagocytosis of Mycobacterium tuberculosis, with BB 
(BsmI VDR polymorphism), AA (ApaI VDR polymorphism) and FF (FokI VDR polymorphism) genotypes 
also demonstrated to have enhanced macrophage phagocytic activity [330, 331].       
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Another key component of vitamin D-induced gene transcription is the vitamin D binding protein 
(VDBP).  Also known as Gc-globulin, it has a major role in binding, solubilising and transporting 
vitamin D and its metabolites, as well as contributing to macrophage activation, chemotaxis, actin 
scavenging, and fatty acid transport [332, 333].  The GC gene encoding the VDBP is highly 
polymorphic, with three common variants (GC1F, GC1S and GC2) and >120 rarer variants, resulting in 
differences in protein function [334].  As with VDR polymorphisms, GC genotype has been associated 
with susceptibility to tuberculosis, with the GC2 variant VDBP strongly increasing active disease in 
people with vitamin D deficiency [335].  However, no association has been made with susceptibility 
to acute respiratory tract infections. 
 
The effect of VDBP variant on the response of serum 25(OH)D to vitamin D supplementation has also 
been assessed.  In adults receiving 600 or 4000 IU/day for one year, genotyping of the VDBP 
functional variant T436K (GC2) demonstrated an increased rise in mean serum 25(OH)D for the KK 
genotype (307%) compared to TK (151%) and TT (97%), although the KK genotype was also 
associated with the lowest baseline 25(OH)D concentration [336].  Therefore, the effects of vitamin 
D supplementation during intervention studies may be dependent on the VDBP variant present. 
 
In addition to this, genetic studies have further displayed a possible link between vitamin D and the 
chronic respiratory diseases of asthma and COPD.  The GC2 VDBP has been demonstrated to be 
significantly associated with the risk of asthma [337], as well as six SNPs in the VDR gene, including 
TaqI, BsmI and ApaI [338].  COPD has been extensively linked to VDBP polymorphisms, with the 
GC1F genotype demonstrated to increase the risk of developing COPD and accelerate the annual 
decline in FEV1 [339, 340], and GC2 homozygosity shown to be protective [341].  
 
Therefore, genetic studies implicating polymorphisms in key genes also demonstrate the potential 
role of vitamin D in the immune response to acute respiratory tract infections.   
 
 
1.12 Immunological actions of vitamin D in in vitro models of respiratory 
infection 
 
In vitro work has further demonstrated the possible association between vitamin D status and 
respiratory tract diseases, while also helping to characterise the underlying effects that it has on the 
immune system.  Since the majority of immune cells express the VDR and the enzyme CYP27B1, thus 
47 
 
allowing the local conversion of circulating 25(OH)D to the active 1,25(OH)2D and providing its 
receptor, the effects that vitamin D has on the immune system are diverse and extensive [241, 252, 
256, 342].   
 
 
1.12.1 Effects of vitamin D on the innate immune response to respiratory pathogens 
 
The most frequently demonstrated effect of vitamin D is that on LL-37, and as such its expression is 
commonly used to demonstrate increased CYP27B1 expression and 1,25(OH)2D activity.  
Cathelicidins are multifunctional antimicrobial peptides, and the sole form in humans is Human 
Cationic Antimicrobial Peptide of 18KDa (hCAP-18), from which the active form of LL-37 is cleaved by 
serine protease 3 [343].  It is expressed primarily by neutrophils and epithelial cells [344], but is also 
present in monocytes, NK cells, B-cells and γδ T-cells [345], and can be secreted by respiratory 
epithelial cells onto the airway surface to form a first line of defence against invading pathogens 
[346].  It has many functions, including direct facilitation of chemotaxis of immune cells [347, 348], 
induction of chemokine production (including CCL2, CCL4, CCL5 and CCL20) from immune and 
epithelial cells [349], up-regulation of chemokine receptors (including CXCR4 and CCR2) [349], 
suppression of neutrophil apoptosis via upregulation of BcL-XL and inhibition of caspase-3 activity 
[350], modification of DC differentiation [351], and immunomodulatory actions via induction of the 
anti-inflammatory cytokine IL-10 and suppression of the pro-inflammatory cytokines TNF-α and IL-1β 
[349, 352].  While LL-37 is traditionally viewed as a component of only the immune response to 
bacteria, with direct microbicidal activity via permeabilisation of bacterial membranes and 
neutralization of LPS observed [353-355], it also acts directly against viruses.  Anti-viral activity of LL-
37 has been demonstrated against both enveloped and non-enveloped viruses, including influenza 
virus and RSV [356].  It has been shown to disrupt the membrane of influenza virus [357], modify 
cytokine production [357], enhance TLR3 signalling [358], and have direct effects on RSV viral 
particles and infected epithelial cells, with diminished spread of infection and inhibited production of 
new virus particles [344].  Numerous studies have demonstrated the role the 1,25(OH)2D-ligated 
VDR plays in binding to a VDRE in the promoter of the cathelicidin gene to enhance hCAP-18 
production [359-361], thus suggesting a potential mechanism by which vitamin D may enhance 
innate immunity to respiratory infections. 
 
The proximal promoter region of DEFB4 gene also contains a VDRE, allowing 1,25(OH)2D to 
upregulate expression of  β-defensin 2 [361].  This is another antimicrobial peptide, which, similarly 
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to LL-37, is able to induce chemotaxis of immune cells and permeabilise bacterial membranes, whilst 
also inhibiting RSV infection [362, 363].   
 
In addition to antimicrobial peptide induction, vitamin D has been demonstrated to modulate the 
innate immune system in a variety of other ways.  Monocyte differentiation into macrophages is 
induced [364], with enhancement of the phagocytic and chemotactic capacity of macrophages [241, 
365].  Phosphatidyinositol 3-kinase regulates anti-mycobacterial activity of 1,25(OH)2D via the 
production of bactericidal reactive oxygen species in monocytes and  macrophages [366], and 
inducible nitric oxide synthase (iNOS) has also been implicated, with suppression of M.tuberculosis 
growth linked to nitric oxide production [367].  However, reports have been opposing on whether 
vitamin D inhibits or stimulates its production in macrophages [368, 369].  The ability of 1,25(OH)2D 
to induce monocyte autophagy has also been demonstrated.  Autophagy acts as part of the immune 
system to remove damaged proteins and organelles, and is an important host defence mechanism 
against viral and intracellular bacterial infections.  Vitamin D has been shown to induce autophagy 
by regulating multiple associated pathways, such as Bcl-2, mammalian target of rapamycin (mTOR), 
class III phosphatidylinositol 3-kinase complex, and cathelicidin production, thus potentially 
enhancing clearance of intracellular pathogens [370-372].    
 
Pattern recognition receptors have also been demonstrated to be regulated by vitamin D.  
Expression of TLR2 and TLR4 is inhibited in monocytes, resulting in impaired downstream signalling 
and hyporesponsiveness to PAMPS.  With the observation that this effect is most prominent after 72 
hours, a negative feedback mechanism has been suggested, whereby excessive TLR activation is 
prevented at later stages of infection to dampen inflammation [241, 373].  Conversely, CD14, an 
accessory protein to TLR4 for LPS recognition which has also been linked to TLR2 [374], was up-
regulated by 1,25(OH)2D [373, 375, 376], but this effect was not sufficient to restore downstream 
TLR signalling [373].  Also, as opposed to its effects in monocytes, 1,25(OH)2D has been 
demonstrated to induce up-regulation of TLR2 in keratinocytes, allowing a mechanism by which 
vitamin D may prevent infection of wounds [377].  Finally, the intracellular receptor NOD2 is induced 
by 1,25(OH)2D in myeloid and epithelial cells, via two distal VDREs in the NOD2 gene.  Addition of 
MDP (a lysosomal breakdown product of bacterial peptidoglycan [241]) to 1,25(OH)2D-induced 
NOD2 enhanced NF-κB signalling and subsequent β-defensin 2 expression [378].  
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1.12.2 Effects of vitamin D on the adaptive immune response to respiratory pathogens 
 
Vitamin D also modulates the adaptive immune response, and acts as a key intermediary between 
innate and adaptive immunity due to its influence on antigen presentation. 
 
Dendritic cells are the most potent antigen-presenting cells, and as such have a direct effect on 
lymphocyte activation and induction of the adaptive immune response.  They reside in peripheral 
tissues in an immature state, sampling the environment and mediating antigen uptake, until a 
maturation signal induces migration to local lymph nodes and subsequent T-cell activation.  Addition 
of 1,25(OH)2D has been demonstrated to inhibit DC differentiation, maturation and antigen 
presentation, with an associated decrease in markers such as CD1a, MHC class II, and the co-
stimulatory molecules CD40, CD80 and CD86 [379-381], as well as abrogating the chemotactic 
response to CCL4 and CCL19 [382].   Already differentiated dendritic cells can also be redirected back 
towards a monocytic phenotype by the restoration of the monocytic marker CD14 [380, 383].  
 
The antigen-presenting and T-cell stimulatory capacity of monocytes and macrophages is also 
impaired by 1,25(OH)2D, with a decrease in MHC class II, CD40, CD80 and CD86.  IL-12 production is 
suppressed in both activated DCs and macrophages, due to the 1,25(OH)2D-mediated down-
regulation of NF-κB activation [384], while influence on the expression of TNF-α is dependent on the 
differentiation state of the cells, with a reduction observed following 1,25(OH)2D administration in 
LPS-stimulated monocytes and PBMCs [373, 385].    
  
The main function of DCs is to initiate T-cell responses, and thus the effect of 1,25(OH)2D on DCs has 
a major impact on T-cells.  The decreased surface expression on DCs of co-stimulatory molecules and 
MHC class II results in a tolerogenic phenotype, with DC production of IL-12 (which is involved in 
driving Th1 differentiation) and IL-23 (which is involved in driving TH17 differentiation) inhibited by 
1,25(OH)2D [241, 383].  Even when cultured with committed T-cells, these tolerogenic DCs caused 
hyporesponsiveness, decreased T-cell proliferation and reduced IFN-γ secretion [379, 386].  IL-12, as 
well as stimulating the development of Th1 T-cells, also inhibits the development of Th2 cells, thus 
resulting in vitamin D shifting the balance of T-cells from a Th1 to a Th2 phenotype [387].    
Concomitantly, DC production of IL-10 is increased.  IL-10 is a cytokine with pleiotropic effects in 
immunoregulation, and levels in BAL fluid have been shown to be inversely correlated with 
severity/incidence of asthma [388, 389].  This IL-10 production drives development of regulatory T-
cells (Tregs), and these Tregs are able to secrete more IL-10 as well as the immunomodulatory 
cytokine TGF-β, while release of the Treg cytokine CCL22 is also increased [241].  Th17 cells and IL-
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17, have also been shown to be decreased, with calcitriol (1,25(OH)2D) reducing IL-17 production in a 
mouse colitis model and impairing commitment to the Th17 lineage in mice with experimental 
autoimmune uveitis [390, 391], although these effects may not translate to the human respiratory 
system.  Th17 cells, by releasing IL-17, initiate an inflammatory response dominated by neutrophils, 
with deficient levels resulting in recurrent bacterial infections.  High levels of IL-17 production are 
associated with chronic inflammation and severe immunopathology [392], and thus vitamin D may 
play a role in attenuating this.      
 
1,25(OH)2D has also been demonstrated to have direct effects on T-cells, independent of DC activity.  
While the role of DCs in the induction of Tregs has been described, it has also been shown that 
1,25(OH)2D in combination with dexamethasone can induce a Treg population in the absence of 
APCs [393].  The proliferation and cytokine profiles of T-cells are also directly altered by 1,25(OH)2D.  
Production of IL-2, IFN-γ, TNF-α, IL-17 and IL-21 are all inhibited [390, 394, 395], with inhibition of 
IFN-γ further precluding macrophage activation, thus attenuating antigen presentation and the 
recruitment of other T-cells [396].  This direct inhibition of Th1-priming cytokines further skews T-
cell differentiation towards a Th2 phenotype.  1,25(OH)2D is also able to upregulate the Th2-specific 
transcription factors GATA-3 and c-maf, resulting in increased production of IL-4, IL-5 and IL-10 
[397].  B-cells are also affected by vitamin D, with modulation of T-cell responses altering the B-cell 
compartment, as well as having direct effects on B-cells themselves [241].  1,25(OH)2D is able to 
inhibit proliferation, plasma-cell differentiation, immunoglobulin secretion and memory B-cell 
generation, while inducing B-cell apoptosis [255].  As such, vitamin D supplementation has been 
used in the treatment of B-cell-associated autoimmune diseases such as systemic lupus 
erythematous [398, 399].  Finally, it has been suggested that vitamin D may affect other lymphocyte 
subsets, with VDR-KO mice presenting with fewer invariant natural killer (iNKT) cells [400], and CD8+ 
T-cells from MS patients secreting less IFN-γ and TNF-α and more IL-5 and TGF-β following 
1,25(OH)2D treatment [401]. 
 
However, the mechanisms behind any potential beneficial role of vitamin D are unclear, with 
conflicting cellular studies on the effects of vitamin D on Th2 cells [402, 403], with both 
enhancement [397] and inhibition [404] of IL-4 synthesis demonstrated.  1,25(OH)2D has also been 
shown to down-regulate DC-derived Ox40L, which is required for Th2 priming, thus resulting in a 
reduced Th2 cytokine response in CD4+ T-cells from patients with allergic bronchopulmonary 
aspergillosis [405], thus contradicting evidence that vitamin D skews the T-cell phenotype towards a 
Th2 one.  Additionally, the decrease in Th1 immunity which has been observed [241] would suggest 
a diminished immune response to pathogens, contrasting to the evidence suggesting an improved 
51 
 
response to respiratory tract infections after vitamin D supplementation.  Finally, while studies have 
demonstrated direct effects of 1,25(OH)2D administration on lymphocytes, others have shown that 
when using the inactive metabolite 25(OH)D,  DCs are required to convert this precursor to the 
active 1,25(OH)2D to exert its immunomodulatory effects [406].  This indicates that administration of 
different vitamin D metabolites may result in a different response.  Therefore, while vitamin D 
clearly acts as an immunomodulatory molecule with a wide range of effects demonstrated, the 
precise mechanisms are currently unclear, with the conflicting results reported also adding to the 
uncertainty of its actions.  The main immunomodulatory effects of vitamin D are summarised in 
Figure 1.4.   
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Figure 1.4:  The immunomodulatory actions of 1,25(OH)2D.  1,25(OH)2D has diverse and extensive effects on the 
immune compartment.  The innate immune response is affected, with monocytes producing more LL-37, β-
defensin and ROS, with increased NOD2 expression and autophagy, while also producing diminished amounts 
of inflammatory cytokines, with decreased expression of TLR2 and TLR4.  Differentiation into macrophages is 
increased, with macrophages having an increased capacity for phagocytosis and chemotaxis. However, their 
APC and T-cell stimulatory capacity is decreased.  On the other hand, differentiation into DCs is inhibited, with 
DCs expressing decreased levels of maturation surface markers.  DC production of IL-12 and IL-23 is decreased, 
while mannose receptor expression and production of IL-10 and CCL22 are increased.  When these tolerogenic 
DCs interact with T-cells, development of Tregs and Th2 cells is increased, with increased production of IL-10, 
TGF-β, IL-4 and IL-5.  The development of Th1 and Th17 cells is inhibited, with decreased production of IL-2, IFN-
γ and TNF-α, and attenuation of macrophage activation.  B-cells are also affected by 1,25(OH)2D, 
demonstrating decreased immunoglobulin production, proliferation and differentiation, but increased 
apoptosis.      
 
Abbreviations used: Ag: antigen; APC: antigen presenting cell; CCL: cysteine-cysteine motif ligand; CD: cluster of differentiation; DC: 
dendritic cell; Ig: immunoglobulin; IL: interleukin; iNOS: inducible nitric oxide synthase; MHC: major histocompatibility complex; NOD: 
nucleotide-binding oligomerisation domain; ROS: reactive oxygen species; TCR: T-cell receptor; TGF: transforming growth factor; TLR: Toll-
like receptor; TNF: tumour necrosis factor.   
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1.13 Regulation of extra-renal vitamin D metabolism 
 
Significantly, a link has been made between TLR ligation and cytokine secretion, and the expression 
of CYP27B1 and the VDR.  The kidneys are classically the major site of 1α-hydroxylation of 25(OH)D 
by CYP27B1 to produce 1,25(OH)2D.  This hydroxylation step is tightly controlled, with renal CYP27B1 
regulated by the serum concentration of calcium, parathyroid hormone (PTH), phosphate, and 
fibroblast growth factor 23 (FGF23) [407-412].  Additionally, 1,25(OH)2D inhibits CYP27B1, both 
directly and by inhibiting PTH and stimulating FGF23 secretion, and stimulates the catabolic 24-
hydroxylase enzyme (CYP24A1), which generates 24,25(OH)2D and 1,24,25(OH)3D from 25(OH)D and 
1,25(OH)2D respectively, thus providing negative feedback pathways [413, 414].  However, extra-
renal 1α-hydroxylation in cells such as monocytes and macrophages is unaffected by these calcium 
homeostatic agents [415-417], except for FGF23 which has been demonstrated to inhibit CYP27B1 
expression in monocytes [418].  Additionally, negative feedback is defective due to expression of a 
splice variant form of CYP24A1 which is catalytically inactive, thus potentially resulting in 
accumulation of 1,25(OH)2D [419, 420].  Instead, regulation is primarily by immune inputs, therefore 
rendering the immune system responsive to circulating levels of 25(OH)D and allowing the sustained 
and potentially beneficial production of 1,25(OH)2D during an immune response [420]. 
 
Vitamin D metabolism in macrophages is linked to pathogen recognition, thus making it an integral 
part of the innate immune response [421].  Ligation of the TLR2/1 heterodimer in macrophages has 
been demonstrated to up-regulate CYP27B1 and the VDR in microarray studies.  This was associated 
with increased downstream production of LL-37 in the presence of 25(OH)D replete human serum 
[422]. The TLR8 ligands CL097 and ssRNA40 have also both been demonstrated to induce a dose-
dependent increase in CYP27B1 mRNA and protein expression in macrophages [423].  Similarly, 
ligation of TLR4 by LPS up-regulated CYP27B1 expression in monocytes [424, 425], again with 
increased LL-37 production with replete serum from in vivo vitamin D-supplemented patients [426], 
and with the same response observed in dendritic cells [427].  Additionally, ligation of TLR4 by 
monophosphoryl lipid A (MPLA), a synthetic LPS derivative with vaccine adjuvant properties which 
utilizes the TRIF signalling pathway, has been demonstrated to induce expression of CYP27B1 in 
dendritic cells, resulting in regulation of DC migration and activation of T-cells [428].  Also in 
dendritic cells, TLR3 ligation by polyI:C resulted in increased CYP27B1 expression, again altering the 
migratory properties of DCs to allow their localisation into non-draining secondary lymphoid organs 
to present antigen peptides to CD4+ T-cells [254, 429].  Similarly, in human tracheobronchial 
epithelial (hTBE) cells, polyI:C stimulation and addition of live RSV were demonstrated to increase 
CYP27B1 expression, enhance 25(OH)D conversion to 1,25(OH)2D, and amplify cathelicidin mRNA 
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[430]. With the expression of TLRs in multiple cell types, and the ability to respond to a variety of 
pathogens, it is also possible that other TLRs or alternate PRRs may promote extra-renal expression 
of CYP27B1, allowing locally generated 1,25(OH)2D to have even more extensive effects on the 
immune response.   
 
The exact mechanism by which TLR ligation enhances CYP27B1 production has not been fully 
defined.  Upregulation of CYP27B1 expression following ligation of TLR4 by LPS in human monocytes 
and the mouse RAW264.7 macrophage cell line has been shown to require the JAK-STAT, NF-κB and 
p38 MAPK pathways.  Each signalling pathway is essential, with inhibitors to block MAPK, NF-κB and 
JAK resulting in inhibition of LPS-induced CYP27B1 production, demonstrating an intricate cross-talk 
between the pathways.  Phosphorylation of the transcription factor C/EBPβ by p38 MAPK was also 
shown to be essential, with direct binding of C/EBPβ to recognition sites in the CYP27B1 promoter 
region necessary in enabling LPS-stimulated upregulation [425].  Additionally, IL-15 has been 
implicated as an intermediary in promoting localized activity of CYP27B1 and synthesis of 
1,25(OH)2D.  TLR 2/1 ligation by a triacylated lipopeptide of the M.tuberculosis 19 kDa antigen in 
human monocytes induced IL-15 secretion, which was required for the upregulation of CYP27B1 and 
the VDR, and subsequent downstream production of LL-37.  Furthermore, IL-15 induces the 
differentiation of monocytes into macrophages with enhanced phagocytic activity against 
M.tuberculosis.  Therefore, IL-15 produced in response to TLR2/1 ligation is able to amplify the 
innate immune response by inducing macrophage differentiation and upregulation of CYP27B1 and 
the VDR, thus increasing 1,25(OH)2D synthesis and subsequent activation of the antimicrobial 
pathway and LL-37 production [431].  With the observation that patients with granulomatous 
diseases such as sarcoidosis frequently present with over-production of 1,25(OH)2D and elevated 
expression of IL-15 [432, 433], it is also possible that IL-15-mediated CYP27B1 induction provides the 
link between vitamin D as a regulator of the normal innate immune response and the dysregulated 
1,25(OH)2D production associated with such inflammatory diseases [434].  
 
As well as IL-15, other cytokines have been implicated in the regulation of CYP27B1 and vitamin D 
metabolism.  Lung epithelial cells express CYP27B1 and are able to convert 25(OH)D to 1,25(OH)2D 
locally [430], with IL-13 demonstrated to increase CYP27B1 and enhance the ability of 25(OH)D to 
increase production of LL-37 [435].  IFNγ induces CYP27B1 expression in differentiated THP1 
macrophages on its own [436], and acting synergistically with LPS stimulation in human monocytes 
[425], while also up-regulating TLR2/1 induction of CYP27B1 and VDR in monocytes [437].  In 
contrast, IL-4 was shown to induce CYP24A1-dependent catabolism of 25(OH)D to the inactive 
24,25(OH)2D both on its own and in combination with the TLR2/1 ligand [437].  While IL-17 has been 
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demonstrated to have no effect on vitamin D metabolism [437], TNF-α, IL-1 and IL-2 were all able to 
increase monocyte CYP27B1, with an associated increase in 1,25(OH)2D production [416, 438].   
The pathways involved in cytokine-regulated transcription of CYP27B1 are likely the same ones as 
utilized by TLR ligation-induced regulation, as described above [436].  Additionally, the 
phospholipase A2 (PLA2)-arachidonic acid pathway has been implicated in influencing macrophage 
1α-hydroxylation.  Specifically, signal transduction through the 5-lipoxygenase pathway with 
generation of leukotriene C4 was critical to an increase in synthesis of 1,25(OH)2D [439].  
Chloroquine, a compound with actions in the PLA2-arachidonic acid pathway, was demonstrated to 
completely inhibit synthesis of 1,25(OH)2D in macrophages, thus explaining its effectiveness in 
patients with sarcoidosis to reduce serum 1,25(OH)2D and hypercalcaemia [440, 441].      
 
Finally, and of potential importance to asthmatics who use glucocorticoids to reduce their chronic 
airway inflammation, dexamethasone has been shown to inhibit 25(OH)D 1 α-hydroxylation in 
pulmonary alveolar macrophages and monocytes [416, 438, 442]  
 
Therefore, extra-renal 1,25(OH)2D synthesis has been shown to be regulated by TLR ligation and 
cytokine secretion, utilizing an intricate cross-talk between various signalling pathways.  As such, in 
the presence of sufficient circulating levels of 25(OH)D, infection by respiratory pathogens resulting 
in recognition by TLRs and cytokine production is able to increase levels of 1,25(OH)2D, 
hypothetically altering the immune response to better respond to these pathogens, as described in 
the previous two sections of this report.  
 
 
1.14 Summary 
 
In summary, respiratory infections are a major burden in terms of economics, morbidity and 
mortality, especially in those with chronic respiratory conditions such as asthma and COPD, and 
vulnerable populations such as the elderly.  In such people, the immune response is altered, 
resulting in an ineffective immune response to respiratory pathogens, with inadequate antimicrobial 
activity and unregulated inflammatory responses potentially causing immunopathology, thus leading 
to an increased chance of hospitalization and death.  Reviews of the literature linking vitamin D 
deficiency to increased incidence of acute respiratory tract infections suggest that supplementing 
with vitamin D3, thus providing the 25(OH)D substrate for extra-renal 1α-hydroxylation to the active 
metabolite 1,25(OH)2D, may prevent such infections, as well as improving lung function in people 
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with asthma or COPD.  However, intervention studies have so far been inconclusive, and the 
mechanisms behind any observed benefits are unclear, with conflicting in vitro results pertaining to 
the effects of vitamin D supplementation on the Th1/Th2 balance.  Thus larger and better-designed 
randomised controlled trials are required, as well as further elucidation of the in vitro effects of 
vitamin D on cell types and function. When the immunomodulatory effects of vitamin D are further 
established, this molecule may provide a cheap and effective preventative agent for those at 
increased risk of acute respiratory infection.  Individuals have been shown to be able to tolerate 
doses as high as 10,000 IU, which corresponds to 250μg per day [443], and the general public are 
unfazed by the consumption of supplements, with £220 million spent on vitamin and mineral tablets 
in 2006 in the UK and 43% admitting to taking some in the past 12 months [444].  
 
 
1.15 Aims of the project 
 
The overarching aim of this PhD project was to test the hypothesis that vitamin D metabolites, given 
in vivo in the form of supplementation in a randomised controlled trial, or used during in vitro cell 
culture, will augment the antimicrobial immune responses to respiratory pathogens and suppress 
immunopathological inflammation, thus potentially translating to beneficial effects in the host in the 
form of prevention of acute respiratory tract infections and exacerbations.   
 
The specific aims were as follows: 
 
1. To develop a whole blood assay to characterise the effects of in vivo vitamin D 
supplementation on ex vivo immune responses to TLR ligands and respiratory pathogens in 
peripheral blood 
2. To characterise the effects of in vitro 25(OH)D and 1,25(OH)2D on epithelial receptor 
expression, cytokine secretion and resistance to rhinovirus infection in alveolar A549 cells 
3. To characterise the effects of in vivo vitamin D supplementation on the cellular profiles of 
the lower airways by analysis of induced sputum samples 
4. To characterise the effects of in vivo vitamin D supplementation on the cellular profile of 
peripheral whole blood  
5. To characterise the effects of in vivo vitamin D supplementation on ex vivo immune 
responses to TLR ligands and respiratory pathogens in peripheral blood 
6. To analyse the differences between sputum cellular profiles in asthma vs. COPD patients  
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7. To analyse the differences between peripheral blood cellular profiles and the ex vivo 
immune responses to TLR ligands and respiratory pathogens in asthma vs. COPD patients vs. 
elderly adults living in sheltered accommodation with neither condition. 
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2. Materials and Methods 
 
2.1 Clinical trial participants 
 
The blood and sputum samples used in this study were from participants of three randomised, 
double-blind, placebo-controlled trials of vitamin D supplementation, in patients with asthma 
(ViDiAs) or COPD (ViDiCO) or in people living or working in sheltered accommodation who had 
neither condition (ViDiFlu) (Table 2.1).   
 
Table 2.1: Summary of the three clinical trials   
  ViDiAs ViDiCO ViDiFlu 
Full Title 
Randomised, multi-centre, 
double-blind, placebo-
controlled trial of vitamin 
D supplementation in 
adult and adolescent 
patients with asthma 
Randomised, multi-centre, 
double-blind, placebo-
controlled trial of vitamin 
D supplementation in 
patients with chronic 
obstructive pulmonary 
disease 
Cluster-randomised, double-
blind, placebo-controlled trial 
of vitamin D supplementation 
for the prevention of 
influenza and other 
respiratory infections in 
sheltered accommodation 
Ref Number 
(ClinicalTrials.gov) 
NCT00978315 NCT00977873 NCT01069874 
Sponsor 
Barts and the London NHS 
Trust 
Barts and the London NHS 
Trust 
Barts and the London NHS 
Trust 
Funding Body 
National Institute of 
Health Research 
National Institute of 
Health Research 
National Institute of  
Health Research 
Ethics Approval 
East London and The City 
Research Ethics 
Committee  
ref 09/H0703/67 
East London and The City 
Research Ethics 
Committee  
ref 09/H0703/76 
East London and The City 
Research Ethics Committee 
ref 09/H0703/112 
EudraCT (EU Drug 
Regulating 
Authorities 
Clinical Trials) 
number 
2009-010083-42 2009-010084-16 2009-010085-35 
Primary Objective 
To determine whether a 2-
monthly oral dose of 3mg 
vitamin D influences time 
to severe exacerbation 
and time to upper 
respiratory tract infection 
in patients with asthma 
To determine whether a 
2-monthly oral dose of 
3mg vitamin D influences 
time to moderate/severe 
exacerbation and time to 
upper respiratory tract 
infection in patients with 
COPD 
To determine whether 
vitamin D supplementation 
prevents respiratory 
infections in sheltered 
accommodation schemes, 
residential care homes, and 
nursing home residents and 
attendees of day centres and 
groups for older adults 
 
 
59 
 
Power calculations for each trial were based on the required sample size to enable detection of a 
clinically significant difference in the co-primary outcomes of time from randomisation to severe 
asthma exacerbation, moderate/severe COPD exacerbation or respiratory tract infection between 
intervention and control arms.  For ViDiAs, with estimates of a median time to exacerbation of 120 
days [445-447], a total of 200 participants (100 in each arm) was needed to be recruited in order to 
detect a 60 day difference in median time to exacerbation between intervention and control groups 
with 80% power using a 2-sided test at the 5% significance level, assuming an accrual period of 2.5 
years and a follow-up period of one year for each participant [448].  A difference of this magnitude 
represents a hazard ratio of 0.67, which would be clinically significant.  To compensate for patient 
drop-out, this number was increased by 25%, giving a total sample size of 250.  Similarly for ViDiCO, 
with estimates of a median time to exacerbation of 60 days [449], a total of 192 participants (96 in 
each arm) was needed to be recruited in order to detect a 30 day difference in median time to 
exacerbation between intervention and control groups with 80% power using a 2-sided test at the 
5% significance level, assuming an accrual period of 3.25 years and a follow-up period of one year for 
each participant [448].  A difference of this magnitude represents a hazard ratio of 0.67, which 
would be clinically significant, and to compensate for patient drop-out, this number was increased 
by 25%, giving a total sample size of 240.  For ViDiFlu, the proportion of the population experiencing 
at least one respiratory tract infection per year has been reported to be between 68% and 92% [13, 
188, 450].  Employing the Xie and Waksman formula for sample size estimation in clinical trials 
with clustered survival times as the primary endpoint [451], and assuming an average of 5 
residents and attendees per cluster, with intra-cluster coefficient of 0.05, and equal numbers of 
units allocated to intervention and control arms of the study, a total of 68 units was estimated 
to be needed to be randomised to demonstrate a 10% reduction in the proportion of residents 
and attendees experiencing at least one respiratory tract infection in one year from 80% to 72%, 
with 80% power at the 5% significance level.  To allow for loss of eight clusters to follow-up, this 
number was increased to a total of 116 clusters to be recruited.  
 
Study design, recruitment of participants and study visits were performed by members of the 
vitamin D research team.  In total, 250 people were recruited and randomised to the ViDiAs trial, 240 
to ViDiCO and 240 to ViDiFlu.  The majority of participants for ViDiAs and ViDiCO were recruited by 
approaching London-based primary care providers, who identified potentially eligible individuals and 
asked them if they would like to be contacted by a member of the study teams.  Additionally, 
posters advertising the studies were displayed in appropriate public places such as hospital out-
patient departments and GP surgeries, and emails were circulated within Queen Mary, University of 
London.  Any individual expressing an interested was provided with a patient information sheet 
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(PIS), before screening was arranged.  For ViDiFlu, London-based units, defined as sheltered 
accommodation schemes, residential care homes, nursing homes, day centres or groups for older 
adults, were approached to participate in the trial.  A representative for the management of each 
unit was required to sign an agreement to participate, and units were excluded if they offered care 
exclusively for clients with dementia, learning disabilities, mental health needs, alcohol dependency 
or drug dependency.  In total, 108 units were eligible and agreed to participate.  Managers of each 
participating unit were provided with letters, and asked to forward these to potentially eligible staff, 
carers, attendees and residents.  These letters provided an introduction to the study and an 
invitation to attend a presentation about the trial within the unit, or to meet with a researcher on a 
one-to-one basis.  Researchers then visited participating units and met with individuals who had 
expressed an interest in the study, clearly explaining the trial and answering any questions.  Patient 
information sheets were provided, and screening was then arranged.   
 
 
2.1.1 Investigational medicinal product (IMP) 
 
Active IMP for all three trials was Vigantol® Oil (Merck Serono, Darmstadt, Germany) – an oily 
solution containing 0.5mg cholecalciferol (vitamin D3) per millilitre.  The placebo was Miglyol® 812 
oil (Caesar and Loretz, Hilden, Germany) – an organoleptically identical mixture of palm oil and 
coconut oil widely used in pharmaceutical practice.  Miglyol® 812 oil is the excipient for 
cholecalciferol in Vigantol® Oil, and is thus identical to Vigantol® Oil in every respect except for the 
absence of cholecalciferol.  Nova Laboratories Ltd (Wigston, UK) produced a computer-generated 
randomisation sequence and bottled study medication, and treatment allocation was concealed 
from trial participants and study staff. 
 
 
2.1.2 ViDiAs trial: participant characteristics 
 
Patients were deemed eligible if they were between 16 and 80 years of age, had a medical diagnosis 
of asthma treated at BTS (British Thoracic Society)  Step 2 (taking inhaled corticosteroids daily [452]) 
or above, and had documented either a ≥12% increase in forced expiratory volume in one second 
(FEV1) after inhalation of 400μg of salbutamol, a ≥20% diurnal variability peak in expiratory flow 
(PEFR), or methacholine PC20 (concentration of methacholine causing a 20% fall in FEV1) < 8g/L.  In 
addition to this, patients agreed to the required visits, were contactable by telephone, were able to 
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give written informed consent to participate and, if a woman of child-bearing potential, agreed to 
use a reliable form of contraception for the duration of the study.   
 
Patients were excluded if they had a diagnosis of COPD, known sarcoidosis, hyperparathyroidism, 
nephrolithiasis, active tuberculosis, vitamin D intolerance, liver failure, renal failure or any 
malignancy not in remission for at least 3 years.  Taking dietary supplements containing >10μg per 
day of vitamin D, a baseline corrected serum calcium >2.65mmol/L, baseline serum creatinine > 
125μmol/L and a smoking history > 15 pack years (calculated by the number of packs of cigarettes 
smoked per day divided by 20, and multiplied by the number of years the person has smoked for) 
were additional exclusion criteria.  Finally, participants were excluded if they were breastfeeding, 
pregnant or planning a pregnancy, undergoing treatment with any other IMP or device up to 4 
months before randomisation onto this trial, or taking a cardiac glycoside (e.g. Digoxin), 
carbamazepine, phenobarbital, phenytoin, primidone or benzothiadiazine derivatives at a dose 
higher than recommended in the British National Formulary (BNF) or in combination with a calcium 
supplement. 
   
Successfully recruited and randomised patients were given 6 x 2-monthly doses of 6ml of active IMP 
(containing 3mg of Vitamin D3, equating to 120,000 IU) or placebo over the period of one year. 
 
 
2.1.3 ViDiCO trial: participant characteristics 
 
Patients were deemed eligible if they were over 40 years old, had a medical diagnosis of COPD, 
emphysema or bronchitis, had a post-bronchodilator ratio of forced expiratory volume in one 
second to forced vital capacity (FEV1/FVC) < 70%, or post-bronchodilator FEV1/slow VC < 70%, and 
had a smoking history ≥ 15 pack years.  In addition to this, patients agreed to the required visits, 
were contactable by telephone, were able to give written informed consent to participate and, if a 
woman of child-bearing potential, agreed to use a reliable form of contraception for the duration of 
the study.   
 
Patients were excluded if they had a current diagnosis of asthma, known clinically significant 
bronchiectasis, sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D 
intolerance, liver failure, renal failure or any malignancy not in remission for at least 3 years.  Taking 
dietary supplements containing >10μg per day of vitamin D, a baseline corrected serum calcium 
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>2.65mmol/L, baseline serum creatinine > 125μmol/L and the requirement of long-term oxygen 
therapy for ≥ 12 hours per day were additional exclusion criteria.  Finally, participants were excluded 
if they were breastfeeding, pregnant or planning a pregnancy, undergoing treatment with any other 
IMP or device up to 4 months before randomisation onto this trial, or taking a cardiac glycoside (e.g. 
Digoxin), carbamazepine, phenobarbital, phenytoin, primidone or benzothiadiazine derivatives at a 
dose higher than recommended in the British National Formulary (BNF) or in combination with a 
calcium supplement. 
 
Successfully recruited and randomised patients were given 6 x 2-monthly doses of 6ml of active IMP 
(containing 3mg of Vitamin D3, equating to 120,000 IU) or placebo over the period of one year. 
 
 
2.1.4 ViDiFlu trial: participant characteristics 
 
 Participants were deemed eligible if they were a permanent resident, attendee, staff member or 
carer at a participating unit, and were aged 16 or over.  In addition to this, patients agreed to the 
required visits, were able to give written informed consent to participate and, if a woman of child-
bearing potential, agreed to use a reliable form of contraception for the duration of the study.   
 
Patients were excluded if they had a current diagnosis of asthma or COPD, chronic respiratory 
infection or chronic cough, any condition requiring treatment with a vitamin D dose of > 10μg per 
day, known sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D 
intolerance, liver failure, renal failure or any malignancy not in remission other than cutaneous 
basal/squamous cell carcinoma.  Taking dietary supplements containing >10μg per day of vitamin D, 
a baseline corrected serum calcium >2.65mmol/L, baseline serum creatinine > 125μmol/L and 
inability to complete the symptom diary were additional exclusion criteria.  Finally, participants were 
excluded if they were breastfeeding, pregnant or planning a pregnancy, undergoing treatment with 
any other IMP or device up to 4 months before randomisation onto this trial, or taking a cardiac 
glycoside (e.g. Digoxin), carbamazepine, phenobarbital, phenytoin, primidone, long-term 
immunosuppressant therapy, or benzothiadiazine derivatives at a dose higher than recommended in 
the British National Formulary (BNF) or in combination with a calcium supplement. 
 
Successfully recruited and randomised participants had various dosing regimens depending on their 
status as resident or staff/carer (Table 2.2), as it was deemed unethical to withhold vitamin D 
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supplementation in individuals aged ≥ 65 with limited sunlight exposure.  As such, staff and carers 
were randomised to receive 6 x 2-monthly doses of 6ml of active IMP (containing 3mg of Vitamin D3, 
denoted PR1) or placebo over the period of one year (denoted PL1), while residents were 
randomised to receive low-dose vitamin D supplementation (a daily dose of 20μl of active IMP for 1 
year, denoted PR3, as well as 6 x 2-monthly doses of 4.8ml of placebo, denoted PL2) or high-dose 
vitamin D supplementation (a daily dose of 20μl of active IMP for 1 year, denoted PR3, as well as 6 x 
2-monthly doses of 4.8ml active IMP containing 2.4mg of Vitamin D3, denoted PR2), thus allowing a 
comparison between high-dose vitamin D3 and placebo in staff and carers, and between high-dose 
vitamin D3 and low-dose vitamin D3 in residents and attendees. 
 
 
Table 2.2: ViDiFlu trial dosing regimens 
 
* PR1, PR2 and PR3 are Vigantol ® regimens 
** PL1 and PL2 are Miglyol ® regimens 
 
2.1.5 Primary and Secondary Endpoints 
The co-primary endpoints for ViDiAs and ViDiCO were time from randomisation to first upper 
respiratory tract infection (URTI), and time from randomisation to first severe asthma exacerbation 
or first moderate/severe COPD exacerbation, respectively.  A severe asthma exacerbation was 
defined as a deterioration in asthma resulting in the need for treatment with oral corticosteroids, 
hospital admission, emergency treatment or a decrease in the morning peak expiratory flow rate 
(PEFR) to more than 25% below the baseline value on 2 or more consecutive days.  COPD 
exacerbations were defined as the occurrence of ≥ 2 major symptoms or 1 major symptom and ≥ 1 
minor symptom for at least 2 consecutive days, with major symptoms comprising an increase in 
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dyspnoea, sputum volume or sputum purulence, and minor symptoms consisting of an increase in 
nasal congestion or discharge, wheeze, sore throat or cough.  Any exacerbation fulfilling these 
requirements plus involving treatment with systemic steroids or antibiotics was classified as 
moderate, while severe exacerbations were defined as those which fulfilled the requirements above, 
involved treatment with systemic steroids or antibiotics, and additionally required hospital 
admission or a visit to a hospital emergency department.  URTIs were defined as influenza-like illness 
(presence of cough, feeling of fever/chilliness, and muscle pain) [453], or using Jackson’s criteria for 
a cold [454].  Participants were asked to score each of the 8 Jackson symptoms (sneezing, sore 
throat, headache, subjective sensation of fever or chilliness, malaise, nasal discharge, nasal 
obstruction, cough) and one additional symptom (muscle pain) from 0 (no symptoms) to 3 
(symptoms severe enough to interfere with activity or sleep) in a provided diary on a daily basis.  A 
cold was recorded when the total Jackson score was ≥ 14 with a subjective impression of having a 
cold, the total Jackson score was ≥ 14 with increased nasal discharge for at least 3 days, or the total 
Jackson score was < 14 with a subjective impression of having a cold plus an increase in nasal 
discharge for ≥ 3 days.   
 
For ViDiFlu, the primary outcome measure was time from randomisation to first respiratory tract 
infection (upper or lower).  Respiratory tract infections were defined as an episode of illness meeting 
the stated criteria of either URTI, lower respiratory tract infection (LRTI), or both.  URTIs were 
defined as described above, while LRTIs were defined using the Macfarlane criteria [450].  When 
completing their daily diary entries, participants were asked whether or not they had a cough, cold 
or flu symptoms, with those answering ‘yes’ asked to score the 5 Macfarlane symptoms (cough, 
sputum production, dyspnoea, wheeze, chest discomfort/pain) from 0 (no symptoms) to 3 
(symptoms severe enough to interfere with activity or sleep).  LRTIs were defined as the presence of 
a cough scoring at least one point over that recorded during the run-on period, plus ≥ 1 other lower 
respiratory tract symptom scoring at least one point over that recorded during the run-in period. 
 
Secondary endpoints encompassed measures of respiratory morbidity, health service use, adverse 
events, medication use, physiological outcomes, microbiological outcomes, immunological 
outcomes, biochemical outcomes, genetic parameters, quality of life, and economic outcomes.  The 
focus of this thesis is on the immunological outcomes, with methodology described in greater detail 
below.  However, since some of the other trial outcomes are presented in later results chapters in 
order to offer a comparison to the immunological findings, a summary of the secondary endpoints 
measured for each of the three trials is provided in Table 2.3.  The majority of these outcomes were 
determined from the diaries which participants were asked to complete on a daily basis, indicating 
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respiratory symptom scores and PEFR (peak expiratory flow rate) readings (ViDiAs only).  
Participants were also asked to record any adverse events, medication use and costs associated with 
this, time off work, and any hospital or GP visits.  A lifestyle questionnaire was completed by each 
participant during their screening visit, with asthma control test (ACT, ViDiAs only), Mini-
rhinoconjunctivitis quality of life questionnaire (Mini-RQLQ, ViDiAs only), St. George’s Respiratory 
Questionnaire (SGRQ, ViDiAs and ViDiCO) and EQ-5D (all 3 trials) questionnaires completed at 
screen, and 2, 6 and 12 months post-randomisation.  For ViDiAs participants, exhaled nitric oxide 
was measured using a handheld Niox Mino device to assess airway inflammation, and FEV1 (forced 
expiratory volume) was measured using a handheld spirometer  In addition to FEV1, spirometry was 
also used in ViDiCO participants to record FVC (forced vital capacity) at screening visits, and 2, 6 and 
12 months post-randomisation.  Blood samples were also collected at screening visits and 2, 6 and 
12 months post-randomisation to allow quantification of concentrations of vitamin D metabolites 
and measures of calcium homeostasis.  Finally, nose and throat swabs were taken from a subset of 
participants from each trial to allow polymerase chain reaction (PCR) detection of respiratory 
pathogens to act as validation for the definitions of respiratory tract infections based on symptom 
scores alone.       
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Table 2.3: Summary of the secondary endpoints for all three clinical trials 
Secondary Endpoints 
Trials outcomes were 
measured in 
Respiratory 
Morbidity 
Rate of severe exacerbation per participant-year ViDiAs; ViDiCO 
Rate of URTI per participant-year ViDiAs; ViDiCO 
Rate of URTI/LRTI per participant-year ViDiFlu 
Proportion of participants experiencing ≥ 1 severe exacerbation during the trial ViDiAs; ViDiCO 
Proportion of participants experiencing ≥ 1 URTI during the trial ViDiAs; ViDiCO 
Proportion of participants experiencing ≥ 1 URTI/LRTI during the trial ViDiFlu 
Proportion of severe exacerbations associated with URTI ViDiAs; ViDiCO 
Proportion of exacerbations associated with increased sputum purulence ViDiCO 
Proportion of exacerbations requiring antibiotics or corticosteroids ViDiCO 
Duration of URTIs/exacerbations ViDiAs; ViDiCO 
Median recovery time for episodes of URTI/LRTI ViDiFlu 
Proportion of nights with awakenings due to asthma ViDiAs 
Asthma control test score ViDiAs 
Asthma symptom score ViDiAs 
Health Service 
Use 
Unscheduled GP consultation with exacerbation or URTI ViDiAs; ViDiCO 
Unscheduled health service use for respiratory tract infection ViDiFlu 
A&E attendance with exacerbation or URTI ViDiAs; ViDiCO 
A&E attendance for respiratory tract infection ViDiFlu 
Unscheduled hospital admission with exacerbation or URTI ViDiAs; ViDiCO 
Unscheduled hospital admission for respiratory tract infection ViDiFlu 
Duration of hospital admissions for exacerbation or URTI ViDiAs; ViDiCO 
Duration of hospital admissions for respiratory tract infection ViDiFlu 
Adverse Events 
Proportion of participants reporting severe adverse events ViDiAs; ViDiCO; ViDiFlu 
Proportion of participants withdrawing from the trial ViDiAs; ViDiCO; ViDiFlu 
Mortality due to exacerbation or respiratory infection ViDiAs; ViDiCO; ViDiFlu 
All-cause mortality ViDiAs; ViDiCO; ViDiFlu 
Medication 
Use 
Use of oral corticosteroids ViDiAs; ViDiCO 
Use of antibiotics ViDiAs; ViDiCO; ViDiFlu 
Use of over-the-counter medication for URTI symptoms ViDiAs; ViDiCO; ViDiFlu 
Use of inhaled relief medication or inhaled corticosteroids ViDiAs; ViDiCO 
Physiological 
Outcomes 
FEV1 (% of predicted value) ViDiAs; ViDiCO 
FVC (% of predicted value) ViDiCO 
Morning PEFR ViDiAs 
Exhaled nitric oxide concentration ViDiAs 
Microbiological 
Outcomes 
Proportion of nasal/throat swabs where respiratory pathogens were detected ViDiAs; ViDiCO; ViDiFlu 
Determination of respiratory pathogens in induced sputum ViDiAs; ViDiCO 
Biochemical 
Outcomes 
Concentrations of vitamin D metabolites in serum and plasma ViDiAs; ViDiCO; ViDiFlu 
Concentrations of measures of calcium homeostasis in serum and plasma ViDiAs; ViDiCO; ViDiFlu 
Genetic 
Parameters 
Polymorphisms in genes influencing vitamin D transport, metabolism and 
signalling ViDiAs; ViDiCO; ViDiFlu 
Quality of Life 
SGRQ ViDiAs; ViDiCO 
mini-RQLQ ViDiAs 
EQ-5D ViDiAs; ViDiCO; ViDiFlu 
Economic 
Outcomes 
Costs incurred by participants due to exacerbation or URTI ViDiAs; ViDiCO 
Costs incurred by participants due to respiratory infection ViDiFlu 
Costs of medical care provided for exacerbation or URTI ViDiAs; ViDiCO 
Costs of medical care provided for participants ViDiFlu 
Days of absence from work due to exacerbation or URTI ViDiAs; ViDiCO 
Days of absence from work due to respiratory infection ViDiFlu 
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2.1.6 Sputum induction 
 
A subset of participants in the ViDiAs (n = 50) and ViDiCO (n = 50) trials were invited to give induced 
sputum samples in addition to other study samples at visits 2 (before IMP administration), 3 (2 
months post randomisation) and 5 (12 months post randomisation).  Further to the normal inclusion 
and exclusion criteria, to be eligible for sputum induction ViDiAs participants must have had 
treatment at BTS step 2 or 3, FEV1> 50% of predicted value and no tobacco product use within the 
previous 6 months, while ViDiCO participants must have had a post-bronchodilator FEV1 ≥ 40% of 
predicted value and have been an ex-smoker for ≥ 6 months.   
 
Sputum inductions were carried out and samples collected according to standard protocols as 
described elsewhere [455].  After  ensuring that the participant had not experienced an exacerbation 
or URTI within the last 28 days, pre- and post-bronchodilator FEV1 values were obtained, with a  
post-bronchodilator FEV1 of  >1 litre necessary to continue.  From these values safety thresholds 
were calculated, with post-bronchodilator FEV1 required to be ≥50% predicted for ViDiAs, and ≥40% 
predicted for ViDiCO.  Induction with 4.5% nebulised saline at a rate of 1ml/minute was then carried 
out for 5 minutes, with expectoration following this.  Nebulisation was carried out a maximum of 3 
times to obtain an adequate sample, with FEV1 determined following each nebulisation to ensure 
that there had not been a ≥ 20% fall in FEV1 from the baseline post-bronchodilator value.  Collected 
sputum samples were kept on ice until processing.    
 
 
2.1.7 Blood samples 
 
Participants from all three trials had blood samples taken at screen, 2 months post randomisation 
and 12 months post randomisation by a member of the study team who was a trained phlebotomist. 
There was a limit to the volume of blood permitted to be taken from each participant at each study 
visit, with 6ml allocated for immunological tests.  This 6ml of blood was collected into a sodium 
heparin vacutainer (BD, Franklin Lakes, USA) and kept at 4oC until stimulation as part of a whole 
blood assay to investigate effects of vitamin D supplementation on the release of inflammatory 
mediators.  
 
Blood was also collected into serum separating tubes (SST) and underwent centrifugation to yield 
serum samples.  Serum concentrations of 25(OH)D2 and 25(OH)D3 were measured by Marion Rowe 
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(Department of Clinical Biochemistry, Homerton Hospital, London) by isotope-dilution liquid 
chromatography–tandem mass spectrometry [456], and summed to give values for total 25(OH)D 
concentration. Sensitivity for this assay was 10nmol/l.  Coulter counts were carried out on whole 
blood samples to enumerate leukocyte populations by the Haematology Laboratory at the Royal 
London Hospital. 
 
 
2.2 Stimulation of whole blood with TLR ligands and pathogens 
 
Whole blood collected from study participants was stimulated with TLR ligands and pathogens.  
180µl of blood was incubated with 20µl of stimulant or D-PBS in a humidified incubator at 37oC and 
5% CO2   for 24 hours.  Following this, plasma was aspirated and stored at -80
oC until further analysis 
by multiplex ELISA. 
 
 
2.2.1 TLR ligand preparation 
 
TLR ligands (InvivoGen, San Diego, USA) were dissolved according to product inserts to provide stock 
solutions, before being further diluted using Dulbecco’s phosphate buffered saline (D-PBS) (Sigma-
Aldrich, St Louis, USA) to produce the required working concentration (Table 2.4).  Sterile 96-well 
polystyrene microplates (Corning Incorporated, Corning, USA) were prepared by adding 20µl of D-
PBS or TLR ligand to the appropriate wells, before being stored at -80oC until use.   
 
Table 2.4: TLR ligands used in this study 
Antigen Dissolve In Stock Conc. Working Conc. Final Conc. 
LPS 1ml sterile water 5mg/ml 1μg/ml 0.1μg/ml 
Pam2CSK4 1ml endotoxin free water 100μg/ml 0.1μg/ml 0.01μg/ml 
Pam3CSK4 1ml endotoxin free water 1mg/ml 10μg/ml 1μg/ml 
CpG-ODN 2216 2ml endotoxin free water 100μg/ml 100μg/ml 10μg/ml 
Poly I:C 2.5ml endotoxin free water 10mg/ml 1mg/ml 100μg/ml 
R848 500μl endotoxin free water 1mg/ml 10μg/ml 1μg/ml 
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2.2.2 Pathogen preparation 
 
Pathogens were kindly provided by Professor Johnston’s lab at the National Heart and Lung Institute, 
Imperial College London.   
 
For both RV-16 and RV-1B, viral stocks were generated following standard procedures [457].  HeLa 
Ohio cell monolayers (MRC Common Cold Unit, Salisbury, UK) were infected and, when cytopathic 
effect (CPE) was fully developed, freeze/thaw cycles were carried out to lyse the cells, before 
centrifugation to pellet the debris.  The viruses were concentrated using filtration columns, before 
aliquots were frozen and placed in -80oC storage.  Titration of the frozen aliquots was performed by 
exposing confluent monolayers of HeLa cells to serial dilutions of the viral stock.  Cells were cultured 
at 37oC in 5% CO2 with plates inspected daily for cytopathic effect before fixation and staining with 
5% formaldehyde, 5% ethanol and 0.1% crystal violet in PBS.  The endpoint titre, defined as the 
highest dilution at which CPE was observed in half or more of the wells, was read and expressed as 
the inverse log of this dilution, giving a final TCID50/ml of 9.82 x 10
7 for RV-16, and 8.76 x 107 for RV-
1B.  
 
Respiratory syncytial virus (RSV) (strain A2) was grown on Hep2 cells and confluent cell monolayers 
were incubated for 4 hours at 37oC, 5% CO2.  2% FCS medium was added, and after 48 hours 
(approximately 70% cytopathic affect) the virus was harvested.  Following a 5 minute sonication 
using an ice bath, samples were centrifuged to remove cell debris, and the viruses were snap frozen 
using liquid nitrogen, before being transferred to -80oC storage.  Titration was carried out on Hep2 
cells by fixing with methanol and staining for RSV, before brown plaques were counted, giving a titre 
of 4 x 106 PFU/ml (plaque forming units). 
 
S.pneumoniae (strain D39) was grown on Todd Hewitt+yeast broth, and once at an OD of 0.4 read at 
600nm, was added to 10% glycerol and aliquoted.  Titration was carried out on solid media 
(Columbia horse blood agar) by serial dilution, and the numbers of colonies were counted, giving a 
titre of 2.3 x 108 CFU/ml (colony forming units).   
 
H.influenzae (Strain ATCC 49247) was grown in Brain Heart Infusion broth + haem supplement.  Once 
at an OD of 0.4 read at 600nm, 10% glycerol was added and it was aliquoted.  Titration was carried 
out on solid media using serial dilutions, and the numbers of colonies were counted, giving a titre of 
8.13 x 108 CFU/ml.   
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Aliquots of the pathogens were thawed daily and added to the prepared 96-well microplates to 
avoid repeated freeze-thaw cycles.  The viruses RV-16, RV-1B and RSV were added neat, with 20μl 
and 180µl of blood per well, resulting in a final concentration in the blood of 1/10.  The bacteria 
H.influenzae and S.pneumoniae were diluted to 1/100 in D-PBS before 20μl was added to each well, 
resulting in a final concentration in the blood of 1/1000.  Therefore, the final titres of each pathogen 
when diluted 1/10 in the blood were: RV-16 9.82 x 106 TCID50/ml, RV-1B 8.76 x 10
6, RSV 4 x 105 
PFU/ml, S.pneumoniae 2.3 x 105 CFU/ml and H.influenzae 8.13 x 105 CFU/ml.   
 
 
2.3 Processing induced sputum samples 
 
2.3.1 Cytospin preparation from induced sputum samples 
 
Sputum samples were processed according to methods described elsewhere [455], and all 
procedures were carried out on ice or at 4oC.  Sputum plugs from induced sputum samples were 
selected using forceps and condensed into one mass of approximately 100mg – 500mg.  A 1% stock 
solution of DL-Dithiothreitol (DTT) (Sigma-Aldrich) was initially prepared using dH2O, with a 
subsequent dilution using D-PBS to produce a 0.1% working solution.  A volume of 4ml of 0.1% DTT 
per 1g of selected sputum was added to the sample, and placed on a bench rocker for 15 minutes.  
Following this, an equal volume of D-PBS was added and the contents filtered through 48μm nylon 
gauze (SEFAR LTD, Bury, UK).  After centrifugation at 790g for 10 minutes, the supernatant was 
aspirated and stored at -80oC for subsequent analysis by multiplex ELISA, and the pellet resuspended 
in D-PBS to give a concentration of 0.5 x 106 cells/ml.  The resulting solution was used to produce 
cytospin slides using a Shandon Cytospin Cytocentrifuge (Thermo Scientific, Waltham, USA), with 3 
slides produced from every sample.  Slides were stained using a Hemacolor Rapid Staining Kit 
(Merck, Whitehouse Station, USA) and a coverslip added, before a differential cell count was carried 
out.      
 
 
2.3.2 Differential cell counts of induced sputum samples 
 
Slides were studied under a microscope and the number of eosinophils, neutrophils, columnar 
epithelial cells, lymphocytes and macrophages were counted using a tally counter until the total 
reached 400 cells.  Counts were done in this way for 3 cytospin slides for each sputum sample and 
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averages were taken.  Percentages of each cell type were recorded, and absolute numbers were 
calculated using the total number of leukocytes in the sample as determined using a 
haemocytometer preceding centrifugation during sputum processing.       
 
 
2.4 Flow cytometry 
 
Flow cytometry was used to enumerate leukocyte populations in induced sputum and peripheral 
whole blood.  Monoclonal mouse anti-human antibodies were acquired from BD (Franklin Lakes, 
USA) or Miltenyi Biotec (Cologne, Germany), as detailed in Table 2.5.  Combinations of monoclonal 
mouse anti-human antibodies were used in equal volumes to create master mixes (Table 2.6), with 
mouse IgG1 isotype controls for FITC, PE, APC and Alexa Fluor 647 (BD, Franklin Lakes, USA) used to 
facilitate determination of DC and Treg populations.  
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Table 2.5 Monoclonal mouse anti-human antibodies used in this study 
Antibody - Conjugate  Target for this Study Manufacturer (catalogue number) 
CD3 - FITC * T-Cells BD (345763) 
CD3 - PerCP T-Cells BD (345766) 
CD4 - APC Helper T-Cells BD (555349) 
CD4 - PE Helper T-Cells BD (345769) 
CD8 - PE Cytotoxic T-Cells BD (555367) 
CD11c - PE Myeloid DCs BD (555392) 
CD14 - FITC * Monocytes BD (345784) 
CD16 - FITC * Granulocytes BD (555406) 
CD19 - FITC * B-Cells BD (555412) 
CD20 - FITC * B-Cells BD (555622) 
CD25 - FITC Regulatory T-Cells BD (555431) 
CD56 - FITC * Natural Killer Cells BD (345811) 
CD127 - Alexa Fluor 647 Naive T-Cells BD (558598) 
BDCA-4 - APC Plasmacytoid DCs Miltenyi Biotec (130-090-900) 
HLA-DR - PerCP Dendritic Cells BD (347402) 
FITC isotype control n/a BD (555748) 
Alexa Fluor 647 isotype control n/a BD (557714) 
APC isotype control n/a BD (555751) 
PE isotype control n/a BD (555749) 
*Antibodies used in Lineage Cocktail 
 
Table 2.6 Antibody master mixes used for flow cytometry  
Master Mix  FITC PE PerCP APC Alexa 647 
Lymphocyte CD19 CD8 CD3 CD4 n/a 
Treg CD25 CD4 CD3 n/a CD127 
DC Lin Cocktail* CD11c HLA-DR BDCA-4 n/a 
Treg Isotype Isotype  CD4 CD3 n/a Isotype 
DC Isotype Lin Cocktail* Isotype HLA-DR Isotype n/a 
* Lineage Cocktail as detailed in Table 2.5 
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2.4.1 Flow cytometric analysis of peripheral whole blood 
 
In addition to stimulation with pathogens and TLR ligands in the whole blood assay, a subset of 
whole blood samples underwent further analysis by flow cytometry. 
 
3µl of the required antibody master mixes (Table 2.6) were incubated with 125µl of whole blood at 
4oC for 45 minutes in the dark.  Following this, 2ml of 1x FACs lysing solution (BD, Franklin Lakes, 
USA), was added and the solution left to stand until reaching transparency, or for a maximum of 5 
minutes, before centrifugation at 200g for 5 minutes.  The supernatant was discarded and the pellet 
resuspended in 1ml of FACSFlow Sheath Fluid (BD, Franklin Lakes, USA), before being centrifuged 
again.  This resuspension and centrifugation was repeated once more, before the pellet was finally 
resuspended in 500µl of FACSFlow.  Samples were left on ice until analysis using a BD FACS Canto II 
machine and FACSDiva software.    
 
 
2.4.2 Flow cytometric analysis of induced sputum 
 
In addition to cytospin production and differential cell counts, a subset of sputum samples 
underwent further analysis by flow cytometry.  Sputum was processed as above until the point of 
filtration.  Upon determination of cell numbers, if adequate cells (> 2 million) were present in the 
sample the solution was split, resulting in one cell suspension for cytospin production (described 
above) and one cell suspension (containing > 1 million cells) for flow cytometric analysis.   
 
The separated cell suspension was centrifuged at 790g for 10 minutes at 4oC, before the pellet was 
re-suspended in 700μl of 4% FCS in FACSFlow Sheath Fluid.  3µl of the required antibody master 
mixes (Table 2.6) were incubated with 100ul of cell suspension at 4oC for 30 minutes in the dark.  
Following this, 1ml of 4% FCS in FACSFlow was added to each tube, before undergoing centrifugation 
at 200g for 5 minutes and the supernatant was discarded.  The pellet was resuspended in 1ml of 4% 
FCS in FACSFlow, centrifuged again, and the resulting pellet resuspended in 250μl of 1% PFA in 
FACSFlow. Samples were left on ice until analysis using a BD FACS Calibur machine and CellQuest Pro 
software.  
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2.4.3 Foxp3 staining 
 
Forkhead box protein 3 (Foxp3) is a transcription factor specifically expressed in Tregs which is 
required in maintaining their regulatory function [458, 459].  A subset of sputum and blood samples 
underwent FoxP3 staining to validate the results generated using CD25 and CD127 as markers of 
Tregs using an Anti-Human Foxp3 APC Staining Set (eBioscience, San Diego, USA). 
 
Two 9µl solutions containing equal volumes of the antibodies CD25-FITC, CD4-PE and CD3-PerCP 
(BD) were each incubated at 4oC for 45 minutes in the dark with 200µl peripheral whole blood, or 
100µl of an induced sputum solution containing at least 1 million cells.  Blood samples underwent an 
additional step at this point of being mixed with 2ml of 1x FACs lysing solution (BD, Franklin Lakes, 
USA) until reaching transparency or for a maximum of 5 minutes, before centrifugation at 200g for 5 
minutes.  After discarding the supernatant, the pellet was resuspended in 1ml FACSFlow, while the 
sputum sample solution had 1ml of 4% FCS in FACS Flow added to it.  Both blood and sputum 
samples were centrifuged at 200g for 5 minutes, the supernatant discarded and the pellet 
resuspended in 1ml FACSFlow or 4% FCS in FACSFlow respectively.  This centrifugation was repeated 
and the pellets resuspended in 1ml of 1x Fixative solution, before being incubated in the dark at 
room temperature for 45 minutes.  Following this, 1ml of 1x permeabilisation buffer was added and 
the samples centrifuged at 200g for 5 minutes.  The supernatant was discarded, the pellet 
resuspended in 1ml of 1 x permeabilisation buffer and the centrifugation repeated, before 5µl of 
FoxP3 or Rat IgG Isotype was added to the appropriate tubes.  The samples were incubated in the 
dark at room temperature for 45 minutes.  Following this, 1ml of 1x permeabilisation buffer was 
added and the samples centrifuged at 200g for 5 minutes.  The supernatant was discarded, the 
pellet resuspended in 500µl of FACSFlow and the centrifugation repeated.  The resulting pellet was 
resuspended in 500µl of FACSFlow, and the samples were left on ice until analysis using a BD FACS 
Calibur machine and CellQuest Pro software (sputum) or BD FACS Canto II machine and FACSDiva 
software (blood). 
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2.4.4 Gating technique to determine lymphocyte populations 
 
Lymphocytes were gated on based on their forward and side scatter properties (Figure 2.1).  B-cells 
were distinguished as the CD3-CD19+ population, while T-cells were selected as being CD3+CD19-.  
The CD3+ population was divided into CD4+ and CD8+ T-cells to enable enumeration of the two main 
phenotypes of helper and cytotoxic T-cells.   
 
 
Figure 2.1:  Gating technique for lymphocytes subtypes. Lymphocytes were gated on based on their forward 
and side scatter properties.  CD19
+
CD3
- 
cells were characterised as B-cells, and CD3
+
 subsets were selected and 
differentiated as CD4
+
 or CD8
+ 
T-cells. 
 
 
 
2.4.5 Gating technique to determine dendritic cell populations 
 
Dendritic cells were selected by gating for lymphocytes based on their forward and side scatter 
properties.  From this population, cells that were Lineage Cocktail negative (CD3-, CD14-, CD16-, 
CD19-, CD20-, CD56-) and HLA-DR+ were selected as being dendritic cells (Figure 2.2).  From this 
population, myeloid DCs were selected as being CD11c+BDCA-4- and plasmacytoid DCs as being 
CD11c-BDCA-4+.  Isotype controls were used to help determine what constituted the CD11c+BDCA-4- 
population. 
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Figure 2.2:  Gating technique for dendritic cells.  Lymphocytes were gated on based on their forward and side 
scatter properties, and dendritic cells were selected as being HLA-DR
+ 
Lineage Cocktail
-
.  From this population, 
mDCs were characterised as being CD11c
+
BDCA-4
-
, and pDCs as being CD11c
-
BDCA-4
+
. 
 
 
 
2.4.6 Gating technique to determine regulatory T-cell populations 
 
To enumerate regulatory T-cells, lymphocytes were gated on based on their forward and side scatter 
properties.  The CD3+CD4+ population was selected and used to determine CD25+CD127- T-regs 
(Figure 2.3).  Isotype controls were used to help determine what constituted the CD25+CD127- 
population. 
 
Figure 2.3:  Gating technique for regulatory T-cells.  Lymphocytes were gated on based on their forward and 
side scatter properties.  CD3
+
CD4
+ 
cells were selected and Tregs were characterised as being CD25
+
CD127
-
. 
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In a subset of samples FoxP3 staining was used to validate the results generated using CD25 and 
CD127 as markers of Tregs, using an Anti-Human Foxp3 APC Staining Set.  Following gating of the 
lymphocyte population based on forward and side scatter properties and selection of the CD3+CD4+ 
population as before, regulatory T-cells were distinguished as being CD4+CD25+FoxP3+ (Figure 2.4).  
Isotype controls were used to help determine what constituted the CD25+ population.  
 
 
Figure 2.4:  Gating technique for regulatory T-cells using the transcription factor FoxP3.  Lymphocytes were 
gated on based on their forward and side scatter properties.  CD3
+
CD4
+ 
cells were selected and Tregs were 
characterised as being CD25
+
FoxP3
+
. 
 
 
2.5 TNF-  and IFN- A2 ELISA 
 
During development of the whole blood assay, aspirated plasma samples from whole blood 
stimulated with TLR ligands or pathogens were analysed by ELISA to assay concentrations of TNF-α 
or IFN-αA2.  Meso Scale Discovery ® (MSD) ultra-sensitive cytokine assay kits (Rockville, Maryland, 
USA) were used for all experiments involved in the development of the whole blood assay except 
the final bacterial dose response, for which a Quantikine ® TNF-α immunoassay (R&D Systems, 
Minneapolis, Minnesota, USA) was used. 
 
 
2.5.1 Meso Scale Discovery ® (MSD) ultra-sensitive assay 
 
Single-spot plates were used for both the IFN-αA2 and TNF-α assays, following the manufacturer’s 
instructions.  All reagents and samples were thawed and brought to room temperature.  25µl of 
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Diluent 2 was added to each well, before incubation on a plate rocker (300 – 1000rpm) at room 
temperature for 30 minutes.  Calibrator solutions were prepared, with an initial 1:100 dilution of the 
stock solution using Diluent 2, before a serial 1:4 dilution.  25µl of sample or calibrator solutions 
were added to the appropriate wells, before incubation on a plate rocker (300 – 1000rpm) at room 
temperature for 2 hours.  The plate was washed three times with PBS-T (phosphate buffered saline 
with 0.05% Tween), before addition of 25µl of 1X Detection Antibody Solution to each well.  
Following a 2 hour incubation on the plate rocker (300 – 1000rpm) at room temperature, the plate 
was washed 3 times with PBS-T, and 150µl of 2X Read Buffer was added to each well.  Plates were 
analysed using a SECTOR Imager 6000 and MSD Discovery Workbench software.    
 
       
2.5.2 Quantikine ® TNF-  immunoassay 
 
A TNF-α ELISA was carried out following manufacturer’s instructions.  All samples and reagents were 
thawed and brought to room temperature, before 50µl Assay Diluent RD1F was added to all wells.  
Plasma samples were diluted 1:5 using Calibrator Diluent RD6-35, and standards were prepared 
using an initial 1:10 dilution and a subsequent 1:2 serial dilution.  200µl of standards or samples 
were added to the appropriate wells, before incubation for 2 hours at room temperature.  The plate 
was washed 4 times using Wash Buffer, before addition of 200µl TNF-α Conjugate to each well.  
Plates were incubated for 2 hours at room temperature, before being washed 4 times using Wash 
Buffer.  200µl Substrate Solution was added to each well, and following a 20 minute incubation at 
room temperature in the dark, 50µl Stop Solution was added to each well.  Plates were read 
immediately on a Bio-Rad 680 microplate reader (Bio-Rad, Hercules, California, USA) at 450nm and 
570nm for wavelength correction.     
 
 
2.6 Multiplex ELISA 
 
Induced sputum supernatants acquired during cytospin preparation, aspirated plasma from whole 
blood stimulation with TLR ligands and pathogens, and supernatants from in vitro cell culture 
underwent multiplex ELISA analysis to enable quantification of the concentration of a panel of 30 
inflammatory mediators (IL-1β, IL-2, IL-4, IL-5, Il-6, IL-7, IL-8 (CXCL8), IL-10, IL-12, IL-13, IL-15, IL-17, 
IL-1RA, IL-2R, IFN-α, IFN-γ, TNF-α, MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), 
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eotaxin (CCL11), MIG (CXCL9), IP-10 (CXCL10), EGF, FGF-basic, HGF, VEGF, G-CSF, GM-CSF).  The 
Invitrogen Human Cytokine Magnetic 30-plex Panel was used (Invitrogen, Camarillo, CA, USA), 
following manufacturer’s instructions.  25µl of the antibody bead solution was added to each well of 
a 96-well plate, before washing two times with 200µl wash solution and the addition of 50µl of 
incubation buffer.  Standards were prepared using a serial 1:2 dilution, with 100µl standard or 50µl 
assay diluents + 50µl sample added to the appropriate wells.  Following a 2 hour incubation at room 
temperature on an orbital shaker, the plate was washed twice with 200µl wash solution, and 100µl 
of 1x biotinylated detector antibody was added to each well.  After a 1 hour incubation at room 
temperature on an orbital shaker, the plate was washed twice with 200µl wash solution, 100µl of 1x 
streptavidin-RPE was added to each well, and the plate was incubated for a further 30 minutes.  
Three washes with 200µl wash solution were carried out, before 125µl wash solution was added to 
each well to re-suspend the beads.  Plates were analysed using the Magpix ® platform (powered by 
Luminex xmap Technology) and the Luminex xponent ® software.  
 
 
2.7 Genetic analysis of SNPs associated with vitamin D status or disease 
risk 
 
All genetic analyses were performed by David Jolliffe (Blizard Institute, Queen Mary University of 
London).  A systemic literature review was carried out which identified 54 single nucleotide 
polymorphisms (SNPs) in 11 genes in the vitamin D pathway, and one SNP in the class I MHC-
restricted T-cell-associated molecule (CRTAM) gene which has been reported to modify the influence 
of vitamin D status on asthma exacerbation risk [460], which were typed using Taqman allelic 
discrimination assays.  For those SNPs in high linkage disequilibrium (r2 ≥ 0.8) according to the 
HapMap database (release #27), six tag SNPs were selected as proxies using a previously-developed 
algorithm [461] and were typed (Table 2.7).  DNA was extracted from peripheral whole blood using 
the salting-out method [462] on the Miomek FX robot (Beckam Coulter), quantified using the 
Nanodrop spectrophotometer and normalized to 5ng/µl.  10ng DNA was used as a template for 2µl 
Taqman assays (Applied Biosystems, Foster City, California, USA) performed on the ABI 7900HT 
platform in 384-well format before analysis with Autocaller software.  Pre-developed assays were 
used to type all SNPs except three, which had customized assays:  
rs2740574 in CYP3A4 (forward primer sequence CCAGGCATAGGTAAAGATCTGTAGGT, reverse primer 
sequence CTCAAGTGGAGCCATTGGCATA, reporter sequences ACAAGGGCAAGAGAG and 
ACAAGGGCAGGAGAG); rs3740165 in CUBN (forward primer sequence 
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GCAATGAGATTAAATCTTCAGGAAACACA, reverse primer sequence 
CTGGAGGTATAGGAAGCAGTGAAG, reporter sequences CCGCCATATGGCCTG and 
CGCCATACGGCCTG); rs7861779 in RXRA (forward primer sequence TGGCCCATGCACGAGTAG, 
reverse primer sequence ACCGAGACAGGCCAAACTC, reporter sequences CAGCAGAGGTGGCCGA and 
CAGCAGAGATGGCCGA).  Alleles at all loci conformed to the Hardy-Weinberg equilibrium. Typing for 
two SNP (rs6127118 and rs11574010) failed.   
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Table 2.7: Single nucleotide polymorphisms (SNPs) identified as putative modifiers of the effects of 
vitamin D supplementation 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 Six tag SNP were selected as proxies for target SNP in high linkage disequilibrium (r
2
 ≥ 0.8) in the HapMap 
database (release #27) and typed 
 
Abbreviations used: CYP: cytochrome p450 family of enzymes; VDR: vitamin D receptor; DBP: vitamin D binding protein; DHCR7: 7-
dehydrocholesterol reductase; CUBN: intrinsic factor-cobalamin receptor / cubilin; RXRA: retinoid x receptor alpha; LRP2: low density 
lipoprotein receptor-related protein 2 / megalin; CRTAM: class I MHC-restricted T-cell-associated molecule; utr: untranslated region 
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2.8 A549 cell culture and stimulation 
 
A549 cells (obtained from Sigma-Aldrich) were cultured in complete Dulbecco’s Modified Eagle 
Medium (DMEM), containing 10% FCS, 1% penicillin/streptomycin and 1% L-glutamine (all obtained 
from Lonza, Basel, Switzerland).  Upon reaching confluence, cells were trypsinized and resuspended 
in complete DMEM giving a concentration of approximately 200,000 cells/ml.  1ml was added to 
each well of a 24-well plate, and cells were incubated for 24 hours at 37oC with 5% CO2.  
Subsequently, supernatants were aspirated and cells were incubated for 48 hours with 25(OH)D or 
1,25(OH)2D at final concentrations of 10
-7M, or vehicle (0.1% ethanol).  Following this, supernatants 
were aspirated, and 200µl of incomplete media, RV-16 (MOI 1), filtered virus, or UV-inactivated virus 
were added.  After incubation at room temperature on an orbital shaker for 1 hour, supernatants 
were aspirated, and replaced with 200µl of incomplete DMEM, before a further 5 or 23 hour 
incubation at 37oC with 5% CO2.  Supernatants were aspirated and either used immediately in the 
toxicology assay, or stored at -80oC for subsequent analysis, and 350µl Buffer RLT (Qiagen, Valencia, 
USA) was used for cell lysis, with the lysates stored at -80oC for subsequent RNA extraction.   
A549 cells used in these experiments were passaged no more than 20 times. 
 
 
2.8.1 Vitamin D metabolite preparation 
 
1α,25-Dihydroxyvitamin D3 and 25-Hydroxycholecalciferol (Sigma-Aldrich) were dissolved in 
anhydrous ethanol to stock concentrations of 10-4M.  They were stored at -80oC under a layer of 
argon to prevent oxidization.  The final concentrations of 10-7M were obtained following dilution in 
incomplete DMEM containing 2% FCS. 
 
 
2.8.2 Stimulant preparation 
 
RV-16 stocks were kindly provided by Professor Johnston’s lab at the National Heart and Lung 
Institute, Imperial College London, and prepared as described previously.  Viral controls were 
obtained by filtering the virus using Amicon Ultra centrifugal filters with a 30kDa molecular weight 
cut-off pore size (Sigma-Aldrich), or by UV-inactivation for 30 minutes at 120,000µJ/cm2 using a UV 
crosslinker.    
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2.8.3 Toxicology assay 
 
Cytotoxicity was measured using a lactate dehydrogenase (LDH)-based in vitro toxicology assay kit 
(Sigma-Aldrich).  50µl supernatants were aspirated following cell culture of A549 cells (as described 
above) and a 100µl mixture of equal volumes of LDH assay substrate solution, LDH assay dye 
solution and 1 x LDH assay cofactor preparation was added.  Following incubation in the dark at 
room temperature for 20 minutes, the reaction was terminated by the addition of 20µl 1N 
hydrochloric acid.  Absorbance was measured spectrophotometrically at a background wavelength 
of 650nm, which was subtracted from the measurements obtained at a wavelength of 450nm. 
 
 
2.8.4 Cytopathic effect (CPE) assay  
 
A549 cells were co-cultured with vitamin D metabolites or vehicle before infection for 6 or 24 hours 
with RV-16, and supernatants were aspirated and stored at -80oC, as described above.  Supernatants 
were thawed and serial 1 in 10 dilutions were prepared using complete DMEM.  Five dilutions were 
prepared for each sample in total, (including a neat sample), and 50µl of each were plated in 
quadruplicate in a 96-well plate.  A 150µl volume of HeLa Ohio cells (1 x 105 cells/ml) was added to 
each well, before incubation at 37oC with 5% CO2 for 4 days.  Cytopathic effect was observed by light 
microscopy, and TCID/50 values were calculated using the Spearman-Kaerber method [463, 464].  
 
 
2.9 RNA extraction and RT-PCR 
 
RNA extraction was carried out using an RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions.  RNA was immediately reverse transcribed using SuperScript VILO Mastermix 
(Invitrogen, Life Technologies), with each reaction volume containing 9µl of RNA following the 
manufacturer’s instructions, and stored at -80oC.   
 
In a 20µl reaction volume, 1µl of cDNA was used for quantitative RT-PCR, using TaqMan gene 
expression master mix (Applied Biosystems, Life Technologies) and pre-developed TaqMan gene 
expression assays for ICAM-1, CYP27B1, CYP24A1, IκBα, IFN-β, IFN-α2, HBD2, CAMP and PafR (Table 
2.8).  Gene expression assays had a FAM reporter dye at the 5′ end of the TaqMan MGB probe and a 
non-fluorescent quencher at the 3′ end of the probe.  Each assay was a 20x mix, with primers 
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present at a concentration of 18µM and probes at a concentration of 5µM.  A gene expression assay 
for viral mRNA was custom-made (Table 2.9), with final concentrations of 50nM forward primer, 
300nM reverse primer and 100nM probe used as described elsewhere [465].  All samples were run 
in triplicate.  A 7500 Real Time PCR System (Applied Biosystems) and 7500 software v2.0.6 were 
used with thermal cycling conditions set according to the manufacturer’s instructions.  Each reaction 
was normalised to the GAPDH content, and the ΔΔCT method was used to give the fold induction 
over unstimulated samples.     
 
Table 2.8 Assay ID for TaqMan Gene Expression Assays Used 
Gene Assay ID (Life Technologies) 
GAPDH Hs02758991_g1 
ICAM-1 Hs00164932_m1 
CYP27B1 Hs01096154_m1 
CYP24A1 Hs00167999_m1 
IκBα Hs00355671_g1 
IFN-β Hs01077958_s1 
IFN-α2 Hs00265051_s1 
HBD2 Hs00823638_m1 
CAMP Hs00189038_m1 
PafR Hs00265399_s1 
 
 
Table 2.9 RV-16 Primer and Probe Sequences (5′ – 3′) 
Gene Forward Primer Reverse Primer Probe 
RV-16 GTGAAGAGCCSCRTGTGCT GCTSCAGGGTTAAGGTTAGCC TGAGTCCTCCGGCCCCTGAATG 
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2.10 Statistical analysis 
 
All data were checked visually for normal distribution.  Analyses of in vitro A549 work, vitamin D 
status, and patient characteristics were carried out using GraphPad Prism version 6.04 (GraphPad 
Software Inc, La Jolla, USA), and normally distributed data are presented as means + SEM, with 
Student’s T-tests or one-way ANOVA used to determine any statistically significant differences 
between data-sets, while non-normally distributed data are presented as median + IQR, with Mann-
Whitney or Kruskal-Wallis tests used to determine any statistically significant differences between 
data-sets.  Contingency tables were also used to compare participant characteristics and were 
analysed using a chi-squared test.  Significance was inferred for p < 0.05 throughout.  Method 
validation was carried out using Pearson’s R Correlation Test and Bland-Altman analysis, also using 
GraphPad Prism.   
 
Clinical samples were analysed using the statistical programme Qlucore Omics Explorer 2.3 (Lund, 
Sweden).  Analyte concentrations were automatically generated from the MFI values recorded 
following Magpix analysis, and values lower than the sensitivity thresholds stated on the technical 
data sheets were assigned a value of 0 pg/ml.  For the whole blood assay results, the unstimulated 
control was subtracted from each stimulus.  A small constant for each analyte was added where 
necessary, sufficient to ensure all values were positive.  Log2 transformation was carried out on all 
data to achieve normal distribution and minimise variance, and K nearest neighbour (KNN) 
imputation was used for missing values.  For prospective analyses, interaction variables were 
generated for each data point for time-point and allocation (i.e. p1 for a baseline placebo sample, p2 
for a 12 month post-randomisation placebo sample, d1 for a baseline intervention sample, d2 for a 
12 month post-randomisation intervention sample).  A multi-group comparison was carried out on 
the log transformed data using Qlucore Omics Explorer on these interaction variables, which equates 
to a repeated measures ANOVA test, with this model including adjustment for time-point, allocation 
and study.  An important assumption of repeated measures ANOVA is sphericity, whereby the 
variance of the differences between all combinations of groups is equal.  A violation in sphericity, 
where the variances are not equal, can increase type I error.  Data were log transformed to minimise 
variance, and Qlucore also automatically measures the extent to which sphericity is violated, with p-
values calculated taking this violation into account using the Greenhouse-Geisser method [466]. 
  
Cross-sectional analysis of baseline data was also carried out on log2 transformed data using Qlucore 
Omics Explorer.  Analysis was modelled using a two-group comparison between each study (i.e. 
asthma, COPD, or people with neither condition living or working in sheltered accommodation), 
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which is the equivalent to Student’s T-test.  The model included adjustment for age, sex, baseline 
25(OH)D concentration, ethnicity, smoking status, vaccination record and inhaled corticosteroid use.               
 
For both prospective and cross-sectional analysis, data are presented as raw median values, i.e. 
before log transformation, with IQRs only stated when a statistical significant difference was 
evident.  The Benjamini-Hochberg procedure for multiple testing correction was applied to analysis 
to give a measure of the false discovery rate at 10% [467].  Significance was inferred for p < 0.05 
throughout when associated with false discovery rate (q) < 0.1.  
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3. Development of a whole blood assay to investigate effects of 
vitamin D on the immune response to TLR ligands and respiratory 
pathogens 
 
3.1 Introduction 
 
As detailed in Chapter 1.10, vitamin D deficiency has previously been associated with an increased 
risk of acute respiratory tract infections, with supplementation demonstrating a protective effect in 
some intervention studies [468].  A variety of immunological actions have also been described from 
in vitro models, although the effects of vitamin D on cytokine and chemokine production have not 
been definitively characterised.  Since the focus of this study is the immunomodulatory actions of 
vitamin D in the protection against respiratory tract infections, an assay was developed to assess the 
effect of in vivo vitamin D supplementation on the release of inflammatory mediators in peripheral 
blood following ex vivo stimulation with TLR ligands and respiratory pathogens.   
 
For these preliminary experiments, aimed around developing the assay for further use, TLR ligand 
concentrations were selected based on the InvivoGen product inserts and the literature available 
[469-474], and pathogens were diluted down from the prepared stock solutions provided by the 
Johnston laboratory (as described in Chapter 2.2.2).  The TLR ligands used are listed in Table 3.1.  The 
only cytokines measured were TNF-α in response to bacterial stimuli, and IFN-αA2 in response to 
viral stimuli.  TNF-  is a pleiotropic pro-inflammatory cytokine and pyrogen, which is vital in the 
innate immune response, especially to bacteria.  Its functions include stimulation of acute phase 
protein synthesis, increasing vascular permeability to enhance leukocyte migration from the blood, 
activation of endothelial cells to trigger clotting and containment of infection, stimulation of DC 
maturation, and generation of reactive oxygen species [77, 475]. Additionally, it has been 
demonstrated to upregulate CYP27B1 mRNA expression in microglia and astrocytes [476], suggesting 
a potential role in the local generation of active 1,25(OH)2D to exert its immunomodulatory effects.  
LPS, H.influenzae and S.pneumoniae are all potent stimulators of TNF-  production [477-479], with 
TNF-  antagonism from agents such as Infliximab associated with an increased risk of upper 
respiratory tract infections [480].  TNF-α is also thought to be of particular importance in asthma and 
COPD, with high levels of TNF-  linked to asthmatic complications [475], and an elevated 
concentration in whole blood associated with COPD disease severity and cachexia development 
[481].  Type I IFNs are vital in innate protection against viral infections, with features of the anti-viral 
state including resistance to viral replication, induction of apoptotic cell death in infected cells, 
88 
 
increased MHC class I expression, activation of DCs and macrophages, and stimulation of NK cells 
[43].  Of the main types of anti-viral IFN, IFN-  is the most strongly induced in whole blood cultures 
and PBMCs, with IFN-  the principal interferon produced in bronchial epithelial cells, and IFN-  
production induced in all cell types [482, 483].  The volume of whole blood used in the assay was 
based on restrictions of the amount of blood that could be taken from trial participants, whilst also 
ensuring a sufficient yield of plasma supernatant for analysis by multiplex ELISA.   
 
Therefore, an assay was developed using whole blood to investigate the effect of in vivo vitamin D 
supplementation on TNF-  or IFN- A2 secretion following ex vivo stimulation with TLR ligands and 
respiratory pathogens.  The optimum duration of co-culture of whole blood with stimuli, and the 
optimum concentration of each stimulus was determined, in order to optimise this assay and allow 
the characterisation of the effects of vitamin D on immune responses from future assays. 
 
  
Table 3.1: TLR ligands used and the PAMPs recognised 
TLR Location PAMP Recognised Relevant Pathogens Ligands (InvivoGen) 
1/2 Plasma membrane Triacyl lipopeptides Mycoplasma pneumoniae Pam3CSK4 
      Haemophilus influenzae  (Pam3) 
2/6 Plasma membrane Zymosan Streptococcus spp Pam2CSK4 
    Lipoteichoic acid Mycoplasma pneumoniae  (Pam2) 
    Diacyl lipopeptides Haemophilus influenzae   
3 Endosomal membrane ds RNA Rhinovirus PolyI:C 
    ss RNA Influenza A   
4 Plasma membrane LPS RSV LPS 
    Mannan Haemophilus influenzae   
    Envelope proteins Chlamydiophila pneumoniae   
    Glycoinositolphospholipids     
7/8 Endosomal membrane ss RNA Rhinovirus R848 
      RSV   
      Influenza A   
      Influenza B   
      Enterovirus   
      Metapneumovirus   
      Coronavirus   
9 Endosomal membrane ds DNA Adenovirus CpG ODN 
    CpG-DNA motifs     
    Hemozoin     
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3.2 Results 
 
3.2.1 Time course to determine the optimum duration of co-culture of whole blood with 
TLR ligands 
 
Initial concentrations of TLR ligands used for the time course were at the higher end of the 
suggested ranges in the literature and InvivoGen product inserts in order to ensure a response was 
seen [469-474].  Peripheral whole blood from 6 donors (2 healthy, 2 with asthma and 2 with COPD) 
was incubated with TLR ligands for 0, 3, 6 or 24 hours, as detailed in Chapter 2.2.  The plasma was 
aspirated and stored at -80oC before analysis by ELISA for either TNF-α or IFN-αA2, with the results 
presented in Figure 3.1.  TNF-α production following stimulation with LPS, Pam2CSK4 and Pam3CSK4 
was highest at the 6 hour time-point.  Incubation of whole blood with bacterial TLR ligands for 3 
hours or 24 hours, while lower than that achieved with 6 hour stimulation, resulted in a robust TNF-
α response, with levels of the cytokine diminished at the 0 hour time-point.  IFN-αA2 production 
following stimulation with CpG ODN and PolyI:C was highest at 24 hours, with concentrations 
undetectable at 0, 3 and 6 hours.  Stimulation of whole blood with R848 resulted in robust IFN-αA2 
production at all time-points, with the highest concentrations observed with co-incubation of 6 or 24 
hours.   As such, the 24 hour time-point was selected for use in further experiments, on the basis 
that this was the only time-point at which both TNF-α and IFN-αA2 responses to stimuli were 
detectable.
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Figure 3.1: Time course data for cytokine secretion in whole blood assay stimulated with TLR ligands.  Data are 
from 6 donors (2 healthy, 2 with asthma, 2 with COPD) with lines joining the data-points for each donor.   Blood 
was stimulated with the TLR ligands LPS (A), Pam2CSK4 (B), Pam3CSK4 (C), CpG ODN (D), PolyI:C (E) or R848 (F)  
for 0, 3, 6 or 24 hours, and TNF-α (A – C) or IFN-αA2 (D – F) concentrations were assayed.  The concentrations 
of TLR ligands used were: LPS 1μg/ml, Pam2CSK4 1μg/ml, Pam3CSK4 10μg/ml, CpG 10μg/ml, PolyI:C 100μg/ml, 
R848 10μg/ml. 
 
 
3.2.2 Dose response to determine the optimum concentration of TLR ligands to use for 
co-culture with whole blood 
 
Peripheral whole blood from 3 healthy donors was incubated with TLR ligands at the concentration 
used for the time-course experiment above, and at dilutions ten times and one hundred times lower 
to determine the optimal concentration to use for co-culture with whole blood.  Following 
incubation for 24 hours, plasma was aspirated and stored at -80oC before analysis by ELISA for either 
TNF-α for supernatants of whole blood stimulated with bacterial TLR ligands, or IFN-αA2 
supernatants of whole blood stimulated with viral TLR ligands, with the results presented in Figure 
3.2.   
 
The concentration of each stimulus to be employed in the assay was selected on the basis that it 
stimulated a cytokine response roughly 50% of the maximal response, so that any decrease or 
increase caused by vitamin D supplementation could be observed, and so that a significant response 
compared to PBS could be seen.  As such, the concentrations selected for use in further assays were 
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LPS at 0.1µg/ml, Pam2CSK4 at 0.01µg/ml, Pam3CSK4 at 1µg/ml, CpG ODN at 10µg/ml, PolyI:C at 
100µg/ml and R848 at 1µg/ml. 
Figure 3.2: Dose response data for cytokine secretion in whole blood stimulated with TLR ligands.  Data are 
from 3 healthy donors with lines joining the data-points for each donor.   Blood was stimulated for 24hours 
with PBS or the TLR ligands LPS (A), Pam2CSK4 (B), Pam3CSK4 (C), CpG ODN (D), PolyI:C (E) or R848 (F), and 
TNF-α (A – C) or IFN-αA2 (D – F) concentrations were detected. The highest concentrations of TLR ligands used 
were: LPS 1μg/ml, Pam2CSK4 1μg/ml, Pam3CSK4 10μg/ml, CpG 10μg/ml, PolyI:C 100μg/ml, R848 10μg/ml, 
with additional dilutions of 1:10 and 1:100.  
 
 
3.2.3 Dose response to determine the optimum titre of viral pathogens to use for co-
culture with whole blood 
 
Whole viruses were added to provide a more physiologically accurate stimulus of blood in order to 
determine the immune response induced by the ligation of multiple PRRs.  Rhinovirus and RSV were 
chosen due to their common precipitation of exacerbations in both asthma and COPD [146, 484-
487].  Two rhinovirus serotypes were used, one major (RV-16) and one minor (RV-1B), with the main 
difference being that major serotypes utilise ICAM-1 for cellular entry [488], while minor serotypes 
exploit low-density-lipoprotein receptors [489].   
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Peripheral whole blood from 6 healthy donors was incubated with virus for 24 hours.  Virus 
preparations were obtained from the Johnston laboratory (as detailed in Chapter 2.2.2) and were 
used undiluted (RV-16 at 9.82 x 107 TCID50/ml, RV-1B at 8.76 x 107 TCID50/ml and RSV at 4 x 106 
PFU/ml), and at dilutions of 1:2 and 1:5, with PBS used for a negative control.  The plasma was 
aspirated and stored at -80oC before analysis by ELISA for IFN-αA2 production, with results 
presented in Figure 3.3.  The titre of RV-16 selected for use in further assays was 9.82 x 107 
TCID50/ml, on the basis that this titre stimulated a cytokine response roughly 50% of the maximal 
response, so that any decrease or increase caused by vitamin D supplementation could be observed, 
and so that a significant response compared to the PBS negative control could be seen.  As it was 
desirable to be able to compare responses to the major and minor serotypes of rhinovirus between 
individuals, titres similar to each other were chosen for RV-16 and RV-1B, with a titre of 8.76 x 107 
TCID50/ml selected for RV-1B.  The IFN-αA2 response to RV-1B and RSV at titres of 8.76 x 107 
TCID50/ml and 4 x 106 PFU/ml respectively did not appear to be saturated, suggesting that any 
increase in cytokine production caused by vitamin D would still be able to be detected using this 
assay.  Additionally, the highest titres of RV-1B and RSV were able to induce detectable IFN-αA2 
production even in the donor with a diminished cytokine response to viral stimuli.  As such, the titre 
of RSV selected for use in further assays was 4 x 106 PFU/ml.         
 
 Figure 3.3: Dose response data for IFN-αA2 secretion in whole blood following stimulation with viral 
pathogens.  Data are from 4 healthy donors with lines joining the data-points for each donor.   Blood was 
stimulated for 24hours with PBS or the viruses RV-16 (A), RV-1B (B) or RSV (C), and IFN-αA2 concentrations 
were detected. The highest titres of viruses used were: RV-16 9.82x10
7
 TCID/50/ml, RV-1B 8.76x10
7 
TCID50/ml, 
RSV 4x10
6
 PFU/ml, with additional dilutions of 1:2 and 1:5. 
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3.2.4 Dose response to determine the optimum titre of bacterial pathogens to use for 
co-culture with whole blood 
 
In addition to viruses, bacteria were also added to provide a more physiologically accurate stimulus 
of blood in order to determine the immune response induced by the ligation of multiple PRRs.  The 
bacteria H.influenzae and S.pneumoniae were chosen for the whole blood assay, as these are the 
most commonly implicated microbes in COPD and asthma exacerbations, and are also common 
causative agents of pneumonia in residents of sheltered accommodation schemes [490-492].  
 
Peripheral whole blood from 4 healthy donors was incubated with bacterial pathogens for 24 hours.  
Bacteria preparations were obtained from the Johnston laboratory (as detailed in Chapter 2.2.2) and 
were used undiluted (H.influenzae at 8.13 x 108 CFU/ml and S.pneumoniae at 2.3 x 108 CFU/ml), and 
at dilutions of 1:2 and 1:5, with PBS used for a negative control.  The plasma was aspirated and 
stored at -80oC before analysis by ELISA for TNF-α production, with results presented in Figure 3.4.  
H.influenzae stimulation at these dilutions resulted in a saturated TNF-α response, with 
concentrations higher than the limit of detection of 10,000pg/ml.  S.pneumoniae stimulation at 
these dilutions also resulted in a saturated TNF-α response for one donor, with concentrations 
higher than the limit of detection of 10,000pg/ml, while the remaining 3 donors produced responses 
at the higher end of detection as well.  
 
Figure 3.4: Dose response data for TNF-α secretion in whole blood stimulated with bacterial pathogens.  Data 
are from 4 healthy donors with lines joining the data-points for each donor.   Blood was stimulated for 24hours 
with PBS or the bacteria H.influenzae (A) or S.pneumoniae (B) and TNF-α concentrations were detected.  The 
highest titres of bacteria used were 8.13 x 10
8
 for  H.influenzae and 2.3 x 10
8 
 for S.pneumoniae, with additional 
dilutions of 1:2 and 1:5.  
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 It was preferable to use titres of stimuli that resulted in cytokine responses falling within the 
detectable range, so as to avoid having to dilute supernatants at the ELISA stage.  This way, it would 
enable the detection of multiple inflammatory mediators from one supernatant at a single dilution 
using multiplex ELISA.  As such, the dose response was repeated, using a highest titre of 8.13 x 106 
CFU/ml for H.influenzae and 2.3 x 106 CFU/ml for S.pneumoniae (1:100 dilutions from the original 
stocks), and additional dilutions of 1:1000 and 1:10000 from the stock preparations received from 
the Johnston laboratory.  Peripheral blood from 3 healthy donors was incubated with the pathogens 
for 24 hours, before plasma aspiration and TNF-α analysis (Figure 3.5).  TNF-α production in 
response to stimulation with H.influenzae was now in the detectable range, with concentrations of 
the cytokine decreasing with the declining titre of pathogen.  Stimulation with decreasing titres of 
S.pneumoniae also resulted in a progressively lower TNF-α response for 2 donors, with the third 
donor showing a steady concentration of the cytokine, although all responses were within the limit 
of detection.  Again, the titre of each stimulus to be employed in the assay was selected on the basis 
that it stimulated a cytokine response roughly 50% of the maximal response, so that any decrease or 
increase caused by vitamin D supplementation could be observed, and so that a significant response 
compared to the PBS negative control could be seen.  As such, the titre of H.influenzae selected for 
use in further assays was 8.13 x 106 CFU/ml, and for S.pneumoniae was 2.3 x 106 CFU/ml. 
Figure 3.5: Dose response data for TNF-α secretion in whole blood stimulated with bacterial pathogens.  Data 
are from 3 healthy donors with lines joining the data-points for each donor.   Blood was stimulated for 24hours 
with PBS or the bacteria H.influenzae (A) or S.pneumoniae (B) and TNF-α concentrations were detected.  The 
highest titres of bacteria used were 8.13 x 10
6
 for  H.influenzae and 2.3 x 10
6 
 for S.pneumoniae, with additional 
dilutions of 1:10 and 1:100.  
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3.3 Discussion 
 
Here I have shown how a whole blood assay was developed to enable the evaluation of how in vivo 
vitamin D supplementation in trial participants affects the ex vivo cytokine response to TLR ligands 
and key pathogens.  The assay was optimised by time course and dose response experiments to give 
the best chance of detecting any effect of in vivo vitamin D supplementation on antigen-stimulated 
immune responses. 
 
The co-culture of whole blood with various stimuli offers several advantages as a model by which to 
investigate the immunomodulatory actions of vitamin D.  Other investigators carrying out similar 
studies have used peripheral blood mononuclear cells (PBMCs) or isolated monocytes, co-cultured 
with TLR ligands for 24 hours [426, 493, 494].  PBMC populations include lymphocytes, monocytes, 
macrophages and dendritic cells, but not polymorphonuclear cells such as eosinophils and 
neutrophils.  Neutrophils have a multitude of roles in the immune response, such as phagocytosis, 
cytokine and chemokine production to co-ordinate the responses of other immune cells, 
microbicidal activity, and formation of neutrophil extracellular traps [495, 496].  While neutrophils 
may have limited function in anti-viral responses [47], they are vital in the defence against 
respiratory bacteria, with depletion resulting in impaired clearance of bacteria such as S.pneumoniae 
and Legionella pneumophila, and repletion improving defence and murine survival in response to 
bacterial infection [497-499].  Eosinophils, while normally associated with allergy, also have an 
important role in the immune response to respiratory pathogens.  They are able to degranulate, 
releasing cytotoxic ribonucleases such as eosinophil cationic protein (ECP) and eosinophil-derived 
neurotoxin (EDN), which have antiviral properties against RSV [500], as well as being able to produce 
NO in response to TLR ligands, with MyD88-dependent accelerated clearance of RSV in 
hypereosinophilic mice [501].  Additionally, eosinophils are important in the immune response to 
bacteria, demonstrating bactericidal properties of ECP and the oxidative burst, plus the ability to 
directly phagocytose bacteria [502-505], with adoptive transfer of eosinophils improving bacterial 
clearance of Pseudomonas aeruginosa and congenital eosinophil deficiency impairing clearance in 
mice [506].  Therefore, a model whereby these cells are not present does not represent the normal 
cellular milieu, and thus the immune response to stimuli may be altered    As such, it was decided to 
use whole blood for the development of this assay, as it is advantageous over PBMCs with all 
immune cell types present.   
 
The use of whole blood also offers an advantage over PBMCs as 25(OH)D received from 
supplementation in the clinical trial would be present in the whole blood, as the vitamin D binding 
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protein and 25(OH)D itself are present at physiological concentrations in plasma.  Studies using 
PBMCs require media supplementation, and thus any vitamin D present becomes diluted, and 
furthermore many cellular assays in the literature have received additional supplementation with 
vitamin D in vitro [494, 507].  The model employed here allows for the effect of physiological 
concentrations of 25(OH)D to be assessed, whilst still being directly associated with the in vivo 
supplementation of trial participants.  Another benefit of this assay is the determination of 
concentrations of stimuli to be used to ensure a detectable cytokine response without the need for 
dilution of the plasma.  This enables multiple samples to be assayed at once with ease, and means 
that numerous inflammatory mediators can be measured in single wells using a multiplex ELISA 
platform.   
 
The decision was made to focus on the innate immune response, as innate antimicrobial responses 
are important in affording protection against respiratory infections, and vitamin D has been 
demonstrated to have a key role in altering this response.  TLR ligands were selected to stimulate an 
innate immune response, especially considering the potential importance of the up-regulation of 
CYP27B1 following TLR ligation allowing conversion of inactive 25(OH)D to the active metabolite 
1,25(OH)2D (as described in Chapter 1.13).  The TLR ligands were chosen based on their relevance to 
pathogens precipitating exacerbations in asthma and COPD, and those commonly implicated in 
respiratory tract infections in the elderly (Table 3.1).  The Class A CpG 2216 was chosen over Classes 
B and C due to its distinct induction of type-I IFN production [508], which is of particular interest in 
this study due to its importance in the defence against respiratory viruses [509].  Whole pathogens 
were also used in order to provide more physiologically accurate stimulation of the blood, as these 
can stimulate signalling through multiple PRRs simultaneously.  Thus, the use of stimuli in the form 
of both TLR ligands and pathogens gives the opportunity to assess the effect of vitamin D on the 
physiologically relevant immune response to whole pathogens, as well as enabling the dissection of 
the immune response to determine the individual TLRs ligated and how vitamin D affects these 
responses.   
 
There are also some limitations to this assay.  Firstly, the methods used in the development of the 
assay may not have allowed for the optimum conditions to be determined.  The time course to 
determine the optimum length of time for co-culture of whole blood with stimuli was only carried 
out with TLR ligands, and the optimum time needed for co-culture with whole pathogens may have 
been different.  Different blood donors were also used for the various preliminary experiments due 
to availability, with some being healthy, and others having asthma or COPD.  As a result, any 
difference between optimum times for co-culture and concentrations of stimuli for different disease 
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states would have been missed.  For example, a dysregulated anti-viral immune response in asthma 
has been demonstrated, with macrophages producing less IFN-λ, bronchial epithelial cells having an 
impaired IFN-β response, PBMCs secreting less IFN-α, and pDCs less able to synthesise IFN-α 
following viral challenge [172, 510-512].  The TNF-α response to LPS stimulation in whole blood and 
isolated monocytes has also been demonstrated to be elevated in severe COPD and COPD with 
associated weight-loss [513, 514].  Therefore, concentrations of stimuli may have been needed to be 
altered to induce a detectable immune response in these populations.  Additionally, only TNF-  and 
IFN- A2 were assayed in preliminary experiments, with other inflammatory mediators potentially 
responding differently to the stimuli and requiring higher or lower concentrations of these stimuli 
for detectable responses.   However, while a separate time-course was not carried out for the 
pathogens, a robust immune response was detected following incubation for 24 hours, thus allowing 
any effects of vitamin D supplementation to be observable, despite this potentially not being the 
optimum conditions.  Equally, while blood donors had differing immune responses following 
stimulation, this was observed in the assays performed with only healthy donors as well as those 
with a mixture of healthy, asthmatic and COPD patient donors, thus negating any potential issues 
over the health status of donors in the development of this assay.      
 
Therefore, an assay was successfully developed for use with whole blood samples from clinical trial 
participants to assess the effects of in vivo vitamin D supplementation on the ex vivo innate immune 
response to TLR ligands and whole pathogens. 
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4. Investigation into the effects of vitamin D metabolites on resistance 
to viral infection, secretion of inflammatory mediators and 
receptor expression in a respiratory epithelial cell line 
 
4.1 Introduction 
 
The respiratory epithelium is the first line of defence against inhaled foreign organisms and 
pathogens.  It acts as a physical barrier, with cell-cell junctions blocking viral access to receptors in 
the basolateral membrane thus preventing entry and dissemination into the submucosa, and goblet 
cells producing mucus, which acts as a barrier impermeable to most pathogens, with ciliated 
epithelial cells allowing clearance of pathogens via the mucociliary escalator [515].    In addition to 
this, airway epithelial cells express the full complement of TLRs, as well as RIG-I, MDA5, NOD1 and 
NOD2, thus allowing recognition of pathogens and regulation of the innate and adaptive immune 
response.  They are able to produce a range of cytokines and chemokines, such as CXCL8, CXCL1 and 
CXCL5 to recruit neutrophils, IL-5, GM-CSF, eotaxin and RANTES to recruit eosinophils, IL-1β, MIP-1α, 
MCP-1 and TNF-α to recruit monocytes/macrophages, and IFN-α, IFN-β and MIP-1α to enhance NK 
cell recruitment and activity.  The adaptive immune response can also be mediated by respiratory 
epithelial cells, via the production of MIP-3α to enhance conventional DC (cDC) migration to the 
epithelium, IL-15 and type I IFNs to drive local cDC differentiation and maturation, RANTES, MIG and 
IP-10 to induce migration of Th1 cells, and IL-1β to stimulate Th2 cell migration to the mucosa.  
Finally, the respiratory epithelium can secrete molecules with direct anti-viral properties, such as 
type I and type III IFNs which initiate the antiviral state, lactoferrin which blocks viral cellular 
receptors, HBD2 which suppress viral replication, nitric oxide which inhibits viral replication and 
possess pro-apoptotic properties, and LL-37 which has numerous anti-microbial actions [515, 516].     
 
It has been demonstrated that the respiratory epithelium is able to convert 25(OH)D to the active 
form of 1,25(OH)2D, and that viral infection increases this local activation of 25(OH)D [430].  
Therefore, a microenvironment with high levels of active 1,25(OH)2D is created, allowing increased 
expression of vitamin D-regulated genes.  Due to the importance of the respiratory epithelium as the 
first line of defence to invading pathogens, the localised immunomodulatory actions of vitamin D 
may play a critical role in protection against acute respiratory tract infections.  
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Therefore, a series of in vitro experiments was conducted to determine the effect of vitamin D 
metabolites on the immune response to rhinovirus in a respiratory epithelial cell line, by looking at 
both mRNA expression of key molecules, and concentrations of a panel of cytokines and chemokines 
in culture supernatants.  Rhinovirus was chosen as the pathogen in this study since it is the most 
common aetiologic agent of the common cold [517], which is the most frequent acute illness in the 
industrialised world, associated with 2-3 episodes per year in adults, and 5-7 per year in children 
[518, 519].  Rhinoviruses are also a frequent cause of exacerbations in both asthma and COPD 
patients [148, 484, 520-522], who are of particular interest in this study due to their increased 
susceptibility to acute respiratory tract infections.  Since 90% of rhinovirus serotypes are in the 
major group, utilizing ICAM-1 for cellular entry, and the majority are also classified as the A species, 
RV-16, a major group A species rhinovirus serotype was chosen for experimental work [523].         
  
 
4.2 Results 
 
4.2.1 Co-culture of A549 cells with vitamin D metabolites results in transient resistance 
to RV-16 infection 
 
As detailed in Chapter 2.8, A549 cells were co-cultured with vitamin D metabolites or vehicle (0.1% 
ethanol) for 48 hours, before incubation for 6 or 24 hours with RV-16 or controls of filtered and UV-
inactivated virus.  Cells were lysed and, following RNA extraction and reverse transcription, RT-PCR 
was used to quantify viral mRNA (Figure 4.1).  Three technical replicates were used for each sample, 
from which an average was taken, and the experiment was repeated 3 times, providing three 
biological replicates.  Due to only having n = 3 biological replicates, statistical tests could not be 
performed on these data.  RV-16 mRNA was increased approximately 2000-fold at both 6 and 24 
hours post-infection in cells co-cultured with vehicle compared to the UV-inactivated RV controls.  In 
cells co-cultured with 25(OH)D or 1,25(OH)2D preceding a 6 hour incubation with RV-16, viral mRNA 
was significantly reduced by 70% and 37% respectively compared to the ethanol control.  Presence 
of vitamin D metabolites did not however significantly reduce viral mRNA expression following a 24 
hour incubation with RV-16.    
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 Figure 4.1: Effect of co-culture with vitamin D metabolites on RV-16 mRNA expression.  A549 cells were co-
cultured with vitamin D metabolites or vehicle (0.1% ethanol) for 48 hours, before incubation with RV-16 or 
control (UV-inactivated RV-16) for 6 (A) or 24 (B) hours.  RV-16 mRNA was quantified by RT-PCR and analysed 
using the ΔΔCT method, compared to the UV-inactivated control.  Each RT-PCR reaction was carried out in 
triplicate and a mean value was taken of the technical replicates.  Data are from 3 repeats of the same 
experiment, represented as mean + SEM.  P-values could not be calculated due to the small sample size of n = 3.  
 
 
4.2.2 Co-culture of A549 cells with vitamin D metabolites results in attenuation of RV-
induced ICAM-1 expression 
 
ICAM-1 is the main receptor for major serotypes of rhinovirus, such as RV-16 [524, 525].  As such, it 
was desirable to test whether the effects of vitamin D metabolites on viral mRNA were associated 
with an effect on ICAM-1 expression.  As described in chapter 2.8, A549 cells were cultured, and cells 
lysed following an overnight incubation.  Culture was extended for some cells, which underwent co-
culture with vitamin D metabolites or vehicle (0.1% ethanol) for 48 hours before lysis.  A final set of 
cells were cultured further following addition of vitamin D metabolites or vehicle, with RV-16 
incubation for 6 or 24 hours before cell lysis.  RNA was extracted from the cell lysates and reverse 
transcription carried out, before RT-PCR was used to quantify ICAM-1 mRNA (Figure 4.2).  Three 
technical replicates were used for each sample, from which an average was taken, and the 
experiment was repeated 3 times, providing three biological replicates.  Due to only having n = 3 
biological replicates, statistical tests could not be performed on these data.  Co-culture with vitamin 
D metabolites had no effect on constitutive expression of ICAM-1 (Figure 4.2 A).  Incubation with RV-
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16 for 6 hours increased ICAM-1 expression 50-fold, with the 24 hour incubation increasing ICAM-1 
to a lesser extent (3.5-fold).  Following co-culture with vitamin D metabolites, RV-16-induced ICAM-1 
expression was attenuated.  Co-culture with 25(OH)D resulted in a 70% reduction in ICAM-1 
expression 6 hours post-infection, and a 30% reduction 24 hours post-infection, while co-culture 
with 1,25(OH)2D resulted in a 37% decrease 24 hours post-infection, and a 30% reduction 6 hours 
post-infection. 
Figure 4.2: Effect of co-culture with vitamin D metabolites and RV infection on ICAM-1 mRNA expression.  A549 
cells were cultured overnight, before co-culture with vitamin D metabolites or vehicle (0.1% ethanol) for 48 
hours, pre-infection (A).  Some cells underwent further culture and were incubated with RV-16 for 6 (B) or 24 (C) 
hours.  ICAM-1 mRNA was quantified by RT-PCR and analysed using the ΔΔCT method. Each RT-PCR reaction 
was carried out in triplicate and a mean value was taken of these technical replicates.  Data are from 3 repeats 
of the same experiment, represented as mean + SEM.  P-values could not be calculated due to the small sample 
size of n = 3. 
 
 
4.2.3 Co-culture off A549 cells with vitamin D metabolites results in increased I B  
expression 
 
ICAM-1 expression has been demonstrated to be regulated by the transcription factor NF-κB [111, 
457, 526].  NF-κB is inactive in the cytoplasm due to the direct binding of inhibitors such as IκBα to 
the p65 subunit of the NF-κB heterodimer.  Upon stimulation of the cell, the IκB kinase complex (IKK) 
is activated, resulting in phosphorylation of IκBα, and subsequent ubiquitination and degradation by 
the proteasome.  Therefore, NF-κB is free to translocate to the nucleus, bind DNA, and activate 
transcription of numerous target genes [527].  It has been demonstrated elsewhere that 1,25(OH)2D 
is  able to increase the expression of the inhibitor IκBα in airway epithelial cells in a dose-dependent 
manner [327].  As such, it was decided to assess the effect of vitamin D metabolites on expression of 
IκBα, to determine whether attenuation of RV-induced ICAM-1 was associated with an increase in 
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IκBα.  A549 cells were co-cultured with vitamin D metabolites or vehicle (0.1% ethanol) for 48 hours, 
before incubation for 6 or 24 hours with RV-16.  Cells were lysed and, following RNA extraction and 
reverse transcription, RT-PCR was used to quantify IκBα mRNA (Figure 4.3).  Three technical 
replicates were used for each sample, from which an average was taken, and the experiment was 
repeated 3 times, providing three biological replicates.  Co-culture of A549 cells with 25(OH)D 
marginally increased constitutive expression of IκBα by 1.3-fold, while co-culture with 1,25(OH)2D 
also increased constitutive expression of IκBα 1.5-fold.  Incubation with RV-16 for 6 or 24 hours had 
no effect on IκBα mRNA expression.  Co-culture of A549 cells with vitamin D metabolites combined 
with a 6 hour incubation with RV-16 increased the expression of IκBα 3-fold compared to cells 
cultured with vehicle and RV-16.  Co-culture of A549 cells with 1,25(OH)2D combined with a 24 hour 
incubation with RV-16 increased IκBα expression 1.7-fold, but no difference was seen with 25(OH)D 
co-culture compared to cells cultured with vehicle and RV-16.   
 
Figure 4.3: Effect of co-culture with vitamin D metabolites and RV infection on IκBα mRNA expression.  A549 
cells were cultured overnight, before co-culture with vitamin D metabolites or control for 48 hours, pre-
infection (A).  Following this, cells were incubated with RV-16 for 6 (B) or 24 (C) hours.  IκBα mRNA was 
quantified by RT-PCR and analysed using the ΔΔCT method.  Each RT-PCR reaction was carried out in triplicate 
and a mean value was taken of the technical replicates. Data are from 3 repeats of the same experiment, 
represented as mean + SEM.  P-values could not be calculated due to the small sample size of n = 3.    
 
 
4.2.4 Co-culture off A549 cells with vitamin D metabolites results in increased 
cathelicidin mRNA expression 
 
Vitamin D is associated with increased expression of antimicrobial peptides (AMPs), such as 
cathelicidin and human beta defensins [528].  The CAMP (cathelicidin antimicrobial peptide) gene 
encodes the pro-peptide hCAP18, which contains an N-terminal cathelin domain and a C-terminal 
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peptide which, once cleaved, has antimicrobial activity and is known as LL-37 [343, 529].  A vitamin D 
responsive element (VDRE) has been identified in the promoter region of the CAMP gene [361], and 
vitamin D has been demonstrated to have a critical role in the regulation of CAMP [359, 530], while 
also increasing the protein hCAP18 [531, 532].  As a result, the effect of vitamin D on expression of 
CAMP was assessed, to determine whether vitamin D-mediated resistance to RV-16 infection was 
associated with an increase in cathelicidin.  A549 cells were co-cultured with vitamin D metabolites 
or vehicle (0.1% ethanol) for 48 hours before incubation for 6 or 24 hours with RV-16.  Cells were 
lysed and, following RNA extraction and reverse transcription, RT-PCR was used to quantify CAMP 
mRNA (Figure 4.4).  Three technical replicates were used for each sample, from which an average 
was taken, and the experiment was repeated 3 times to provide three biological replicates.  Due to 
only having n =3 biological replicates, statistical tests could not be performed on these data.  Co-
culture of A549 cells with vitamin D metabolites resulted in increased constitutive expression of 
CAMP, with 25(OH)D resulting in a 4-fold increase, and 1,25(OH)2D in a 5.5-fold increase compared 
to vehicle.  Incubation with RV-16 resulted in decreased CAMP expression, by 50% 6 hours post-
infection and 40% 24 hours post-infection.  Co-culture with 25(OH)D preceding incubation with RV-
16 for 6 hours resulted in a modest 2-fold increase in CAMP expression compared to co-culture with 
ethanol, while there was no difference following infection for 24 hours.  Co-culture with 1,25(OH)2D 
increased CAMP expression compared to the ethanol + RV-16 control, with a 3-fold increase both 6 
hours and 24 hours post-infection. 
 
 
Figure 4.4: Effect of co-culture with vitamin D metabolites and RV infection on CAMP mRNA expression.  A549 
cells were cultured overnight, before co-culture with vitamin D metabolites or control for 48 hours, pre-
infection (A).  Following this, cells were incubated with RV-16 for 6 (B) or 24 (C) hours.  CAMP mRNA was 
quantified by RT-PCR and analysed using the ΔΔCT method.  Each RT-PCR reaction was carried out in triplicate 
and a mean value was taken from these technical replicates.  Data are from 3 repeats of the same experiment 
and are expressed as mean + SEM.  P-values could not be calculated due to the small sample size of n = 3.  
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4.2.5 Co-culture off A549 cells with vitamin D metabolites results in increased IFN- 2 
mRNA expression 
 
Type I IFNs are vital in the immune response to viral infection, with a broad range of effects such as 
inducing apoptosis of infected cells, enhancing antigen presentation by increasing expression of 
MHC Class I, and enhancing cytolytic activity of NK cells [533].  Surprisingly, given the reported 
protective effect of vitamin D against viral infections, other studies have demonstrated that culture 
of monocytes or human tracheobronchial epithelial cells with 1,25(OH)2D suppresses type I IFN 
expression following antigenic stimulation [327, 382, 534].  As such, the effect of vitamin D 
metabolites on expression of IFN-α and IFN-β was assessed, to determine whether vitamin D-
mediated resistance to RV-16 infection was associated with an increase in type I IFNs.  A549 cells 
were co-cultured with vitamin D metabolites or vehicle (0.1% ethanol) for 48 hours before 
incubation for 6 or 24 hours with RV-16 or controls.  Cells were lysed and, following RNA extraction 
and reverse transcription, RT-PCR was used to quantify IFN-α and IFN-β mRNA (Figure 4.5).  Three 
technical replicates were used for each sample, from which an average was taken, and the 
experiment was repeated 3 times to provide 3 biological replicates.  Due to only having n = 3 
biological replicates, statistical tests could not be performed on these data.   Constitutive expression 
of IFN-β was decreased by 25(OH)D by 27% and increased 1.5-fold by 1,25(OH)2D compared to 
vehicle, and similarly constitutive IFN-α expression was decreased by 25(OH)D by 30%, and 
increased 2-fold by 1,25(OH)2D.  Incubation with RV-16 resulted in decreased expression of IFN-α 
both 6 hours and 24 hours post-infection, by 51% for both.  Co-culture with 25(OH)D was able to 
attenuate RV-induced reduction of IFN-α expression 6 hours post-infection with a 2-fold increase,  
while 1,25(OH)2D had no effect.  At 24 hours post-infection, co-culture with vitamin D metabolites 
decreased IFN-α expression by 60% for 25(OH)D and 40% for 1,25(OH)2D compared to vehicle.  
Incubation with RV-16 also resulted in a 73% reduction in IFN-β expression 24 hours post-infection, 
although this effect was not observed 6 hours post-infection.  Co-culture with vitamin D metabolites 
reduced IFN-β expression 6 hours post-infection by 80% compared to vehicle.  25(OH)D marginally 
increased IFN-β expression by 1.7-fold at 24 hours post-infection, while 1,25(OH)2D increased 
expression 3-fold compared to vehicle. 
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Figure 4.5: Effect of co-culture with vitamin D metabolites and RV infection on type I IFN mRNA expression.  
A549 cells were cultured overnight, before co-culture with vitamin D metabolites or control for 48 hours, pre-
infection (A and D).  Following this, cells were incubated with RV-16 for 6 (B and E) or 24 (C and F) hours.  IFN-
α2 (A to C) and IFN-β (D to F) mRNA was quantified by RT-PCR and analysed using the ΔΔCT method.  Each RT-
PCR reaction was carried out in triplicate and a mean value was taken of these technical replicates.  Data are 
from 3 repeats of the same experiment, represented as mean + SEM.  P-values could not be calculated due to 
the small sample size of n = 3.  
 
 
4.2.6 Co-culture off A549 cells with vitamin D metabolites results in decreased PafR 
mRNA expression 
 
Viral infections are commonly seen to predispose patients to an increased incidence and severity of 
secondary bacterial infections, with the majority of bacterial sepsis cases reportedly following acute 
viral infections, and the majority of deaths during the 1918 influenza pandemic attributable to 
secondary bacterial infections [100, 535-537].  Platelet activating factor receptor (PAF-r) has been 
shown to be a receptor for S.pneumoniae and H.influenzae, the two most common bacterial 
respiratory pathogens, and its expression has been shown to be increased by RSV, RV-14, influenza 
and coronavirus infections [88, 101, 102].  While vitamin D has been demonstrated to have many 
anti-bacterial functions [538], such as stimulating the production of antimicrobial peptides, we 
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hypothesised that vitamin D may further act in the inhibition of secondary bacterial infections by 
attenuating viral induced receptor expression.  As such, A549 cells were co-cultured with vitamin D 
metabolites or vehicle (0.1% ethanol) for 48 hours before incubation for 6 or 24 hours with RV-16 or 
controls.  Cells were lysed and, following RNA extraction and reverse transcription, RT-PCR was used 
to quantify PafR mRNA (Figure 4.6).  Three technical replicates were used for each sample, from 
which an average was taken, and the experiment was repeated 3 times to provide three biological 
replicates.  Due to only having n = 3 biological replicates, statistical tests could not be performed on 
these data.  Co-culture of A549 cells with vitamin D metabolites did not affect constitutive 
expression of PafR.  Incubation with RV-16 for 6 hours resulted in a 2.5-fold increase in PafR mRNA, 
with co-culture with both vitamin D metabolites resulting in an 80% reduction compared to vehicle.   
Conversely, incubation with RV-16 for 24 hours resulted in a 53% decrease in PafR expression, with 
co-culture with vitamin D metabolites having no further effect. 
 
Figure 4.6: Effect of co-culture with vitamin D metabolites and RV-16 infection on PafR mRNA expression.  A549 
cells were cultured overnight, before co-culture with vitamin D metabolites or control for 48 hours, pre-
infection (A).  Following this, cells were incubated with RV-16 for 6 (B) or 24 (C) hours.  PafR mRNA was 
quantified by RT-PCR and analysed using the ΔΔCT method.  Each RT-PCR reaction was carried out in triplicate 
and a mean value was taken of these technical replicates.  Data are from 3 repeats of the same experiment, 
represented as mean + SEM.  P-values could not be calculated due to the small sample size of n = 3.  
 
 
4.2.7 Cytokine and chemokine response to RV-16 infection of A549 cells co-cultured 
with vitamin D metabolites 
 
The respiratory epithelium is able to secrete cytokines and chemokines to mount an immune 
response following pathogenic stimulation [539-542].  It has been demonstrated that respiratory 
epithelial cells can convert 25(OH)D to 1,25(OH)2D [430], and this active form can alter the 
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production of local inflammatory mediators [327].  Therefore, it was decided to employ a multiplex 
approach to determine the effect of vitamin D metabolites on the cytokines, chemokines and growth 
factors secreted following RV-16 infection.  A549 cells were co-cultured with vitamin D metabolites 
or vehicle (0.1% ethanol) for 48 hours before incubation for 6 or 24 hours with RV-16 or controls.  
Supernatants were aspirated and analysed by multiplex ELISA and significant results are presented in 
Figures 4.7 (for 6 hours post-infection) and 4.8 (for 24 hours post-infection).  Incubation with RV-16 
resulted in increased concentrations of a large number of inflammatory mediators in the 
supernatants of cultured A549 cells.  RV-16 incubation for 6 hours increased concentrations of IL-6 
(p = 0.0006), IL-8 (p = 0.007), IL-12 (p = 0.001), IL-2R (p = 0.009), IFN-α (p < 0.0001), IFN-γ (p < 
0.0001), RANTES (p = 0.005), eotaxin (p = 0.01), MIP-1α (p = 0.01), MIP-1β (p = 0.007), MCP-1 (p = 
0.002), EGF (p = 0.002), HGF (p < 0.0001) and VEGF (p < 0.0001).  Incubation with RV-16 for 24 hours 
also increased concentrations of IL-6 (p = 0.0001), IL-8 (p = 0.0005), IFN-α (p = 0.002), RANTES (p = 
0.0005), MIP-1β (p < 0.0001), MCP-1 (p = 0.01), EGF (p = 0.008) and HGF (p = 0.008).  Infection of 
A549 cells with RV-16 did not affect supernatant concentrations of IL-1β, IL-2, IL-4, IL-5, IL-7, IL-10, 
IL-13, IL-15, IL-17, IL-1RA, TNF-α, MIG, IP-10, FGF-Basic, G-CSF or GM-CSF either 6 or 24 hours post-
infection.  Co-culture with 1,25(OH)2D for 48 hours before a 6 hour incubation with RV-16 resulted in 
decreased concentrations of IL-2R (p = 0.02), IFN-γ (p = 0.01), RANTES (p = 0.009), MIP-1β (p = 0.04), 
EGF (p = 0.04), HGF (p = 0.02) and VEGF (p = 0.005) compared to cells co-cultured with vehicle alone 
preceding viral infection. However, the magnitude of the decrease was very small in all cases.  These 
effects were not observed following a 24 hour incubation with RV-16, with co-culture of A549 cells 
with 1,25(OH)2D resulting in an increased concentration of IL-6 (p = 0.008), although again by a very 
small magnitude (1.2-fold), while both 25(OH)D and 1,25(OH)2D caused an increased concentration 
of FGF-Basic in the supernatant of cultured A549 cells (2-fold, p = 0.04 for both).    
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 Figure 4.7: Effect of co-culture with vitamin D metabolites and RV-16 infection for 6 hours on inflammatory 
mediator concentration in supernatants.  A549 cells were cultured overnight, before co-culture with vitamin D 
metabolites or control for 48 hours. Following this, cells were incubated with RV-16 for 6 hours before 
supernatants were collected and multiplex ELISA was carried out.  Supernatants were collected from 3 repeats 
of the same experiment, and n=10 samples were analysed for each variable.  Data are expressed as scatter 
plots with mean + SEM, and p-values were calculated using a paired T-test.  
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Figure 4.8: Effect of co-culture with vitamin D metabolites and RV-16 infection for 24 hours on inflammatory 
mediator concentration in supernatants.  A549 cells were cultured overnight, before co-culture with vitamin D 
metabolites or control for 48 hours. Following this, cells were incubated with RV-16 for 24 hours before 
supernatants were collected and multiplex ELISA was carried out.  Supernatants were collected from 3 repeats 
of the same experiment, and n=10 samples were analysed for each variable.  Data are expressed as scatter 
plots with mean + SEM, and p-values were calculated using a paired T-test.  Concentrations below the lower 
limit of detection for each analyte, as specified by the technical data sheet, were recorded as 0. 
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4.2.8 Co-culture of A549 cells with vitamin D metabolites increases A549 viability 24 
hours post RV-16 infection 
 
Control experiments were carried out to check that the observed transient effect of vitamin D 
metabolites on viral mRNA expression was not due to vitamin D directly effecting A549 viability.  The 
lactate dehydrogenase (LDH) assay can be used to assess cytotoxicity in vitro.  It is based on the 
reduction of nicotinamide adenine dinucleotide (NAD+) to NADH by LDH, which is utilized in the 
stoichiometric conversion of a tetrazolium dye, with the resulting coloured compound measured 
spectrophotometrically.  LDH is a cytosolic enzyme present in many different cell types.  When the 
plasma membrane is damaged, for example following infection, LDH is released into the culture 
media, allowing the reduction of NAD+, and the detection of the resulting coloured compound.  A549 
cells were co-cultured with vitamin D metabolites or vehicle (0.1% ethanol) for 48 hours before 
incubation for 6 or 24 hours with RV-16 or controls (filtered virus or UV-inactivated virus).  
Supernatants were aspirated and analysed by a lactate dehydrogenase-based toxicology assay, as 
described in Chapter 2.8.3, to determine the effects of vitamin D metabolites on A549 cell viability 
(Figure 4.9).  Three technical replicates were used for each sample, from which an average was 
taken, and the experiment was repeated 3 times to provide three biological replicates.  Due to only 
having n = 3 biological replicates, statistical tests could not be performed on these data.  Infection of 
A549 cells with RV-16 for both 6 and 24 hours resulted in increased cellular cytotoxicity, regardless 
of pre-incubation with vehicle by between 2 and 3.5-fold.  Vitamin D metabolites did not affect RV-
induced cytotoxity 6 hours post infection compared to cells co-cultured with vehicle.  However, at 24 
hours post-infection, vitamin D metabolites reduced cytotoxicity compared to A549 cells co-cultured 
with vehicle, with a 28% reduction in cytotoxicity of 25(OH)D-treated RV-infected cells vs. vehicle-
treated RV-infected cells, and a 20% reduction in cytotoxicity of 1,25(OH)2D-treated RV-infected cells 
vs. vehicle-treated RV-infected cells. 
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Figure 4.9: Effect of co-culture with vitamin D metabolites and RV-16 infection on A549 cytotoxicity.  A549 cells 
were cultured overnight, before co-culture with vitamin D metabolites or vehicle control for 48 hours.  
Following this, cells were incubated with RV-16 or controls of filtered virus and UV-inactivated virus for 6 (A) or 
24 (B) hours, and supernatants were aspirated.  NAD
+
 reduction by LDH was measured using a lactate 
dehydrogenase-based toxicology assay, with the reduced compound NADH enabling the stoichiometric 
conversion of a tetrazolium dye to produce a coloured compound to be measured spectrophotometrically and 
expressed as an absorbance value.  Each reaction was carried out in triplicate and a mean value was taken of 
these technical replicates.  Data are from 3 repeats of the same experiment, represented as mean + SEM.  P-
values could not be calculated due to the small sample size of n = 3.  
 
 
4.2.9 Co-culture of A549 cells with vitamin D metabolites does not affect viral titre 
present in culture supernatant 
 
An additional control experiment was carried out to assess whether the transient effect of vitamin D 
metabolites on viral mRNA expression was associated with a decreased release of the live virus into 
culture supernatant.  Cytopathic effect assays are used to assess the damage done to host cells 
during viral invasion, thus allowing quantification of viral titre.  This approach was utilised to 
determine whether co-culture with vitamin D metabolites affected viral release from A549 cells 
following infection.  A549 cells were co-cultured with vitamin D metabolites or vehicle (0.1% 
ethanol) for 48 hours before incubation for 6 or 24 hours with RV-16.  Supernatants were aspirated 
and stored, before being used in a cytopathic effect assay, as described in Chapter 2.8.4.  Viral titres 
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(TCID/50) were calculated using the Spearman-Kaerber method [463, 464].  Co-culture with vitamin 
D metabolites did not significantly affect viral titre at either 6 or 24 hours post-infection, despite an 
observed trend towards an increase in TCID/50 in cells cultured with 1,25(OH)2D compared to cells 
cultured with vehicle (Figure 4.10).  
 
Figure 4.10: Effect of co-culture with vitamin D metabolites on supernatant viral titre following infection with 
RV.  A549 cells were cultured overnight, before co-culture with vitamin D metabolites or control for 48 hours.  
Following this, cells were incubated with RV-16 for 6 (A) or 24 (B) hours and supernatants were aspirated.  A 
cytopathic effect assay was carried out using supernatants harvested at each time point from which TCID/50 
values were calculated. Data are expressed as mean + SEM, and  P-values were calculated using a paired T-test.  
 
 
4.2.10 CYP24A1 is highly expressed in A549 cells compared to CYP27B1 
 
Vitamin D metabolism is regulated by the cytochrome p450 superfamily of enzymes.  CYP27B1 is a 1-
α-hydroxylase which is able to convert circulating 25(OH)D into the active form of 1,25(OH)2D.  
CYP24A1, a 24-hydroxylase enzyme, acts as part of a feedback mechanism to catabolise 1,25(OH)2D 
into 1,24,25(OH)3D, as well as metabolising 25(OH)D to the relatively inactive metabolite 
24,25(OH)2D.  As such, the amount of active 1,25(OH)2D is decreased.  Therefore, the relative 
expression of these two enzymes has an impact on the activity of vitamin D.  It has been described 
elsewhere that A549 cells express relatively high levels of CYP24A1, and relatively low levels of 
CYP27B1 [430], suggesting that vitamin D may not be able to exert any effects in A549 cells.  As such, 
the relative expression of CYP24A1 compared to CYP27B1 was measured.  A549 cells cultured 
overnight, before co-culture with vitamin D metabolites or vehicle (0.1% ethanol) for 48 hours.  Cells 
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were lysed and, following RNA extraction and reverse transcription, RT-PCR was used to quantify 
CYP27B1 and CYP24A1 mRNA (Figure 4.11).  Three technical replicates were used for each sample, 
from which an average was taken, and the experiment was repeated 3 times to provide three 
biological replicates.  Due to only having n = 3 biological replicates, statistical tests could not be 
performed on these data.  Using the CYP27B1 expression in the overnight culture of A549 cells as the 
denominator, it was evident that expression of CYP24A1 was much greater, with a 105-fold increases 
in CYP24A1 expression.  48 hour culture with vehicle or vitamin D metabolites did not affect 
expression of either CYP27B1 or CYP24A1.   
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Expression of CYP27B1 and CYP24A1 in A549 cells.  A549 cells were cultured overnight, before co-
culture with vitamin D metabolites or control for 48 hours.  CYP27B1 and CYP24A1 mRNA were quantified by 
RT-PCR and analysed using the ΔΔCT method.  Each reaction was carried out in triplicate and a mean value was 
taken of these technical replicates.  Data are from 3 repeats of the same experiment, represented as mean + 
SEM.  P-values could not be calculated due to the small sample size of n = 3.  
 
 
4.3 Discussion 
 
It has been demonstrated here that co-culture with a physiological concentration of 25(OH)D 
renders A549 cells transiently resistant to infection with rhinovirus-16 following incubation with RV-
16 for 6 hours.  This effect was associated with attenuation of RV-induced ICAM-1 expression.  
Additionally, 25(OH)D was able to transiently inhibit RV-induced up-regulation of PafR and 
transiently reduce A549 cytotoxicity following RV infection.  
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On observing the significant reduction in viral mRNA following co-culture of A549 cells with vitamin 
D metabolites 6 hours post-infection (Figure 4.1), it was hypothesized that this outcome may be due 
to effects on the receptor ICAM-1, the main receptor for the major serotypes of rhinovirus, such as 
RV-16 [524, 525].  Infection with rhinovirus was seen to significantly increase ICAM-1 expression, 
both 6 hours and 24 hours post-infection, as also observed in other studies [457, 543-545], with 
vitamin D metabolites attenuating this RV-induced increase (Figure 4.2).  Previously, RV-induced 
ICAM-1 expression has been demonstrated to be NF-κB-dependent [457], with ICAM-1 known to be 
one of the numerous genes regulated by this transcription factor [111, 457, 526].  The NF-κB family 
of transcription factors has a major role in the regulation of innate and adaptive immunity and 
inflammatory responses, with the p50/p65 heterodimer being the most ubiquitously expressed.  In 
un-stimulated cells NF-κB dimers reside primarily in the cytoplasm in an inactive state due to 
association with members of the IκB (inhibitors of κB) family of proteins.  While several non-
receptor-mediated pathways such as UV-irradiation and oxidative stress have been demonstrated to 
activate NF-κB, the most common and best studied activation pathway used by the majority of 
stimuli is the canonical pathway.  Ligation of receptors such as TLRs and TNF-R1 (TNF receptor-1) 
results in recruitment and activation of the IκB kinase (IKK) complex, which consists of two 
catalytically active kinases (IKKα and IKKβ) and a regulatory scaffold protein (IKKγ/NEMO).  The 
activated IKK complex phosphorylates IκBα, leading to its polyubiquitination and subsequent 
proteasomal degradation.  The degradation of IκBα results in the exposure of a strong nuclear 
localisation sequence in the p65 subunit of NF-κB, thus facilitating its translocation to the nucleus, 
where it can bind to κB motifs present in the promoter regions of many genes and regulate 
transcription [546-548].  It has previously been demonstrated that 1,25(OH)2D is able to increase 
expression of the inhibitor IκBα in airway epithelial cells in a dose-dependent manner [327].  As 
such, it was hypothesized that the attenuation of RV-induced ICAM-1 expression resulting in 
decreased detection of viral mRNA may be due to effects of vitamin D metabolites on IκBα (Figure 
4.12).  Co-culture of A549 cells with vitamin D metabolites and subsequent incubation with RV-16 for 
6 hours resulted in a 3-fold increase in IκBα mRNA expression, although statistical significance was 
not reached, and no increase was seen following incubation for 24 hours, suggesting potential time-
dependent effects of vitamin D metabolites (Figure 4.3).  Previous studies have also demonstrated 
an effect of 1,25(OH)2D on inhibition of NF-κB activity, with an association with increased IκBα [327, 
549].   
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Figure 4.12: Hypothesized inhibition of NF-κB activation by vitamin D metabolites.  Following rhinovirus 
infection, the IKK complex is activated to phosphorylate the inhibitor IκBα, resulting in its degradation.  This 
allows NF-κB to translocate to the nucleus and bind to promoter regions, resulting in transcription of target 
genes such as ICAM-1, which in turn allows increased viral cellular entry.  In the presence of vitamin D 
metabolites, the degradation of IκBα is inhibited, thus leaving NF-κB in its inactive state in the cytoplasm, 
attenuating RV-induced ICAM-1 expression and thus decreasing RV-16 cellular entry.      
 
Abbreviations used: 1,25(OH)2D: 1,25 di-hydroxyvitamin D; 25(OH)D: 25-hydroxyvitamin D; ICAM-1: intercellular adhesion molecule-1;  
IκBα: nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha; IKK: inhibitor of NF-κB kinase; NF-κB: nuclear factor 
kappa B; RV: rhinovirus. 
 
 
Other pathways known to be involved in anti-viral immunity were also investigated.  The type I IFNs 
represent the major molecules associated with anti-viral immunity, with numerous functions 
including activation of DCs, induction of MHC class I expression, and stimulation of NK cells  [550].  
Incubation of A549 cells with RV-16 for 6 hours or 24 hours resulted in significantly reduced 
expression of IFN-α2, with the 24 hour time-point also resulting in decreased IFN-β mRNA (Figure 
4.5).  In contrast to this, other studies have demonstrated RV-induced production of type I IFNs in 
primary human bronchial epithelial cells (HBECs) [172, 551], BEAS-2B cells [482, 552], 
bronchoalveolar lavage (BAL) fluid [553], PBMCs [554], and bronchial smooth muscle cells [555].  
However, the majority of these studies used minor group rhinoviruses [551, 552, 554, 555], which 
have been demonstrated to induce greater production of IFN-β in primary HBECs, while major group 
rhinovirus infection resulted in diminished production of IFN-β, with levels comparable to cells 
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stimulated with serum-free media [556].  Therefore, the differences seen in the study here 
compared to other published studies may be due to the serotype of rhinovirus used, with minor 
group rhinoviruses suggested to be more efficient at infecting cultured epithelial cells [557], and 
thus eliciting a stronger anti-viral immune response.  In addition to this, while not finding a decrease 
in type I IFN production, two studies in A549 cells using major group rhinoviruses observed no 
induction of IFN-β following rhinovirus infection, which was attributed to impairment of IRF-3 
activation due to inhibition of phosphorylation, prevention of homodimer formation and absence of 
nuclear accumulation [558, 559].  The inhibition of type I IFN production by rhinovirus may be an 
important evasion mechanism to allow replication and survival in host cells [560]. 
 
This study also demonstrated that A549 cells co-cultured with 25(OH)D resulted in increased 
expression of IFN-α2 6 hours post infection with RV-16, and co-culture with 1,25(OH)2D resulted in 
increased IFN-β 24 hours post infection (Figure 4.5).  Conversely, IFN-α2 expression was decreased 
by 25(OH)D 24 hours post-infection, and IFN-β expression was decreased by vitamin D metabolites 6 
hours post-infection.  These differences with the length of incubation with RV-16 may reflect the 
kinetics of the production of these type I IFNs, with IFN-α typically produced early on in the immune 
response, and IFN-β at a later time-point [482].  Together, this data suggests that the beneficial 
effects of vitamin D on the immune response to viruses may in part be due to an increase in type I 
IFN production.  Conversely, vitamin D has been demonstrated elsewhere to decrease transcription 
of NF-κB driven genes such as IFN-β following infection of human tracheobronchial epithelial cells 
with RSV, with an associated reduction in IFN-stimulated proteins.  However, in this case this was 
not observed to be detrimental, with the anti-viral state maintained and viral clearance unaffected 
[327].           
 
While not typically associated with anti-viral immunity, LL-37 has been demonstrated to be 
important in the immune response to viruses [344, 356-358], and has been shown to be regulated by 
vitamin D [359, 530, 531].  Here it was demonstrated that co-culture with A549 cells with 25(OH)D 
and 1,25(OH)2D significantly increased constitutive CAMP mRNA expression (Figure 4.4).  
Additionally, the positive control of 1,25(OH)2D significantly increased CAMP expression following 
incubation with RV-16 for both 6 and 24 hours.   
 
Another receptor, PafR, which has implications for virus-induced secondary bacterial infections, was 
also studied.  The most cited example of the devastating impact of secondary bacterial infections is 
that of the 1918 influenza A pandemic, where an estimated 40-50 million deaths were attributable 
to secondary bacterial pneumonia [537, 561, 562].  Numerous mechanisms have been proposed to 
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explain this phenomenon, with one being the viral-induced up-regulation of receptors required for 
bacterial adhesion and colonization.  Increasing evidence has demonstrated that vulnerability to 
bacterial pneumonia is mediated by the expression of bacterial receptors on lower airway cells, with 
blocking of PafR shown to attenuate infection [563].  PafR has been shown to be a receptor for 
S.pneumoniae and H.influenzae, and its expression has been shown to be increased by RSV, RV-14, 
influenza and coronavirus infections [88, 101, 102].  This study demonstrated RV-induced up-
regulation of PafR at 6 hours post-infection, although infection for 24 hours resulted in decreased 
PafR expression (Figure 4.6).  Both 25(OH)D and 1,25(OH)2D were able to inhibit RV-induced up-
regulation of PafR 6 hours post-infection.  Viral-induced PafR has been associated with NF-κB 
activation [102, 109], suggesting that, similar to ICAM-1, vitamin D metabolites may be having their 
effects by increasing IκBα expression and thus inhibiting NF-κB activation. 
 
Supernatants were also collected to measure the concentrations of a panel of inflammatory 
mediators.  Rhinovirus infection induced up-regulation of the pro-inflammatory cytokines IL-6, IL-12 
and IFN-γ, the chemokines IL-8, MIP-1α, MIP-1β, MCP-1, eotaxin and RANTES, the growth factors 
EGF, HGF and VEGF, and the anti-viral agent IFN-α, all important mediators of the immune response 
to  acute viral infection (Figures 4.7 and 4.8).  Co-culture of A549 cells with 1,25(OH)2D 
demonstrated decreased concentrations of IL-2R, IFN-γ, RANTES, MIP-1β, EGF, HGF and VEGF 6 
hours post-infection, compared to those cells cultured with vehicle.  However, 1,25(OH)2D was used 
as a positive control at concentrations 1000-times greater than seen in the circulation, with these 
responses not seen following co-culture with physiological concentrations of 25(OH)D.  In addition to 
this, the magnitude of the differences observed was minimal, so, while effects such as vitamin D 
decreasing secretion of RANTES, VEGF and MIP-1β have been demonstrated elsewhere [564-566], 
these data are not conclusive. 
 
Finally, supernatants were also utilised to assess the effects of vitamin D metabolites of cytotoxicity 
and viral release following RV infection.  Viral incubation for both 6 and 24 hours resulted in a 
significant increase in A549 cytotoxicity (Figure 4.9).  However, while co-culture with vitamin D 
metabolites had no effect on cytotoxicity 6 hours post-infection, at 24 hours post-infection both 
25(OH)D and 1,25(OH)2D inhibited RV-mediated cytotoxicity, although only by a small magnitude 
(1.4- and 1.2-fold respectively).  Cell death following infection may be damaging to the host, with 
virions using the disrupted cell remnants as vehicles to spread and infect more cells.  Conversely, cell 
death may also be beneficial to the host by killing virions by destroying the reservoir in which the 
virus replicates in [567].  Picornaviruses (the family of viruses which rhinoviruses belong to) have 
been demonstrated to initiate cell death upon infection, suggesting that they utilise this mechanism 
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to facilitate viral progeny release [568].  As such, the 25(OH)D- and 1,25(OH)2D-mediated reduction 
in cytotoxicity at 24 hours post-infection reported here may be advantageous to the host, with 
increased cellular viability reflecting less invasion by virions and thus containing the spread of 
disease.  A cytopathic effect assay was also carried out to quantify the viral titre present in the cell 
culture supernatants following infection.  Co-culture with vitamin D metabolites was demonstrated 
to have no effect on viral titre present in the supernatant (Figure 4.10).  The disconnect between the 
observed reduction in intracellular RV mRNA expression 6 hours post-infection following co-culture 
with vitamin D metabolites, and the lack of any effect of vitamin D metabolites on the viral titre in 
culture supernatants at 6 hours post-infection could be due to a lack of power.  The effect on viral 
mRNA was subtle, and as such a larger sample size for the cytopathic effect assay may have been 
required to detect any vitamin D metabolite-induced changes in supernatant viral titre.  
 
 The use of A549 cells in this study offers an advantage over the other work carried out in this PhD 
using blood, since they represent the site of infection.  Additionally, with the discovery that 
epithelial cells are able to convert inactive 25(OH)D to 1,25(OH)2D [430], the respiratory epithelium 
is likely to be a key component of the effects of vitamin D on the immune response to respiratory 
pathogens.  However, A549 cells are a transformed cell-line, and as such are not as physiologically 
accurate as using primary cells.  They are also derived from the alveoli and are a model of type II 
pneumocytes, which are typically associated with surfactant production, although they have also 
been demonstrated to have a key role in the immune response [569-572].  Additionally, they 
represent cells of the lower respiratory tract, although, while typically thought of as a pathogen of 
the upper respiratory tract, rhinovirus has been demonstrated to cause bronchiolitis and pneumonia 
in the lower respiratory tract [16, 17, 573].  Furthermore, the immune response mounted by 
different cell-lines may be dissimilar, with distinct pathways involved in LPS-induced activation of 
A549 cells and the bronchiolar-derived BEAS-2B cells [574].  This may play a role in observed 
differences in RV induction of type I IFNs in BEAS-2B and A549 cells as described above.  Finally, 
A549 cells have been shown to have relatively high levels of CYP24A1 (the enzyme which catabolises 
active 1,25(OH)2D), and relatively low levels of CYP27B1 (the enzyme which hydroxylases 25(OH)D to 
produce the active metabolite) [430], suggesting that vitamin D may not be able to exert any effects 
in A549 cells.  As such, expression of CYP24A1 and CYP27B1 were measured in this study, 
demonstrating markedly increased expression of CYP24A1 compared to CYP27B1 (Figure 4.11).  
Nevertheless, CYP27B1 was detectable, and the effects shown following co-incubation of A549 cells 
with vitamin D metabolites suggest that 25(OH)D is able to be hydroxylated to the active form, and 
that 1,25(OH)2D is not being catabolised before it can exert any effect.  However, the abundance of 
CYP24A1 may explain why, even though 1,25(OH)2D was being used as a positive control in this 
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study, its effects on expression of RV mRNA, and ICAM-1 were diminished compared to that exerted 
by 25(OH)D.  High expression of CYP24A1 may also explain the transient effects of co-culture with 
vitamin D metabolites on viral mRNA expression, RV-induced PafR expression and A549 viability 
observed in this study.  By 24 hours post-infection, the CYP24A1 may have catabolised all of the 
active 1,25(OH)2D, thus not replicating the results seen at 6 hours post-infection.  Therefore, due to 
all of the factors described, to accurately determine the effects of vitamin D metabolites on the 
immune response to RV infection, it would be beneficial to utilise different cell-lines, such as BEAS-
2B cells, in addition to primary cells.   
 
There are also a number of additional experiments which would be useful to carry out to further 
elucidate the effects of vitamin D metabolites in the protection against acute respiratory tract 
infections.  Aside from using different cell types, a wider variety of respiratory pathogens could also 
be utilised.  As already discussed, different rhinovirus serotypes elicit distinct immune responses, so 
the effect of vitamin D metabolites on other common respiratory viruses such as RSV, influenza and 
coronavirus could also be investigated.  In addition, bacterial pathogens could also be studied, 
especially with respect to the observed effects of vitamin D on PafR expression.  An adhesion assay 
looking into the effects of vitamin D metabolites on virus-induced bacterial adhesion would help to 
establish the importance of vitamin D metabolites in preventing secondary bacterial infections.  The 
involvement of the NF-κB activation pathway in the effects of vitamin D could also be further 
elucidated in a variety of ways.  Firstly, phosphorylation of IκBα could be determined by western 
blot, to assess whether vitamin D is increasing IκBα mRNA by inhibiting its phosphorylation and 
degradation, thus resulting in reduced activation of NF-κB.  Silencing and antagonism of IκBα, ICAM-
1, type I IFNs and LL-37 would also help to determine how important each of these components are 
in the observed vitamin D mediated resistance to RV infection.  Finally, detection of the type III IFN, 
IFN-λ, would be advantageous in addition to the observed effects on type I IFNs.  Type III IFNs have 
been demonstrated to be induced by viruses and play an important role in anti-viral immunity [575-
578].  Many of the studies already discussed demonstrated RV-induced production of IFN-λ [482, 
551, 552, 555], with its expression shown to be higher and more prolonged than that of the type I 
IFNs, and also more commonly associated with bronchial epithelial cells [482, 551].  As such, the 
effect of vitamin D on RV-induced IFN-λ would be interesting.  
 
Therefore, here it has been demonstrated that co-culture with a physiological concentration of 
25(OH)D, using  1,25(OH)2D as a positive control, renders A549 cells transiently resistant to infection 
with rhinovirus-16 6 hours post-infection.  This effect was associated with attenuation of RV-induced 
ICAM-1 expression, as well as an increase in CAMP expression and an altered type I IFN response.  
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Co-culture with 25(OH)D was also able to transiently significantly inhibit RV-induced up-regulation of 
PafR, with implications in the prevention of secondary bacterial infections. 
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5. Characterisation of the effects of vitamin D supplementation on the 
cellular profile of the lower airways and the production of induced 
sputum inflammatory mediators in people with asthma or COPD 
 
5.1 Introduction 
 
Sputum is the expectorated secretion of the lower respiratory tract, containing fluid saliva, cellular 
components, and inflammatory mediators such as cytokines and chemokines.  It is a useful tool for 
profiling the airways, and is safer, less invasive and better tolerated than BAL (bronchoalveolar 
lavage) fluid, which involves a bronchoscope being passed into the airways, whist still providing 
reliable results [579-583].  Asthma and COPD are diseases of chronic airway inflammation, and thus 
assessment of the cells and inflammatory mediators present in the respiratory tract is important in 
determining the pathophysiology of these diseases and risk of exacerbation [584-587].  In recent 
years improvements in the methodology of collecting and processing sputum have aided in the 
importance of this technique.  The use of hypertonic saline nebulisation has enabled individuals 
unable to spontaneously produce a sample to expectorate an induced sample, safety has been 
enhanced with monitoring of lung function throughout the procedure and pre-medication with β2-
agonists, and methodology has improved with the identification of DL-Dithiothreitol (DTT) as an 
agent to disperse cells, the introduction of selecting cells from the expectorate rather than using the 
whole sample to reduce the confounding influence of saliva, and the use of cytospins to examine the 
cells microscopically [587-591].  With these advances, the use of induced sputum to assess airway 
inflammation is reproducible, and provides accurate and valid results [455]. 
 
As described in Chapter 1, vitamin D is an immunomodulatory agent which has been linked to 
respiratory health.  Numerous observational studies have indicated a beneficial effect of vitamin D, 
with deficiency associated with a greater risk of acute respiratory tract infections [260, 272, 274, 
279], longer duration of respiratory illnesses [279, 282], increased risk of asthma exacerbations 
[290], and impaired lung function [272, 293].  Intervention studies have also demonstrated that 
vitamin D supplementation reduces the incidence of respiratory tract infections [300, 303-305], and 
asthma and COPD exacerbations [303, 306-308].  However, where the immunomodulatory actions of 
in vivo supplementation have been assessed, peripheral blood has been used, which does not 
represent the site of infection when investigating respiratory health.  The one study which did carry 
out sputum inductions on trial participants to determine whether the clinical effects of vitamin D 
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supplementation observed were associated with changes in the underlying inflammatory phenotype 
of the airways only looked at differential cell counts, with no analysis of inflammatory mediators in 
sputum supernatants [315].  Additionally, mechanistic studies into the effects of vitamin D on the 
immune response have largely been carried out in mice or using cell lines, and thus may not 
accurately represent the changes occurring in an in vivo system.   
 
Therefore, the effect of vitamin D supplementation on the underlying inflammatory profile of the 
respiratory tract was investigated in people with asthma or COPD, in order to help determine 
whether it may be a useful therapy in improving respiratory health and preventing exacerbations 
and acute upper respiratory tract infections.   
 
For the analysis of sputum inflammatory mediators and the subsequent analysis of peripheral blood 
as presented in later chapters, a 30-plex ELISA platform was used.  Vitamin D has been 
demonstrated to have pleiotropic effects, and as such it was desirable to asses a range of 
inflammatory mediators to include Th1 and Th2 cytokines, innate cytokines, chemokines, type I IFNs 
and growth factors.  Therefore, a 30-plex panel was chosen, allowing quantification of the following: 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12, IL-13, IL-15, IL-17, IL-1RA, IL-2R, IFN-α, IFN-γ, 
TNF-α, MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), eotaxin (CCL11), MIG (CXCL9), 
IP-10 (CXCL10), EGF (epidermal growth factor), FGF-basic (basic fibroblast growth factor), HGF 
(hepatocyte growth factor), VEGF (vascular endothelial growth factor), G-CSF (granulocyte colony-
stimulating factor) and GM-CSF (granulocyte macrophage colony-stimulating factor).    
 
In this chapter, in order to increase the power with which to characterise the effects of vitamin D 
supplementation on the cellular profile of the lower airways and the production of induced sputum 
inflammatory mediators, data from asthma and COPD patients were pooled.  Asthma and COPD 
were also analysed separately, with no differences demonstrated, and this data is not presented for 
presentational ease.  Therefore, data from asthma and COPD patients were pooled, accepting that 
these are markedly different diseases.    
 
 
Primary clinical results for the ViDiAs and ViDiCO trials 
While not in the scope of this thesis to expand on, the primary results of the clinical trials provide 
important information on the physical effects of vitamin D supplementation from which to compare 
the immunological results to.  We aimed here to carry out a study whereby any effect of vitamin D 
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supplementation on primary outcomes such as time to first upper respiratory tract infection (URTI) 
could be mechanistically associated with observed changes in inflammatory markers and cellular 
profiles of induced sputum samples.  As such, a summary of the primary outcomes of the ViDiAs 
(Table 5.1) and ViDiCO (Table 5.2) trials is provided (results not yet published).  In addition to these 
primary findings, when stratifying by baseline vitamin D deficiency (defined as a serum 25(OH)D 
concentration < 50nmol/L), vitamin D supplementation significantly reduced the risk of moderate or 
severe exacerbation in the n = 148 COPD patients who were vitamin D deficient at baseline (aHR 
0.57, 95% CI 0.35 to 0.92, p = 0.021). 
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Table 5.1: Clinical and biochemical outcomes by allocation in the ViDiAs trial 
-- represents undefined values 
Asthma symptoms scored from 0 (no symptoms) to 3 (severe symptoms); Jackson symptoms (sneezing, sore 
throat, headache, subjective sensation of fever or chilliness, malaise, nasal discharge, nasal obstruction, cough) 
each scored from 0 (no symptoms) to 3 (severe symptoms) and summed for each day of URI. 
 
Abbreviations used: CI: confidence interval; IQR: inter-quartile range; URI: upper respiratory infection; ACT: asthma control test; s.d.: 
standard deviation; FEV1: forced expiratory volume in one second; PEFR: peak expiratory flow rate; ppb: parts per billion; PTH: parathyroid 
hormone; SGRQ: St George’s Respiratory Questionnaire 
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Table 5.2: Clinical and biochemical outcomes by allocation in the ViDiCO trial 
-- represents undefined values 
Exacerbation symptom score calculated by coding 7 exacerbation symptoms (increase in dyspnoea, sputum 
volume, sputum purulence, nasal congestion/discharge, wheeze, sore throat or cough) as 0 (symptom absent) 
or 1 (symptom present) and summing the scored to give a daily symptom score between 0 and 7; Jackson 
symptoms (sneezing, sore throat, headache, subjective sensation of fever or chilliness, malaise, nasal discharge, 
nasal obstruction, cough) each scored from 0 (no symptoms) to 3 (severe symptoms) and summed for each day 
of URI. 
 
Abbreviations used: CI: confidence interval; IQR: inter-quartile range; URI: upper respiratory infection; s.d.: standard deviation; FEV1: forced 
expiratory volume in one second; FVC: forced vital capacity; PTH: parathyroid hormone; SGQR: St George’s Respiratory Questionnaire 
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5.2 Results 
 
5.2.1 Study recruitment 
 
As described in chapter 2.1, a subset of participants recruited onto the ViDiAs and ViDiCO clinical 
trials were invited to give induced sputum samples.  These samples were collected during 
randomisation (month 0), and at 2 and 12 month follow-up visits, to enable characterisation of 
baseline characteristics, and determination of any effect caused by supplementation with vitamin 
D3.  Figure 5.1 and 5.2 show the recruitment profiles for ViDiAs and ViDiCO respectively, with 
randomisation, the number of samples collected at each time point, and the number of participants 
lost to follow-up represented.  Of those randomised into the sputum arm in the ViDiAs trial, 48% of 
people were on the intervention arm, and 52% on the control (placebo) arm.  Similar numbers of 
follow-up samples were collected at each time point between the two arms, with n = 19 and n = 16 
producing a 2 month sample in each arm, and n = 18 and n = 15 producing a 12 month sample in 
each arm.  Over the duration of the study, 6 participants in the intervention arm and 11 participants 
in the control arm withdrew consent, left the sputum arm or were lost to follow-up, with reasons 
including poor lung function results, inability to expectorate, and being unable to attend morning 
study visits to provide a sample.  Rates of differential cell count success were also similar between 
arms and at each time-point, with success rates of over 90% at all time-points in the intervention 
arm, and at month 12 in the control arm.  The success rate was marginally lower in the control arm 
at baseline (70%) and at 2 month follow-up (88%), with differential cell count failures due to high 
levels of squamous cell contamination obscuring other cell types and rendering cell counts 
impossible.  The success rate of being able to carry out flow cytometry was more varied, ranging 
from 37% in the intervention arm at baseline, to 0% in the control arm at month 2.  The most 
common reason for not being able to carry out flow cytometry was an insufficient cell count, with a 
minimum of 1 million cells needed after sputum processing and cytospin preparation to ensure 
enough cells for staining to be successful and accurate results to be yielded.  Additionally, a subset of 
samples were taken before the implementation of flow cytometry.  
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Figure 5.1: Recruitment profile for the sputum sub-study in asthma patients at baseline, month 2 and month 
12, separated by allocation. 
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Of those randomised into the sputum arm in the ViDiCO trial (Figure 5.2), 56% of people were on the 
intervention arm, and 44% on the control arm.  Similar numbers of follow-up samples were collected 
at each time point between the two arms, although numbers in the control arm were marginally 
smaller, with n = 21 and n = 16 producing a 2 month sample in each arm, and n = 18 and n = 12 
producing a 12 month sample in each arm.  Over the duration of the study, 10 participants in the 
intervention arm and 10 participants in the control arm withdrew consent, left the sputum arm or 
were lost to follow-up.  Rates of differential cell count success were 100% at all time-points for both 
arms of the study.  The success rate of being able to carry out flow cytometry was more varied, 
ranging from 65% in the control arm at baseline, to 33% in the intervention arm at month 2.  The 
most common reason for not being able to carry out flow cytometry was an insufficient cell count, 
with a minimum of 1 million cells needed after sputum processing and cytospin preparation to 
ensure enough cells for staining to be successful and accurate results to be yielded.  Additionally, a 
subset of samples were taken before the implementation of flow cytometry, and some were omitted 
due to time constraints, with study visits being carried out at an alternative site resulting in 
transportation times not allowing for the additional steps involved in preparing the samples for flow 
cytometric analysis.  Rates of flow cytometry success were higher than in the asthma study, with 
COPD patients able to produce larger samples of sputum, thus containing higher numbers of cells.   
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Figure 5.2: Recruitment profile for the sputum sub-study in COPD patients at baseline, month 2 and month 12, 
separated by allocation 
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5.2.2 Vitamin D supplementation results in a higher concentration of serum 25(OH)D in 
asthma patients, but not COPD patients in the sputum sub-study 
 
The serum concentration of 25(OH)D was measured in all participants at baseline, 2 month and 12 
month follow-up by liquid-chromatography-tandem mass spectrometry, as described in chapter 
2.1.6 and elsewhere [456].  This was used to determine whether randomisation into the intervention 
arm of the study resulted in a significant increase in circulating serum 25(OH)D over the time-course 
of the study, and whether it resulted in a significantly higher concentration of serum 25(OH)D 
compared to participants in the placebo arm.  In the ViDiAs study (Figure 5.3 A), there was a 
significantly higher concentration of mean serum 25(OH)D in the intervention arm compared to the 
placebo arm at both 2 months (mean 17.86 nmol/L difference 95% confidence interval [CI] 4.44 to 
31.27, p = 0.01) and 12 months (mean 28.75 nmol/L difference, 95% CI 15.52 to 41.98, p < 0.0001).  
When compared to baseline concentrations, mean serum 25(OH)D was significantly higher at 2 
month (mean 15.57 nmol/L difference, 95% CI 5.01 to 26.13, p = 0.006) and 12 month (mean 22.43 
nmol/L difference, 95% CI 9,63 to 35.23, p = 0.002) follow-up in the intervention arm, with no 
change seen in the control arm.  In the ViDiCO study (Figure 5.3 B), there was no difference in mean 
serum 25(OH)D concentration between the intervention arm and the control arm at each time-point 
(2 month: mean 2.27 nmol/L difference, 95% CI -9.91 to 14.45, p = 0.71; 12 month: mean 8.51 
nmol/L difference 95% CI -7.13 to 24.15, p = 0.28).  When compared to baseline concentrations, 
mean serum 25(OH)D concentration was significantly higher at 2 month (mean 15.20 difference, 
95% CI 8.69 to 21.71, p < 0.0001) and 12 month (mean 20.50 nmol/L difference, 95% CI 9.86 to 
31.14, p = 0.0006) follow-up in the intervention arm, and at 2 month follow-up in the control arm 
(mean 8.65 difference, 95% CI 1.14 to 16.16, p = 0.03).   
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Figure 5.3: Change in serum 25(OH)D concentration over the course of the study for those enrolled in the 
intervention and placebo arms of the sputum sub-studies of the ViDiAs and ViDiCO trials. Serum samples were 
collected from trial participants at 0, 2 and 12 month visits and the concentration of 25(OH)D was measured by 
liquid-chromatography-tandem mass spectrometry.  Data are expressed as means + SEM, and are only from 
participants who were enrolled into the sputum sub-study (n = 50 for ViDiAs and n = 50 for ViDiCO).  P-values 
were calculated using an unpaired T-test.  
 
 
As well as being an immunomodulator, vitamin D has a well established role in calcium homeostasis.  
The active metabolite 1,25(OH)2D is able to increase intestinal calcium absorption, thus raising the 
concentration of calcium in the extracellular fluid.  Extracellular calcium concentration is monitored 
by the calcium-sensing receptor (CaSR).  Decreased calcium stimulates the secretion of parathyroid 
hormone (PTH) from the parathyroid glands.  PTH is able to stimulate osteoclastic activity to 
promote bone reabsorption, increase tubular calcium reabsorption in the kidneys, and stimulate the 
transcription of the CYP27B1 gene, while also suppressing renal CYP24 mRNA expression, resulting in 
an increased concentration of 1,25(OH)2D.  The resulting increase in extracellular calcium inhibits 
PTH secretion, thus making a negative feedback loop [592-594].  There is an inverse relationship 
between PTH and 25(OH)D, and therefore PTH is a useful alternative marker for vitamin D status.  As 
such, PTH was analysed in COPD patients in the sputum sub-study to determine whether, despite 
observing a non-significant increase in serum 25(OH)D in the intervention arm, supplementation did 
significantly decrease serum PTH concentration (Figure 5.4).  Blood was collected from all trial 
participants at baseline, 2 month and 12 month follow-up visits and serum PTH was quantified using 
an Architect ci8200 analyser (Abbott Diagnostics, Chicago, Illinois, USA).  While the serum PTH 
concentration appeared to be lower in the intervention arm compared to the placebo arm at 12 
months, the difference was not statistically significant (mean 1.10 pmol/L difference, 95% CI -0.15 to 
2.35, p = 0.08).  Compared to baseline, PTH concentration was significantly lower at 12 months in 
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the intervention arm (mean -1.46 pmol/L difference, 95% CI -2.21 to -0.71, p = 0.0005), while there 
was no difference in the placebo arm (mean -0.9 pmol/L difference, 95% CI -2.07 to 0.27, p = 0.12).  
 
 
 
 
 
 
 
 
 
Figure 5.4: Change in serum PTH concentration over the course of the study for those enrolled in the 
intervention and placebo arms of the sputum sub-study of the ViDiCO trial. Serum samples were collected from 
trial participants at 0, 2 and 12 month visits and the concentration of PTH was measured using an Architect 
ci8200 analyser.  Data are expressed as means + SEM, and are only from participants who were enrolled into 
the sputum sub-study (n = 50).  P-values were calculated using an unpaired T-test.  
 
 
5.2.3 Vitamin D supplementation has no effect on the cellular profile of the lower 
airways in patients with asthma or COPD 
 
Induced sputum samples were collected and processed as described in Chapter 2.3 for participants 
in the sputum sub-study of ViDiAs and ViDiCO, at baseline, month 2 and month 12.  Following 
cytospin preparation, differential cell counts were carried out, with averages taken from counts of 
400 non-squamous cells from 3 cytospins for each participant at each time-point.  Results were 
calculated as the percentage of each cell type counted, and also as absolute cell counts.  
Additionally, flow cytometry was carried out on a subset of samples at each time-point, as 
represented in Figures 5.1 and 5.2, to determine percentages and numbers of B-cells, CD4+ T-cells, 
CD8+ T-cells, myeloid dendritic cells (mDCs), plasmacytoid dendritic cells (pDCs) and regulatory T-
cells (Tregs).  The methodology is described in Chapter 2.4, with the gating techniques 
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demonstrated.  Each data point was assigned an interaction variable for the time-point at which the 
sample was taken, and whether that participant was on the intervention or control arm of the study.  
Data for asthma and COPD patients were pooled for this analysis to provide greater power with 
which to assess any affect of vitamin D supplementation on the cellular profile of the lower airways.  
As described in Chapter 2.10, Qlucore Omics Explorer 2.3 was used to analyse the data, with the 
model using a multi-group analysis (i.e. repeated measures ANOVA) on interaction variables using 
log-transformed data, and including adjustment for time-point, allocation and study.  P-values were 
deemed significant when less than 0.05 and with a corresponding q-value of less than 0.1.  No 
statistically significant effect of vitamin D supplementation was observed on the cellular profile of 
the lower airways (Table 5.3).   
 
 
Table 5.3: Effect of vitamin D supplementation on the cellular profiles of induced sputum in pooled 
data from asthma and COPD patients  
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5.2.4 Vitamin D supplementation has no effect on the concentrations of inflammatory 
mediators in induced sputum supernatants 
 
Induced sputum samples were collected and processed as described in Chapter 2.3 for participants 
in the sputum sub-study of ViDiAs and ViDiCO, at baseline, month 2 and month 12.  Supernatants 
were aspirated and stored at -80oC, before being analysed by multiplex ELISA.  As before, each data 
point was assigned an interaction variable for the month the sample was taken, and whether that 
participant was on the intervention or control arm of the study.  Data for asthma and COPD patients 
were pooled for this analysis to provide greater power with which to assess any effect of vitamin D 
supplementation on induced sputum inflammatory mediators.  Qlucore Omics Explorer 2.3 was used 
to analyse the data, modelling using a multi-group analysis (i.e. repeated measures ANOVA) on 
interaction variables with log-transformed data, and including adjustment for time-point, allocation 
and study.  P-values were deemed significant when less than 0.05 and with a corresponding q-value 
of less than 0.1.  No statistically significant effect of vitamin D supplementation was observed on 
induced sputum inflammatory mediators (Table 5.4).   
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Table 5.4: Effect of vitamin D supplementation on the concentrations of inflammatory mediators in 
induced sputum in pooled data from asthma and COPD patients  
 
All medians are given in pg/ml 
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5.2.5 Sub-group analysis by baseline 25(OH)D deficiency and genotype shows no effect 
of vitamin D supplementation on supernatant concentrations of inflammatory 
markers 
 
Other studies have demonstrated a beneficial effect of vitamin D supplementation, but only in those 
participants who were profoundly deficient at baseline [308].  As such, it was decided to stratify 
results by baseline 25(OH)D deficiency, with a concentration of < 50nmol/L used as the cut-off.    As 
before, data for asthma and COPD patients were pooled to provide greater power with which to 
assess any affect of vitamin D supplementation.  Qlucore Omics Explorer 2.3 was used to analyse the 
data, modelling using a multi-group analysis (i.e. repeated measures ANOVA) on interaction 
variables with log-transformed data, and including adjustment for time-point, allocation and study.   
P-values were deemed significant when less than 0.05 and with a corresponding q-value of less than 
0.1.  No statistically significant effect of vitamin D supplementation was observed on induced 
sputum inflammatory mediators or the cellular profile of the lower airways in participants with a 
baseline vitamin D status of less than 50nmol/L (Table 5.5) 
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Table 5.5: Effect of vitamin D supplementation on the cellular profile and presence of induced sputum 
inflammatory mediators in pooled data from asthma and COPD patients with baseline vitamin D 
deficiency  
Analyte medians are given in pg/ml, cell medians are given as absolute numbers or percentages 
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Other studies have also demonstrated that effects of vitamin D supplementation on respiratory 
diseases are modified by genotype [328, 329, 336].  As such, it was decided to stratify analysis by 
genotype, looking specifically at single nucleotide polymorphisms (SNPs) in the vitamin D receptor 
(VDR) and retinoid x receptor (RXRA) genes.  The clinical analysis of the ViDiCO trial showed an 
interaction effect, with genotype modifying the effect of allocation on the primary outcome of time 
to upper respiratory tract infection in people with COPD (methodology described in Chapter 2.7).  
Vitamin D was demonstrated to be protective by increasing the time to experiencing an upper 
respiratory tract infection in COPD patients with the minor alleles for the VDR SNPs rs4334089, 
rs11568820, rs7976091 and rs7970314, and the RXRA SNP rs7861779, and the major homozygous 
alleles for the VDR SNP rs10783219 (results not yet published, but summarised in Table 5.6).  As 
such, these genotypes were used for further stratification of the analysis.  Qlucore Omics Explorer 
2.3 was used as before for analysis, modelling using a multi-group analysis (i.e. repeated measures 
ANOVA) on interaction variable, with adjustment for time-point and allocation.  However, the 
number of participants with each genotype for each SNP was deemed to be too small to accurately 
make any significant conclusions on whether the effect of vitamin D supplementation on 
inflammatory markers of induced sputum and the lower airways was modified by genotype (Table 
5.7).    
 
Table 5.6: Hazard ratios for time to URI and time to exacerbation by allocation and genetic sub-group 
– statistically significant results    
Abbreviations used: VDR: vitamin D receptor; RXRA retinoid X receptor; URI: upper respiratory infection; HR: hazard ratio; CI: confidence 
interval; SNP: single nucleotide polymorphism  
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Table 5.7: The number of COPD patients in the sputum sub-study in each genetic sub-group, 
separated by time-point and allocation  
Abbreviations used: VDR: vitamin D receptor; RXRA retinoid X receptor; SNP: single nucleotide polymorphism  
 
 
5.3 Discussion 
 
It has been demonstrated here that supplementation with vitamin D resulted in a significant 
increase in serum 25(OH)D concentration throughout the course of the ViDiAs study.  However, this 
increase was not demonstrated in the ViDiCO study, and was not associated with any effect on the 
cellular and inflammatory profiles of sputum samples from participants with asthma or COPD.  
 
Most intervention studies looking into the effects of vitamin D supplementation on acute respiratory 
tract infections have not analysed sputum samples to go alongside the clinical findings.  We aimed 
here to carry out a study whereby any effect of vitamin D supplementation on the primary outcomes 
of time to URI and time to exacerbation could be mechanistically associated with observed changes 
in inflammatory markers and cellular profiles of induced sputum samples.  For two clinical trials 
carried out in asthma and COPD, 50 participants from each were recruited into the sputum arm of 
the study, entailing undergoing sputum induction at months 0, 2 and 12.  Samples were processed, 
and supernatants were collected to undergo multiplex ELISA, cytospins were produced to perform 
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differential cell counts, and a subset of samples were stained for flow cytometric analysis.  In pooled 
data from asthma and COPD samples, there was shown to be no effect of vitamin D 
supplementation on any of these inflammatory mediators over the course of the study.  For the 
asthma trial this corroborates the primary findings from the clinical trial, which saw no effect of 
vitamin D supplementation on time to first severe exacerbation or time to first URI (data not yet 
published, but summarised in Table 5.1).  Additionally, the trial results indicated no effect of 
supplementation on asthma symptom control (measured by asthma control test scores), health 
service or medication use, or measures of respiratory physiology such as FEV1, exhaled nitric oxide 
and peak expiratory flow rate (PEFR), although a modest improvement in quality of life as 
determined by St George’s Respiratory Questionnaire (SGRQ) scores was observed (p = 0.03).  Thus 
the immunological findings presented in this chapter support the clinical findings from the ViDiAs 
trial.   
 
For the COPD trial, the primary clinical findings also demonstrated no effect of vitamin D 
supplementation on time to first exacerbation or time to first URI (data not yet published, but 
summarised in Table 5.2).  Additionally, no effect was seen on symptom scores, quality of life (via 
SGRQ scores), health service or medication use, or measures of respiratory function such as FEV1 and 
FVC.  However, when stratifying by baseline vitamin D deficiency (defined as a serum 25(OH)D 
concentration < 50nmol/L), vitamin D supplementation significantly reduced the risk of moderate or 
severe exacerbation in the n = 148 people who were vitamin D deficient at baseline (aHR 0.57, 95% 
CI 0.35 to 0.92, p = 0.021).  Similar stratification was attempted in the sputum sub-study, to 
determine if supplementation would have any effect on inflammatory markers in those people who 
were vitamin D deficient at baseline.  Data were pooled from the asthma and COPD trials to increase 
power, but no effect of vitamin D supplementation on induced sputum inflammatory markers was 
observed.  However, even after pooling the data, numbers for the flow cytometric cellular analysis 
were still small and unlikely to provide sufficient power to determine any significant effects.  
Likewise, when stratifying by genotype in the ViDiCO study population as a whole, an interaction 
effect was demonstrated with genotype modifying the effect of allocation on time to first URTI (as 
summarised in Table 5.6).  However, the numbers in the sputum sub-study for the genotypes 
associated with each SNP were too small to provide sufficient power to carry out the analysis.  
Therefore, while the pooled immunological findings presented in this chapter support the clinical 
findings from the ViDiAs and ViDiCO trials as a whole, they are unable to support the clinical findings 
obtained from stratifying by baseline vitamin D deficiency or genotype.                 
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In the studies which found a protective effect of vitamin D supplementation in preventing 
exacerbations in asthmatic subjects [303, 306, 307], sputum samples were not collected and 
analysed in any of them.  As such, any protective effect of vitamin D in these studies cannot be 
associated with mechanistic data on the effect of vitamin D on inflammatory mediators and the 
cellular profile of the respiratory tract.  Similarly in COPD, the study which demonstrated a 
protective effect of vitamin D supplementation in reducing incidence of exacerbations in profoundly 
deficient subjects, only  offered the mechanistic explanation that there was an increase in monocyte 
phagocytic capacity in the blood [308].  While sputum samples were collected, they were only used 
for analysis of the bacterial cultures present in the airways and not to determine whether 
phagocytosis by the cells present in the lower airways, and thus at the site of infection, was 
improved as was shown in the blood.  One study which did collect sputum samples showed no effect 
of vitamin D supplementation on differential cell counts, while inflammatory mediators were not 
looked at [315].  As with the ViDiAs trial, the overall clinical findings of this trial demonstrated no 
effect of vitamin D supplementation on rate of exacerbations, lung function, quality of life, or 
treatment failure in asthma patients.  Therefore, the main strength of the study carried out here was 
in the collection and analysis of induced sputum samples to determine the effects of vitamin D 
supplementation at the site of infection. 
 
Observational studies have also investigated the association between serum 25(OH)D concentration 
and markers of airway inflammation.  One study, looking at children with asthma, collected sputum 
samples and BAL fluid, but failed to show any association between vitamin D status and eosinophilic 
or neutrophilic airway inflammation [595].  Another study, however, did show an association 
between vitamin D deficiency in people with bronchiectasis, with higher concentrations of 
neutrophil elastase, IL-8, TNF-α and IL-1β in sputum samples [596].  Therefore, while observational 
studies have indicated a potential association between vitamin D status and markers of respiratory 
inflammation, causal inference cannot be made without robust intervention studies.     
 
The main limitation of this study was in the inability to have sufficient power when stratifying by 
baseline vitamin D deficiency or genotype, and in the study group as a whole for flow cytometric 
analysis, which may have enabled corroboration with the clinical findings.  A number of participants 
withdrew their consent or were lost to follow-up in both studies. This was in part due to being 
unable to expectorate and thus not being willing to undergo further sputum induction at subsequent 
visits after finding nebulisation an unpleasant experience.  As such, only 66% of asthma and 60% of 
COPD patients attended the final visit at month 12.  To attempt to compensate for this lack of 
power, data from the ViDiAs and ViDiCO trials were pooled during analysis, with study (i.e. which 
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trial the participants were in) eliminated as a confounder.  To allow for this rate of drop-out, and to 
enable stratification of analysis, and thus increase power, larger numbers would have needed to 
have been recruited into the sputum sub-study.  Alternatively, recruitment would have needed to 
focus on those who were vitamin D deficient and thus might benefit more from supplementation, or 
those with a specific genotype.  The pooling of data from the 2 trials also raises another potential 
limitation of the study, with asthma and COPD defined as distinct diseases with different 
inflammatory profiles.  There is a large degree of heterogeneity within asthmatic and COPD patient 
populations, with, for example, both neutrophilic and eosinophilic airway inflammation reported in 
both asthma and COPD patients [597-599], resulting in the phenotypic distinction between the two 
populations being obscured.  However, in this study asthma and COPD were well-defined due to the 
specific inclusion and exclusion criteria used during recruitment.  As such, “study” was eliminated as 
a confounder during analysis, to remove any influence of having asthma or COPD on the outcome of 
the analysis.  
   
Another limitation is the observation that, while there was an increase in mean serum 25(OH)D 
concentration over the course of the study in the intervention arm of ViDiCO, there was not a 
significant difference between the 25(OH)D concentration between the 2 arms at both months 2 and 
12.  This appears to be due to the fact that, by chance, participants in the control arm of the sputum 
sub-study had a higher baseline 25(OH)D concentration compared to the intervention arm.  As such, 
the effect of intervention resulted in serum 25(OH)D concentrations only marginally greater than 
those in the control arm.  This lack of a difference in serum 25(OH)D concentration between the two 
arms may have obscured any effect of vitamin D supplementation in the intervention arm.  Since it is 
the trough levels which were measured here, with participants taking the IMP dose before returning 
2 months later when a blood sample was taken and the next dose given, serum 25(OH)D 
concentration was likely to be higher immediately after IMP administration.  It has been shown 
elsewhere that peak vitamin D status is achieved 1 week after supplementation [316], so any 
difference in serum 25(OH)D concentration between the two arms of the study may have been 
masked.  However, there was also no statistically significant difference in PTH concentration 
between the two arms at 12 months, further indicating that supplementation in the intervention 
arm of the ViDiCO trial was not sufficient to significantly increase vitamin D status compared to the 
control arm.  In the COPD study group as a whole, as summarised in Table 5.2, a significantly higher  
serum 25(OH)D concentration was observed in the intervention group compared to the placebo 
group, which was also associated with a lower concentration of PTH.    
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Therefore, here it has been demonstrated that, while supplementation was successful in increasing 
the vitamin D status of ViDiAs trial participants, this was not associated with any change in the 
cellular profile or concentration of inflammatory markers in induced sputum from patients with 
asthma or COPD.  There may be a beneficial effect of vitamin D supplementation in those with 
profound baseline deficiency or in people with certain genotypes, but we were not powered to 
accurately assess these hypotheses in this study.  
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6. Characterisation of the effects of vitamin D supplementation on the 
inflammatory response in peripheral whole blood following 
stimulation with TLR ligands or whole pathogens 
 
6.1 Introduction 
 
As reviewed in Chapter 1, some intervention studies have demonstrated that vitamin D 
supplementation reduces the incidence of respiratory tract infections [300, 303, 305] and asthma 
and COPD exacerbations [303, 306-308].  However, while blood samples were collected in these 
trials to measure 25(OH)D concentration and safety markers such as corrected calcium and 
creatinine, an analysis of the inflammatory markers present was not carried out.    Blood provides a 
useful and readily available tool in assessing the immune response to pathogens, since many of the 
leukocytes which are required to mount an effective immune response are represented in this 
sample.  As well as the cellular components such as lymphocytes, neutrophils, monocytes, dendritic 
cells and eosinophils, blood also contains plasma which contains complement components and 
inflammatory mediators.  Additionally blood platelets, as well as causing blood coagulation to limit 
the spread of infection, express TLRs, and when activated can secrete the contents of their granules, 
containing over 300 proteins including antimicrobial peptides, cytokines and chemokines [600-603].  
As such, blood samples collected from clinical trial participants undergoing vitamin D 
supplementation were stimulated ex vivo with TLR ligands and whole pathogens to enable 
determination of the effects of vitamin D supplementation on the inflammatory response mounted, 
by analysis of the cellular profile and quantification of the inflammatory mediators released. 
 
As described in Chapter 5, a multiplex ELISA platform was used in order to asses a range of 
inflammatory mediators which may be encompassed by the pleiotropic immunomodulatory actions 
of vitamin D.  Therefore, a 30-plex panel was chosen, allowing quantification of the following: IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12, IL-13, IL-15, IL-17, IL-1RA, IL-2R, IFN-α, IFN-γ, TNF-
α, MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), eotaxin (CCL11), MIG (CXCL9), IP-10 
(CXCL10), EGF (epidermal growth factor), FGF-basic (basic fibroblast growth factor), HGF (hepatocyte 
growth factor), VEGF (vascular endothelial growth factor), G-CSF (granulocyte colony-stimulating 
factor) and GM-CSF (granulocyte macrophage colony-stimulating factor).    
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In this chapter, in order to increase the power with which to characterise the effects of vitamin D 
supplementation on the inflammatory response in peripheral whole blood following stimulation with 
TLR ligands or whole pathogens, data from participants on the same dosing regimen were pooled.  
ViDiAs, ViDiCO, ViDiFlu staff and ViDiFlu residents were also analysed separately, with no differences 
demonstrated, and this data is not presented for presentational ease. 
 
 
 
 
Primary clinical results for the ViDiAs, ViDiCO and ViDiFlu trials 
 
As explained in Chapter 5, while not in the scope of this thesis to expand on the primary clinical 
results of the trials, these results are undoubtedly important for comparing the immunological 
results to, in order to determine whether any effects of vitamin D supplementation on primary 
outcomes such as time to first upper respiratory tract infection (URTI) could be mechanistically 
associated with observed changes in inflammatory markers and cellular profiles.  Since the results of 
these trials have not yet been published, a summary of the ViDiAs and ViDiCO trials was provided in 
chapter 5.  The only statistically significant outcomes were increased mean serum 25(OH)D 
concentration, decreased PTH concentration, and an improved SGRQ score in the intervention arm 
of ViDiAs, and in ViDiCO increased mean serum 25(OH)D concentration, decreased PTH 
concentration and an improved symptom score during exacerbation.  When stratifying by baseline 
vitamin D deficiency (defined as a serum 25(OH)D concentration < 50nmol/L), vitamin D 
supplementation also significantly reduced the risk of moderate or severe exacerbations in COPD 
patients who were vitamin D deficient at baseline (adjusted hazard ratio [aHR] 0.57, 95% CI 0.35 to 
0.92, p = 0.021).   
 
A summary of the primary outcomes of the ViDiFlu trial is provided in Table 6.1.  Among ViDiFlu 
participants, there was no difference in time to acute respiratory infection between high and low-
dose intervention (aHR 1.18, 95% CI 0.84 to 1.66, p = 0.34).  Surprisingly, allocation to the high-dose 
intervention arm was associated with an increased risk of upper respiratory tract infection (URTI) 
(aHR 1.48, 95% CI 1.02 to 2.16, p = 0.04), but there was no effect on lower respiratory tract infection 
(LRTI) (aHR 1.12, 95% CI 0.75 to 1.66, p = 0.57).  A significant difference in serum 25(OH)D 
concentration was observed between the two arms of the study (p < 0.001). 
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Table 6.1: Clinical and biochemical outcomes by allocation in the ViDiFlu trial 
-- Represents undefined values 
Jackson symptoms (sneezing, sore throat, headache, subjective sensation of fever or chilliness, malaise, nasal 
discharge, nasal obstruction, cough) each scored from 0 (no symptoms) to 3 (severe symptoms) and summed 
for each day of URI. 
 
Abbreviations used: CI: confidence interval; IQR: interquartile range; ARI: acute respiratory infection; URTI: upper respiratory tract 
infection; LRTI: lower respiratory tract infection; s.d.: standard deviation; PTH: parathyroid hormone 
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6.2 Results 
 
6.2.1 Study recruitment 
 
As described in Chapter 2.1, participants from all three trials provided blood samples at baseline, 2 
month and 12 month follow-up.  A subset of these samples was used in a whole blood assay to 
determine the inflammatory response mounted in peripheral blood to a range of TLR ligands and 
pathogens. Figures 6.1, 6.2 and 6.3 show the recruitment profiles for all three trials, and the number 
of samples included in the whole blood assay at each time-point.  For this analysis, residents and 
staff in the ViDiFlu trial were analysed separately, due to different dosing regimens being used (low 
dose vs. high dose vitamin D in residents; placebo vs. high dose in staff – as described in Chapter 2). 
 
ViDiAs Trial Recruitment 
 
Of those randomised in the ViDiAs trial who provided a sodium heparin blood sample for whole 
blood assay, 53% were in the intervention arm and 47% were in the control arm (Figure 6.1).  Similar 
numbers of follow-up samples were collected at each time-point between the two arms, with n = 50 
and n = 42 producing a 2 month sample, and n = 42 and n = 42 producing a 12 month sample in each 
arm respectively.  Over the course of the study, 9 participants in the intervention arm and 3 
participants in the control arm were lost to follow-up.  From the offset of the whole blood assay, all 
samples were stimulated with a panel of TLR ligands (LPS, Pam2CSK4, Pam3CSK4, PolyI:C and R848), 
as well as providing unstimulated whole blood and serum samples.  At a later date, following 
procurement of the whole pathogens from collaborators at Imperial College London and 
optimisation of the conditions needed (as described in chapter 3), the pathogens RV-16, RV-1B, RSV, 
Haemophilus influenzae and Streptococcus pneumoniae were added as stimuli in the whole blood 
assay.  Due to budgetary constraints, not all plasma samples generated during the whole blood assay 
could be analysed by multiplex ELISA.  As such, the decision on which samples to analyse was based 
on having both baseline and 12 month samples stimulated with the whole range of stimuli.  This 
resulted in 0 month and 12 month samples being analysed for n = 22 people in the intervention arm, 
and n = 23 people in the control arm.  12 month samples were analysed rather than 2 month 
samples due to a larger inter-arm difference in 25(OH)D concentration at this later time-point, with 
more time for 25(OH)D levels to impact the inflammatory response.    
149 
 
Figure 6.1: Recruitment profile for the whole blood assay in asthma patients at baseline, month 2 and month 
12, separated by allocation 
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ViDiCO Trial Recruitment 
Of those randomised in the ViDiCO trial who provided a sodium heparin blood sample for whole 
blood assay, 51% were in the intervention arm and 49% were in the control arm (Figure 6.2).  Similar 
numbers of follow-up samples were collected at each time-point between the two arms, with n = 41 
and n = 40 producing a 2 month sample, and n = 31 and n = 35 producing a 12 month sample in each 
arm.  Over the course of the study, 14 participants in the intervention arm and 9 participants in the 
control arm were lost to follow-up.  As with ViDiAs, not all plasma samples generated during the 
whole blood assay could be analysed by multiplex ELISA.  As such, 0 month and 12 month samples 
were analysed for n = 8 people in the intervention arm, and n = 14 people in the control arm. 
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Figure 6.2: Recruitment profile for the whole blood assay in COPD patients at baseline, month 2 and month 12, 
separated by allocation 
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ViDiFlu Trial Recruitment 
Of those randomised in the ViDiFlu trial who provided a sodium heparin blood sample for whole 
blood assay, 57% were in the intervention arm and 43% were in the control arm (Figure 6.3).  
Analysis was separated into participants living in sheltered accommodation schemes (labelled as 
residents) and participants working as staff or carers in sheltered accommodation schemes (labelled 
as staff).  This was due to the differing dosing regimens used between staff and residents, with 
residents randomised to daily low dose + 2-monthly placebo vs. intermittent bolus dose vitamin D, 
and staff randomised to 2-monthly placebo vs. 2-monthly bolus dose vitamin D.    
 
For the residents, 61% of those whose samples underwent ex vivo stimulation were in the 
intervention arm and 39% were in the control arm.  Slightly more participants in the intervention 
arm provided follow-up samples at each time-point compared to the control arm, with n = 38 and n 
= 24 respectively producing a 2 month sample, and n = 34 and n = 24 respectively producing a 12 
month sample in each arm.  Over the course of the study, 6 participants in the intervention arm and 
2 participants in the control arm were lost to follow-up.  For the staff members, 41% were on the 
intervention arm and 59% were on the control arm.  Similar numbers of follow-up samples were 
collected at each time-point between the two arms, with n = 7 and n = 10 respectively producing a 2 
month sample, and n = 7 and n = 9 respectively producing a 12 month sample in each arm.  Over the 
course of the study, 0 participants in the intervention arm and 1 participant in the control arm were 
lost to follow-up.   
 
Unlike ViDiAs and ViDiCO, all samples with both a baseline and 12 month sample were analysed by 
multiplex ELISA, regardless of whether the whole panel of stimuli were used.  This was due to the 
fact that the primary results of the ViDiFlu clinical trial indicated an effect of vitamin D 
supplementation on risk of URTI, whereas no such effect was observed in ViDiAs and ViDiCO.  
Therefore, it was desirable to attempt to offer a mechanistic explanation behind this finding by way 
of analysis of inflammatory mediators released in the blood following ex vivo stimulation.  As such, 0 
month and 12 month samples were analysed for n = 34 in the intervention arm for residents, n = 24 
in the control arm for residents, n = 7 in the intervention arm for staff members, and n = 9 in the 
control arm for staff members. 
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Figure 6.3: Recruitment profile for the whole blood assay in healthy patients at baseline, month 2 and month 
12, separated by allocation and into staff and residents 
1
Two n values represents 0 month and 12 month samples – some serum samples had insufficient volume to be 
assayed 
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Flow Cytometry Study 
 
The sodium heparin blood samples used for the whole blood assay at 12 months were also used to 
analyse the cellular profile of the blood in a subset of participants.  Flow cytometry was used to 
determine numbers of B-cells, CD4+ T-cells, CD8+ T-cells, plasmacytoid dendritic cells (pDCs), myeloid 
dendritic cells (mDCs) and regulatory T-cells (Tregs) and Figures 6.4, 6.5 and 6.6 show the 
recruitment profiles for the flow cytometry sub-study.  Due to the late implementation of this 
technique during the progress of the clinical trials, only 12 month blood samples were analysed, thus 
baseline data for this outcome were unavailable.  However, it was reasoned that any significant 
effect of vitamin D supplementation would still be observable, with the assumption that all baseline 
values would be similar between the two arms of the trials, thus any difference at the 12 month 
time-point should be attributable to the intervention. 
 
In the ViDiAs trial, 51% of people who provided a 12 month blood sample were in the intervention 
arm, and 49% were in the control arm.  74% of 12 month blood samples in the intervention arm 
were analysed by flow cytometry, compared to 76% of those in the control arm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Recruitment profile for flow cytometric analysis of whole blood in asthma patients at month 12, 
separated by allocation 
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In the ViDiCO trial, 48% of people who provided a 12 month blood sample were in the intervention 
arm, and 52% were in the control arm.  53% of 12 month blood samples in the intervention arm 
were analysed by flow cytometry, compared to 71% of those in the control arm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Recruitment profile for flow cytometric analysis of whole blood in COPD patients at month 12, 
separated by allocation 
 
 
In the ViDiFlu trial, 60% of residents who provided a 12 month blood sample were in the 
intervention arm, and 40% were in the control arm.  54% of residents 12 month blood samples in the 
intervention arm were analysed by flow cytometry, compared to 72% of those in the control arm.  In 
staff members, 48% of participants who provided a 12 month blood sample were in the intervention 
arm, and 52% were in the control arm.  43% of 12 month blood samples in the intervention arm 
were analysed by flow cytometry, compared to 40% of those in the control arm. 
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Figure 6.6: Recruitment profile for flow cytometric analysis of whole blood in controls at month 12, separated 
by allocation and into staff and residents 
 
 
6.2.2 Vitamin D supplementation results in a higher concentration of serum 25(OH)D 
 
The serum concentration of 25(OH)D was measured in all participants at baseline, 2 month and 12 
month follow-up by liquid-chromatography-tandem mass spectrometry, as described in Chapter 
2.1.6.  This was used to determine whether randomisation into the intervention arm of the study 
resulted in a significant increase in circulating serum 25(OH)D over the time-course of the study, and 
whether it resulted in a significant difference between the control and intervention arms of the 
study.  Since multiplex ELISA analysis was only carried out on 0 and 12 month samples, only these 
time-points are presented in Figure 6.7.  Additionally, results are only presented for the sub-set of 
participants who had immunoassays carried out on their blood samples.  In the ViDiAs study, the 
concentration of serum 25(OH)D was significantly higher at the 12 month time-point compared to 
baseline in the intervention arm (mean 25.27 nmol/L difference, 95% CI 16.30 to 34.24, p < 0.0001), 
while there was no difference over time in the control arm (mean -1.13 nmol/L difference, 95% CI -
8.71 to 6.45, p = 0.76).  There was also no difference between the two arms at baseline (mean -6.62 
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nmol/L difference, 95% CI -18.89 to 5.64, p = 0.28), but at 12 month follow-up 25(OH)D in the 
intervention arm was significantly higher than in the control arm (mean 33.03 nmol/L difference, 
95% CI 23.39 to 42.76, p < 0.0001).  The same was seen in the ViDiCO study, with 25(OH)D 
significantly higher at 12 months compared to 0 months in the intervention arm (mean 40.00 nmol/L 
difference, 95% CI 20.32 to 59.68, p = 0.002), but not in the control arm (mean -5.46 nmol/L 
difference, 95% CI -12.61 to 1.68, p = 0.12).  There was also no difference between the two arms at 
baseline (mean 16.68 nmol/L difference, 95% CI -1.85 to 35.21, p = 0.08), but at 12 month follow-up 
25(OH)D in the intervention arm was significantly higher than in the control arm (mean 28.79 nmol/L 
difference, 95% CI 8.16 to 49.42, p = 0.009). 
 
Analysis of the ViDiFlu study was separated into residents and staff members due to the different 
dosing regimens used for the two groups.  For ViDiFlu residents, the concentration of serum 
25(OH)D was significantly higher at the 12 month time-point compared to baseline in both the 
intervention arm (mean 35.48 nmol/L difference, 95% CI 26.69 to 44.28, p < 0.0001) and the control 
arm (mean 12.75 nmol/L difference, 95% CI 4.73 to 20.77, p = 0.003).  This is due to the fact that in 
the control arm participants were receiving low-dose vitamin D supplementation, as it was deemed 
unethical to withhold vitamin D in older adults with limited sunlight exposure.  As such, within the 
ViDiFlu residents population, the comparison is between low-dose supplementation (4.8ml of 
placebo every 2 months + daily 10µl of active IMP for a year) and high-dose supplementation (4.8ml 
of active IMP every 2 months + daily 10µl of active IMP for a year).  However, there was still a 
difference observed between the two arms at 12 month follow-up, with serum 25(OH)D significantly 
higher in the intervention arm (high-dose vitamin D) compared to the control arm (low-dose vitamin 
D) (mean 24.13 nmol/L difference, 95% CI 12.28 to 35.99, p = 0.0001), while there was no difference 
at baseline (mean -0.63 nmol/L difference, 95% CI -13.49 to 12.24, p = 0.92).  Staff members 
participating in ViDiFlu underwent the same dosing regimen as that used in ViDiAs and ViDiCO.  The 
concentration of serum 25(OH)D was higher at the 12 month time-point compared to baseline in the 
intervention arm, although statistical significance was not quite obtained, likely due to the small 
numbers present in this sub-group (mean 34.33 nmol/L difference, 95% CI -9.31 to 77.98, p = 0.09), 
while no difference over time in the control arm was observed (mean 0.22 nmol/L difference, 95% CI 
-13.38 to 13.83, p = 0.97).  There was also no difference between the two arms at baseline (mean 
4.76 nmol/L difference, 95% CI -24.56 to 34.09, p = 0.73), but at 12 month follow-up 25(OH)D in the 
intervention arm was significantly higher than in the control arm (mean 37.28 nmol/L difference, 
95% CI 4.64 to 69.91, p = 0.03).   
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Figure 6.7: Change in serum 25(OH)D concentration over the course of the study for those enrolled in the 
intervention and control arms of all three trials, who provided samples for multiplex ELISA analysis.  Serum 
samples were collected from trial participants at 0 and 12 month visits and the concentration of 25(OH)D was 
measured by liquid-chromatography-tandem mass spectrometry.  Data are expressed as means + SEM, and are 
only from those participants who provided blood samples for the whole blood assay which underwent 
subsequent analysis by multiplex ELISA (intervention n = 22, control n = 23 for ViDiAs; intervention n = 8, control 
n = 14 for ViDiCO; high-dose intervention n = 34, low-dose intervention n = 24 for ViDiFlu residents; intervention 
n = 7, control n = 9  for ViDiFlu staff).  P-values were calculated using an unpaired T-test. 
 
 
 
6.2.3 High-dose vitamin D supplementation results in decreased absolute and 
percentage of B-cells in older adults without asthma or COPD, but has no effect in 
asthma and COPD patients 
 
Peripheral whole blood samples were collected from participants in all 3 trials at baseline, 2 month 
and 12 month follow-up.  As shown in figures 6.4 to 6.6, a subset of 12 month samples underwent 
flow cytometric analysis, to determine percentages and absolute numbers of B-cells, CD4+ T-cells, 
CD8+ T-cells, mDCs, pDCs and Tregs.  The methodology and gating strategies are described in Chapter 
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2.4.  Additionally, coulter counts were carried out in all participants to determine the number of 
basophils, eosinophils, lymphocytes, monocytes and neutrophils circulating in peripheral blood.  To 
allow corroboration with the other variables analysed in this chapter, only the counts from people 
who provided sodium heparin samples which were analysed by multiplex ELISA or flow cytometry 
are included, rather than using results from all participants from all trials.   
 
Each data point was assigned an interaction variable for time-point at which the sample was taken 
(i.e. months post randomisation), and whether the participant was in the intervention or control arm 
of the study.  As for the sputum analysis presented in Chapter 5, and for all subsequent data 
presented in this chapter, data for participants on the same dosing regimen were pooled for this 
analysis to provide greater power with which to assess any affect of vitamin D supplementation on 
the cellular profile of peripheral whole blood.  As such, data from asthma patients, COPD patients 
and staff on the ViDiFlu trial were pooled, while data from the residents of the ViDiFlu trial (i.e. older 
adults living in sheltered accommodation with neither asthma nor COPD) were analysed separately.  
Qlucore Omics Explorer 2.3 was used to analyse the data, modelling using a multi-group analysis (i.e. 
repeated measures ANOVA) on interaction variables with log-transformed data, and including 
adjustment for time-point, allocation and study (i.e. whether participants had asthma, COPD or 
neither condition).  P-values were deemed significant when less than 0.05 and with a corresponding 
q-value of less than 0.1.  No statistically significant effect of vitamin D supplementation was 
observed in pooled data from asthma and COPD patients and ViDiFlu staff members (Table 6.2) on 
the cellular profile of whole blood. 
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Table 6.2: Effect of vitamin D supplementation on the cellular profile of peripheral whole blood in 
data pooled from asthma patients, COPD patients and carers or staff members of sheltered 
accommodation schemes 
Absolute cell counts are given as x 10
9
 cells/L 
 
 
Analysis of ViDiFlu residents provides a population of older adults living in sheltered accommodation 
without either asthma or COPD, to assess the effects of low-dose vitamin D supplementation versus 
high-dose vitamin D supplementation.  As with the other trials, each data point was assigned an 
interaction variable for the time-point at which the sample was taken, and whether the participant 
was in the intervention or control arm of the study.  Qlucore Omics Explorer 2.3 was used to analyse 
the data, modelling using a multi-group analysis (i.e. repeated measures ANOVA) on interaction 
variables with log-transformed data, and including adjustment for time-point and allocation.  P-
values were deemed significant when less than 0.05 and with a corresponding q-value of less than 
0.1.  High-dose vitamin D supplementation resulted in significantly fewer B-cells (Table 6.3, Figure 
6.8), both in terms of percentage of total lymphocytes (median difference of -4.3%, p = 0.001, q = 
0.01) and absolute numbers (median difference of -0.08 x 109 cells/ml, p = 0.0005, q = 0.008).  No 
statistically significant effect of vitamin D supplementation was observed in any other cellular 
components of the blood in ViDiFlu residents (Table 6.3). 
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Table 6.3: Effect of high-dose vitamin D supplementation on the cellular profile of peripheral whole 
blood in older adults living in sheltered accommodation  
Absolute cell counts are given as x 10
9
 cells/L 
IQRs are given for statistically significantly different results only 
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Figure 6.8: Effect of high-dose vitamin D supplementation on the B-cell population in peripheral whole blood of 
older adults living in sheltered accommodation.  Peripheral blood was collected for n = 38 residents of sheltered 
accommodation schemes at their 12 month visit.  Flow cytometry was used to determine the cellular profile, 
with B-cells defined as being CD3
-
CD19
+
 cells.  Percentages were calculated from the total lymphocyte 
population, and absolute numbers were calculated using lymphocyte values obtained from coulter counts.  
Data are represented as scatter plots with median + IQR, with p-values calculated using a multi-group 
comparison on an interaction variable for time-point and allocation, adjusting for time-point and allocation 
using the programme Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with 
a corresponding q-value of less than 0.1.   
 
 
 
6.2.4 Vitamin D supplementation has no effect on concentrations of inflammatory 
mediators present in the serum of asthma and COPD patients, or older adults with 
neither condition 
 
Peripheral blood samples were collected from all participants at baseline, 2 month and 12 month 
follow-up visits into serum separating tubes (SST) to obtain serum samples.  Serum samples from 
baseline and 12 month visits were analysed by multiplex ELISA, giving the concentrations of a panel 
of 30 inflammatory mediators.  Each data point was assigned an interaction variable for the time-
point at which the sample was taken, and whether the participant was in the intervention or control 
arm of the study.  Qlucore Omics Explorer 2.3 was used to analyse the data, modelling using a multi-
group analysis (i.e. repeated measures ANOVA) on interaction variables with log-transformed data, 
and including adjustment for time-point, allocation and study.  P-values were deemed significant 
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when less than 0.05 and with a corresponding q-value of less than 0.1.  No statistically significant 
effect of vitamin D supplementation on the serum concentrations of inflammatory mediators was 
observed in data pooled from asthma and COPD patients and ViDiFlu staff members (Table 6.4), or in 
data from older adults living in sheltered accommodation (Table 6.5). 
 
Table 6.4: Effect of vitamin D supplementation on the serum concentration of inflammatory 
mediators in data pooled from asthma patients, COPD patients and carers or staff members of 
sheltered accommodation schemes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All medians are given in pg/ml 
2
 For one analyte numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit 
of detection, resulting in concentrations being unable to be calculated. 
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Table 6.5: Effect of high-dose vitamin D supplementation on the serum concentration of 
inflammatory mediators in older adults living in sheltered accommodation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All medians are given in pg/ml 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in 
concentrations being unable to be calculated. 
 
 
 
 
165 
 
6.2.5 Vitamin D supplementation has no effect on the inflammatory response to 
bacterial TLR ligands in the peripheral whole blood of asthma and COPD patients, 
or older adults with neither condition 
 
Peripheral whole blood samples were stimulated with a panel of 3 bacterial TLR ligands (LPS, 
Pam2CSK4 and Pam3CSK4), as described in chapter 2 and 3, at baseline, 2 month and 12 month 
follow-up visits in participants in all three clinical trials.  Plasma samples were aspirated and baseline 
and 12 month samples were analysed by multiplex ELISA for 30 inflammatory mediators.  Each data 
point was assigned an interaction variable for the time-point at which the sample was taken, and 
whether the participant was in the intervention or control arm of the study.  Qlucore Omics Explorer 
2.3 was used to analyse the data, modelling using a multi-group analysis (i.e. repeated measures 
ANOVA) on interaction variables with log-transformed data, and including adjustment for time-
point, allocation and study.  P-values were deemed significant when less than 0.05 and with a 
corresponding q-value of less than 0.1.  No statistically significant effect of vitamin D 
supplementation on the concentrations of inflammatory mediators released following stimulation 
with LPS, Pam2CSK4 or Pam3CSK4 was observed in data pooled from asthma and COPD patients and 
ViDiFlu staff members (Table 6.6), or in data from older adults living in sheltered accommodation 
(Table 6.7).  Stimuli were analysed separately, but are all presented in the same table. 
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Table 6.6: Effect of vitamin D supplementation on the release of inflammatory mediators following bacterial TLR stimulation of peripheral whole blood in 
data pooled from asthma patients, COPD patients and carers or staff members of sheltered accommodation schemes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All medians are given in pg/ml 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in concentrations being unable to be calculated. 
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Table 6.7: Effect of high-dose vitamin D supplementation on the release of inflammatory mediators following bacterial TLR stimulation of peripheral 
whole blood in older adults living in sheltered accommodation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All medians are given in pg/ml 
2 
For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in concentrations being unable to be calculated
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6.2.6 Vitamin D supplementation has no effect on the inflammatory response to viral 
TLR ligands in the peripheral whole blood of asthma and COPD patients, or older 
adults with neither condition 
 
Peripheral whole blood samples were stimulated with a panel of viral TLR ligands (polyI:C and R848), 
as described in Chapters 2 and 3, at baseline, 2 month and 12 month follow-up visits in participants 
in all three clinical trials.  Plasma samples were aspirated and baseline and 12 month samples were 
analysed by multiplex ELISA for 30 inflammatory mediators.  Each data point was assigned an 
interaction variable for the time-point at which the sample was taken, and whether the participant 
was in the intervention or control arm of the study.  Qlucore Omics Explorer 2.3 was used to analyse 
the data, modelling using a multi-group analysis (i.e. repeated measures ANOVA) on interaction 
variables with log-transformed data, and including adjustment for time-point, allocation and study.  
P-values were deemed significant when less than 0.05 and with a corresponding q-value of less than 
0.1.  No statistically significant effect of vitamin D supplementation on the concentrations of 
inflammatory mediators released following stimulation with polyI:C or R848 was observed in data  
pooled from asthma and COPD patients and ViDiFlu staff members (Table 6.8), or in data from older 
adults living in sheltered accommodation (Table 6.9).  Stimuli were analysed separately, but are all 
presented in the same table. 
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Table 6.8: Effect of vitamin D supplementation on the release of inflammatory mediators following 
viral TLR stimulation of peripheral whole blood in data pooled from asthma patients, COPD patients 
and carers or staff members of sheltered accommodation schemes 
All medians are given in pg/ml 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in 
concentrations being unable to be calculated 
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Table 6.9: Effect of high-dose vitamin D supplementation on the release of inflammatory mediators 
following viral TLR stimulation of peripheral whole blood in older adults living in sheltered 
accommodation  
All medians are given in pg/ml 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in 
concentrations being unable to be calculated
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6.2.7 Vitamin D supplementation has no effect on the inflammatory response to 
bacterial pathogens in the peripheral whole blood of asthma and COPD patients, 
or older adults with neither condition 
 
Peripheral whole blood samples were infected with 2 bacterial pathogens (Haemophilus influenzae 
and Streptococcus pneumoniae), as described in Chapters 2 and 3, at baseline, 2 month and 12 
month follow-up visits in participants in all three clinical trials.  Plasma samples were aspirated and 
baseline and 12 month samples were analysed by multiplex ELISA for 30 inflammatory mediators.  
Each data point was assigned an interaction variable for the time-point at which the sample was 
taken, and whether the participant was in the intervention or control arm of the study.  Qlucore 
Omics Explorer 2.3 was used to analyse the data, modelling using a multi-group analysis (i.e. 
repeated measures ANOVA) on interaction variables with log-transformed data, and including 
adjustment for time-point, allocation and study.  P-values were deemed significant when less than 
0.05 and with a corresponding q-value of less than 0.1.  No statistically significant effect of vitamin D 
supplementation on the concentrations of inflammatory mediators released following stimulation 
with H-influenzae or S.pneumoniae was observed in data pooled from asthma and COPD patients 
and ViDiFlu staff members (Table 6.10), or in data from older adults living in sheltered 
accommodation (Table 6.11).  Stimuli were analysed separately, but are all presented in the same 
table. 
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Table 6.10: Effect of vitamin D supplementation on the release of inflammatory mediators following 
bacterial pathogen stimulation of peripheral whole blood in data pooled from asthma patients, COPD 
patients and carers or staff members of sheltered accommodation schemes 
All medians are given in pg/ml 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in 
concentrations being unable to be calculated 
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Table 6.11: Effect of high-dose vitamin D supplementation on the release of inflammatory mediators 
following bacterial pathogen stimulation of peripheral whole blood in older adults living in sheltered 
accommodation  
All medians are given in pg/ml 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in 
concentrations being unable to be calculated 
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6.2.8 Vitamin D supplementation has no effect on the inflammatory response to viral 
pathogens in the peripheral whole blood of asthma and COPD patients, or older 
adults with neither condition 
 
Peripheral whole blood samples were infected with 2 viral pathogens (Rhinoviurs-16, Rhinovirus-1B, 
and respiratory syncytial virus), as described in Chapters 2 and 3, at baseline, 2 month and 12 month 
follow-up visits in participants in all three clinical trials.  Plasma samples were aspirated and baseline 
and 12 month samples were analysed by multiplex ELISA for 30 inflammatory mediators.  Each data 
point was assigned an interaction variable for the time-point at which the sample was taken, and 
whether the participant was in the intervention or control arm of the study.  Qlucore Omics Explorer 
2.3 was used to analyse the data, modelling using a multi-group analysis (i.e. repeated measures 
ANOVA) on interaction variables with log-transformed data, and including adjustment for time-
point, allocation and study.  P-values were deemed significant when less than 0.05 and with a 
corresponding q-value of less than 0.1.  No statistically significant effect of vitamin D 
supplementation on the concentrations of inflammatory mediators released following stimulation 
with RV-16, RV-1B, or RSV was observed in data pooled from asthma and COPD patients and ViDiFlu 
staff members (Table 6.12), or in data from older adults living in sheltered accommodation (Table 
6.13).  Stimuli were analysed separately, but are all presented in the same table. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
Table 6.12: Effect of vitamin D supplementation on the release of inflammatory mediators following viral pathogen stimulation of peripheral whole  
blood in data pooled from asthma patients, COPD patients and carers or staff members of sheltered accommodation schemes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All medians are given in pg/ml 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in concentrations being unable to be calculated 
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Table 6.13: Effect of high-dose vitamin D supplementation on the release of inflammatory mediators following viral pathogen stimulation of peripheral 
whole blood in older adults living in sheltered accommodation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All medians are given in pg/ml 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in concentrations being unable to be calculated 
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6.2.9 Sub-group analysis by baseline deficiency and genotype shows no effect of vitamin 
D supplementation on the release of inflammatory mediators from stimulated 
whole blood 
 
It has previously been demonstrated that an effect of vitamin D supplementation may only be 
observable in those people who were profoundly deficient at baseline [308].  As such, it was decided 
to stratify the results from the whole blood assay by baseline 25(OH)D deficiency, with a 
concentration of < 50nmol/L used as the cut-off.  As with the main analysis, as already presented in 
this chapter, data for asthma and COPD patients and ViDiFlu staff were pooled, while ViDiFlu 
residents were evaluated separately. Results were analysed systematically, looking at the cellular 
profile, and inflammatory mediators in serum and blood stimulated by a range of TLR ligands and 
pathogens.  Each data point was assigned an interaction variable for the time-point at which the 
sample was taken, and whether the participant was in the intervention or control arm of the study.  
Qlucore Omics Explorer 2.3 was used to analyse the data, modelling using a multi-group analysis (i.e. 
repeated measures ANOVA) on interaction variables with log-transformed data, and including 
adjustment for time-point, allocation and study. 
  
The results are shown for all variables which had a p-value of less than 0.05 (Table 6.14), showing a 
potential effect of vitamin D supplementation in increasing LPS-stimulated RANTES concentration in 
data pooled from deficient COPD and asthma patients and ViDiFlu staff (p = 0.04), and PolyI:C-
stimulated IL-2R (p = 0.047), and IL-12 (p = 0.04) and RSV-stimulated G-CSF (p = 0.049) 
concentrations in deficient ViDiFlu residents.  There was also a potential effect of high-dose 
supplementation in decreasing PolyI:C-stimulated MIP-1α (p = 0.01), TNF-α (p = 0.03), IL-1β (p = 
0.03), IL-2 (p = 0.045) and IL-8 (p = 0.049) concentrations in deficient ViDiFlu residents when 
compared to 12 month samples in the placebo arm.  Additionally, the effect of high-dose vitamin D 
supplementation on reducing the number of B-cells in peripheral blood was demonstrated again in 
vitamin D deficient older adults living in sheltered accommodation (p = 0.04).  However, all of these 
results were associated with a q value of greater than 0.1, meaning that there is a high likelihood of 
false positives among the discoveries, and thus they cannot reliably be deemed significant. 
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Table 6.14: Effect of vitamin D supplementation on the release of inflammatory mediators in the 
blood of people with baseline vitamin D deficiency (<50nmol/L) 
Medians for analytes are given in pg/ml; absolute B-cells are given as x 10
9
 / L 
For pooled samples, comparison was between placebo and intervention, for ViDiFlu residents comparison was 
between low-dose and high-dose vitamin D supplementation. 
2
 For some analytes numbers were smaller due to MFI values exceeding the upper limit of detection, resulting in 
concentrations being unable to be calculated 
 
 
Other studies have also demonstrated that the various effects of vitamin D supplementation in 
respiratory diseases are modified by genotype [328, 329, 336].  As such, it was decided to stratify 
analysis by genotype, looking specifically at SNPs in the vitamin D receptor (VDR) and retinoid x 
receptor (RXRA) genes.  The clinical analysis of the ViDiCO trial showed an interaction effect, with 
genotype modifying the effect of allocation on the primary outcome of time to upper respiratory 
tract infection (methodology described in Chapter 2.7).  Vitamin D was demonstrated to be 
protective by increasing the time to experiencing an upper respiratory tract infection in COPD 
patients with the minor alleles for the VDR SNPs rs4334089, rs11568820, rs7976091 and rs7970314, 
and the RXRA SNP rs7861779, and the major homozygous alleles for the VDR SNP rs10783219 
(results not yet published, but summarised in Table 5.6 of Chapter 5).  As such, these genotypes 
were chosen for stratification of the whole blood assay analysis.  Each data point was assigned an 
interaction variable for the month the sample was taken, and whether the participant was on the 
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intervention or control arm of the study as before.  Qlucore Omics Explorer 2.3 was used to analyse 
the data, modelling using a multi-group comparison (i.e. repeated measures ANOVA) on interaction 
variable, and adjusting for time-point and allocation.  However, the number of participants with 
each genotype for each SNP was deemed to be too small to accurately make any significant 
conclusions on whether the effect of vitamin D supplementation on the release of inflammatory 
mediators from stimulated blood was modified by genotype due to a lack of statistical power (Table 
6.15). 
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Table 6.15:  The number of COPD patients with each SNP genotype, separated by time-point and 
allocation 
Gene SNP Genotype 
Control Control Intervention Intervention 
0 Month 12 Month 0 Month 12 Month 
VDR rs4334089 
GG 10 10 3 3 
AG 3 3 4 4 
AA 1 1 1 1 
VDR rs10783219 
AA 6 6 4 4 
AT 5 5 3 3 
TT 3 3 0 0 
VDR rs11568820 
CC 9 9 2 2 
CT 4 4 6 6 
TT 0 0 0 0 
VDR rs7976091 
CC 10 10 2 2 
CT 4 4 6 6 
TT 0 0 0 0 
VDR rs7970314 
AA 10 10 2 2 
AG 4 4 6 6 
GG 0 0 0 0 
RXRA rs7861779 
GG 11 11 5 5 
AG 3 3 2 2 
AA 0 0 0 0 
Abbreviations used: RXR: retinoid X receptor; SNP: single nucleotide polymorphism; VDR: vitamin D receptor 
 
 
6.3 Discussion 
 
It has been demonstrated here that supplementation with vitamin D resulted in a significant 
increase in serum 25(OH)D concentration throughout the course of the study for all four study 
populations.  This was associated with a decrease in the number and percentage of B-cells in the 
peripheral whole blood of older adults with neither asthma nor COPD living in sheltered 
accommodation in a comparison between high-dose and low-dose vitamin D supplementation.  
However, no other differences in the cellular profile or the inflammatory response mounted to 
antigenic stimulation in the blood of asthmatics or COPD patients were observed. 
 
B-cells are components of the adaptive immune system, which are able to secrete antibodies, and 
inflammatory mediators, as well as acting as antigen presenting cells in response to infection by 
viruses or bacteria.  The B-cell population in this study was quantified by selecting lymphocytes 
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based in forward and side scatter properties, before defining B-cells as being CD3- CD19+.  CD19 is a 
component of the B-cell co-receptor complex, which modulates signal transduction through the B-
cell receptor (BCR) to affect tolerance, differentiation, proliferation, activation and antigen 
presentation.  It is present on the surface of B-cells from the early pro-B-cell stage in the bone 
marrow, to mature B-cells in the periphery which are able to bind antigens and secrete antibodies, 
as well as on regulatory B-cells, which aid in maintaining tolerance [604].  Expression of CD19 is only 
lost upon terminal differentiation into plasma cells [605, 606].  Therefore, the B-cell population 
quantified here potentially includes immature, naive, activated and memory B-cells, but not plasma 
cells, with distinction between the different types impossible without further staining for cell surface 
markers such as the use of CD27 to distinguish memory B-cells.  CD19 is also expressed on follicular 
dendritic cells, however, since they are only present in the follicles of lymphoid organs, CD19 can be 
used accurately as a marker B-cells in peripheral blood without detecting any other cell types [605, 
607].   
 
B-cells are known to express the vitamin D receptor and CYP27B1, and thus can be modulated by 
1,25(OH)2D [252, 255].  It has previously been demonstrated that 1,25(OH)2D suppresses cellular 
proliferation and antibody production following activation of B-cells in PBMCs [608], while also 
increasing apoptosis and decreasing proliferation, plasma cell differentiation and memory cell 
differentiation in activated primary B-cells [255].  B-cells have been demonstrated to have a role in 
autoimmune diseases, by way of secretion of autoantibodies and presentation of autoantigens [398, 
609, 610].  It has been shown that people with autoimmune diseases such as systemic lupus 
erythematous (SLE) often have low serum concentrations of 25(OH)D, with an inverse correlation 
with disease activity [611-613].  As such, vitamin D supplementation has been trialled in patients 
with SLE, demonstrating a decrease in memory B-cells in PBMCs [399].  However, no effect was seen 
when looking at circulating B-cell subsets and immunoglobulin production in the plasma of multiple 
sclerosis patients supplemented with 20,000IU /day of vitamin D3 [614]. 
 
As previously mentioned, none of the intervention studies of vitamin D supplementation in acute 
respiratory tract infections took blood samples to investigate the effects of vitamin D on the cellular 
components and inflammatory mediators present in peripheral whole blood stimulated with TLR 
ligands or pathogens ex vivo.  As such, the results of this study cannot be compared with others in 
the literature.  While in vitro work has demonstrated an effect of 1,25(OH)2D on B-cell proliferation, 
this was only shown in cells activated by molecules such as IL-21 and CD40 [255, 608].  However, the 
population in this study which demonstrated an effect of high-dose vitamin D supplementation in 
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decreasing the number of B-cells in peripheral whole blood was made up of older adults living in 
sheltered accommodation.  It has been demonstrated that aging is associated with chronic 
inflammation and impaired immunity [615], with an increased serum leptin concentration one 
potential component of this [616, 617].  Leptin is an adipokine which can induce secretion of pro-
inflammatory cytokines such as TNF-α and IL-6 [618], and has also been shown to induce activation 
of B-cells [619, 620].  As such, the B-cells of the aged ViDiFlu residents population in this study may 
have been chronically activated, and thus the decrease in CD3-CD19+ B-cells demonstrated here may 
corroborate the other studies on the effects of vitamin D on B-cells.  Additional staining would have 
been needed to be carried out to determine the activation status of the B-cells present, and also if 
any sub-populations were specifically effected.  Therefore, while a decrease in B-cell numbers may 
not be beneficial in protecting against acute respiratory tract infections, since B-cells are a vital part 
in adaptive immunity, it may be advantageous in reducing age-related chronic inflammation. 
 
While a vitamin D-induced reduction in the proportion and absolute numbers of B-cells was 
observed in older adults living in sheltered accommodation, it was not shown in data pooled from 
asthma and COPD patients.  Asthma and COPD are both diseases of chronic inflammation, and thus 
it might be expected that, if this effect of vitamin D was dependent on the activation state of the B-
cells, that these patients would also have chronically activated B-cells and thus exhibit a reduction in 
numbers following vitamin D supplementation.  Additionally, both asthma and COPD have been 
reported to be associated with increased concentrations of B-cell activating factor (BAFF) [621, 622].  
Thus, this may contradict the hypothesis that the vitamin D reduction of B-cells was dependent on 
their activation state, suggesting that other factors present in the elderly but not in asthma and 
COPD patients may be behind this effect.  As evaluated in Chapter 8 in a cross-sectional analysis of 
the inflammatory mediators in serum and in blood following antigenic stimulation, the inflammatory 
phenotype of COPD, asthma and older adults is markedly different.  As such, while asthma and COPD 
patients do exhibit chronic inflammation, there are many differences compared to the elderly, which 
may be behind the discrepancies observed in this study.  Finally, even though the p and q-values for 
this analysis were significant, the fact that only one outcome out of the vast number of analyses 
performed showed any effect of vitamin D supplementation means that type I error cannot be ruled 
out. 
 
Somewhat surprisingly, vitamin D supplementation was not shown to have any other effects on the 
cellular profile of whole blood, or on the release of inflammatory mediators following stimulation 
with TLR ligands and pathogens.  As reviewed in chapter 1, in vitro work has shown that vitamin D 
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has an extensive effect on the immune system, primarily by inhibition of DC differentiation and the 
antigen-presenting functions of APCs, increased IL-10 secretion, and skewing of the Th1/Th2 
balance.  However, the results from these immunological assays do largely corroborate the results 
from the primary outcomes of the clinical trials.  Except for a modest improvement in quality of life 
in asthma patients (determined by St George’s Respiratory Questionnaire (SGRQ) scores), no effects 
of vitamin D supplementation were observed on time to first exacerbation, or time to first URI in the 
ViDiAs and ViDiCO trials.  In ViDiCO, when stratified by baseline vitamin D deficiency (defined as 
serum 25(OH)D concentration < 50nmol/L), vitamin D supplementation significantly reduced the risk 
of moderate or severe exacerbation (aHR 0.57, 95% CI 0.35 to 0.92, p = 0.021).  An attempt was 
made to do similar stratification for the results of the immunological assays from pooled data from 
asthma and COPD patients and ViDiFlu staff members, with an increase in LPS-stimulated release of 
RANTES demonstrated, but with a q-value of greater than 0.1 a false positive could not be ruled out.  
Likewise, in the primary outcomes, the effect of vitamin D supplementation on time to URI was 
modified by genotype, but we were again underpowered to carry out similar stratification for the 
immunological assays presented in this chapter.   
 
In the ViDiFlu trial, high-dose vitamin D supplementation was associated with an increased risk of 
URI (aHR 1.48, 95% CI 1.02 to 2.16, p = 0.04).  While the majority of the results presented here 
demonstrated no effect following vitamin D supplementation, the reduction in B-cells could play a 
role in this increased risk of acute respiratory tract infection.  Likewise, false positives could not be 
ruled out with q-values of greater than 0.1, although a trend towards a decreased pro-inflammatory 
response following polyI:C stimulation was observed when stratifying by baseline vitamin D 
deficiency, also potentially suggesting a mechanism by which administration of bolus vitamin D may 
increase the risk of infection compared to daily dosing. 
 
The main limitation of this study was in being underpowered, especially when stratifying by baseline 
vitamin D deficiency or by genotype.  Power calculations for the trials were calculated based on the 
primary outcomes of time to first exacerbation/URI, and with the delays in implementation of 
immunological assays and budgetary constraints on the magnitude of the analyses carried out, 
sufficient numbers may not have been gained to reach significance thresholds.  To attempt to 
increase power, data from asthmatics, COPD patients and ViDiFlu staff members who all underwent 
similar vitamin D dosing regimens were pooled.  This raises another possible limitation, since the 
inflammatory response for these three distinct populations was likely to differ markedly.  To 
compensate for this, “study” was eliminated as a confounder during analysis, thus removing any 
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influence of having asthma or COPD on the outcome of the analysis.  Power was also reduced for 
analytes such as IL-6, IP-10 and RANTES which had concentrations frequently exceeding the upper 
limit of detection, with KNN-imputation used during analysis to attempt to compensate for this.  If 
samples had been diluted to allow such analytes to fall within the detectable range, many more 
analytes would have been at concentrations below the sensitivity threshold for the assay.  
Additionally, it would not have been feasible to run singleplex ELISAs with samples diluted 
accordingly for each individual assay for the number of analytes that we wished to quantify and the 
number of samples to be tested.  While samples could be diluted and re-analysed in the future for 
the analytes which were consistently highly expressed, currently this is not possible due to 
budgetary constraints.     
 
The use of peripheral blood is another limitation of this study.  Asthma and COPD are both 
respiratory diseases, the pathogens used were all respiratory pathogens, and the main outcomes of 
the trial were associated with respiratory health.  Thus investigations into the immune response 
mounted and the effects of vitamin D would have been more valuable at the site of infection.  
However, blood provides a readily available model for assessing the release of inflammatory 
mediators, and is much better tolerated than the use of techniques such as experimental rhinovirus 
challenge, sputum induction, and bronchoscopy, thus enabling greater numbers to be recruited.   
 
Therefore, here it has been demonstrated that, while supplementation was successful in increasing 
the vitamin D status of trial participants, the only immunological effect observed was a decrease in 
peripheral blood B-cells in older adults without asthma or COPD.  There may be additional effects of 
vitamin D supplementation in those with profound vitamin D deficiency at baseline or in people with 
certain genotypes, but we were not adequately powered to accurately assess these hypotheses in 
this study. 
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7. Comparison of cellular profiles and supernatant inflammatory 
mediators in induced sputum of patients with asthma or COPD 
 
7.1 Introduction 
 
In addition to the primary analyses evaluating the effect of vitamin D supplementation on the 
cellular profile and inflammatory mediators present in induced sputum, and the inflammatory 
response to antigenic stimulation of peripheral whole blood as presented in Chapters 5 and 6 
respectively, clinical samples were further utilised to perform cross-sectional comparisons of the 
underlying phenotypes associated with asthma and COPD. 
 
As previously described, induced sputum provides a useful tool for profiling the cellular components 
and inflammatory mediators present in the lower airways.  Asthma and COPD are both diseases of 
chronic airway inflammation, and thus assessment of induced sputum is a useful tool to determine 
the pathophysiology of these diseases and associated risk of exacerbation.  Both diseases have 
similar characteristics, such as mucus hypersecretion and airway remodelling and hyper-
responsiveness, dyspnoea, cough, wheezing and chest tightness, as well as the intermittent 
occurrence of exacerbations.  However, the underlying inflammatory profile of the two diseases is 
markedly different [140, 623, 624], and these differences may affect susceptibility to respiratory 
tract infections and response to treatments.  It is also becoming increasingly clear that asthma is a 
heterogeneous disease, comprised of subgroups with different underlying inflammatory profiles 
[180, 181, 625-627] and the typical airway eosinophilia and TH2 phenotype not observed in all 
patients. [628].  Likewise, COPD is also emerging as a heterogeneous disease, with eosinophilic 
inflammation reported in sub-groups rather than the typical neutrophilic inflammation [598, 629].  A 
better understanding of the underlying inflammatory profile of both disease types has the potential 
to provide insight into pathogenesis and improve the management of these conditions. 
 
Therefore, a cross-sectional analysis of the differences in lower airway inflammation between 
asthma and COPD was conducted by analysis of induced sputum samples in patients at enrolment to 
the ViDiAs and ViDiCO trials by differential cell count, flow cytometry and multiplex ELISA of induced 
sputum supernatants. 
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As with the prospective analyses presented in the two previous chapters, a 30-plex panel was 
chosen for analysis of induced sputum supernatants to include a range of inflammatory mediators to 
encompass any potential differences between asthma and COPD.  The following analytes were thus 
included in the analysis: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12, IL-13, IL-15, IL-17, IL-
1RA, IL-2R, IFN-α, IFN-γ, TNF-α, MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), eotaxin 
(CCL11), MIG (CXCL9), IP-10 (CXCL10), EGF (epidermal growth factor), FGF-basic (basic fibroblast 
growth factor), HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), G-CSF 
(granulocyte colony-stimulating factor) and GM-CSF (granulocyte macrophage colony-stimulating 
factor).          
 
 
7.2 Results 
 
7.2.1 Study recruitment and baseline characteristics of trial participants 
 
As described in Chapter 2.1, a subset of participants recruited onto the ViDiAs and ViDiCO clinical 
trials were invited to give induced sputum samples.  These samples were collected at randomisation 
(month 0), and at 2 and 12 month follow-up visits, to enable characterisation of baseline 
characteristics, and determination of any effect caused by supplementation with vitamin D3.  Figure 
7.1 shows the recruitment profile for these two clinical trials and the number of participants who 
were able to provide baseline samples.  In total, 88% of participants in both studies produced an 
induced sputum sample at baseline.  Of those who did not produce a sample, 4 asthma and 1 COPD 
participant were unable to expectorate, 2 asthma participants had baseline lung function tests which 
rendered it unsafe to proceed with nebulisation, and 5 COPD participants withdrew consent. In 
participants with asthma, 20% produced samples with a high degree of squamous cell 
contamination, thus obscuring other cell types and rendering differential cell counts impossible, 
compared to 0% in participants with COPD.  Flow cytometry was implemented 1 year after 
recruitment for the trials began, resulting in 10 asthma and 6 COPD participants having already 
provided baseline samples before this period.   The procedure was only carried out in samples with 
more than 1 million cells remaining after sputum processing and cytospin preparation, ensuring 
enough cells for the staining to be successful and accurate results to be yielded.  Additionally, a 
subset of COPD participants had their study visits at an alternative site.  Due to the importance of 
sputum being processed within 2 hours to ensure optimum staining, as reported elsewhere [587, 
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630], transportation times did not allow for the additional steps involved in preparing the samples 
for flow cytometric analysis.  Thus 34% of ViDiAs participants and 52% of ViDiCO participants who 
provided a sputum sample sufficient for a differential cell count to be carried out also had a sample 
which was sufficient to undergo additional analysis by flow cytometry.  
Figure 7.1: Recruitment profile for sputum sub-study at baseline. 
 
 
 
 The baseline characteristics of participants who were able to produce a sample sufficient for 
differential cell count are presented in Table 7.1.  There was no significant difference between the 
sex, ethnic distribution, BMI, uptake of influenza vaccine, baseline 25(OH)D status and inhaled 
corticosteroid use in subjects with asthma and COPD.  However, a difference in age (p < 0.0001), 
pack years (p < 0.0001) and pneumococcal vaccine uptake (p = 0.006) was observed.  All can be 
attributed to the nature of the two disease states, with COPD usually caused by smoking, and the 
likelihood of it developing increasing with age and smoke exposure.  While influenza vaccination is 
routinely given both to the elderly and those with chronic respiratory conditions such as asthma and 
COPD, pneumococcal vaccination is only routinely given to older adults.  Thus the difference in the 
two groups observed here is likely due to the higher median age in the COPD study.  These data also 
reflect the eligibility criteria for the studies, with participants excluded from ViDiAs if older than 80 
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or with a smoking history of greater than 15 pack years, while ViDiCO participants were ineligible if 
they were younger than 40 or had a smoking history of less than 15 pack years.   
 
 Table 7.1: Baseline characteristics of participants with asthma and COPD 
  Asthma (n = 35) COPD (n = 44) P-Value 
Median Age (IQR) 54 (38 to 63) 66 (62 to 71) < 0.0001 
Sex     0.27 
                      Male, n (%) 18 (51) 28 (64)   
                      Female, n (%) 17 (49) 16 (36)   
Ethnic Group     0.26 
                      White, n (%) 31 (88) 42 (95)   
                      Black, n (%) 2 (6) 2 (5)   
                      Other, n (%) 2 (6) 0 (0)   
Median Pack Years (IQR)1 0.0 (0.0 to 5.0) 41.3 (30.3 to 60.0) < 0.0001 
Median BMI (IQR) 26.6 (24.3 to 30.1) 28.4 (25.7 to 33.0) 0.22 
Pneumococcal Vaccine     0.006 
                       Received, n (%) 13 (37) 30 (68)   
                       Did not receive, n (%) 22 (63) 14 (32)   
Influenza Vaccine     0.1 
                       Received, n (%) 31 (89) 43 (98)   
                       Did not receive, n (%) 4 (11) 1 (2)   
Median 25(OH)D status in nmol/L (IQR) 45 (35 to 69) 39 (30 to 55) 0.2 
Median inhaled corticosteroid (ICS) use 
(IQR) 2 (µg) 400 (200 to 1000) 400 (0 to 1000) 0.2 
1
 Pack years calculated by number of cigarettes smoked per day divided by 20 and multiplied by the number of 
years smoked for 
2
 ICS dose given as betamethasone equivalents: 1 microgram betamethasone assumed equivalent to 1 µg 
budesonide, 0.5 µg fluticasone dipropionate and 0.75 µg ciclesonide. 
 
Contingency tables were used to calculate p-values for sex, ethnicity, pneumococcal vaccine uptake and 
influenza vaccine uptake; unpaired T-tests were used to calculate p-values for age, BMI and 25(OH)D status 
(due to these data being normally distributed); Mann-Whitney tests were used to calculate p-values for pack 
years and ICS use (due to these data being non-normally distributed).  
 
Abbreviations used: IQR: interquartile range; BMI: body mass index (individuals body mass divided by the square of their height); ICS: 
inhaled corticosteroid; COPD: chronic obstructive pulmonary disease; 25(OH)D: 25-hydroxy vitamin D. 
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7.2.2 Analysis of induced sputum by differential cell counts shows a difference in the 
percentage of macrophages and neutrophils between asthma and COPD 
 
Induced sputum samples were collected and processed as described in Chapter 2.3.  Following 
cytospin preparation, differential cell counts were carried out.  Averages were taken from counts of 
400 non-squamous cells from 3 cytospins for each participant.  Results were calculated as the 
percentage of each cell type counted and also as absolute cell counts.  Qlucore Omics Explorer 2.3 
was used to analyse the data, modelling using a two-group analysis (i.e. Student’s T-Test) on study 
(i.e. whether participants had asthma or COPD) with log-transformed data, and including adjustment  
for age, sex, baseline 25(OH)D concentration, ethnicity, smoking status, vaccination record and 
inhaled corticosteroid use.  All results are presented in Table 7.2, and those with a significant 
difference between participants with asthma and COPD are presented in Figure 7.2.  There was a 
higher percentage of macrophages in people with asthma compared to COPD (p = 0.04), while 
people with COPD had a greater number of neutrophils, as assessed both by percentage and 
absolute cell count (p = 0.03 and 0.04 respectively).  No significant difference was found in 
eosinophil, lymphocyte or epithelial cell counts.      
 
Table 7.2: Comparison of sputum differential cell counts in people with asthma or COPD  
The interquartile range (IQR) is only stated where statistical significant difference was evident 
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Figure 7.2:  Cross-sectional comparison of differential cell counts in people with asthma or COPD.  Induced 
sputum samples were processed and differential cell counts carried out on n = 35 for asthma and n = 44 for 
COPD.  Each count was done in triplicate with an average value calculated.  Data are represented as scatter 
plots with median + IQR, with p-values calculated using a Two-Group Comparison (i.e. an unpaired Student’s T-
Test) with the model including adjustment for age, sex, baseline 25(OH)D status, ethnicity, smoking status, 
vaccination record and inhaled corticosteroid use, using the program Qlucore Omics Explorer 2.3.  P-values 
were deemed significant when less than 0.05, with a corresponding q-value of less than 0.1. 
 
 
Since differential cell counting is subject to human error due to the subjective nature of identifying 
different cell types, validation of cell count data was carried out.  A subset of 10 asthma and 10 
COPD cytospins were chosen at random, and cells were counted by another assessor (Will Monteiro, 
Leicester Respiratory Biomedical Research Unit, Glenfield Hospital, UK) following the same protocol, 
with results presented in Figure 7.3.  The correlation between the original counts carried out and the 
counts calculated during validation was strong for neutrophils, macrophages, eosinophils and 
epithelial cells (r > 0.9 and p<0.0001 for all 4).  However, there was no correlation in the percentage 
of lymphocytes (r = 0.1, p = 0.7)    
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Figure 7.3:  Validation of differential cell counts.  A subset of n = 20 had differential cell counts carried out by 
two different people.  Counts were compared using Pearson’s R Correlation Test.  
 
 
A Bland-Altman plot can also be used to assess the agreement between two methods, with a high 
correlation, as seen above, not automatically implying good agreement between the two.  As such, 
Bland-Altman analysis was carried out on the two sets of cell counts, with plots displaying the mean 
of each pair of values, and the difference between each pair of values (Figure 7.4).  The bias value 
calculated represents the mean difference between the two data sets, with a smaller bias indicating 
similar results, and thus validating the data.  The bias values for macrophages (0.96), eosinophils 
(0.05), epithelial cells (0.54) and lymphocytes (-0.21) were all between -1 and 1, with neutrophils 
marginally outside this range (-1.34), thus showing a good agreement between the two sets of cell 
counts.  Additionally, the 95% limits of agreement (calculated as the mean bias ± 1.96 * SD, and 
represented as dotted lines on the plots below) were narrow for each cell type, also demonstrating a 
good agreement between the two sets of cell counts.  Therefore, using a sub-set of n=20, we have 
successfully validated the differential cell counts carried out on sputum sample slides.          
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Figure 7.4:  Validation of differential cell counts.  A subset of n = 20 had differential cell counts carried out by 
two different people.  Counts were compared using Bland-Altman analysis, with dotted lines representing the 
upper and lower 95% limits of agreement.  
 
 
7.2.3 Analysis of induced sputum by flow cytometry shows no differences in absolute 
numbers or proportions of any cell type between asthma and COPD 
 
Induced sputum samples were collected and processed as described in Chapter 2.3.  In a subset of 
samples (n = 12 for asthma and n = 23 for COPD) additional analysis was carried out by flow 
cytometry.  This was to enable further determination of the cellular profiles of asthma and COPD, in 
addition to the differential cell counts. The gating strategies described in Chapter 2 were used to 
establish the proportion of B-cells, CD4+ T-cells, CD8+ T-cells, myeloid dendritic cells (mDCs), 
plasmacytoid dendritic cells (pDCs) and regulatory T-cells (Tregs) present in the sputum samples.  
Since all of them were based on a lymphocyte population, lymphocyte counts from the differential 
cell counts were used to calculate absolute cell counts for each cell type.  A comparison between the 
baseline cellular profile of asthma and COPD patients was then carried out (Table 7.3).  Qlucore 
Omics Explorer 2.3 was used to analyse the data, modelling using a two-group analysis (i.e. Student’s 
T-Test) on study (i.e. whether participants had asthma or COPD) with log-transformed data, and 
including adjustment  for age, sex, baseline 25(OH)D concentration, ethnicity, smoking status, 
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vaccination record and inhaled corticosteroid use.  No statistically significant difference was seen 
between asthma and COPD patients for any of the cell types looked at.  
 
Table 7.3: Cross-sectional comparison of cellular profiles of asthma and COPD as determined by flow 
cytometry   
 
 
7.2.4 Validation of methodology used for flow cytometric analysis of induced sputum 
 
The addition of dithiothreitol (DTT) is vital during the sputum processing procedure, since it 
facilitates the dissociation of disulphide bonds present in mucin molecules, thus allowing the 
complete homogenisation of the sample.  This results in cells being released from the mucus present 
in the sample, and enables a clearer distinction between different cell types during cell counts, 
therefore facilitating more accurate results [630-633].  However, other studies have demonstrated  
detrimental effect of using DTT, with a reduction in viable cells [588], altered cell function [634], and 
diminished fluorescence intensity for some leukocyte surface markers [635].  It was also observed in 
the results generated from carrying out flow cytometry on sputum samples that CD127 APC staining 
was visibly diminished.  Therefore, the effect of DTT on staining and the subsequent characterisation 
of cell populations was determined.  Peripheral whole blood was used for this analysis, since sputum 
samples would be hard to process and stain without the use of DTT for homogenisation, and blood 
provided higher cell counts to work with.  Blood samples were incubated with an equal volume of 
0.1% DTT for 15 minutes, as per the sputum processing protocol, before undergoing staining for flow 
cytometry, as described in Chapter 2.4.  The results from this analysis are displayed in Figure 7.5.  
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Populations of lymphocyte subsets, dendritic cells and regulatory T-cells were comparable between 
normal samples and those treated with DTT.  As with the sputum samples, diminished staining with 
APC CD127 was observed following DTT treatment, with the CD127+CD4+ population reduced 3-fold 
from 45% to 15% following incubation with DTT (Figure 7.5 C).  However, this effect was shown to be 
CD127 specific and did not affect other antigens conjugated with the APC fluorophore, with, for 
example, comparable percentages of CD4+ T-cells (42% and 46%, Figure 7.5 A), and pDCs (28% and 
25%, Figure 7.5 B) which also used the APC fluorophore.  Since only CD127- cells were of importance 
for this analysis, this effect on APC CD127 staining was deemed to be unimportant in this context, 
and analysis of sputum samples was continued with the use of DTT. 
 
 
Figure 7.5: Effect of DTT on staining for flow cytometry in peripheral whole blood.  Lymphocyte subsets (A), 
dendritic cells (B) and regulatory T-cells (C) were stained following the normal protocol (left panel) and 
following incubation with DTT (right panel) to compare fluorescence intensities and the cell percentages 
observed between the two protocols. 
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The discovery of the transcription factor FoxP3 (forkhead box P3) has enabled the accurate detection 
of regulatory T-cells by flow cytometry, with CD4+CD25+FoxP3+ cells representing this population.  
However, due to the time constraints and low cell numbers encountered when performing flow 
cytometry on sputum samples, the intracellular staining protocol involved in FoxP3 detection 
becomes unfeasible.  As such, CD127 was used instead, due to its strong inverse correlation with 
FoxP3 expression [636, 637].  Since the use of FoxP3 is the gold standard for Treg detection, Foxp3 
staining was carried out in a subset of n = 11 blood and sputum samples to compare the proportion 
of Tregs counted by each method.  Regulatory T-cells were distinguished as being CD4+CD25+CD127- 
or as being CD4+CD25+FoxP3+ as described in Chapter 2.4, and isotype controls were used to help 
determine what constituted the CD25+ population.  A strong correlation was seen between the 
amount of Tregs calculated from the two methods (r=0.99, p<0.0001, Figure 7.6).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6:  Validation of the use of CD127 in place of Foxp3 when defining regulatory T-cell populations.  A 
subset of n = 11 blood and sputum samples underwent staining for CD4
+
CD25
+
CD127
-
 and  CD4
+
CD25
+
FoxP3
+
 
cells to compare the number of Tregs calculated using each method.  Counts were compared using Pearson’s R 
Correlation Test.  
 
 
Again, a Bland-Altman analysis was also carried out in order to further assess the agreement 
between the two methods used for calculating the Treg population.  A small bias value was 
calculated (0.03) with narrow 95% limits of agreement (Figure 7.7), thus demonstrating a strong 
agreement between the two methods used, and corroborating the use of CD127 instead of FoxP3 in 
this study. 
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Figure 7.7:  Validation of the use of CD127 in place of Foxp3 when defining regulatory T-cell populations.  A 
subset of n = 11 blood and sputum samples underwent staining for CD4
+
CD25
+
CD127
-
 and  CD4
+
CD25
+
FoxP3
+
 
cells to compare the number of Tregs calculated using each method.  Counts were compared using Bland-
Altman analysis, with dotted lines representing the upper and lower 95% limits of agreement. 
 
7.2.5 Analysis of induced sputum supernatant inflammatory mediators shows 
differences between asthma and COPD patients 
 
Cytokines and chemokines play an important role in orchestrating the recruitment, activation and 
regulation of inflammatory cells in the respiratory tract of people with asthma and COPD.  While 
asthma and COPD are both characterised by airway obstruction and have many similar clinical 
features, there is a marked difference in their underlying inflammatory phenotype [140, 623, 624].  
However, very few studies have investigated the protein constituents of sputum from asthma and 
COPD patients during their steady state.  Those that have, have focused mainly on proteins such as 
eosinophilic cationic protein and IL-8, which are associated with the eosinophils and neutrophils 
which are major components of airway inflammation in these patient groups, have assessed levels 
during exacerbation, or have focused solely on one of the disease types  [455, 625, 638-640].  As 
such, it was desirable to use a multiplex approach to determine the profiles of a wide range of 
cytokines and chemokines to compare between these two disease states.  
 
Induced sputum samples were collected and processed as described in Chapter 2.3.  Supernatants 
were aspirated and stored at -80oC, before being analysed by multiplex ELISA.  Qlucore Omics 
Explorer 2.3 was used to analyse the data, modelling using a two-group analysis (i.e. Student’s T-
Test) on study with log-transformed data, and including adjustment  for age, sex, baseline 25(OH)D 
concentration, ethnicity, smoking status, vaccination record and inhaled corticosteroid use.  All 
results are presented in Table 7.4, and significant results are presented in Figure 7.8.  Concentrations 
of IL-2 (p = 0.0006), IL-4 (p = 0.002), IL-13 (p = 0.04) and GM-CSF (p = 0.04) were all significantly 
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higher in asthma samples compared to COPD (Figure 7.8 A – D).  Concentrations of IFN-α (p<0.0001), 
MIP-1α (p = 0.0003), IL-8 (p = 0.0003), IL-6 (p = 0.0004), G-CSF (p = 0.0006), IL-1RA (p = 0.001), 
eotaxin (p = 0.005), MCP-1 (p = 0.02), HGF (p = 0.02) and IL-1β (p = 0.04) were all significantly higher 
in COPD compared to asthma (Figure 7.8 E – N).  The remaining inflammatory mediators assayed 
(FGF Basic, IL-10, IL-12, RANTES, IL-17, MIP-1β, IL-15, EGF, IL-5, VEGF, IFN-γ, TNF-α, IL-7, IP-10, IL-2R 
and MIG) displayed no difference between participants with asthma and those with COPD (Table 
7.4). 
 
Table 7.4: Comparison of induced sputum supernatant inflammatory mediators in people with 
asthma or COPD 
All medians are given in pg/ml 
The interquartile range (IQR) is only stated where statistical significant difference was evident 
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Figure 7.8:  Cross-sectional comparison of inflammatory mediators in people with asthma or COPD.  Induced 
sputum samples were collected and supernatants from n = 44 asthma and n = 43 COPD patients were used in a 
multiplex ELISA.  Data are represented as scatter plots with median + IQR, with p-values calculated using a 
Two-Group Comparison (i.e. unpaired T-Test) with the model including adjustment for age, sex, baseline 
25(OH)D status, ethnicity, smoking status, vaccination record and inhaled corticosteroid use, using the program 
Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with a corresponding q-
value of less than 0.1.  Any values under the limit of detection according to the product data sheet for each 
analyte were given a value of 0. 
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7.3 Discussion 
 
It has been demonstrated here that there is a significant difference in the underlying cellular and 
inflammatory profile of asthma and COPD.  Asthmatic subjects had an increased proportion of 
macrophages, with higher concentrations of IL-2, IL-4, IL-13 and GM-CSF present in their induced 
sputum samples, while COPD patients demonstrated greater numbers of neutrophils, and increased 
production of IFN-α, MIP-1α, IL-8, IL-6, G-CSF, IL-1RA, eotaxin, MCP-1, HGF and IL-1β.  
 
Asthma is typically classified as a disease of eosinophilic airway inflammation, with an increased 
number of CD4+ T-cells found in the airways and an associated Th2 phenotype [140].  In this study, 
asthma was not found to be associated with an increased proportion of eosinophils or CD4+ T-cells 
when compared to people with COPD.  When defining eosinophilic airway disease as having a 
sputum eosinophil percentage of >2% (as defined in other studies [625, 641, 642]), in this study at 
baseline 32 people had eosinophilic airway disease, 13 of whom had asthma and 19 who had COPD.  
This equates to 37% of asthma participants and 43% of COPD participants.  As such, it is clear that 
not all asthmatics have underlying eosinophilic airway disease, and that COPD patients can also have 
an eosinophilic phenotype.  Other studies have also demonstrated the importance of eosinophils in 
COPD, with eosinophilic inflammation reported to be present in 20 – 40% of cases [597, 598], and a 
reduction in sputum eosinophilia associated with a reduction in COPD exacerbations [629].  In 
addition to this, it has been recognised that only 50% of asthmatics have airway eosinophilia [598, 
599].  Thus with the frequency of non-eosinophilic asthma and eosinophilic COPD, it is unsurprising 
that no difference in eosinophil count was observed between the two study groups.   
 
CD4+ T-cells are classically described as helper T-cells, which function by producing pro-inflammatory 
Th1 cytokines, or allergy-related Th2 cytokines.  While asthma was not associated with an increased 
population of CD4+ T-cells in this study, there was a Th2 phenotype compared to COPD patients.  IL-4 
is produced by Th2 T-cells, mast cells, basophils and eosinophils.  It drives further Th2 T-cell 
differentiation and inhibits Th1 production, as well as stimulating B-cell proliferation, driving B-cell 
production of IgE, stimulating dendritic cell maturation and increasing MHC class II expression [643, 
644].  Its over-production is also associated with allergy [645].  IL-4 shares sequence homology, 
receptors and functional effects with IL-13 [646-648], so it is unsurprising that both cytokines were 
shown to be increased in asthma when compared to COPD.  GM-CSF was also upregulated in 
asthmatics in this study.  This cytokine induces proliferation and differentiation of neutrophils, 
eosinophils and macrophages, is important in dendritic cell development, and has been associated 
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with atopy, with a role in allergic sensitisation [649-653].  Therefore, an allergic phenotype has been 
demonstrated in asthmatic subjects in this study, despite no increase in eosinophils or CD4+ T-cells.  
The lack of difference in CD4+ T-cells may be due to lack of power, with sufficient sputum samples for 
flow cytometry hard to obtain in people with mild asthma who could not easily expectorate a 
sample.  Additionally, invariant T cell receptor-positive natural killer T (iNKT) cells have been 
demonstrated to play a role similar to CD4+ T-cells in asthma, including the production of Th2 
cytokines, and have been demonstrated to be required for airway inflammation induced by 
environmental antigens [654, 655].  Therefore, they could represent an important subpopulation to 
look at in any subsequent studies, and could be behind the increased production of Th2 cytokines.   
 
IL-2 is a growth and activating factor for both Th1 and Th2 cells [656, 657].  It has been 
demonstrated to be produced by Th2 cells in response to allergen stimulation, and its production 
has been shown to be increased in BAL of asthmatics [658, 659].  Additionally, use of inhaled IL-2 in 
the treatment of metastasising renal cell carcinoma has been demonstrated to cause temporary 
symptomatic, functional and inflammatory alterations similar to those typical of bronchial asthma, 
thus further demonstrating its importance in asthma [660].  As such, our finding that IL-2 
concentration was increased in asthma compared to COPD corroborates previously demonstrated 
associations. 
 
Finally, the percentage of macrophages was demonstrated to be increased in asthma.  Since 
absolute numbers of macrophages were not increased, this difference is likely due to the nature of 
differential cell counts and the use of percentages rather than whole numbers, rather than any 
functional explanation.  The majority of cells counted were either macrophages or neutrophils, so in 
the absence of neutrophilic disease, as seen in the asthma participants compared to COPD, more 
macrophages were counted to fulfil the requirement of counting 400 non-squamous cells. 
 
COPD is typically classified as a disease of neutrophilic airway inflammation, with an increased 
number of CD8+ T-cells found in the airway wall [140].  In this study, COPD was found to be strongly 
associated with the percentage and absolute number of neutrophils found in the sputum.  Defining 
neutrophilia as a sputum neutrophil content greater than 60%, while a subset of 40% of asthmatics 
did exhibit a neutrophilic phenotype, 86% of COPD patients were classified as having sputum 
neutrophilia.  Profound neutrophilia has been demonstrated numerous times in COPD patients , and 
is thought to contribute to the pathophysiology of COPD by stimulating EGFR-dependent mucus 
hypersecretion, releasing elastase which causes goblet cell degranulation,  secreting proteases which 
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mediate tissue damage, and releasing reactive oxygen species which damage the epithelium, reduce 
ciliary function and increase mucosal permeability [175, 661, 662].  Neutrophil migration into the 
respiratory tract has been demonstrated to be orchestrated by IL-8 and TNF-α, with IL-8 mobilising 
the MAC-1 (macrophage-1) antigen to the neutrophil surface to facilitate adhesion to the 
endothelium and subsequent extravasation into the airways [175, 663, 664].  Neutrophils are also 
able to produce IL-8 themselves, and thus it is unsurprising that, as in other studies [665, 666], we 
found a significantly greater concentration of IL-8 in the sputum of COPD patients compared to 
asthma.  While we didn’t find a difference in TNF-α expression, this was also observed in other 
studies [665].  Additionally G-CSF, which is involved in neutrophil proliferation and maturation [667, 
668], was also demonstrated to be up-regulated in the sputum of COPD patients in this study.   
 
The pro-inflammatory cytokines IL-1β and IL-6 were shown to up-regulated in people with COPD in 
this study.  IL-1β has been implicated in the development of emphysema and induces leukocytosis 
and fibroblast proliferation, while IL-6 is a marker of inflammation, and both have been shown 
elsewhere to be up-regulated in COPD [665, 669-671].  Additionally, the chemokines MCP-1 and 
MIP-1α which attract macrophages and T-cells to exacerbate to the inflammation of the airways 
were shown to be increased in the sputum of COPD patients when compared to asthma in this study 
and elsewhere [671-673].  The chemokine eotaxin, which attracts eosinophils, was also 
demonstrated to be at an increased concentration in COPD sputum compared to asthma.  While 
COPD has been linked to increased eotaxin production compared to healthy subjects [671, 674], its 
increase compared to asthma is surprising, but may be associated with the lack of eosinophilia 
observed in asthmatics in this study, and has also been reported in serum in another study [675].    
 
Less easy to explain in the context of COPD, are the up-regulation of IFN-α, HGF and IL-1RA.  IFN-α is 
typically associated with anti-viral immunity, with functions such as stimulation of NK cells, increased 
MHC class I expression, and induction of apoptotic cell death of infected cells [43].  HGF is a growth 
factor, which has not been linked to COPD, but has been demonstrated to prevent neutrophil 
extravasation in the kidneys of mice to inhibit endothelial injury [676], thus contrasting to the 
neutrophilic pathophysiology of COPD.  Finally, IL-1RA is an anti-inflammatory agent, which blocks 
the actions of IL-1, again leading to questions surrounding its role in the inflammatory airways of 
COPD.   
 
Cross sectional studies such as this are important in defining the underlying inflammatory 
phenotypes associated with diseases such as asthma and COPD.  The increasingly clear view that 
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asthma is a heterogeneous condition comprised of subgroups with different underlying 
inflammatory profiles makes such studies vital, with different inflammatory phenotypes potentially 
requiring different treatment strategies [180, 625, 626, 628].  Non-allergic forms of asthma, 
triggered by stimuli such as air pollution, stress, obesity and viral infection, respond poorly to 
corticosteroids, which are the most common therapy for asthma [677].  Likewise, COPD patients can 
have underlying eosinophilic airway inflammation rather than the classical neutrophilia [597, 598], 
again having implications on how it should be treated, as it has been demonstrated that 
corticosteroids are only effective against eosinophilic inflammation, and not neutrophilic [179, 180, 
597, 678-680].     
 
Other studies have carried out similar comparisons between asthma and COPD in induced sputum 
samples, although none have used such a large panel of inflammatory mediators and cell 
populations to allow a definitive comparison between the two disease types.  Such studies have also 
seen no difference in sputum eosinophils in asthma and COPD [681, 682], again demonstrating that 
eosinophilia is not just a feature of asthma, but is in fact observed in both diseases.  No differences 
were observed between asthma and COPD in one study, looking at IL-4, IL-5, Il-6, Il-8, Il-10, LTB-4, 
TNF-α, IFN-γ and TGF-β in the induced sputum samples of 37 asthma and 36 COPD patients, 
although levels of TGF-β, IL-8 and LTB-4 were elevated in COPD patients compared with healthy 
subjects, and differences were seen when stratifying by smoking status or presence of eosinophilic 
airway disease [623].  They concluded that there is ambiguity between the two diseases, with 
overlapping phenotypes making it difficult to distinguish between the two, thus requiring 
stratification by the underlying phenotype of the inflammation instead. 
 
Where this study is limited in comparison to the other similar studies is in the lack of a healthy 
control to compare asthma and COPD phenotypes to.  More differences may have been observed in 
asthma and COPD if they had been able to be compared to healthy subjects, with, for example, an 
increased likelihood of observing eosinophilia in asthmatic patients.  The ViDiFlu study could 
potentially have been used to provide a healthy (i.e. no asthma or COPD) population to study, but 
due to the nature of the visits involving travelling to sheltered accommodation residences, including 
inducing sputum to the protocol was not feasible.  Additionally, people without airway inflammation 
are likely to find expectoration difficult, even following nebulisation, thus resulting in samples with a 
high squamous content which renders differential cell counts less accurate.  The majority of this 
population were also older adults, thus potentially exhibiting an altered cellular and inflammatory 
phenotype compared to healthy younger adults.  Finally, these participants did not undergo 
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spirometry, and thus undiagnosed asthma or COPD could not be ruled out, and other co-morbidities 
may also have been present, thus preventing the use of ViDiFlu patients as healthy controls. 
 
The study is also limited due to being underpowered, especially for the flow cytometric analysis.  
Due to the nature of requiring high cell numbers to be able to perform flow cytometry in sputum as 
a result of the large amount of mucus and debris present in the samples, only a sub-set of those 
undergoing sputum induction provided samples adequate for this additional procedure.  Therefore, 
any differences in numbers of CD4+ or CD8+ T-cells, for example, between the asthma and COPD 
populations may have been missed.  Larger numbers would need to be recruited to ensure sufficient 
power to reach accurate conclusions.   
 
 An interesting sub-analysis would have been to investigate differences due to disease severity, or by 
comparing eosinophilic to non-eosinophilic, and neutrophilic to non-neutrophilic disease.  However, 
the nature of the recruitment protocol meant that only people with mild asthma or COPD were 
randomised to the sputum arm, due to the potential dangers of nebulisation in people with severe 
disease.  Additionally, more people would have needed to be recruited to have the power to stratify 
results by inflammatory phenotype for analysis. 
 
Therefore, here it has been demonstrated that induced sputum is a useful tool in assessing airway 
inflammation, and that there is a significant difference underlying the inflammatory profiles of the 
airways of people with asthma and COPD.  Asthmatics were shown to have a Th2 cytokine profile, 
while COPD patients had an increased number of neutrophils in their airways and a variety of other 
pro-inflammatory cytokines and chemokines.  However, it should also be taken into account that 
asthma and COPD are heterogeneous diseases, and that phenotypes between the two may overlap, 
thus obscuring a clear distinction between them.    
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8. Comparison of TLR ligand- and pathogen-stimulated whole blood 
inflammatory responses in patients with asthma vs. COPD vs. 
controls with neither condition 
  
8.1 Introduction 
 
As previously described, blood is a suspension of cellular components and inflammatory mediators, 
and as such provides a useful and readily available tool in assessing the immune response to 
pathogens.  Asthma and COPD are both diseases of chronic airway inflammation, with acute 
respiratory infections more frequent and resulting in more severe disease and longer-lasting 
symptoms compared to healthy people [158-163].  In asthma, this has been associated with a 
deficient innate immune response to rhinovirus infection [172], increased infiltration of neutrophils 
resulting in tissue damage [169], and a Th2-skewed adaptive immune response inhibiting the Th1 
response required for viral clearance [170, 683].  In COPD, this is associated with an impaired innate 
immune response in alveolar macrophages to respiratory pathogens mediated by diminished TLR 
responses [684], and, conversely, a disproportionate increase in cytokine expression following viral 
infection both locally and systemically [163, 685].  However, studies looking at whole blood 
inflammatory responses to a broad range of stimuli have not been carried out, and investigation into 
the differences in the peripheral blood inflammatory response between asthma and COPD patients 
is lacking, with previous studies using induced sputum instead [665]. 
 
Therefore, a cross-sectional analysis of the differences in whole blood inflammatory responses 
between asthma, COPD and people with neither condition was conducted, using the whole blood 
assay and multiplex ELISA, with baseline samples from patients enrolled in the three clinical trials 
ViDiAs, ViDiCO and ViDiFlu. 
 
As previously discussed, a multiplex ELISA platform was used to quantify the following 30 
inflammatory mediators: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12, IL-13, IL-15, IL-17, 
IL-1RA, IL-2R, IFN-α, IFN-γ, TNF-α, MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), 
eotaxin (CCL11), MIG (CXCL9), IP-10 (CXCL10), EGF (epidermal growth factor), FGF-basic (basic 
fibroblast growth factor), HGF (hepatocyte growth factor), VEGF (vascular endothelial growth 
factor), G-CSF (granulocyte colony-stimulating factor) and GM-CSF (granulocyte macrophage colony-
stimulating factor). 
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8.2 Results 
 
8.2.1 Study recruitment and baseline characteristics of trial participants 
 
As described in chapter 2.1, participants from all three trials provided blood samples at baseline, 2 
month and 12 month follow-up.  A subset of these samples were used in a whole blood assay to 
determine the immune response mounted in peripheral blood to a range of TLR ligands and 
pathogens.  Figures 8.1, 8.2 and 8.3 shows the recruitment profiles for all three trials, and the 
number of samples included in the whole blood assays at baseline.  The implementation of the 
whole blood assay was not achieved until part-way through the trials, resulting in only a subset of 
participants providing baseline sodium heparin blood samples to undergo this analysis (n = 119 for 
ViDiAs; n = 99 for ViDiCO; n = 88 for ViDiFlu).  From the offset of the whole blood assay, all samples 
were stimulated with the panel of TLR ligands (LPS, Pam2CSK4, Pam3CSK4, PolyI:C and R848), as well 
as providing unstimulated blood and serum samples.  At a later date, following procurement of the 
whole pathogens from collaborators at Imperial College London and optimization of the conditions 
needed (as described in chapter 3), the pathogens RV-16, RV-1B, RSV, Haemophilus influenzae and 
Streptococcus pneumoniae were added as stimuli in the whole blood assay.  Due to budgetary 
limitations, only a subset of samples that had undergone baseline whole blood assays were analysed 
by multiplex ELISA.  The decision on which samples to run was based on having undergone the whole 
blood assay with the whole range of stimuli, and having provided both baseline and 12 month 
samples, in order to allow prospective analysis of the effects of vitamin D on the immune response 
to stimulation and adjustment for baseline values.  As such, n = 45 participants samples were 
analysed for ViDiAs, and n = 22 for ViDiCO.  Of these, the whole panel of stimuli, including serum and 
unstimulated blood, were incorporated into statistical analysis for all ViDiCO samples, while, due to 
the plate-reader failing to generate results for one column of one plate, 8 variables had 44 rather 
than 45 samples for ViDiAs.  For ViDiFlu, residents and staff members were pooled to provide a 
control population of participants with neither asthma nor COPD.  As with the prospective analysis, 
all samples with both a baseline and 12 month sample were analysed by multiplex ELISA, regardless 
of whether the whole panel of stimuli were used.  This was due to the fact that the primary results of 
the ViDiFlu clinical trial indicated an effect of vitamin D supplementation on risk of URTI, whereas no 
such effect was observed in ViDiAs and ViDiCO.  As such, the samples analysed consisted of n= 24 
participants who had blood samples stimulated by the whole range of whole blood assay stimuli, n = 
14 with samples stimulated by TLR ligands and viral pathogens, and n = 36 with samples stimulated 
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just by TLR ligands.  Each participant also provided a serum sample for analysis (n = 73), with n = 1 
having insufficient volume to be included.       
Figure 8.1: Recruitment profile for the whole blood assay at baseline in the ViDiAs trial.  
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Figure 8.2: Recruitment profile for the whole blood assay at baseline in the ViDiCO trial. 
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Figure 8.3: Recruitment profile for the whole blood assay at baseline in the ViDiFlu trial. 
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The baseline characteristics of participants who produced samples for the whole blood assay at 
baseline are presented in Table 8.1.  There was no difference in the ethnic composition, BMI and 
pneumococcal vaccine uptake between the three groups of participants.  However, there was a 
difference in the age (p < 0.0001), sex (p = 0.003), smoking status (p = 0.02), influenza vaccine uptake 
(p = 0.01) and 25(OH)D status (p = 0.002) between the three trials, with an additional difference 
seen in inhaled corticosteroid use between asthma and CODP patients (p = 0.02).  While ViDiFlu 
participants are considered controls for this cross-sectional analysis, due to absence of asthma or 
COPD, the populations making up this study were either adults living in sheltered accommodation, 
or staff members at participating units.  In the subset studied in the whole blood assay, 20% were 
staff, with the remaining 80%, mostly older adults, and as such, the median age was higher in this 
control population than in asthma patients.  Additionally, with the likelihood of developing COPD 
increasing with age and smoke exposure, and the eligibility criteria excluding those who were 
younger than 40, the median age in COPD patients was higher than in asthmatics.  Also due to the 
nature of the disease and the eligibility criteria of having a smoking history of at least 15 pack years, 
a higher proportion of COPD patients were current smokers compared to asthmatics.  ViDiAs 
participants also displayed a lower proportion of current smokers compared to ViDiFlu controls, 
potentially refraining from smoking in response to it exacerbating their asthma.  Influenza 
vaccination is routinely offered to older adults, and those with chronic respiratory conditions such as 
asthma and COPD.  Vaccine uptake was high in both asthma and COPD patients, however the 
presence of younger care staff in the ViDiFlu population may be the cause of the difference in 
vaccine uptake in this group.  Median 25(OH)D concentration indicated deficiency in all three study 
populations, but was significantly lower in COPD patients compared to controls, potentially due to 
decreased mobility and thus limited time outside with associated lack of sun exposure in these 
participants.  By chance, the subset of whole blood assay samples analysed had differing proportions 
of males and females within the three studies, with the ratio in asthma fairly even, but more males 
in the COPD study, and more females amongst the control ViDiFlu participants.  Finally, inhaled 
corticosteroid (ICS) use was higher in asthmatics compared to COPD patients, with ICS use an 
inclusion criterion for the ViDiAs trial, but not for the ViDiCO trial.     
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Table 8.1: Baseline characteristics of participants undergoing whole blood assay at baseline from all 
three trials 
  
Asthma 
 (n = 45) 
COPD  
(n = 22) 
Control  
(n = 74) P-Value 
Median Age (IQR) 50 (38 to 63) 67 (63 to 73) 67 (60 to 74) < 0.0001 
Sex       0.003 
                    Male, n (%) 26 (58) 17 (77) 28 (38)   
                    Female, n (%) 19 (42) 5 (23) 46 (62)   
Ethnic Group       0.65 
                    White, n (%) 38 (84) 21 (95) 62 (84)   
                    Black, n (%) 3 (7) 1 (5) 5 (7)   
                    Other, n (%) 4 (9) 0 (0) 7 (9)   
Current Smoker       0.02 
                     Yes, n (%) 2 (4) 6 (27) 17 (23)   
                     No, n (%) 43 (96) 16 (73) 57 (77)   
Median BMI (IQR) 
26.5 (23.8 to 
29.5) 
25.7 (21.3 to 
31.6) 
27.51 (24.5 to 
32.2) 0.05 
Pneumococcal Vaccine       0.17 
                     Received, n (%) 12 (27) 11 (50) 26 (35)   
                     Did not receive, n (%) 33 (73) 11 (50) 48 (65)   
Influenza Vaccine       0.01 
                     Received, n (%) 39 (87) 21 (95) 52 (70)   
                     Did not receive, n (%) 6 (13) 1 (5) 22 (30)   
Median 25(OH)D Concentration 
in nmol/L (IQR) 37 (26 to 54) 31 (15 to 39) 50 (31 to 67) 0.002 
Median Inhaled Corticosteroid  600 (250 to 
1000) 
200 (0 to 
850) 
n/a 0.02 
Use in µg (IQR)1 
1
 Inhaled corticosteroid dose given as betamethasone equivalents: 1 microgram betamethasone assumed 
equivalent to 1 µg budesonide, 0.5 µg fluticasone dipropionate and 0.75 µg ciclesonide.  
 
Ordinary one-way ANOVA tests were used to calculate p-values for age and 25(OH)D status (due to these data 
being normally distributed); a Kruskal-Wallis tests was used to calculate the p-value for BMI (due to data being 
non-normally distributed); a Mann-Whitney test was used to calculate the p-value for ICS use (due to data 
being non-normally distributed); Chi-Squared tests were used to calculate p-values for sex, ethnicity, smoking 
status, pneumococcal vaccine uptake and influenza vaccine uptake. 
 
Abbreviations used: IQR: interquartile range; BMI: body mass index (individuals body mass divided by the square of their height); 25(OH)D: 
25-hydroxy vitamin D. 
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8.2.2 Serum concentrations of inflammatory mediators and leukocyte numbers in 
peripheral blood differ between asthma, COPD and controls 
 
Peripheral blood samples were collected from participants at baseline into both sodium heparin 
tubes and serum separating tubes (SST).   Sodium heparin blood samples were used in the whole 
blood assay (as described in Chapter 2.2), with samples incubated with PBS for 24 hours as a 
negative control.  SST tubes were used to obtain serum samples, which underwent analysis by 
multiplex ELISA to determine the concentrations of inflammatory mediators in the serum of 
controls, and people with asthma or COPD.  Qlucore Omics Explorer 2.3 was used to analyse the 
data, modelling using a two-group comparison (i.e. Student’s T-Test) between each study (i.e. 
participants with asthma, COPD, or neither condition) with log-transformed data, and including 
adjustment  for age, sex, baseline 25(OH)D concentration, ethnicity, smoking status and vaccination 
record.  All results are presented in Table 8.2, and concentrations of inflammatory mediators that 
were significantly different between groups are presented in Figure 8.4.  When compared to 
controls, the concentrations of EGF (p < 0.0001 for asthma; p = 0.0005 for COPD) and MIP-1β (p = 
0.003 for asthma; p = 0.01 for COPD) were lower in both asthma and COPD patients, while the 
concentration of TNF-α was lower in asthmatics compared to controls (p = 0.003).  The 
concentrations of IL-6 (p = 0.01) and IL-8 (p = 0.02) were both lower in COPD patients compared to 
control participants, while the concentrations of IL-1RA (p = 0.002), IL-17 (p = 0.01) and IL-2R (p = 
0.02) were all higher.  In a comparison of the inflammatory mediators present in the serum of 
people with asthma or COPD, the concentration of EGF was higher in COPD patients (p < 0.0001).  
The remaining inflammatory mediators assayed displayed no differences between control 
participants, asthmatics, and COPD patients (Table 8.2). 
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Table 8.2: Comparison of serum inflammatory mediator concentrations in controls, and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1) 
213 
 
Figure 8.4: Cross-sectional comparison of inflammatory mediators present in the serum of controls, and those 
with asthma and COPD.  Peripheral whole blood was collected and centrifuged before aspiration of serum and 
analysis by multiplex ELISA (n = 44 for asthma, n = 22 for COPD and n = 73 for controls).  Data are represented 
as scatter plots with median + IQR, with p-values calculated using two-group comparisons between each 
patient group, with the model including adjustment for age, sex, baseline 25(OH)D status, ethnicity, smoking 
status and vaccination record, using the programme Qlucore Omics Explorer 2.3.  P-values were deemed 
significant when less than 0.05, with a corresponding q-value of less than 0.1.  Any values under the limit of 
detection (as specified within the product data sheet for each analyte) were given a value of 0.    
 
 
Finally, coulter counts were carried out on unstimulated peripheral whole blood samples, to 
determine any differences in cell types between controls and those with asthma and COPD.  Qlucore 
Omics Explorer 2.3 was used to analyse the data, modelling using a two-group comparison (i.e. 
Student’s T-Test) between each study with log-transformed data, and including adjustment  for age, 
sex, baseline 25(OH)D concentration, ethnicity, smoking status and vaccination record.  All results 
are presented in Table 8.3, and significant results are presented in Figure 8.5. The number of 
eosinophils was significantly higher in both asthma (p = 0.002) and COPD (p = 0.008) compared to 
controls, while COPD patients also displayed increased lymphocyte (p = 0.0003), neutrophil (p = 
0.002) and monocyte (p = 0.003) counts compared to controls.  In a comparison of asthma versus 
COPD, COPD patients were shown to have a greater number of neutrophils (p = 0.003) and 
lymphocytes (p = 0.01) compared to asthmatics.     
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Table 8.3: Comparison of peripheral whole blood cell populations in controls, and patients with asthma or COPD 
 
 
Absolute cell counts are given as x 10
9
 cells/L 
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Figure 8.5: Cross-sectional comparison of cells present in peripheral blood of controls, and those with asthma 
and COPD.  Peripheral whole blood was collected and cells were counted by coulter counter (n = 45 for asthma, 
n = 22 for COPD and n = 74 for controls).  Data are represented as scatter plots with median + IQR, with p-
values calculated using a two-group comparisons between each patient group, with the model including 
adjustment for age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, using the 
programme Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with a 
corresponding q-value of less than 0.1.  Any values under the limit of detection (as specified within the product 
data sheet for each analyte) were given a value of 0.    
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8.2.3 Analysis of the secretion of inflammatory mediators in the blood following LPS 
stimulation shows differences between asthma, COPD and controls 
 
Peripheral blood samples were stimulated with LPS, a ligand for TLR 4, which is typically found on 
the outer membrane of Gram-negative bacteria such as Haemophilus influenza.  Qlucore Omics 
Explorer 2.3 was used to carry out comparisons between the three clinical groups, modelling using a 
two-group comparison (i.e. Student’s T-Test) between each group with log-transformed data, and 
including adjustment  for age, sex, baseline 25(OH)D concentration, ethnicity, smoking status and 
vaccination record.  All results obtained from 30-plex ELISA analysis of supernatants from stimulated 
whole blood are presented in Table 8.4, and significant results are presented in Figure 8.6.  When 
compared to controls, the supernatant concentration of LPS-stimulated eotaxin was lower in asthma 
and COPD patients (p < 0.0001 and p = 0.001 respectively), while the concentrations of LPS-
stimulated IL-4 (p = 0.0007), IL-15 (p = 0.001), IL-12 (p = 0.01) and IFN-  (p = 0.01) were all higher in 
COPD patients.  In a comparison of the inflammatory response to LPS in patients with asthma or 
COPD, concentrations of IL-2R (p = 0.0006), FGF-Basic (p = 0.001), IL-12 (p = 0.003), IL-15 (p = 0.008), 
IL-6 (p = 0.009), EGF (p = 0.01) and IL-1RA (p = 0.02) were all higher in COPD.  The remaining 
inflammatory mediators assayed in the supernatants of LPS-stimulated whole blood displayed no 
statistically significant differences between controls, asthmatics, and COPD patients (Table 8.4).      
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Table 8.4: Comparison of inflammatory mediators released following whole blood stimulation by LPS in controls and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1) 
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Figure 8.6: Cross-sectional comparison of inflammatory mediators released in response to LPS stimulation in 
the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected and stimulated 
with LPS for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 45 for asthma, n = 22 
for COPD and n = 74 for controls).  Data are represented as scatter plots with median + IQR, with p-values 
calculated using two-group comparisons between each clinical group, with the model including adjustment for 
age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, using the programme 
Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with a corresponding q-
value of less than 0.1.  Any values under the limit of detection (as specified within the product data sheet for 
each analyte) were given a value of 0.  
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8.2.4 Analysis of the secretion of inflammatory mediators in the blood following 
Pam2CSK4 stimulation shows differences between asthma, COPD and controls 
 
Peripheral blood samples were stimulated with Pam2CSK4 (Pam2), a synthetic diacylated bacterial 
lipopeptide which is a ligand for TLR 2/6 heterodimers, and associated with infections caused by 
bacteria such as Streptococcus pneumoniae.  Qlucore Omics Explorer 2.3 was used to carry out 
comparisons between the three clinical groups, modelling using a two-group comparison (i.e. 
Student’s T-Test) between each group with log-transformed data, and including adjustment  for age, 
sex, baseline 25(OH)D concentration, ethnicity, smoking status and vaccination record.  All results 
obtained.  All results obtained from 30-plex ELISA analysis of supernatants from stimulated whole 
blood are presented in Table 8.5, and significant results are presented in Figure 8.7.  When 
compared to controls, the concentration of eotaxin was lower in supernatants of Pam2-stimulated 
whole blood from asthma and COPD patients (p < 0.0001 and p = 0.008 respectively), while the 
concentrations of MCP-1 (p = 0.0005), and FGF-Basic (p = 0.001) were higher in COPD patients.  
However, the magnitude of all differences was minimal.  In a comparison of the immune response to 
Pam2 in patients with asthma or COPD, no differences were observed.  The remaining inflammatory 
mediators assayed displayed no statistically significant differences between controls, asthmatics, 
and COPD patients (Table 8.5). 
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Table 8.5: Comparison of inflammatory mediators released following whole blood stimulation by Pam2CSK4 in controls and patients with  
asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
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Figure 8.7: Cross-sectional comparison of inflammatory mediators released in response to Pam2CSK4 
stimulation in the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected 
and stimulated with Pam2CSK4 for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 
45 for asthma, n = 22 for COPD and n = 74 for controls).  Data are represented as scatter plots with median + 
IQR, with p-values calculated using two-group comparisons between each clinical group, with the model 
including adjustment for age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, 
using the programme Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with 
a corresponding q-value of less than 0.1.  Any values under the limit of detection (as specified within the 
product data sheet for each analyte) were given a value of 0.    
 
 
8.2.5 Analysis of the secretion of inflammatory mediators in the blood following 
Pam3CSK4 stimulation shows differences between asthma, COPD and controls 
 
Peripheral blood samples were stimulated with Pam3CSK4 (Pam3), a synthetic triacylated bacterial 
lipopeptide, which is a ligand for TLR 2/1 heterodimers, and associated with infections caused by 
bacteria such as Mycoplasma pneumoniae.  Qlucore Omics Explorer 2.3 was used to carry out 
comparisons between the three clinical groups, modelling using a two-group comparison (i.e. 
Student’s T-Test) between each group with log-transformed data, and including adjustment  for age, 
sex, baseline 25(OH)D concentration, ethnicity, smoking status and vaccination record.  All results 
obtained from 30-plex ELISA analysis of supernatants from stimulated whole blood are presented in 
Table 8.6, and significant results are presented in Figure 8.8.  The only statistical significant 
difference seen was when comparing COPD patients to controls, with higher levels of Pam3-
stimulated IFN-  produced by COPD patients (p < 0.0001).  The remaining inflammatory mediators 
assayed displayed no statistically significant differences between controls, asthmatics, and COPD 
patients (Table 8.6). 
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Table 8.6: Comparison of inflammatory mediators released following whole blood stimulation by Pam3CSK4 in controls and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated  
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
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Figure 8.8: Cross-sectional comparison of inflammatory mediators released in response to Pam3CSK4 
stimulation in the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected 
and stimulated with Pam3CSK4 for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 
45 for asthma, n = 22 for COPD and n = 74 for controls).  Data are represented as scatter plots with median + 
IQR, with p-values calculated using two-group comparisons between each clinical group, with the model 
including adjustment for age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, 
using the programme Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with 
a corresponding q-value of less than 0.1.  Any values under the limit of detection (as specified within the 
product data sheet for each analyte) were given a value of 0.    
 
 
8.2.6 Analysis of the secretion of inflammatory mediators in the blood following PolyI:C 
stimulation shows differences between asthma, COPD and controls 
 
Peripheral blood samples were stimulated with PolyI:C, a synthetic analogue of dsRNA which is a 
ligand for TLR 3, and typically associated with viruses such as influenza and rhinovirus.  Qlucore 
Omics Explorer 2.3 was used to carry out comparisons between the three clinical groups, modelling 
using a two-group comparison (i.e. Student’s T-Test) between each group with log-transformed data, 
and including adjustment  for age, sex, baseline 25(OH)D concentration, ethnicity, smoking status 
and vaccination record.  All results obtained from 30-plex ELISA analysis of supernatants from 
stimulated whole blood are presented in Table 8.7, and significant results are presented in Figure 
8.9.  When compared to controls, the concentrations of PolyI:C-stimulated TNF-  (asthma p < 
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0.0001; COPD p = 0.005), MIP-1  (asthma p = 0.004; COPD p = 0.003), IL-6 (asthma p = 0.007; COPD 
p = 0.002), VEGF (asthma p = 0.02; COPD p = 0.005), MIP-1  (asthma p = 0.02; COPD p = 0.003) and 
IL-15 (asthma p = 0.04; COPD p < 0.0001) were higher in both asthma and COPD patients 
respectively, while the concentration of eotaxin (asthma p = 0.0009; COPD p = 0.03) was lower in 
both.  The concentrations of PolyI:C-stimulated G-CSF (p = 0.003), IL-2 (p = 0.01), HGF (p = 0.02), IL-
1  (p = 0.03), IL-7 (p = 0.03) and FGF-Basic (p = 0.04) were all higher in asthma patients compared to 
controls, while the concentrations of IL-17 (p = 0.0006), IP-10 (p = 0.001), IL-1RA (p = 0.004), IFN-  (p 
= 0.007) and MIG (p = 0.03) were higher in COPD patients compared to controls.  There was no 
difference in the inflammatory response to PolyI:C  when comparing patients with asthma and 
COPD, with all of the remaining inflammatory mediators assayed displaying no statistically significant 
differences between controls, asthmatics, and COPD patients (Table 8.7).  
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Table 8.7: Comparison of inflammatory mediators released following whole blood stimulation by PolyI:C in controls and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
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Figure 8.9: Cross-sectional comparison of inflammatory mediators released in response to PolyI:C stimulation in 
the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected and stimulated 
with PolyI:C for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 44 for asthma, n = 
22 for COPD and n = 74 for controls).  Data are represented as scatter plots with median + IQR, with p-values 
calculated using two-group comparisons between each clinical group, with the model including adjustment for 
age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, using the programme 
Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with a corresponding q-
value of less than 0.1.  Any values under the limit of detection (as specified within the product data sheet for 
each analyte) were given a value of 0.    
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8.2.7 Analysis of the secretion of inflammatory mediators in the blood following R848 
stimulation shows differences between asthma, COPD and controls 
 
Peripheral blood samples were stimulated with R848, an imidazoquinoline compound which mimics 
the ssRNA activation of TLR 7/8, and is typically associated with viruses such as RSV and rhinovirus.  
Qlucore Omics Explorer 2.3 was used to carry out comparisons between the three clinical groups, 
modelling using a two-group comparison (i.e. Student’s T-Test) between each group with log-
transformed data, and including adjustment  for age, sex, baseline 25(OH)D concentration, ethnicity, 
smoking status and vaccination record.  All results from 30-plex ELISA analysis of supernatants from 
stimulated whole blood are presented in Table 8.8, and significant results are presented in Figure 
8.10.  When compared to controls, the concentration of R848-stimulated IFN-  (asthma p = 0.0004; 
COPD p = 0.0002) was higher in both asthma and COPD patients, while the concentrations of R848-
stimulated eotaxin (asthma p < 0.0001; COPD p = 0.0007) and IL-8 (asthma p = 0.004; COPD p = 
0.002,) were lower in both.  The concentrations of R848-stimulated IL-4 (p < 0.0001), IL-7 (p = 
0.0001), IL-10 (p = 0.0007), HGF (p = 0.009), VEGF (p = 0.01), IL-15 (p = 0.01), IL-2R (p = 0.01), IL-1RA 
(p = 0.01), FGF-Basic (p = 0.02), IL-6 (p= 0.02), IL-17 (p = 0.02), IL-12 (p = 0.03), IL-2 (p = 0.03) and MIG 
(p = 0.04) were all higher in COPD patients compared to controls.  In a comparison of the immune 
response to R848 in patients with asthma or COPD, concentrations of FGF-Basic (p = 0.0007), IL-12 (p 
= 0.001), IL-2R (p = 0.002), IL-1RA (p = 0.005), EGF (p = 0.01) and IL-15 (p = 0.02) were all higher in 
COPD.  The remaining inflammatory mediators assayed displayed no statistically significant 
differences between controls, asthmatics, and COPD patients (Table 8.8).  
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Table 8.8: Comparison of inflammatory mediators released following whole blood stimulation by R848 in controls and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
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Figure 8.10: Cross-sectional comparison of inflammatory mediators released in response to R848 stimulation in 
the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected and stimulated 
with R848 for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 44 for asthma, n = 
22 for COPD and n = 74 for controls).  Data are represented as scatter plots with median + IQR, with p-values 
calculated using two-group comparisons between each clinical group, with the model including adjustment for 
age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, using the programme 
Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with a corresponding q-
value of less than 0.1.  Any values under the limit of detection (as specified within the product data sheet for 
each analyte) were given a value of 0.    
 
 
 
230 
 
8.2.8 Analysis of the secretion of inflammatory mediators in the blood following RV-16 
stimulation shows differences between asthma, COPD and controls 
 
Peripheral blood samples were stimulated with RV-16, a major type rhinovirus, with infection 
causing diseases such as the common cold.  Qlucore Omics Explorer 2.3 was used to carry out 
comparisons between the three clinical groups, modelling using a two-group comparison (i.e. 
Student’s T-Test) between each group with log-transformed data, and including adjustment  for age, 
sex, baseline 25(OH)D concentration, ethnicity, smoking status and vaccination record.  All results 
obtained from 30-plex ELISA analysis of supernatants from stimulated whole blood are presented in 
Table 8.9, and significant results are presented in Figure 8.11.  When compared to controls, the 
concentrations of RV16-stimulated G-CSF (asthma p < 0.0001; COPD p = 0.0003) and IFN-  (asthma p 
< 0.0001; COPD p = 0.0002) were higher in both asthma and COPD patients, while the concentrations 
of RV16-stimulated IL-2R (asthma p = 0.002; COPD p = 0.01) and VEGF (asthma p = 0.01; COPD p < 
0.0001) were lower in both.  The concentration of RV16-stimulated EGF was lower in asthmatics 
compared to controls (p = 0.005), while concentrations of RV16-stimulated MIG (p < 0.0001), IL-17 (p 
< 0.0001), IFN-  (p < 0.0001), IL-1RA (p < 0.0001), IL-7 (p = 0.0002), IL-4 (p = 0.0004), IL-6 (p = 0.002), 
FGF-basic (p = 0.006), MIP-1  (p = 0.006), HGF (p = 0.01), IL-2 (p = 0.02) and IL-15 (p = 0.03) were all 
higher in COPD patients compared to controls.  RV16-stimulated eotaxin concentration was lower in 
COPD patients compared to controls.  In a comparison of the immune response to RV-16 in patients 
with asthma or COPD, concentrations of IL-2R (p = 0.002), MIG (p = 0.002), IL-1RA (p = 0.003), IL-15 
(p = 0.004), IFN-γ (p = 0.004) and FGF-Basic (p = 0.01) were all lower in asthma compared to COPD.  
The remaining inflammatory mediators assayed displayed no statistically significant differences 
between controls, asthmatics, and COPD patients (Table 8.9).   
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Table 8.9: Comparison of inflammatory mediators released following whole blood stimulation by RV-16 in controls and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
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Figure 8.11: Cross-sectional comparison of inflammatory mediators released in response to RV-16 infection in 
the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected and stimulated 
with RV-16 for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 44 for asthma, n = 
22 for COPD and n = 38 for controls).  Data are represented as median + IQR, with p-values calculated using 
two-group comparisons between each clinical group, with the model including adjustment for age, sex, 
baseline 25(OH)D status, ethnicity, smoking status and vaccination record, using the programme Qlucore Omics 
Explorer 2.3.  P-values were deemed significant when less than 0.05, with a corresponding q-value of less than 
0.1.  Any values under the limit of detection (as specified within the product data sheet for each analyte) were 
given a value of 0. 
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8.2.9 Analysis of the secretion of inflammatory mediators in the blood following RV-1B 
stimulation shows differences between asthma, COPD and controls 
 
Peripheral blood samples were stimulated with RV-1B, a minor type rhinovirus, with infection 
causing diseases such as the common cold.  Qlucore Omics Explorer 2.3 was used to carry out 
comparisons between the three clinical groups, modelling using a two-group comparison (i.e. 
Student’s T-Test) between each group with log-transformed data, and including adjustment  for age, 
sex, baseline 25(OH)D concentration, ethnicity, smoking status and vaccination record.  All results 
obtained from 30-plex ELISA analysis of supernatants from stimulated whole blood are presented in 
Table 8.10, and significant results are presented in Figure 8.12.  When compared to controls, the 
concentration of RV1B-stimulated G-CSF (asthma p = 0.0006; COPD p < 0.0001) was higher in both 
asthma and COPD patients, while the concentration of RV1B-stimulated eotaxin (asthma p = 0.0002; 
COPD p = 0.001) was lower in both.  The concentrations of RV1B-stimuated EGF (p = 0.002) and IL-2R 
(p = 0.002) were lower in asthmatics compared to controls, while concentrations of RV1B-stimulated 
MIG (p < 0.0001), IL-1RA (p < 0.0001), IL-17 (p < 0.0001), IL-4 (p < 0.0001), IFN-γ (p < 0.0001), IL-7 (p 
< 0.0001), VEGF (p < 0.0001), HGF (p = 0.002), IL-15 (p = 0.006), MIP-1β (p = 0.02), FGF-Basic (p = 
0.04), IL-12 (p = 0.04), IFN-α (p = 0.04) were all higher in COPD patients compared to controls.  In a 
comparison of the immune response to RV-1B in patients with asthma or COPD, concentrations of IL-
2R (p = 0.0008), IL-15 (p = 0.001), MIG (p = 0.002), IL-1RA (p = 0.003), IFN-γ (p = 0.008), FGF-Basic (p = 
0.009) and IL-4 (p = 0.02) were all lower in asthma compared to COPD.  The remaining inflammatory 
mediators assayed displayed no statistically significant differences between controls, asthmatics, 
and COPD patients (Table 8.10).   
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Table 8.10: Comparison of inflammatory mediators released following whole blood stimulation by RV-1B in controls and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated  
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
235 
 
Figure 8.12: Cross-sectional comparison of inflammatory mediators released in response to RV-1B infection in 
the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected and stimulated 
with RV-1B for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 44 for asthma, n = 
22 for COPD and n = 38 for controls).  Data are represented as scatter plots with median + IQR, with p-values 
calculated using two-group comparisons between each clinical group, with the model including adjustment for 
age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, using the programme 
Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with a corresponding q-
value of less than 0.1.  Any values under the limit of detection (as specified within the product data sheet for 
each analyte) were given a value of 0. 
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8.2.10 Analysis of the secretion of inflammatory mediators in the blood following RSV 
stimulation shows differences between asthma, COPD and controls 
 
Peripheral blood samples were stimulated with RSV, which causes diseases such as bronchiolitis and 
the common cold.  Qlucore Omics Explorer 2.3 was used to carry out comparisons between the 
three clinical groups, modelling using a two-group comparison (i.e. Student’s T-Test) between each 
group with log-transformed data, and including adjustment  for age, sex, baseline 25(OH)D 
concentration, ethnicity, smoking status and vaccination record.  All results obtained from 30-plex 
ELISA analysis of supernatants from stimulated whole blood are presented in Table 8.11, and 
significant results are presented in Figure 8.13.  When compared to controls, the concentrations of 
RSV-stimulated G-CSF (asthma p < 0.0001; COPD p = 0.0003), IL-7 (asthma p = 0.007; COPD p = 
0.0002) and TNF-α (asthma p = 0.007; COPD p = 0.002) were higher in both asthma and COPD 
patients, while the concentration of RSV-stimulated eotaxin (asthma p = 0.005; COPD p = 0.007) was 
lower in both.  The concentrations of RSV-stimulated EGF (p = 0.007), IL-1RA (p = 0.01) and IL-2R (p = 
0.02) were lower in asthmatics compared to controls, while concentrations of RSV-stimulated MIG (p 
= 0.0006), IL-17 (p = 0.0009), IL-1RA (p = 0.01) and MIP-1β (p = 0.03) were all higher in COPD patients 
compared to controls.  In a comparison of the immune response to RSV in patients with asthma or 
COPD, the concentration of IL-1RA (p = 0.0007) was lower in asthma compared to COPD.  The 
remaining inflammatory mediators assayed displayed no statistically significant differences between 
controls, asthmatics, and COPD patients (Table 8.11).   
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Table 8.11: Comparison of inflammatory mediators released following whole blood stimulation by RSV in controls and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable 
to be calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
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Figure 8.13: Cross-sectional comparison of inflammatory mediators released in response to RSV infection in the 
blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected and stimulated with 
RSV for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 44 for asthma, n = 22 for 
COPD and n = 38 for controls).  Data are represented as scatter plots with median + IQR, with p-values 
calculated using two-group comparisons between each clinical group, with the model including adjustment for 
age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, using the programme 
Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with a corresponding q-
value of less than 0.1.  Any values under the limit of detection (as specified within the product data sheet for 
each analyte) were given a value of 0. 
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8.2.11 Analysis of the secretion of inflammatory mediators in the blood following 
Haemophilus influenzae stimulation shows differences between asthma, COPD and 
controls 
 
Peripheral blood samples were stimulated with H.influenzae, a Gram-negative bacteria which causes 
diseases such otitis media and pneumonia.  Qlucore Omics Explorer 2.3 was used to carry out 
comparisons between the three clinical groups, modelling using a two-group comparison (i.e. 
Student’s T-Test) between each group with log-transformed data, and including adjustment  for age, 
sex, baseline 25(OH)D concentration, ethnicity, smoking status and vaccination record.  All results 
obtained from 30-plex ELISA analysis of supernatants from stimulated whole blood are presented in 
Table 8.12, and significant results are presented in Figure 8.14.  When compared to controls, the 
concentrations of H.influenzae-stimulated FGF-Basic (p = 0.0001), IL-2R (p = 0.0003), eotaxin (p = 
0.09), IL-15 (p = 0.01) and IL-5 (p = 0.02) were lower in asthmatics compared to controls, while 
concentrations of H.influenzae-stimulated IL-1RA (p = 0.0002), IL-12 (p = 0.0004), IL-13 (p = 0.0006), 
VEGF (p = 0.002), IL-7 (p = 0.002), IL-15 (p = 0.02), IL-17 (p = 0.02) were all higher in COPD patients 
compared to controls.  In a comparison of the immune response to H.influenzae in patients with 
asthma or COPD, the concentrations of FGF-Basic (p = 0.0007), IL-15 (p = 0.006), IL-1RA (p = 0.09), IP-
10 (p = 0.01), IL-12 (p = 0.01) and IL-2R (p = 0.02) were all lower in asthma compared to COPD.  The 
remaining inflammatory mediators assayed displayed no statistically significant differences between 
controls, asthmatics, and COPD patients (Table 8.12).   
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Table 8.12: Comparison of inflammatory mediators released following whole blood stimulation by H.influenzae in controls and patients with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable to be 
calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
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Figure 8.14: Cross-sectional comparison of inflammatory mediators released in response to H.influenzae 
infection in the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected and 
stimulated with H.influenzae for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 
44 for asthma, n = 22 for COPD and n = 24 for controls).  Data are represented as scatter plots with median + 
IQR, with p-values calculated using two-group comparisons between each clinical group, with the model 
including adjustment for age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, 
using the programme Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with 
a corresponding q-value of less than 0.1.  Any values under the limit of detection (as specified within the 
product data sheet for each analyte) were given a value of 0. 
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8.2.12 Analysis of the secretion of inflammatory mediators in the blood following 
Streptococcus pneumoniae stimulation shows differences between asthma, COPD 
and controls 
 
Peripheral blood samples were stimulated with S.pneumoniae, a Gram-positive bacteria which 
causes diseases such as bronchitis and pneumonia.  Qlucore Omics Explorer 2.3 was used to carry 
out comparisons between the three clinical groups, modelling using a two-group comparison (i.e. 
Student’s T-Test) between each group with log-transformed data, and including adjustment  for age, 
sex, baseline 25(OH)D concentration, ethnicity, smoking status and vaccination record.  All results 
obtained from 30-plex ELISA analysis of supernatants from stimulated whole blood are presented in 
Table 8.13, and significant results are presented in Figure 8.15.  When compared to controls, the 
concentrations of S.pneumoniae-stimulated FGF-Basic (p = 0.0004) and IL-5 (p = 0.006) were lower in 
asthmatics compared to controls, while concentrations of S.pneumoniae-stimulated MCP-1 (p < 
0.0001), G-CSF (p = 0.0001), IL-7 (p = 0.0006), IFN-α (p = 0.0006), IL-1RA (p = 0.0007), IL-4 (p = 
0.0007), HGF (p = 0.0009), IL-13 (p = 0.001), MIG (p = 0.002), IL-15 (p = 0.003), IL-2R (p = 0.003), IL-17 
(p = 0.005), MIP-1α (p = 0.008), IL-12 (p = 0.03), VEGF (p = 0.04), IP-10 (p = 0.04) were all higher in 
COPD patients compared to controls.  There was no difference in the immune response to 
S.pneumoniae when comparing patients with asthma and COPD, with all of the remaining 
inflammatory mediators assayed displaying no statistically significant differences between controls, 
asthmatics, and COPD patients (Table 8.13). 
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Table 8.13: Comparison of inflammatory mediators released following whole blood stimulation by S.pneumoniae in controls and patients  
with asthma or COPD 
Medians are given in pg/ml. 
2 
For some analytes numbers were smaller due to mean fluorescence index (MFI) values exceeding the upper limit of detection, resulting in concentrations being unable to be 
calculated 
The interquartile range (IQR) is only stated where statistical significant difference was evident (p < 0.05, q < 0.1)
244 
 
 
Figure 8.15: Cross-sectional comparison of inflammatory mediators released in response to S.pneumoniae 
infection in the blood of controls, and those with asthma and COPD.  Peripheral whole blood was collected and 
stimulated with S.pneumoniae for 24 hours, before supernatant aspiration and analysis by multiplex ELISA (n = 
44 for asthma, n = 22 for COPD and n = 24 for controls).  Data are represented as scatter plots with  median + 
IQR, with p-values calculated using two-group comparisons between each clinical group, with the model 
including adjustment for age, sex, baseline 25(OH)D status, ethnicity, smoking status and vaccination record, 
using the programme Qlucore Omics Explorer 2.3.  P-values were deemed significant when less than 0.05, with 
a corresponding q-value of less than 0.1.  Any values under the limit of detection (as specified within the 
product data sheet for each analyte) were given a value of 0. 
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8.3 Discussion 
 
It has been demonstrated here that there are significant differences in inflammatory responses 
mounted to a range of stimuli in the blood of asthmatics, COPD patients and controls with neither 
condition.  Overall, the biggest differences were seen between COPD patients versus patients with 
asthma and versus controls with neither condition, with increased release of inflammatory 
mediators observed.  The discussion of these results is separated into sections, looking at 
comparisons between the three study populations in circulating inflammatory mediators and 
stimulated results in turn, before a summary at the end (Table 8.14). 
 
Circulating inflammatory markers, COPD vs. controls 
An increased concentration of IL-1RA was observed when comparing the serum inflammatory 
mediators present in COPD patients versus controls.  IL-1RA inhibits signalling by IL-1β, with the 
balance between the two playing an important role inflammation, and the susceptibility to and 
severity of many diseases [686].  While the anti-inflammatory effects of IL-1RA are potentially 
beneficial in dampening chronic inflammation, as shown in the treatment of the systemic 
inflammation of rheumatoid arthritis [687, 688], and demonstrated with an associated reduction in 
airway hypersensitivity in asthmatic guinea pigs [689], higher concentrations of IL-1RA in mice have 
been associated with increased susceptibility to Listeria monocytogenes infection, with IL-1RA KO 
demonstrating enhanced resistance to listeriosis [690].  Additionally, gene expression analysis of 
peripheral blood neutrophils has shown increased levels of IL-1RA mRNA in patients with severe 
COPD compared to moderate COPD, with an associated reduction in lung function, suggesting an 
important role in the pathophysiology of COPD [691].  A study in serum has also shown increased 
concentrations of IL-1RA, with associated increased rate of exacerbations and reduced FEV1 [692].    
 
In addition to IL-1RA, serum concentrations of IL-17 and IL-2R were higher in COPD patients 
compared to controls.  IL-17 is a pro-inflammatory cytokine, implicated in neutrophil activation and 
recruitment, induction of pro-inflammatory cytokine release, and up-regulation of airway 
remodelling [693].  Th17 cells have been demonstrated to be increased in the bronchial mucosa of 
COPD patients [694], with a positive correlation to airflow limitation [695], as well as IL-17-secreting 
CD8+ T-cells [696], thus resulting in increased expression of IL-17 in sputum and serum of COPD 
patients [692, 697].  IL-2R, on the other hand, has not been specifically linked to COPD or respiratory 
disease before, but the CD25 component of this heterotrimeric receptor has been implicated as a 
potential inflammatory marker [698-701].   
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Interestingly, EGF and MIP-1β were both shown to be present in reduced concentrations in the 
serum of COPD patients compared to controls.  MIP-1β is a chemoattractant for lymphocytes, 
monocytes and eosinophils.  It has been shown to be elevated in the serum and sputum of COPD 
patients, contributing to airway inflammation [623, 702-704].  One study looking at gene expression 
in peripheral blood neutrophils only showed increased expression of MIP-1β in very severe COPD, 
and not in moderate COPD [691].  EGF is important in epithelial repair, and thus the decreased 
expression seen here may indicate a reduction in epithelial repair and thus be a contributing factor 
to the tissue damage that occurs in the airways of COPD patients.  However, COPD has typically been 
associated with elevated levels of EGF, contributing to airway remodelling, goblet cell metaplasia, 
and increased chemokine expression [692, 704, 705].  Surprisingly, IL-6 and IL-8 were also both 
shown to be reduced in the serum of COPD patients compared to controls.  IL-6 is a pro-
inflammatory cytokine which has previously been shown to be increased in the sputum and serum of 
COPD patients, with an inverse correlation with lung function and high expression associated with 
increased mortality and poor clinical outcomes [706-711].  While some studies have demonstrated 
no difference in serum IL-6 between COPD patients and healthy people [623, 692], no other studies 
have demonstrated lower concentrations.  Likewise, IL-8, a neutrophil chemoattractant, is strongly 
associated with COPD, having been shown to be upregulated in sputum, BAL and serum [623, 640, 
692, 712], and also demonstrated to be negatively correlated with FEV1/FVC [640, 692], and 
positively correlated with exacerbation rate [692].  One study, however, did show no difference in 
the gene expression of IL-8 in peripheral blood neutrophils between healthy people and COPD 
patients [691].    
 
Stimulated inflammatory responses, COPD vs. controls 
The immune response to a range of stimuli was markedly different in the blood of COPD patients 
compared to controls, most notably in response to whole pathogens and TLR ligands associated with 
viral infection.  The response to TLR ligands associated with bacterial infection showed fewer 
differences between the two groups.  Secretion of IFN-α was increased in COPD patients in response 
to whole blood stimulation with LPS and Pam3CSK4, while LPS stimulation also resulted in increased 
secretion of the pro-inflammatory cytokines IL-4, IL-15 and IL-12.  Pam2CSK4 induced lower MCP-1 
and FGF-Basic secretion compared to controls.   
 
A wide range of inflammatory mediators were present in higher concentrations in the supernatants 
of whole blood of COPD patients in response to the virus-associated TLR ligands polyI:C and R848 
compared to controls.  Stimulation with polyI:C or R848 induced increased secretion of the 
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proinflammatory cytokines IL-15, IL-17 and IL-6, the chemokine MIG, the growth factor VEGF, and IL-
1RA compared to controls.  MIG is a chemoattractant for a range of leukocytes, thus increasing 
inflammation, while VEGF increases endothelial permeability and plays a role in the production of 
pro-inflammatory cytokines, and has been implicated in systemic inflammation and COPD 
pathogenesis [713-715].  IL-1RA acts as an anti-inflammatory cytokine, blocking the effects of IL-1, 
with over-expression associated with inhibition of primary immune responses to pathogens [716].  
Stimulation with polyI:C also resulted in increased secretion of the chemokines IP-10, MIP-1β, MIP-
1α, and the pro-inflammatory cytokines TNF-α and IFN-γ in COPD patients compared to controls, 
while R848 caused elevated secretion of the pro-inflammatory cytokines IL-2 and IL-12 (as well as 
the IL-2 receptor), the growth factors HGF and FGF-Basic, cytokines involved in B-cell activation and 
proliferation IL-4, and IL-7, the anti-inflammatory cytokine IL-10 and the anti-viral agent IFN-α.  
Surprisingly, R848-induced secretion of IL-8 was reduced in COPD patients compared to controls.   
 
Similar to the effects caused by TLR ligation by polyI:C and R848, RV-16, RV-1B and RSV all induced 
increased secretion of MIG, IL-17 and IL-1RA in COPD patients compared to controls.  As seen with 
polyI:C stimulation, all three viral pathogens induced increased secretion of MIP-1β, with RV-16 and 
RV-1B also increasing IFN-γ secretion, and RSV infection causing increased concentrations of TNF-α 
in COPD patients compared to controls.  More similarities were seen with R848 stimulation, with all 
three viral pathogens inducing increased IL-7 secretion in COPD patients.  Additionally, both RV-16 
and RV-1B stimulation caused increased secretion of IL-4, IFN-α, FGF-Basic and HGF, as seen 
following R848 stimulation, while RV-16 also induced increased concentrations of IL-2R and IL-2, and 
RV-1B increased concentrations of IL-12.  The only inflammatory mediator seen to have increased 
secretion in COPD patients compared to controls in response to viral pathogens but not to virus-
related TLR ligands, and thus suggesting a role for other immune receptors, was G-CSF, a growth 
factor which plays a role in neutrophil trafficking and has been shown to exacerbate inflammatory 
conditions such as rheumatoid arthritis [717, 718], as well as being associated with increased risk of 
mortality following influenza infection [719]. 
 
The bacterial pathogens also induced higher secretion of a range of inflammatory mediators in COPD 
patients compared to controls.  Similar to LPS stimulation, both S.pneumoniae and H.influenzae 
caused increased secretion of the pro-inflammatory cytokines IL-12 and IL-15, with S.pneumoniae 
also stimulating increased secretion of IFN-α and IL-4.  Unrelated to any of the bacteria-related TLR 
ligands, stimulation with both S.pneumoniae and H.influenzae resulted in increased secretion of the 
pro-inflammatory cytokines IL-17, IL-7 and IL-13, which are involved in B-cell growth and 
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proliferation, as well as VEGF, and IL-1RA.  Stimulation with S.pneumoniae also resulted in increased 
secretion of the chemokines MCP-1, MIG, MIP-1α and IP-10, IL-2R, and the growth factors HGF and 
G-CSF in COPD patients compared to controls.  
 
Overall, these results indicate a more marked inflammatory response to a range of stimuli in COPD 
patients compared to controls.  Data comparing the immune response in COPD patients with healthy 
controls are lacking, but it has previously been suggested that the cytokine response in COPD is 
dysregulated, with a disproportionate response to immune stimuli.  Studies looking at cells from 
tracheobronchial tissue, induced sputum supernatants, BAL and peripheral blood neutrophils of 
COPD patients have demonstrated an increase in RV-induced expression of inflammatory mediators 
such as IL-6 and IL-8 [163, 720-722], with one study in mice demonstrating a skewed Th2 response to 
RV infection, with increased IL-13 and IL-5 and associated impairment of viral clearance [723].  This is 
the first study to look at a broad range of stimuli and inflammatory mediators, and it also 
demonstrates a more marked inflammatory response, consisting of pro-inflammatory cytokines, 
chemokines and growth factors.  Cytokine and chemokine release plays a critical role in the 
clearance of both bacterial and viral infections, but an exaggerated response may have a detrimental 
effect, with increased tissue damage, airway inflammation and obstruction, and elevated mucus 
production, thus resulting in a more severe disease phenotype [724, 725]. 
 
Circulating inflammatory markers, asthma vs. controls 
A range of differences were also observed between asthmatics and controls in this study.  In the 
serum of asthmatic patients, as seen in COPD, EGF and MIP-1β were shown to be present at reduced 
concentrations compared to controls.  Both EGF and its receptor (EGFR) have previously been 
demonstrated to have elevated expression in the respiratory epithelium of asthma patients, 
correlating with disease severity [726-728], with the EGFR antagonist AG1478 inhibiting bronchial 
hyper-responsiveness and inflammation [729], thus making these results surprising.  Additionally, 
the serum concentration of TNF-α was also lower in asthmatics compared to controls.         
 
Stimulated inflammatory responses, asthma vs. controls 
Ex vivo whole blood inflammatory responses to a range of stimuli were altered in the blood of 
asthma patients compared to controls, although the differences were not as large in number as seen 
in COPD.  The only difference seen in the inflammatory response to the bacteria-related TLR ligands 
in asthma and controls was decreased eotaxin secretion in asthmatics in response to both LPS and 
Pam2CSK4 stimulation.  Eotaxin secretion was consistently decreased in response to the whole 
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range of stimuli in both asthma and COPD patients compared to controls.  It is a chemoattractant, 
which also activates and promotes degranulation of eosinophils, immune cells which have been 
shown to have increased expression in asthma and COPD, as also shown in this study in Figure 7.6.  
Thus, it was surprising to see such a consistent abrogated eotaxin response to a range of stimuli 
compared to controls, also opposing the observation of persistent eosinophilia following rhinovirus 
infection in asthma patients [171].  However, this decreased eotaxin expression may play a role in 
the increased susceptibility to viral infections seen in asthma and COPD patients, with eosinophils 
having an important protective role especially against RNA viruses such as RSV [730].  Additionally, 
the difference in eotaxin concentration between population groups in this study, while statistically 
significant, was only small in magnitude, thus questioning the biological significance of these 
findings. 
 
Stimulation with the virus-related TLR ligand polyI:C resulted in a markedly different immune 
response in asthma compared to controls.  Secretion of the pro-inflammatory cytokines TNF-α, IL-6, 
IL-2, IL-1β and IL-15, IL-7, the growth factors G-CSF, VEGF, HGF and FGF-Basic, and the chemokines 
MIP-1β and MIP-1α were all elevated compared to controls following polyI:C stimulation.  The only 
differences observed following R848 stimulation were an increase in IFN-α, but decreased secretion 
of eotaxin and IL-8 in asthma compared to controls, as also seen in COPD patients.  Similar to the 
effects caused by TLR ligation by polyI:C, the viral pathogens all induced increased secretion of G-CSF 
in asthma patients compared to controls, with RV-16-induced IFN-α and VEGF, and RSV-induced IL-7 
and TNF-α also elevated.  All three viral pathogens had decreased IL-2R and EGF secretion compared 
to controls, with RSV-induced IL-1RA also reduced. 
 
The immune response induced by bacterial pathogens was also different in asthmatic subjects 
compared to controls, with secretion of FGF-Basic and IL-5 following both H.influenzae and 
S.pneumoniae decreased in asthmatics.  H.influenzae-induced secretion of IL-2R, eotaxin and IL-15 
was also reduced in asthma patients compared to controls. 
 
Therefore, in comparison to COPD, where the inflammatory responses were mostly exaggerated 
compared to that induced in samples from controls, asthmatic patients demonstrated a more 
complex pattern.  Little difference was observed in the response to TLR ligands, except polyI:C, 
where an exaggerated inflammatory response was detected.  Inflammatory mediator release 
following infection with viruses was diminished in the case of mediators such as IL-2R and EGF, but 
increased in the case of G-CSF, while the inflammatory response was diminished for bacterial 
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pathogens.  As such, the results presented here do not entirely corroborate the view that the innate 
immune response is deficient in asthma patients.  A previous study has demonstrated decreased 
release of IFN-β following infection of bronchial epithelial cells with RV-16 in asthmatic cells 
compared to healthy controls [172].  The type I IFNs are innate cytokines which induce the anti-viral 
state, and are thus very vital in anti-viral immunity.  However, in our study, RV-16 induced higher 
secretion of IFN-α, another type I IFN, in asthmatic subjects compared to controls.  Other studies 
have shown discrepancies in the release of pro-inflammatory cytokines, with no differences 
observed in the release of IL-6 and IL-8 in nasal lavage and induced sputum inoculated with RV-16 
[168], but increased release of IL-1β and IL-1RA in RV-16-infected nasal lavage samples in asthma 
patients compared to healthy controls [167].  In bacteria, one study has shown a decreased pro-
inflammatory response in whole blood non-specifically stimulated with PMA in asthmatic patients, 
but no difference in the response to S.pneumoniae infection [731].  However, many of these studies 
looked at the airway epithelium rather than peripheral blood, which may explain the disconnect 
between their results and those presented here.   
 
Therefore, the study presented here has helped to elucidate the differences in the inflammatory 
response between asthmatics and controls to a range of stimuli.  Unlike COPD, there does not 
appear to be a clear picture of simply having a decreased or exaggerated immune response to 
contribute to the more severe and increased duration of symptoms experienced by asthma patients 
during infection by respiratory pathogens. 
 
Circulating inflammatory markers and stimulated inflammatory responses, asthma vs. COPD 
Fewer differences were observed between asthma and COPD, than by comparing to controls.  In 
serum, the concentration of EGF was higher in COPD patients compared to asthmatics.  Following 
TLR stimulation, differences between COPD and asthma were only shown in the inflammatory 
response to LPS and R848 stimulation.  Following stimulation by both TLR ligands, asthma patients 
secreted lower levels of FGF-Basic, IL-12, IL-2R, IL-1RA, EGF and IL-15 compared to COPD, with LPS-
induced IL-6 also decreased.  Secretion of IL-1RA was reduced in asthma compared to COPD 
following stimulation by all three viral pathogens, with RV-16 and RV-1B-induced IL-2R, MIG, IL-1RA, 
IL-15, IFN-γ and FGF-Basic also decreased.  Finally, H.influenzae-induced secretion of FGF-Basic, IL-
15, IL-1RA, IP-10, IL-12 and IL-2R were decreased in asthma compared to COPD patients, with no 
differences seen following S.pneumoniae infection.  Therefore, as seen in the comparison against 
controls, the inflammatory responses in COPD patients are also heightened compared to asthma 
patients.    
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Conclusions 
Here it has been demonstrated that there is a vast difference in the inflammatory mediator profile of 
serum and stimulated blood between asthma, COPD and controls.  The main limitation of this study 
is that it was carried out in peripheral blood.  Asthma and COPD are both respiratory diseases, and 
the pathogens used were all respiratory pathogens, thus investigation of the inflammatory response 
mounted and the differences between the diseases and controls would have been more valuable at 
the site of infection.  However, blood provides a good model for the systemic inflammation 
occurring following infection, and is a useful marker in assessing the inflammatory response 
occurring.  Blood is also much better tolerated than the use of techniques such as experimental 
rhinovirus challenge, sputum induction, and bronchoscopy which are utilised in assessing the airway 
epithelium directly, and thus this enables greater numbers to be recruited. 
 
Analysis may also have been underpowered for some analytes, such as IL-6, RANTES and IP-10, due 
to concentrations frequently exceeding the upper limit of detection, with KNN-imputation used 
during analysis to attempt to compensate for this.  If samples had been diluted to allow such 
analytes to fall within the detectable range, many more analytes would have been at concentrations 
below the sensitivity threshold for the assay.  Additionally, it would not have been feasible to run 
singleplex ELISAs with samples diluted accordingly for each individual assay for the number of 
analytes that we wished to quantify and the number of samples to be tested.  While samples could 
be diluted and re-analysed in the future for the analytes which were consistently highly expressed, 
currently this is not possible due to budgetary constraints.  Of note, as well as the use of KNN-
imputation to compensate for missing data, adjustment for potential confounders such as age, sex 
and ethnicity was also carried out to ensure any inter-group differences observed were due to 
respiratory physiology rather than effects of demographics.  Additionally, to allow for the large 
number of comparisons carried out, the Benjamini-Hochberg procedure for multiple testing 
correction was applied to analysis to control the false discovery rate at 10% [467].         
   
The other limitation in this study is in the use of ViDiFlu participants as controls.  These participants 
were used as a sample of convenience, representing a population without diagnosed asthma or 
COPD, as these were exclusion criteria for the trial.  However, the majority of participants in the 
ViDiFlu trial were older adults, and thus their immune response may not be comparable with that of 
younger healthy adults.  For example, immunosenescence has been demonstrated [204], with 
numerous changes in the immune response and immune regulation, such as decreased antigen 
presenting ability by dendritic cells [208], less cytolytic activity by NK cells [210], and reduced T-cell 
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memory [211].  Additionally, a low-grade chronic inflammatory state has been described, with 
increased expression of bacterial receptors [87].  In mice, an age-related delay in cytokine release 
and cellular infiltration has been observed following infection with RSV and influenza [732, 733] , 
while older humans have been shown to have a diminished IFN-γ and IL-13 response in whole blood 
inoculated with RV-16 [734].  Systemic levels of circulating IL-6, TNF-α and IL-1 have also been 
demonstrated in older adults [706], which may, for example, obscure any increase in IL-6 compared 
to healthy controls as has been reported in COPD patients in other studies [708, 710]. However, the 
median age of ViDiFlu participants was not significantly different compared to the COPD participants 
in this study, so any differences seen between these two groups were likely down to the COPD 
alone, and not a result of an aged control population.  Of note, ViDiFlu patients did not undergo 
spirometry at any point during their study visits, and as such undiagnosed asthma or COPD could not 
be ruled out in this study population.  Additionally, other co-morbidities are likely to be present in 
this population due to the older age group sampled, with conditions such as diabetes, 
atherosclerosis, stroke and heart disease potentially influencing inflammatory indices.   
 
Therefore, it has been demonstrated here that the inflammatory response to a range of pathogens is 
altered in patients with COPD or asthma compared to controls (Table 7.13) , which may contribute 
to the more severe pathophysiology experienced by these patient groups during acute respiratory 
tract infections and exacerbations. 
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Table 8.14: Summary of the differences in inflammatory mediators between study populations 
grouped by stimulant  
  
Asthma vs.  
COPD (reference) 
Asthma vs.  
Control (reference) 
COPD vs.  
Control (reference) 
Circulating 
↓ EGF ↓ EGF ↓ EGF 
↓ Neutrophils ↓ MIP-1β ↓ MIP-1β 
↓ Lymphocytes ↓ TNF-α ↓ IL-6 
  ↑ Eosinophils ↓ IL-8 
    ↑ IL-1RA 
    ↑ IL-17 
    ↑ IL-2R 
    ↑ Lymphocytes 
    ↑ Neutrophils 
    ↑ Monocytes 
    ↑ Eosinophils 
Viral TLR 
    ↑ IL-15 
    ↑ IL-17 
    ↑ IL-6 
    ↑ IL-1RA 
    ↑ VEGF 
    ↑ MIG 
Viruses 
↓ IL-1RA ↑ G-CSF ↑ IL-7 
  ↓ IL-2R ↑ G-CSF 
  ↓ EGF ↑ MIG 
    ↑ IL-17 
    ↑ IL-1RA 
    ↑ MIP-1β 
Bacterial TLR     ↑ IFN-α 
Bacteria 
  ↓ FGF-Basic ↑ IL-1RA 
  ↓ IL-5 ↑ IL-12 
    ↑ IL-13 
    ↑ VEGF 
    ↑ IL-7 
    ↑ IL-15 
    ↑ IL-17 
Circulating: serum and coulter counts; Viral TLR: PolyI:C- and R848-stimulated blood; Viruses: RV-16-, RV-1B- 
and RSV-stimulated blood; Bacterial TLR: LPS-, Pam2CSK4- and Pam3CSK4-stimulated blood; Bacteria: 
H.influenzae- and S.pneumoniae-stimulated blood. 
Results only shown if differences statistically significant (p < 0.05, q < 0.1) for all stimuli in that group 
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9. Discussion and Concluding Remarks 
 
This thesis tested the hypothesis that vitamin D metabolites augment antimicrobial responses to 
respiratory pathogens, and suppress immunopathological inflammation in diseases such as asthma 
and COPD, thus preventing acute respiratory tract infections and exacerbations, and ameliorating 
the symptoms associated with these events.  An in vitro cell-line model was utilised to quantify gene 
expression, a whole blood assay was developed to enable quantification of the release of 
inflammatory mediators following ex vivo stimulation with TLR ligands or pathogens, and clinical trial 
blood and sputum samples were used to assess cellular profiles.  The main result presented in this 
thesis demonstrates that in vitro incubation with 25(OH)D or 1,25(OH)2D in A549 cells reduces 
rhinovirus-16 infection.  Immunological analysis of clinical trial samples did not demonstrate any 
consistent effect of in vivo vitamin D3 supplementation on circulating, TLR-stimulated or pathogen-
stimulated inflammatory profiles, or on inflammatory indices in induced sputum.  The only effect 
demonstrated was a reduction in the number of B-cells in older adults with neither asthma nor 
COPD given high-dose vitamin D supplementation, although type I error cannot be ruled out with 
this finding. 
 
Main Findings 
The in vitro study carried out offers a mechanistic explanation as to how vitamin D supplementation 
may prevent acute respiratory tract infections, as has been observed in some clinical trials [300-305].  
We have shown for the first time that co-culture with a physiological concentration of 25(OH)D 
increases resistance of A549 cells to infection with rhinovirus-16, with this effect also seen when 
incubating with 1,25(OH)2D as a positive control.  This was associated with attenuation of RV-
induced ICAM-1 expression, the main receptor for major serotypes of rhinovirus [524, 525].  Other 
studies have also demonstrated upregulation of ICAM-1 following infection by RSV [735-737] and 
rhinovirus [457, 543, 545, 738], with augmented ICAM-1 expression resulting in cellular 
transmigration and increased epithelial adherence [735, 739, 740].  This upregulated expression of 
ICAM-1 may facilitate further infection by rhinovirus, and the subsequent spreading of rhinovirus to 
adjacent cells, with the increased influx of leukocytes contributing to localised inflammation and 
immunopathology.  Therefore, 25(OH)D inhibition of RV-induced ICAM-1 upregulation may prevent 
viral spreading and reduce any immunopathology experienced, potentially reducing the severity of 
the disease.   Additionally, co-culture with 25(OH)D was demonstrated to lessen RV-induced A549 
cytotoxicity, thus further inhibiting the facilitation of viral spreading.      
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RV-induced upregulation of ICAM-1 has been demonstrated to be mediated by IL-1α [736], IL-1β 
[736, 738] and NFκB [111, 457, 526, 737].  However, we did not observe any effect of co-incubation 
with vitamin D metabolites on IL-1β concentrations released, suggesting that vitamin D is not 
inhibiting upregulation of ICAM-1 through effects on this cytokine.  It has previously been 
demonstrated that 1,25(OH)2D is able to increase the expression of the NF-κB inhibitory protein IκBα 
[327, 549], thus inhibiting NF-κB signalling, but still maintaining the anti-viral state [327].  However, 
while a trend towards increased expression of IκBα was observed in this study following co-culture 
of A549 cells with 25(OH)D or 1,25(OH)2D, statistical significance was not reached.   
 
Significantly, in vitro experiments also demonstrated an effect of vitamin D metabolites in inhibiting 
RV-induced upregulation of the platelet activating factor receptor (PafR).  This has been 
demonstrated to be a major receptor for Streptococcus pneumoniae and Haemophilus influenzae, 
facilitating adherence and colonization of the respiratory tract, with expression upregulated by RSV, 
RV-14, influenza and coronavirus infections [88, 101, 102].  Additionally, ICAM-1 may play a role in 
bacterial adherence and infection, with H.influenzae demonstrated to use ICAM-1 as a receptor 
[741].  As such, vitamin D may be beneficial in preventing secondary bacterial infections, via 
inhibition of viral-induced upregulation of receptors such as PafR and ICAM-1.  Since viral-induced 
PafR expression has been associated with NF-κB activation [102, 109], the effect of vitamin D 
metabolites observed here may again be mediated through increased IκBα expression.   
 
Therefore, in vitro work has demonstrated that vitamin D metabolites are able to reduce infection of 
A549 cells by rhinovirus-16, while also inhibiting virus-induced upregulation of the receptors ICAM-1 
and PafR, although the mechanisms behind this are not entirely clear.  However, clinical trials carried 
out in conjunction with these experiments did not show any reduction in the incidence of upper 
respiratory tract infections or exacerbations in asthmatics, COPD patients, or people living in 
sheltered accommodation (results not yet published).  Immunological assays using blood samples 
from trial participants stimulated ex vivo with a panel of TLR ligands and pathogens also did not 
demonstrate any effects of vitamin D supplementation on the release of inflammatory mediators.  
Finally, the cellular profiles and underlying inflammation in the sputum and blood of patients with 
asthma or COPD were not affected by vitamin D supplementation, with only the number of B-cells 
reduced in the intervention arm in older adults living in sheltered accommodation.  However, while 
an effect of vitamin D on B-cell proliferation, antibody production and memory cell differentiation 
has been shown elsewhere [255, 608], with the vast number of analyses carried out in this study and 
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the fact that only one parameter showed any difference following vitamin D supplementation, type I 
error cannot be ruled out, despite having a q-value of less than 0.1.    
 
The discord between the positive effect of co-culture with 25(OH)D in decreasing RV-16 infection in 
A549 cells, and the lack of any effect of vitamin D supplementation in the immunological assays and 
the majority of the clinical trials results could be due to a number of reasons.  In the in vitro work 
carried out, only one pathogen was studied.  It is possible that vitamin D has differentially protective 
effects for different respiratory pathogens, with one study demonstrating reduced incidence of 
influenza A following vitamin D supplementation with 1200 IU/day, but no effect on incidence of 
influenza B [303].  Only RV-16 was used to infect A549 cells in cell culture work, whereas the clinical 
trials patients would have been exposed to a wide range of different respiratory pathogens.  As such, 
it is possible that vitamin D supplementation did reduce incidence of rhinovirus infection, but had no 
effect on other acute respiratory tract infections experienced.  Rhinovirus is the most common ARI, 
as shown elsewhere [7, 517] and in the ViDiFlu study, with 6 out of the 11 PCR positive episodes 
which achieved Jackson symptom criteria of being a URI associated with rhinovirus infection.  
However, the lack of any effect of vitamin D on other respiratory pathogens, such as parainfluenza, 
enterovirus, RSV and influenza, could have masked any effect of vitamin D on rhinovirus infection.  
Additionally, effects of vitamin D could be group, species or even serotype specific, with only RV-16 
investigated, which is a major group, A species serotype of rhinovirus.  Finally, the use of symptom 
scores to define URIs may not have been accurate in clinical trial patients, with the potential to miss 
true URIs or record false URIs.  The gold standard of PCR was performed in nose and throat swabs 
from a subset of ViDiFlu participants (n = 166), with 95% of those presenting with a negative 
symptom score also being PCR negative for the presence of a panel of pathogens (RSV, influenza A 
and B, parainfluenza 1-3, adenovirus, enterovirus, rhinovirus, metapneumovirus).  However, only 
52% of those presenting with a positive symptom score were PCR positive for any of those 
pathogens, suggesting that false positives may have been reported in URI incidence in all three trials.  
Likewise, 39% of PCR positive swabs were associated with negative symptom scores, indicating that 
true URIs may have been missed.   
 
Host factors may also offer an explanation as to the discord in results from cell culture work and 
analysis of clinical trials samples.  Firstly, in vivo supplementation represents a much more complex 
system than co-culture in a cell line.  In the host, all cell types are present, with interplay and cross-
talk between epithelial cells and leukocytes to regulate immune homeostasis, inflammation and 
tissue repair [742], whereas the use of a A549 cells involves only one cell type, in this case 
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adenocarcinomic human alveolar basal epithelial cells.  The vitamin D supplementation regimen may 
also have had an effect.  A549 cells were co-cultured with a 100 nmol/L concentration of 25(OH)D, 
thus experiencing a sustained steady high concentration of 25(OH)D for the duration of their culture.  
In vivo concentrations of 25(OH)D on the other hand fluctuated, from a peak of likely greater than 
100 nmol/L at one week post-dose, where concentrations following bolus supplementation have 
been shown to be highest [316], to a much lower trough concentration 2 months post-dose, which is 
the point at which blood and sputum samples were taken for use in immunological assays and serum 
25(OH)D concentrations were quantified.  Therefore, the difference between the intervention and 
placebo arms was probably much greater immediately post dosing, and it is possible that if the 
immunological tests had been carried out at this point a greater difference between the vitamin D 
status of the two arms could have resulted in an effect of vitamin D on the release of inflammatory 
mediators being observable.  While bolus dosing is beneficial due to improved compliance, a smaller 
daily dose may provide a more stable serum 25(OH)D concentration.  It has also been hypothesized 
that high-dose bolus supplementation with vitamin D may result in induction of CYP24 [743], the 24-
hydroxylase enzyme which is able to catabolise 1,25(OH)2D into 1,24,25(OH)3D, as well as 
metabolising 25(OH)D to the relatively inactive metabolite 24,25(OH)2D [318, 744, 745].  Therefore, 
the amount of active 1,25(OH)2D is reduced, both by accelerating its catabolism and by decreasing 
the availability of the 25(OH)D substrate for 1-hydroxylation.   This could explain the results 
observed in the ViDiFlu trial, with acute upper respiratory tract infection incidence increased in the 
intervention arm.  
 
While supplementation did result in a statistically significant increase in vitamin D status from 
baseline levels to 12 month follow-up in all studies, the difference in serum 25(OH)D concentration 
between the two arms at 12 months was modest in size in some cases, and did not reach statistical 
significance in the COPD sputum sub-study (Table 9.1).  The average difference in mean vitamin D 
status at the 12 month time-point between the 2 arms of each study was 26.7nmol/L.  Using a cut-
off of 50nmol/L to define deficiency and sufficiency, at the 12 month time-point the means for the 
intervention arm for all studies were above this threshold.  However, in half of the studies, the 
means for the 12 month time-point in the placebo arm were also above this threshold, thus 
potentially masking any effects of vitamin D supplementation.  Additionally, there were a number of 
participants above the sufficiency threshold of 50nmol/L in the placebo arms of each sub-study at 12 
month follow-up, and a number of participants who failed to reach sufficiency in the intervention 
arm.   
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Table 9.1: Mean serum 25(OH)D concentration at 12 month follow-up for both arms of all trials  
Study 
12 month placebo / low-dose vitamin 
D 
1
 
12 month intervention / high-dose 
vitamin D 
1
 
Statistics 
n with 
25(OH)D > 
50nmol/L 
n with 
25(OH)D < 
50nmol/L 
mean 
(nmol/L) 
n with 
25(OH)D > 
50nmol/L 
n with 
25(OH)D < 
50nmol/L 
mean 
(nmol/L) 
difference 
between 
means, 
nmol/L 
(95% CI) 
p-value  
ViDiAs 
sputum 
sub-study 
9 14 42.39 18 3 71.14 
28.75 
(15.5 to 
42.0) 
< 0.0001 
ViDiCO 
sputum 
sub-study 
8 5 54.62 17 7 63.13 
8.51 (-7.1 
to 24.2) 
0.28 
ViDiAs 
WBA  
sub-study 
5 18 37.57 20 2 70.59 
33.03 
(23.3 to 
42.8) 
< 0.0001 
ViDiCO 
WBA  
sub-study 
2 11 32.46 5 3 61.25 
28.79 (8.2 
to 49.4) 
0.009 
ViDiFlu 
residents 
WBA  
sub-study 
16 8 62.63 
1
 32 1 86.76 
24.13 
(12.3 to 
36.0) 
0.0001 
ViDiFlu 
staff WBA  
sub-study 
5 4 52.56 6 0 89.83 
37.28 (4.6 
to 69.9) 
0.03 
In all sub-studies, 25(OH)D was measured in serum samples. 
1
 ViDiFlu residents on different dosing regimen, with 12 month placebo participants having also received 
vitamin D supplementation (low-dose) throughout the study 
 
Abbreviations used:25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; WBA: whole blood assay 
 
 
The serum 25(OH)D concentration also does not necessarily correlate with the concentration 
experienced in the airways, the site of infection for ARIs, with one study demonstrating significantly 
lower 25(OH)D and 1,25(OH)2D concentrations in BAL compared to serum [746].  As such, the effect 
of vitamin D supplementation on the airway concentration of vitamin D cannot be determined in this 
study, and thus it is possible that the immune cells of the respiratory tract did not reach a high 
enough 1,25(OH)2D concentration to exert any immunomodulatory effects and alter ARI incidence.  
For the cell culture work on the other hand, we can be sure that the epithelial cells being challenged 
with RV-16 had experienced a sustained high concentration of 1,25(OH)2D or 25(OH)D.  Finally, the 
metabolites were used individually in separate cell culture experiments for the in vitro work, 
whereas in vivo there is likely a complex interplay between all of the different vitamin D metabolites, 
with effects on metabolism and catabolism.   
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A number of other clinical trials have also not demonstrated any effect of vitamin D 
supplementation, with no effects on hospital readmission rates due to respiratory tract infections 
[309], self-reported URTI incidence, duration or severity [310], pneumonia incidence [311, 312], 
influenza-like illness incidence or URTI duration [313, 314],  or the rate of asthma exacerbations, 
lung function and airway hyperreactivity [315].  The reasons behind why effects of vitamin D have 
been observed in some clinical trials but not in others, including the ones reported in this study, 
remains to be elucidated.  The inconsistencies in dosing regimens in intervention studies may play a 
role, with the optimum dose of vitamin D yet to be determined, and issues surrounding bolus dosing 
versus daily dosing, while the follow-up period for each trial may also be a determinant, with 
sufficient duration required to allow prolonged vitamin D repletion.   
 
Stratification of analyses by genotype or baseline vitamin D deficiency may also provide explanations 
as to why some trials report positive results and some do not.  In the three clinical trials reported in 
this study, COPD patients did show that effects of vitamin D supplementation were modified by 
genotype.  However, these effects were not observed in the other 2 trials, and no other published 
intervention studies into vitamin D supplementation in acute respiratory tract infections have 
determined the genotype of participants.  Likewise, baseline vitamin D deficiency may be an 
important determinant which was not addressed in a number of other intervention studies.  In the 
ViDiCO study, vitamin D supplementation was shown to reduce the risk of exacerbation in patients 
with baseline deficiency (aHR 0.57, 95% CI 0.35 to 0.92, p = 0.021), and in the study by Lehouck et al. 
exacerbations were decreased in COPD patients with profound baseline deficiency [308].  However, 
one study has demonstrated that in individuals with 25(OH)D concentrations greater than 
140nmol/L the risk of active tuberculosis was increased [317], suggesting that supplementation may 
be detrimental in vitamin D replete individuals by raising their vitamin D status by too much.  In 
order to address these potential determinants, trials would have to recruit participants based on 
their genotypes and baseline vitamin D status to provide enough power, which would add to the 
complications of trial design and recruitment procedures.   
 
Finally, and separate from the main aim of this study in determining effects of vitamin D, clinical trial 
samples were further utilised to perform cross-sectional analyses to compare the underlying 
inflammatory profiles in patients with asthma or COPD, and those with neither condition.  
Interesting differences were observed, with the sputum of asthmatics having increased proportions 
of macrophages and higher concentrations of IL-2, IL-4, IL-13 and GM-CSF compared to COPD 
patients, while the sputum of COPD patients had an increased number of neutrophils present and 
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elevated concentrations of IFN-α, MIP-1α, IL-8, IL-6, G-CSF, IL-1RA, eotaxin, MCP-1, HGF and IL-1β.  
Differences were also observed in the concentrations of inflammatory mediators released following 
ex vivo stimulation of the blood, with COPD patients demonstrating a more marked inflammatory 
response compared to controls, potentially increasing immunopathology in this disease. In 
asthmatics, a more complex pattern was demonstrated, with increased release of inflammatory 
mediators following viral stimulation, but a decrease following bacterial stimulation when compared 
to controls.  In a comparison of the inflammatory response in asthma versus COPD, the release of 
inflammatory mediators such as IL-2R, IL-12, IL-15 and IL-1RA was higher in COPD following 
stimulation with pathogens, LPS and R848, again demonstrating a heightened inflammatory 
response with the potential to contribute to immunopathology. 
 
Strengths and limitations of the studies carried out 
The main limitation of the studies presented in this thesis was insufficient power.  During trial 
design, power calculations were based on being able to detect an effect of vitamin D 
supplementation on the primary outcomes of time to first exacerbation/URI.  Due to patients being 
lost to follow-up, delays in the implementation of immunological assays, and budgetary constraints 
on the quantity of the analyses carried out, sufficient numbers may not have been gained to reach 
significance thresholds.  In an attempt to increase power, data from asthmatics, COPD patients and 
ViDiFlu staff members who all underwent similar vitamin D dosing regimens were pooled, raising 
another possible limitation.  The inflammatory response for these three distinct populations was 
likely to differ markedly, as shown in the cross-sectional comparisons carried out, with effects of 
vitamin D potentially depending on disease phenotype.  This effect was partly observed by the 
finding that vitamin D reduced exacerbations in COPD patients with baseline deficiency, but had no 
effect in deficient asthma patients.  However, this was compensated for by using a statistical analysis 
platform which allowed for adjustment of confounders, with study eliminated during all analysis to 
remove any influence of having asthma or COPD.  Additionally, although not presented here, 
analyses of sputum inflammatory mediators and cellular profiles, and ex vivo responses to 
stimulation of peripheral blood were carried out stratified by disease type, with no effect of vitamin 
D supplementation observed.     
 
Power was also reduced in the analysis of inflammatory mediator release, with analytes such as IL-6, 
IP-10 and RANTES frequently presenting with concentrations exceeding the upper limit of detection,.  
While KNN-imputation was used during analysis to attempt to compensate for this, it would have 
been preferable to dilute samples and re-analyse them.  However, if samples had been diluted to 
261 
 
allow such analytes to fall within the detectable range, many more analytes would have been at 
concentrations below the sensitivity threshold for the assay.  Additionally, it would not have been 
feasible to run singleplex ELISAs with samples diluted accordingly for each individual assay for the 
number of analytes that we wished to quantify and the number of samples to be tested.  While 
samples could be diluted and re-analysed in the future for the analytes which were consistently 
highly expressed, currently this is not possible due to budgetary constraints.     
 
As already touched upon, the use of a bolus-dosing regimen in clinical trials patients is also a 
potential limitation to study.  This regimen likely resulted in fluctuations in serum 25(OH)D 
concentration, with potential induction of CYP24, and increased catabolism of the active metabolite 
1,25(OH)2D.  Another hypothesis relating to worth of bolos-dosing is that immune cells require 
parent vitamin D3 which they then 25-hydroxylate themselves [747].  Since the half-life of vitamin D3 
is only approximately 24 hours, bolus-dosing would not be sufficient to influence circulating vitamin 
D3 levels, and thus immunomodulatory actions on immune cells would not be possible. 
 
 However, there were also a number of strengths in the studies carried out.  The clinical trials were 
all well-designed, in that they were double-blind, with directly observed dosing and detailed 
assessments carried out.  A vast range of assays and techniques were used to try and capture any 
immunomodulatory effects of vitamin D, with quantification of circulating and sputum supernatant 
inflammatory mediators, cellular profiles of both the airways and circulation, and stimulated 
responses to both TLR ligands and whole pathogens.  No other clinical trials into vitamin D 
supplementation in the prevention against acute respiratory infections have carried out concomitant 
analysis of both sputum and blood samples from clinical trials patients, to try to offer a mechanistic 
explanation behind any primary effects observed.  The ex vivo stimulation of whole blood was also 
novel in this context, analysing the effects of in vivo vitamin D supplementation on the inflammatory 
response to a wide range of stimuli.  This investigation is especially important, since pathogenic 
stimulation has been demonstrated to upregulate CYP27B1, thus increasing the potential to detect 
an immunomodulatory effect of vitamin D supplementation even in participants without on-going 
infection or inflammation.   The in vitro investigations were also the first of their kind to be carried 
out, with an effect of physiological concentrations of 25(OH)D observed in reducing rhinovirus 
infection, as well as associated and potentially important inhibition of RV-induced ICAM-1 and PafR 
expression, and improved cell viability.  While only rhinovirus was looked at, this is the most 
common respiratory pathogen, thus justifying this choice.   
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Future Work 
As such, while the majority of the results presented here were negative, the questions and 
hypothesis addressed in the studies carried out were worth asking, and lots of new and interesting 
data has been produced.  In spite of the number of observational and intervention studies 
demonstrating a protective effect of vitamin D in the prevention of acute respiratory infections, it 
cannot be ruled out that vitamin D is not able to have such a profound effect on incidence and 
severity of ARI, with a number of trials, including the ones presented here, indicating that this may 
be the case.   
 
The main thing to be elucidated before any more intervention studies into the effects of vitamin D 
on ARIs is the optimum dosing regimen to use.  From what I have already discussed, it seems likely 
that daily dosing would provide a better system when assessing the effects of supplementation.  
However, this brings about issues surrounding compliance, with it being impossible to directly 
observe the consumption of a daily dose, and an increased chance of participants forgetting or losing 
doses.  Future clinical trials may also benefit from only recruiting participants with baseline vitamin 
D deficiency, since the effects of vitamin D supplementation may be more marked or more beneficial 
in this population.  Similarly, genotyping participants may provide insight into whether effects are 
influenced by the genetics of an individual.  Large-scale trials would be needed to address these 
questions, with high enough numbers recruited to reach sufficient power. 
 
Finally, the in vitro work carried out should be expanded on in the future to further elucidate the 
effects of vitamin D in the prevention against rhinovirus infection, as well as other pathogens.  The 
first step would be to repeat the experiments in primary human bronchial epithelial cells, to see if 
these results can be replicated.  A549 cells are a transformed cancerous cell-line, and as such are not 
as physiologically accurate as using primary cells.  It has also been shown both here and elsewhere 
that A549 cells have relatively high expression of CYP24A1 and low expression of CYP27B1, 
suggesting that the presence of the active metabolite 1,25(OH)2D may be diminished in this cell type, 
thus preventing some of the immunomodulatory effects of vitamin D to be observed [430].  The 
abundance of CYP24A1 in this cell-line may also effect the time-frame of any effects, potentially 
being the cause of the transient effects of co-culture with vitamin D metabolites on viral mRNA 
expression, RV-induced PafR expression and A549 viability observed in this study.  A number of 
additional experiments should also be carried out to explain the mechanisms by which vitamin D 
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metabolites are able to reduce rhinovirus infection.  Firstly, the involvement of the NF-κB activation 
pathway in the effects of vitamin D could be further elucidated in a variety of ways.  Phosphorylation 
of IκBα could be determined by western blot, to assess whether vitamin D is increasing IκBα mRNA 
by inhibiting its phosphorylation and degradation, thus resulting in reduced activation of NF-κB.  
Silencing and antagonism of IκBα, ICAM-1, type I IFNs and LL-37, as well as NF-κB itself, would also 
help to determine how important each of these components are in the observed vitamin D mediated 
resistance to RV infection.  An adhesion assay looking into the effects of vitamin D metabolites on 
virus-induced bacterial adhesion would help to establish the importance of vitamin D metabolites in 
preventing secondary bacterial infections, following on from our findings that 25(OH)D was able to 
inhibit RV-induced upregulation of the bacterial receptor PafR.  Finally, a wider variety of respiratory 
pathogens could also be utilised.  As already discussed, vitamin D may be differentially protective 
against different pathogens, thus the use of other common respiratory viruses such as RSV, influenza 
and coronavirus could also be investigated.   
 
Conclusion 
This study has demonstrated that in vitro co-incubation of A549 cells with 25(OH)D increases 
transient resistance to infection with rhinovirus-16, while also inhibiting RV-induced upregulation of 
ICAM-1 and PafR.  These findings did not translate to any effects in the immunological analysis of 
clinical trial samples from participants with asthma, COPD or neither condition, with no changes in 
the cellular profile of the airways or circulation, the inflammatory profile of induced sputum 
supernatants, or the inflammatory mediator release following ex vivo stimulation of peripheral 
whole blood.  While one effect was observed between low-dose and high-dose vitamin D 
supplementation, with a decrease in the number of B-cells in the blood of older adults living in 
sheltered accommodation following a combined daily and bolus high-dosing supplementation 
regimen, type I error cannot be ruled out with this finding.  
 
Therefore, further studies should be carried out to determine whether vitamin D supplementation 
would be beneficial in preventing acute respiratory tract infections, especially in vulnerable 
populations such as the elderly and those with chronic inflammatory conditions such as asthma and 
COPD. 
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